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2 Introduction
The control of numerous infectious diseases is still a challenge for animal health. To address
this challenge, understanding the within-host dynamics, i.e. the interactions between the patho-
gen and the immune response, is a prerequisite (Section 1). It is even more so for pathogens that
target immune cells, such as the porcine reproductive and respiratory syndrome virus (PRRSv),
on which we focused in this thesis. PRRSv is a respiratory pathogen with a major impact of
the swine industry worldwide (Section 2). There are still many gaps in the knowledge and the
understanding of PRRSv within-host dynamics. It involves complex interactions and can vary
depending on several factors, such as the animal susceptibility to the pathogen, its infection
past, its infectious environment... We hence identified three major issues, which we tackled in
this thesis (Section 3). Given the complexity of the immune mechanisms and their potential
variability, we chose a modelling approach, as it is a powerful tool to explore the within-host
dynamics, to test biological hypotheses or to assess the impact of control strategies, which would
not be feasible or would be too expensive by experimentation (Section 4).
At the end of this introduction, we provide a description of the thesis organisation and
contents (Section 5).
1 Within-host scale
1.1 Controlling animal infectious diseases : inputs from between- and within-
host scales
Understanding the pathogen spread in a population and its development in the host is essential
to develop effective prevention and control strategies. At the between-host scale, the infection
spread, the infectiousness of infected individuals and the host contact structure determine the
exposure of susceptible individuals, which can trigger new infections. At the within-host scale,
the exposure, the individual susceptibility and the pathogen virulence drive the immune dyna-
mics, which dictates the infection duration and severity, as well as the infectiousness of infected
individuals. Exposure hence links the between-host to the within-host dynamics, whereas infec-
tiousness links the within-host to the between-host dynamics.
Control strategies include (i) treatment of infected animals to cure them or at least reduce
their symptoms ; (ii) limitation of contacts between infectious and susceptible individuals to
reduce the infection spread at the herd level ; (iii) management measures and genetic selection
to reduce the susceptibility to the pathogen ; and (iv) vaccination to protect the animals from
infection or at least limit their susceptibility and infectiousness, and consequently the pathogen
spread. Vaccination is a strategy currently used to control numerous animal infectious diseases,
which has an impact at both the within- and between-host scales. At the within-host scale, the
vaccine efficiency depends on the immune response and subsequent host protection it induces.
At the between-host scale, the vaccine efficiency depends on how many and which animals are
efficiently vaccinated. So a first step to evaluate a vaccination strategy is to determine the
vaccine efficiency at the within-host scale before the between-host scale. Similarly, an infectious
disease control at the herd level first requires a good understanding of the within-host dynamics.
However, our knowledge of the immune response to respiratory animal pathogens is still partial
and needs more insight.
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1.2 Within-host scale : immune response dynamics
The immune system is a system of biological structures and processes within an organism that
protect from diseases. It consists of layered defences of increasing specificity. First, physical
barriers prevent pathogens from entering the organism. If a pathogen breaches these barriers,
the innate immune system provides an immediate, but non-specific response. If pathogens suc-
cessfully evade the innate response, a second layer of protection is provided by the adaptive
immune system, which is activated by innate cells and confers specific long-lasting protective
immunity to the host. The adaptive response also provides an immunological memory, which is
then retained after the pathogen has been eliminated and improves the pathogen elimination in
case of re-exposure thanks to a quick, specific and strong re-activation of the adaptive response.
The immune cells exhibit specific immune functions, which are activated and/or regulated by
(i) the binding with a pathogen, (ii) the binding with another immune cell and (iii) various
cytokines, which are extra-cellular proteins synthesised by activated immune cells. Activation
induces cascaded reactions within the cell, including the regulation of RNA expression. So the
immune response involves complex reactions at the within- and between-cell scales.
In a context of disease control at the within-host scale, one needs to take into account
the exposure of the animal and to infer its infectiousness, which derives from the within-host
pathogen dynamics. Moreover, vaccination, which is a control measure of particular interest,
mainly involves the adaptive immune response. The latter is initiated and interacts with the
innate immune response. Consequently, an integrative view of the pathogen dynamics and the
immune response at the between-cell scale is required to define the host infectiousness and to
assess vaccine efficiency.
Respiratory pathogens, which enter the body through the mucosal surfaces of the respiratory
tract, are responsible for local inflammation and tissue damages [1, 2]. The first interaction
between the pathogen and the immune system involves the innate immune cells. The innate
cells mainly consist of pulmonary macrophages, dendritic cells and natural killers. Macrophages
and dendritic cells, which are antigen presenting cells (APC), induce the inflammation process,
destroy the pathogen through phagocytosis and activate the adaptive cells, whereas natural
killers destroy the infected cells. The adaptive immune system mainly involves the cellular, the
humoral and the regulatory responses. The cellular effectors destroy the infected cells, whereas
the humoral effectors release antibodies, which are responsible for the neutralisation of free viral
particles. The regulatory response mainly inhibits the adaptive response. The best strategy to
control the severity of respiratory pathogens at the within-host scale is to limit the inflammation,
while maintaining an efficient immune response.
Some respiratory pathogens, such as influenza viruses, Mycobacterium tuberculosis or the
porcine reproductive and respiratory syndrome virus (PRRSv), replicate in the cells of the res-
piratory tract, including APC. They hinder the immune functions of the APC and consequently
reduce the efficacy of the immune response. With these pathogens, activated APC (i) either
phagocyte and destroy the pathogen, or are infected and excrete the pathogen ; (ii) produce
cytokines that promote the migration of immune cells to the infection site ; (iii) synthesise cy-
tokines that regulate the adaptive immunity ; (iv) express antigen proteins on their cell surface
that activate the adaptive response. In turn, the adaptive cell effectors and cytokines regulate
the immune functions of the APC. However, the influence of APC–pathogen interactions on the
immune response has been poorly studied and needs more insights [1–4]. Among the pathogens
targeting pulmonary macrophages, we focused on PRRSv.
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2 Porcine Reproductive and Respiratory Syndrome virus
The porcine reproductive and respiratory syndrome virus (PRRSv), also named blue ear disease,
is a widespread disease affecting domestic pigs. The symptoms include reproductive failure,
pneumonia and increased susceptibility to secondary bacterial infections. PRRSv is a major
concern for the swine industry, as it is responsible for significant economic losses worldwide,
impacting commercial pig production in North America, Europe and Asia [5–7]. There is no
treatment for PRRSv and current vaccines are efficient to limit the symptoms, but of limited
use to control and eliminate the disease [7–11].
Our incapacity to better control this disease is due to our incomplete understanding of the
immune response induced by PRRSv [8, 11, 12] :
• PRRSv exhibits a strong tropism for the pulmonary macrophages [5, 6, 12, 13], resulting in
a prolonged viraemia (viral titer in the blood) thanks to its ability to hamper the immune
response [5, 6, 14]. However, the ways PRRSv interferes with the immune response and
the immune mechanisms determining the infection resolution are not yet fully identified
[8, 11, 12].
• The infection and immune dynamics are highly variable among hosts [15] and viral strains
[12]. Consequently, apparent inconsistencies in terms of immune mechanisms determining
the infection resolution may appear among experimental studies, which usually involve a
single strain and few animals.
In this section, we first give outlines for PRRSv epidemiology (Section 2.1) and immunology
(Section 2.2). Then we focus of PRRSv variability factors, namely strain virulence and pig
susceptibility (Section 2.3). Finally we present PRRSv current control measures (Section 2.4).
2.1 PRRSv epidemiology outlines
PRRSv was first recognised in the United States in 1987 and the virus was identified in the
Netherlands in 1991 [16]. Diagnostic assays became available during the 1990s [6]. PRRSv is
now found in most intensive livestock production areas [7]. The estimated prevalence within
infected regions reaches 60–80% of herds [6]. After an initial epidemic period, characterised by
a high incidence lasting two to three months, the infection is either eradicated or it becomes
endemic. Most farms are chronically infected.
PRRSv is highly infectious, i.e. the exposure of the animal to relatively few virus particles
results in transmission, but not highly contagious [17]. Transmission requires that the pathogen
successfully exits an infected host, survives potential threats in the environment, avoids the
host defence system of its new susceptible host and reaches its replication site in the host.
PRRSv transmission can occur vertically and horizontally [6]. Vertical transmission is defined
as transmission from one generation to the next by infection of the embryo or fetus in utero.
PRRSv vertical transmission occurs most readily during the third trimester of pregnancy [6].
Horizontal transmission is defined as transmission either from physical contacts with infected
animals (direct transmission) or via an intermediate vehicle (indirect transmission), which can
be the environment (e.g. water, food, soil), living carriers (wildlife reservoirs, vectors) or aerosols.
PRRSv transmission most commonly occurs by direct horizontal transmission, i.e. close nose-to-
nose contacts between animals[6]. Infection of susceptible animals results in the virus shedding
in saliva, nasal secretions, urine, semen, and possibly faeces. Shedding occurs simultaneously
from many sites at low levels or intermittently [6].
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PRRSv spread in a herd depends on PRRSv prevalence, the pig contact network, the pig
infectiousness and the pig susceptibility [18, 19]. The contact network, combined with the herd
prevalence, defines the probability of a susceptible pig to be in contact with an infected pig.
The pig infectiousness results from its within-host dynamics and determines the probability for
an infected pig to transmit the pathogen to a susceptible pig in contact. The pig susceptibility
(or resistance) results from its own characteristics (linked to its genotype or management) and
its previous contacts with pathogens ; it determines the probability for a susceptible pig to be
infected by an infectious pig in contact.
2.2 PRRSv immunology outlines
Our knowledge of PRRSv immune response is detailed in reviews based on experimental studies
[5, 6, 8–12, 15], presented in Section I.1. Here, we just synthesise the main characteristics of
PRRSv within-host dynamics, partly based on more synthetic reviews [13, 14, 20, 21], also
detailed in Section I.1.
Immune response characteristics PRRSv enters the pig through the mucosal surfaces and
infects antigen presenting cells (APC), consisting of pulmonary macrophages and dendritic cells,
through its binding with the internalisation cellular receptors. Within one day, it has infected
macrophages throughout the body, especially in the lung and lymph nodes, which are the two
main infection sites. As mentioned in Section 1.2, antigen presenting cells belong to the in-
nate immune response and have key immune functions which are expressed after the pathogen
recognition involving various receptors :
• first, APC (mainly the macrophages) destroy the viral particles via phagocytosis,involving
principally the Fc-receptors ;
• then, the recognition of the viral nucleic acids by the toll-like receptors (TLR) induces the
synthesis of various cytokines. Cytokines regulate numerous immune mechanisms including
pro-inflammatory, antiviral and immuno-regulatory functions ;
• finally, APC (mainly the dendritic cells) present the viral antigens to the naive adaptive
cells, corresponding to the adaptive response activation step.
The interactions between PRRSv and APC initiate consequently both infection and immune
response. Their interactions and dynamics are regulated in a complex way by other immune
cells (such as cytotoxic lymphocytes), cytokines (such as antiviral and immuno-modulatory
cytokines) and antibodies (in particular neutralising antibodies). All these mechanisms need to
be considered in order to understand what determines the infection resolution.
Moreover, the APC infection by PRRSv hampers its immune functions. In particular, PRRSv
amplifies the target cell permissiveness, promotes the synthesis of immuno-modulatory over
antiviral cytokines and inhibits the adaptive response activation. PRRSv is responsible for a slow
and weak innate immune response. Some studies defend the hypothesis that the altered adaptive
response only results from the altered innate response, whereas others assume that PRRSv could
also directly hamper the adaptive mechanisms [5, 8–12, 15]. The adaptive response to PRRSv is
characterised by a delayed and weak production of neutralising antibodies and cytotoxic T cells.
The viraemia generally lasts between 28 and 42 days [6, 8, 22], but the virus can remain for
even longer durations in the lungs and lymph nodes. The viraemia reaches a peak within about
a week and diminishes steadily. Neutralising antibodies and cytotoxic T cells are protective
against a wide variety of viral infections, but seemingly not against PRRSv infections [8, 9]. The
virus is largely eliminated before neutralising antibodies are detected and animals lack effective
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cytotoxic T cells. However, the mechanisms determining PRRSv resolution are still controversial
[5, 8–12, 15].
The virus PRRSv belonging to the Arterivirus genus [5–7] is an enveloped RNA virus [23, 24].
As illustrated in Figure 1, the virion consists of a nucleocapsid, composed of a positive-strand
RNA genome and the nucleocapsid protein (N), which is surrounded by a lipid bilayer envelope.
The virion expresses 14 functional non-structural proteins (nsp) and the lipid envelope consists
of six embedded structural proteins : the glycoproteins GP2 to GP5, and the non-glycosylated
proteins M and N. These structural proteins defined the viral epitopes, which is the part of
an antigen that is recognized by the adaptive immune system and are involved in the immune
response activation and differentation. The major envelope proteins GP5 and M may be the basic
protein matrix of the virion envelope. The most abundant N protein is a highly basic protein.
The three main structural proteins GP5, M and N are indispensable for both virion formation
and viral infectivity, whereas the minor proteins (GP2, GP3 and GP4) only for infectivity.
GP5/M heterodimers, GP4 and GP2 protein have been suggested to play roles in PRRSv entry
into the target cells. GP5/M heterodimers are involved in virus attachment and internalisation
through binding with heparan sulphate and sialoadhesin cellular receptors [25, 26]. GP4 and
GP2 interact with CD163, which is considered as a receptor for viral uncoating and genome
release.
Figure 1 PRRSv virion, an Arterivirus consisting of a small enveloped RNA (nucleocapsid
core). The nucleocapsid includes structural proteins : the glycoproteins GP2 to GP5, and the
non-glycosylated proteins M and N. c©ViralZone 2007 Swiss Institute of Bioiformatics, http:
//viralzone.expasy.org/all_by_species/28.html
Viral epitopes that are capable of inducing neutralising antibodies appear to reside on the M,
GP2a, GP3, GP4 and GP5 proteins [9]. Among these, GP5 neutralising antibodies appear to be
the most relevant for protection. Antibodies directed against the N protein are most abundant,
but these are not neutralising and do not correlate with protection.
2 Porcine Reproductive and Respiratory Syndrome virus 7
2.3 Variability in PRRSv strain virulence and pig susceptibility
PRRSv infection severity and induced immune response are highly variable between hosts and
PRRSv strains, which probably partly explains the apparent inconsistencies among experimental
results, which usually involve a single strain and few animals [11, 15].
PRRSv strains As many other RNA viruses, PRRSv exhibits a large genetic variability,
which is amongst other things reflected in variation in virulence, interaction with the immune
system and antigenic properties of viral proteins [6, 12]. Virus strains are usually classified as
type 1 or European-like genotype(prototype Lelystad) and type 2 or North American-like (proto-
type VR-2332) genotype, sharing only 55–70% nucleotide identity [23]. European genotypes are
globally less virulent than American genotypes. A high genetic diversity and so various virulence
levels can be found within each genotype [23, 27, 28]. PRRSv virulence level, which determines
the infection severity, is not only related to the global level of the immune response activa-
tion, but also to differences including the relative levels of antiviral over immuno-modulatory
cytokines, neutralising antibodies and cytotoxic T cells levels, suggesting various influences of
PRRSv strains on the immune mechanisms.
Complete viral genome studies of a given PRRSv strain are limited and most studies focused
on a single or a few set of strains [27]. Most of the papers deal with variations in GP5 and N
proteins to explore the PRRSv genetic diversity. Among PRRSv proteins, the non structural
proteins are the most variable among PRRSv strains. They are involved in the interplay between
the virus and the host response, by down-regulating the regulations of interferons and other
cytokines [27].
GP5, the major envelope protein is highly variable, with only 50–55% identity between the
two genotypes. It is involved in inducing neutralising antibodies and different levels of cross-
neutralisation [9]. Because each PRRSv structural protein carries common and type-specific
antigenic determinants, European and North American strains can be differentiated from each
other. The neutralising ability of GP3-specific antibodies is interesting, because the GP3 protein
was reported as a non-structural protein for some North American PRRSv isolates, while it was
described as a structural protein for some European PRRSv isolates [29].
Activated T cells appear to be directed against GP2 to GP7, but their protective role is
virtually unknown [9]. Among the structural proteins of the virus, M and N proteins, followed
by GP4, are the stronger inducers of the cellular response [5]. The M protein is the most potent
inducer of T cell proliferation [9]. For most proteins, T cell epitopes have not yet been identified at
amino acid level. Consequently, it is unknown whether conserved T cell epitopes might provide
cross-protection against different PRRSv strains. Two distinct regions on GP5 for the North
American genotype appear to contain immunodominant T-cell epitopes based on their ability to
stimulate cytotoxic T-cells [9]. These two sites appear to be relatively conserved among American
genotypes.
Host susceptibility PRRSv infection and host immune dynamics differ among pig breeds
[15, 30–34]. For instance, Duroc, Pietrain or Hampshire × Duroc pigs exhibit more severe infec-
tions than Meishan, Miniature pigs and pigs selected for improved reproductive traits [15, 33].
These differences in infection severity are associated with qualitative and quantitative differences
of the immune response. Experimental results suggest that cytokines are key contributors to the
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genetic control of the innate immune response [15, 30]. The more susceptible pigs develop pro-
longed viraemia, with lower titers of neutralising antibodies [32, 35], probably linked to a high
macrophage permissiveness and/or specific cytokine profiles [34].
Synthesis Both viral virulence and pig susceptibility seem linked to (i) the virus capacity to
infect a cell and replicate, (ii) the host capacity to synthesise antiviral vs immuno-modulatory
cytokines in response to PRRSv infection and (iii) the activation and orientation of the adaptive
response. Recent studies hypothesise that these variations of the immune dynamics are due to
cascaded reactions initiated by the macrophage–virus interactions [9, 15, 28, 34].
2.4 Current control strategies
Specific treatments for PRRSv are not available and none of the current vaccines fully protects
against PRRSv infection. PRRSv transmission occurs within and between herds [6, 10]. The-
refore, the objective for PRRSv control is to limit the effect of the virus [6] and to prevent its
spread [10].
In general, fading out of PRRSv infection can be expected in small herds [10]. The probability
of PRRSv persistence at the herd level increases exponentially with increased herd size. Basically,
sufficient numbers of susceptible and infectious pigs are always present to maintain the chain of
infection in the endemic herds with sporadic outbreaks.
Several management techniques implemented to control the PRRSv spread consist in redu-
cing both vertical and horizontal transmissions [10]. Briefly, management techniques aim either
to protect PRRSv-free farms against infected animal introduction or to limit the between-host
transmission and to stop introducing new PRRSv strains in PRRSv-positive farms. Limiting the
between-host transmission requires (among other strategies) the homogenisation of the health
status within PRRSv-positive farms (through sow herd stabilisation, all in/all out batch mana-
gement, medicated early weaning, segregated early weaning and nursery depopulation, as well
as vaccination with incomplete success).
For the chronically infected farms, management strategies aim to reduce vertical transmission
from infected sows and horizontal transmission among pigs in order to decrease pre- and post-
weaning mortality [10]. The PRRSv stable sow herd is characterised by successful stabilisation
of sow herds and seronegative weaned pigs (or sero-positive due to maternal antibidies) and
fattening pigs up to 16 weeks of age. This is the most wanted status with no or possibly low
virus shedding from immunised sows.
Finally, the ultimate status is PRRSv-free, which requires many strict control strategies [10].
Without vaccination, PRRSv was successfully eliminated from positive herds using costly mea-
sures such as depopulation/re-population and later, an intensive surveillance system. However,
a depopulation/re-population method is very costly. It can be used in chronically infected herd
and the partial depopulation/re-population is particularly interesting following early PRRSv
detection in a previously negative herd.
3 Three major issues
If the factors determining PRRSv spread at the herd level are well identified, its control remains
a challenge, as many gaps in the knowledge and the understanding of the within-host dynamics
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during PRRSv infection persist. We focused on three majors issues related to PRRSv within-host
dynamics.
First, the mechanisms determining PRRSv infection duration are still poorly understood
and exhibit a strong variability among PRRSv strains and hosts. Depending on the studies,
various components of the immune response have been highlighted as having an impact on
PRRSv infection duration : (i) the macrophage permissiveness and the viral excretion rate ;
(ii) the levels of antiviral and immuno-modulatory cytokines ; and (iii) the balance between the
cellular (related to the cytotoxic T cells), humoral (related to the antibodies) and regulatory
responses [8]. Clearly,the mechanisms underlying protective immunity have not been firmly
established. Neutralising antibodies are defined as important determinants of immunity, but the
implication of the cellular response is less understood. Further knowledge on the determinants
of neutralising antibodies and cytotoxic T cells by different PRRSv strains is therefore needed
for the development of improved vaccines [9]. Moreover, PRRSv infection in the field involves
various pig susceptibility and potentially various PRRSv strains in the same farm and at the
same time. Consequently, the identification of the immune mechanisms which determine PRRSv
infection resolution whatever (or for various) PRRSv strains and host susceptibilities would
provide significant inputs to better control PRRSv infection. We tackled this issue in Chapter II.
Secondly, as PRRSv is mainly transmitted by direct contact, exploring the impact of variable
PRRSv exposures on the within-host dynamics is a key issue [36–38]. The pig infectiousness and
susceptibility are influenced by several factors, which probably interact in a complex way [39] :
PRRSv strain virulence [8–10, 40], the pig genetic resistance to PRRSv infection [8, 15, 33], as
well as the exposure intensity and transmission route [41–43]. Experimental studies found that
(i) the infectiousness is a log-normal-like function of the time post-infection [41] and that (ii)
PRRSv infection probability is a logistic function of the initial inoculum dose [42]. Studies on
other viruses showed that the initial inoculum dose determines the within-host immune dynamics
and course of infection [36, 37]. However, no such studies were conducted for PRRSv. We tackled
this issue in Chapter III.
Thirdly, current PRRSv vaccines exhibit are not efficient enough to resolve and protect
against PRRSv infection. PRRSv vaccination is a challenge that has been discussed in numerous
studies [8–10, 44]. Increasing evidence is provided that PRRSv uses multiple strategies to evade
the host immune system. Each of them could seriously hamper the adaptive immunity induced
by vaccination. Vaccination strategies anticipating these escape mechanism are warranted. With
regard to PRRSv pathogenesis and immunity there are still a number of unresolved issues that
need to be considered to improve vaccine efficiency. One of these is the contribution of host
susceptibility and strain virulence on the course of infection and the induction of immunity. An
exploration of vaccination efficiency at the within-host scale requires the consideration of such
factors, which can differ between hosts and which impact the within-host dynamics. We tackled
this issue in Chapter IV.
These three issues require an integrative view of the within-host dynamics, detailed enough
to consider the various immune mechanisms involved in infection resolution and immunity. Given
the high complexity of the immune system and the high variability linked to the strain virulence
and host susceptibility, experimental approaches would be limited and expensive. Consequently,
we chose a modelling approach, based on knowledge acquired from experimental approaches.
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4 Our modelling approach
4.1 Why a model ?
Mathematical models are powerful tools to represent and explore the complex mechanisms in-
volved in the infection and immune dynamics [3, 45]. They complement experimental and field
studies. On the one hand, they are based on experimental data. On the other hand, they can
be used to test biological hypotheses or assess the impact of control strategies, which would not
be feasible or would be too expensive by experimental ans field studies. They can also guide
experimentation by identifying key parameters or mechanisms that need further exploration.
Strengths and limits of experimental approaches Recent advances in molecular and
genomic tools have added another dimension to our knowledge base, by providing a detailed
insight of the genes and pathways involved in the host immune response. However, results from
empirical studies are often limited in scope and validity as they are constrained by physical boun-
daries. The stark contrast between the large body of research findings and the sparse translation
of these findings into practical disease control strategies points to substantial knowledge gaps
that need to be overcome. Successful disease control strategies not only require knowledge about
individual components of the host or pathogen dynamics, but also some understanding of the
system as it functions as a whole [46].
Published experimental data on PRRSv infection, reviewed in [5, 6, 8–10, 15, 20, 27, 47],
are highly heterogeneous and differ on : (i) the monitoring duration, (ii) the measured immune
components, (iii) the viral strain and (iv) the pig genotype. Moreover, among the immune
variables assumed to determine the infection resolution, only a few were monitored in each
experimental study and there were few measures over time. Key limitations include : (a) inability
to identify the immune mechanisms which confer an efficient protection over PRRSv infection
whatever the strain and the host ; and (b) inability to extrapolate the immune system efficiency
for a given PRRSv strain and host susceptibility [8].
Strengths and limits of modelling approaches Models are based on knowledge acquired
from experimental approaches and provide a powerful tool to integrate diverse empirical findings
into a holistic quantitative framework [46, 48]. Modelling studies should be develop in close
collaboration with experimentalists [49].
Moreover, models are free from physical constraints, thus enabling to test a wide spectrum
of scenarios that may be difficult to test experimentally. The possibility to calculate the state
of all system components represented in the model for any desired duration of time and at any
desired frequency may provide the information needed to explain the phenomena observed in
empirical studies in which only limited amounts of measurements can be taken.
Finally, models not only help to test hypotheses emerging from experimental studies, but
can also reveal and fill important knowledge gaps leading to the generation of new hypotheses
that can be tested in future experiments.
However, models need to be calibrated validated by comparing simulated and experimental
data. They can consequently not be considered independently from experimental approaches.
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4.2 Which model ?
There are numerous dynamic immunological models in the literature, which describe the evolu-
tion over time, and possibly space, of immune variables and their interactions. We were interested
in developing models that describe the host immune response in a rather comprehensive manner
to account for its complex regulations. The criteria we used to determine our modelling approach,
detailed in Section I.2.1, are (i) the biological scale, (ii) the immune processes represented and
(iii) the mathematical formalism.
Biological scale We focused on the between-cell scale, i.e. we did not detail the intra-cellular
mechanisms but represented between-cell and cell–pathogen interactions. Indeed, an integrative
model at the within-cell scale would include too many processes and an integrative model at the
immune function scale would be too simplified to meet our goals.
Processes represented Our approach corresponds to host–pathogen interaction models des-
cribing the within-host infection and immune system dynamics [50]. Such models represent the
host-pathogen interactions and include at least some immune components from the innate and/or
adaptive response, such as immune cells, cytokine syntheses and regulations, etc. We chose to
represent the dynamics of innate effectors (antigen presenting cells and natural killers) effectors,
adaptive effectors (T cells and antibodies) and major cytokines (pro-inflammatory, antiviral and
immuno-regulatory).
Mathematical formalism We were not interested neither in spatially-explicit models, as we
assumed that the lungs and lymph nodes were both rather homogeneous environments, nor in
individual-based models, which would be too computation-intensive as each cell or free viral
would need to be represented. Moreover, most published models at the between-cell scale are
deterministic continuous time models based on ordinary differential equations (ODE). So we
also chose this ODE formalism.
4.3 Our models
We synthesise here the main points of our models, detailed in Chapter I. We built our models
from the review of immunological knowledge on the within-host dynamics during PRRSv infec-
tion (detailed in Section I.1) and published integrative immunological models at the within-host
and between-cell scales with an ODE formalism (detailed in Section I.2).
These mathematical models were developed to explore the immune and infection dynamics
for various human and animal diseases. However, very few models represent the innate mecha-
nisms explicitly and APC–pathogen interactions need to be better represented in models [51].
There is only one published model applied to PRRSv disease [52], but it does not detail the
immune mechanisms enough to address our issues. Several models describe pathogens targe-
ting APC, such as influenza viruses (reviewed in [45, 51, 53]) and Mycobacterium tuberculosis
(reviewed in [54, 55]). These models focus more on the adaptive than on the innate response,
which is represented in a very simplified manner or even fully ignored. In particular, few of these
models include the immune functions of innate cells explicitly and the cytokine regulations are
simplified. Moreover, none takes into account the regulatory adaptive response.
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We clearly needed to develop adapted models to address our issues. So we propose in this
thesis three original models of the immune response to a respiratory virus infecting APC, applied
to the PRRSv :
1. The first is an integrative model of the immune and infection dynamics in PRRSv first
infection site, the lungs (denoted by Ê in Section I.2). We considered with particular
attention the macrophage–virus interactions. We highly detailed the mechanisms of the
innate response and the cytokine regulations. We included the cellular, the humoral and
the regulatory orientation of the adaptive response, as well as their main functions. We
represented the interactions between innate and adaptive components. This model was
used to address our first issue (Chapter II) : identification of the immune mechanisms that
determine the infection duration, taking into account the variability in pathogen virulence
and host susceptibility.
2. The second is a simplified version of the first model (denoted by Ë in Section I.2). The mo-
difications mainly consist in grouping some variables and using simpler cytokine regulation
functions. This model was used to address our second issue (Chapter III) : exploration of
PRRSv exposure influence on the within-host infection and immune dynamics for various
strain virulence levels.
3. The third and last model is an integrative model of the immune and infection dynamics in
the whole pig (denoted by Ì in Section I.2). It extends the first two models with a detailed
representation of the adaptive response. This extension was required to address our third
and last issue (Chapter IV) : exploration of vaccination strategies at the within-host scale,
taking into account the variability in strain virulence and exposure.
5 Thesis contents
The global objective of this thesis is the exploration of the within-host dynamics to a respi-
ratory pathogen targeting antigen presenting cells by a modelling approach, in the perspective
to better control the pathogen spread.
Background This thesis couples mathematical modelling and immunology and so requires an
overview of each field regarding our objective and our application, the porcine reproductive and
respiratory syndrome virus (PRRSv). Chapter I aims at providing the biological (Section I.1)
and modelling (Section I.2) bases as well as the specificities linked to PRRSv.
Within our global objective, we identified three issues, each addressed in a separate chapter
(II to IV). These chapters can be read separately, but are ordered according to perspective of
coupling immunological to epidemiological approaches to better control PRRSv spread at the
population level.
Infection resolution The first issue, addressed in Chapter II, tackles the immune mecha-
nisms determining the infection resolution of a PRRSv infected pig whatever the PRRSv strain
virulence or pig susceptibility. We built an original and integrative model of the immune res-
ponse in the lung to the PRRSv. This model provides an interesting framework to explore the
macrophage–pathogen interactions for pathogens targeting antigen presenting cells. Our integra-
tive model allowed to simulate contrasted dynamics in terms of immune response and infection
duration, suggesting hypotheses to explain the apparent contradictions between experimental
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data. We also identified some indicators to characterise the immune dynamics and guide the
interpretation of experimental data. This work was published in PLoS ONE (September 2014)
[56].
Exposure The second issue, addressed in Chapter III, tackles the influence of various PRRSv
exposure on the within-host dynamics whatever the PRRSv strain virulence. The exposure in-
fluence has not been fully explored yet, neither in experimental infections, nor in modelling
studies, which mostly represent exposure by a punctual dose. We built designs of numerical
experiments to explore the impact of exposure intensity, duration and peak, as well as strain
virulence, on characteristics of the viral and immune dynamics. We found that the exposure (in-
tensity and duration) strongly impacted various components of the immune response and hence
the viral dynamics. Moreover, the exposure interacted in complex and various ways with the
virulence level. We discussed our results regarding in a prospect of coupling immunological and
epidemiological approaches, the exposure linking the between-host to the within-host dynamics.
This work was submitted to Veterinary Research (October 2014).
Vaccination The last issue, addressed in Chapter IV, tackles vaccination efficiency on the
within-host dynamics, whatever the PRRSv strain virulence and PRRSv exposure. This part
is a preliminary work to illustrate how our model can be used to test the efficiency of current
vaccines and guide the development of more efficient vaccines. The immune response induced
by preventive vaccination was estimated by a model simulation as there is few published expe-
rimental data to inform it. Then the immune response to PRRSv infection of vaccinated and
non-vaccinated pigs were compared. We showed that, depending on the strain virulence and
PRRSv exposure, the vaccination efficiency varied and the immune mechanisms involved were
different.
Conclusion We conclude this thesis, in Chapter Conclusion, by summarising the main results
of our within-host approach, their insights and limits to better understand and control PRRSv
infection. We then discuss prospects offered by extending our approach to multi-strain infections
and immuno-epidemiological models.
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20 Background on the immune response and models
In this thesis, we aim at representing the within-host response to a respiratory pathogen
at the between-cell scale, by a mathematical modelling approach, with a focus on PRRSv.
Prior to presenting our work, we need to provide some background on the immune mechanisms
induced by respiratory pathogens. Because of the scale chosen, we do not detail the intra-cellular
mechanisms, but we focus on the numerous interactions among immune cells and the pathogen,
as well as their regulations. We also need to situate our work among the dynamic immunological
models developed at the between-cell scale. As we want to represent the whole immune response,
we do not consider models that detail specific mechanisms. As PRRSv is a respiratory pathogen
targeting pulmonary macrophages and dendritic cells, which are antigen presenting cells (APC)
with key immune functions, we focus our literature review on respiratory pathogens targeting
APC.
In Section I.1, we synthesise knowledge on the interactions between respiratory pathogens
and the immune system. We present the specificities linked to our application, PRRSv. Then in
Section I.2, we present the most relevant published immunological models. We point out their
interests and limits regarding our objectives and application. Finally in Section I.2.5, we give an
overview of our models, which are used in chapters II, III and IV.
I.1 Immune response to respiratory pathogens targeting antigen
presenting cells
We first give an overview of the main mechanisms involved in the immune response to a pa-
thogen targeting antigen presenting cells (APC) at the between-cell scale (Section I.1.1). Then
we present PRRSv infection at the within-host scale, in terms of pathogenesis, target cells and
infection duration (Section I.1.2). Following these two introductory sections, we detail the inter-
actions between the pathogen and its target cells (Section I.1.3), the innate immune response
(Section I.1.4) and the adaptive immune response (Section I.1.5). In each of these three detai-
led sections, PRSSv specificities are highlighted. Finally we conclude by a synthesis of PRRSv
immune response (Section I.1.6).
Sections I.1.1, I.1.2 and I.1.6 provide a good summary to readers who wish to skip the details
of the immune response. Table I.1 lists the various immune components, their activation and
their immune functions. Table I.3 gives a synthetic description of PRRSv within-host infection
and the immune response to PRRSv.
I.1.1 Immune response at the between-cell scale
Respiratory pathogens, which enter the body through the mucosal surfaces of the respiratory
tract, are responsible for local inflammation and tissue damages. They initiate the infection
and the immune response. The first interaction between the pathogen and the immune system
involves the innate immune system. This first line of defence provides an immediate but non-
specific response. If pathogens successfully evade the innate response, a second layer of protection
is provided by the adaptive immune system, which is activated by the innate response and confers
specific long-lasting protective immunity to the host. The immune system adapts its response
during an infection to improve its recognition of the pathogen. This improved response is then
retained after the pathogen has been eliminated, in the form of an immunological memory,
and allows the adaptive immune system to mount faster and stronger attacks each time this
pathogen is encountered. Innate and adaptive immune cells synthesise cytokines, small extra-
cellular proteins which regulate the immune mechanisms in complex ways.
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The main components of the immune response at the between-cell scale, as well as their
functions and activation/synthesis, are presented in Table I.1. It is based on reviews focusing
on the immune response to a respiratory pathogen targeting antigen presenting cells [1–8].
I.1.1.1 Innate response
The innate response includes anatomical barriers, the inflammation process, the complement
system and innate cells. The innate immune cells mainly consists of antigen presenting cells
(APC), including macrophages and dendritic cells, and natural killers.
Antigen presenting cells (APC) recognise the pathogen through its binding with Toll-like re-
ceptors (TLR), which are pattern recognition receptors directed against key pathogen-associated
molecules. Through the recognition of pathogens or their products, TLR can induce the produc-
tion of cytokines in APC [9]. These cytokines drive the differentiation of the adaptive response.
Pathogens are also captured by phagocytosis via TLR themselves [9]. Captured pathogens are
then processed and presented to naive adaptive T cells as major histocompatibility complex-
–antigen (MHC) [9]. In the cases of pathogens targeting APC, the APC–pathogen interactions
involve either Toll-like receptors or internalisation receptors that initiate the cell infection. Both
ways induce APC activation, but infection can hamper the cell immune functions, which have
consequences on the whole immune response :
• Activated APC participate in the regulation of the immune mechanisms via the synthesis
of various cytokines.
• Activated APC (mainly macrophages) destroy the pathogen via the phagocytosis.
• Activated APC (mainly dendritic cells) partly migrate from the infection site to the lymph
nodes, where they activate the adaptive response via the expression of major histocompa-
tibility complex (MHC).
Natural killers are an important cellular feature of innate immunity. They respond in an
antigen-independent manner to help contain viral infections before the development of adaptive
immune responses [10, 11]. They are responsible for the destruction of infected cells and the
synthesis of IFNγ and TNFα, which are antiviral cytokines [10, 11].
I.1.1.2 Adaptive response
The activation of the adaptive response starts with the activation and proliferation of helper
T cells (also known as CD+4 T cells/lymphocytes). They differentiate into type 1 helper Th1,
type 2 helper Th2, regulatory Treg or memory T cells and they orientate the adaptive response.
• The cellular response is associated with Th1 ; it is characterised by the activation and pro-
liferation of cytotoxic T cells Tc, which destroy the infected cells, and by the synthesis of
the antiviral and immuno-regulatory cytokine IFNγ .
• The humoral response is associated with Th2 ; it is characterised by the synthesis of an-
tibodies A produced by B lymphocytes and by the synthesis of the immuno-modulatory
cytokine IL10.
• The regulatory response is associated with Treg ; it is characterised by the synthesis of the
immuno-modulatory cytokine TGFβ, which inhibits numerous immune functions.
The orientation of the adaptive response towards the cellular, humoral or regulatory response
is determined in a complex way by the cytokine environment.
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Cytokines Cytokines have three major functions :
• Pro-inflammatory cytokines (Pi) amplify the recruitment of innate cells (macrophages, den-
dritic cells and natural killers) to the infection place.
• Antiviral cytokines (%(Ai+IFNγ)) inhibit the cells infection and the viral replication.
• Immuno-regulatory cytokines (Ir) orientate the adaptive response. Among these cytokines,
the immuno-modulatory cytokines inhibit various immune functions.
Table I.1 Overview of the immune response to a respiratory pathogen targeting antigen
presenting cells [1–8].
Component Immune functions Activated by...
Innate effectors
Macrophages (M)
Phagocytosis
(Pi, Av, IL12, IL10) synthesis
Antigen presentation
Pathogen
Dendritic cells (D)
(Pi, Av, Ir) synthesis
Antigen presentation
Pathogen
Natural killers (NK)
Cytolysis
(TNFα, IFNγ) synthesis
IL12, IFNγ
Adaptive effectors
Helper T cells (Th)
Type 1 helper T cell (Th1)
(Tc, BG) activation
(IFNγ , IL2) synthesis
D+(IFNγ , IL12)
Type 2 helper T cell (Th2)
(BG, BM ) activation
(IL4, IL10) synthesis
D+(IL4, IL6)
Regulatory T cell (Treg)
BA activation
(TGFβ , IL10) synthesis
D+(TGFβ)
Cytotoxic T cells (Tc)
Cytolysis
(IFNγ , IL12, TNFα) synthesis
Th1
B lymphocytes (B)
(BM ) IgM antibody synthesis Th2
(BG) IgG antibody synthesis Th1, Th2
(BA) IgA antibody synthesis Treg
(BE) IgE antibody synthesis Th2
Antibodies
Neutralising IgM, IgG, IgA (AN ) Neutralisation BM , BG, BA
Marker IgM, IgG, IgA (AM ) Marking BM , BG, BA
Cytokines
Pro-inflammatory (Pi)
Interleukin-1β (IL1β) (IL6, IL8) synthesis M , D
Tumor necrosis factor (TNFα) (IL6, IL8) synthesis M , D, Tc
Interleukin-6 (IL6) ↗ (M , D, NK) recruitment (M , D)+(IL1β ,TNFα)
Interleukin-8 IL8 ↗ (M , D, NK) recruitment (M , D)+(IL1β ,TNFα)
Antiviral (Av)
Tumour necrosis factor (TNFα)
Cell apoptosis
↗ Antigen presentation, phagocytosis
↘ Cell infection, pathogen replication
M , D, Tc
Colour code : innate, adaptive, innate & adaptive components ↗ amplification, ↘ inhibition
Continued on next page...
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Table I.1 – continued from previous page
Component Immune functions Activated by...
Interferon-α (IFNα)
↗ Antigen presentation, phagocytosis
↘ Cell infection, pathogen replication Infected M , D
Interferon-γ (IFNγ)
↗ Antigen presentation, phagocytosis
↘ Cell infection, pathogen replication D, NK, Th1, Tc
Immuno-regulatory (Ir)
Interleukin 12 (IL12)
(NK, Th1) activation
↗ (Th, Tc) proliferation
↗ IFNγ synthesis
M , D, Tc
Interferon-γ (IFNγ)
(NK, Th1) activation
↗ (IFNγ , IL12) synthesis D, NK, Th1, Tc
Interleukin 6 (IL6) Th2 activation (M , D)+(IL1β ,TNFα)
Immuno-modulatory
Interleukin 4 (IL4) Th2 activation Th2
Transforming growth
factor-β
(TGFβ)
Treg activation
↘ Antigen presentation, phagocytosis
↘ Cell infection
↘ (Th, Tc, B) proliferation
↘ (IFNγ , IL10 by Th2) synthesis
↗ IL10 by Treg synthesis
D, Treg
Interleukin-10 (IL10)
↘ Antigen presentation, phagocytosis
↗ Cell infection
↘ NK activation
↘ (Pi, Av, IL12) synthesis
↗ IL10 synthesis
M , D, Th2, Treg
Colour code : innate, adaptive & innate and adaptive components ↗ amplification, ↘ inhibition
I.1.2 PRRSv infection at the within-host scale
PRRSv induces a prolonged viremia (viral titer in the blood) due to its ability to hamper
the immune response [12–14]. The immune response is not efficient enough to control PRRSv
replication, as the virus has developed a certain number of anti-immune tricks to escape from
elimination.
I.1.2.1 Pathogenesis
PRRSv infection dynamics is not yet fully known [15–17]. However, it is thought that in the
course of PRRSv infection, the virus replicates and persists mostly in the lungs and lymph nodes
[13, 15]. Immunofluorescence techniques allowed to identify three infection steps [16]. First, an
early acute infection predominantly in macrophages of lymphoid tissues and lungs developed
within the first week. Second, a delayed acute infection of the lung was observed, which was
most pronounced during the second and third week post infection. The acute infection of lymph
nodes was resolved at this time. Highly virulent virus isolates reached a peak of infection more
rapidly than isolates with moderate or low virulences. Third, a late persistent infection with
restricted virus replication lasted several months. The virus persisted in lymph nodes and in
the lung, but the viremia was resolved between 28 and 42 days post infection. At this step,
attempts to isolate the virus were in most cases unsuccessful. Indications for a re-occurrence of
acute infection were observed in restricted areas of the lung.
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I.1.2.2 Target cells
Macrophages, particularly Porcine Alveolar Macrophages (PAM), are considered to be the pri-
mary targets for PRRSv infection and replication [13, 15, 18].
PRSSv can also infect dendritic cells. There are several dendritic cell sub-types, including
the conventional Dc and plasmocytoid Dp sub-types, which are supposed to play a key role
in PRRSv infection [19, 20]. Different types of dendritic cells, including bone marrow-derived
and monocyte-derived dendritic cells (Dc model), may support PRRSv replication, whereas the
plasmocytoid dendritic cells (Dp) do not [21–24]. In in vitro PRRSv infections, mature monocyte-
derived dendritic cells are considered as a good model for conventional dendritic cells [21–25].
Plasmocytoide dendritic cells are professional IFNα and TNFα producing cells and these innate
antiviral cytokines are assumed to play a key role for PRRSv resolution [26–28]. Moreover, Dp
ability to synthesise innate antiviral cytokines is altered by PRRSv and seems strain-dependent
[19].
The immune function modulations induced by PRRSv infection are similar for the ma-
crophages and the Dc [27]. The Dc permissiveness to PRRSv is lower than the macrophage
permissiveness [21], but all published studies point out a similar PRRSv replication rate in Dc
and macrophages once infected [21, 22, 25]. PRRSv replication in macrophages occurs within
twelve hours and infected pigs are viremic (virus detected in the blood) 24 hours post infection
[29]. Thus, within one day post infection, the virus is disseminated throughout the body.
I.1.2.3 Infection duration
PRRSv viremia lasts between 28 to 42 days in the blood [14, 15, 26] and around 56 days in
the lung [14]. However, the infection duration is highly variable between pigs and viral strains
and can be higher than 200 days [26, 30]. Comparatively, pig influenza infection lasts around
10 to 14 days and pig foot-and-mouth disease virus infection lasts around 14 to 21 days [26].
Interestingly, viremia is undetectable in the blood of most animals after 28 to 42 days, although
the virus may still be isolated months later in lymph nodes or lung due to continued low-level
replication [31–33]. Consequently, animals can still shed the virus at the end of their infection
period, suggesting an inefficient viral clearance by adaptive response [26]. Comparing the viral
titer data from published experimental studies is tricky as experimental procols exhibit a strong
variability (inoculated PRRSv strain, pig breed, age at infection, monitoring duration, viral
titration method...) as illustrated in Table I.2.
Depending on the studies, various components of the immune response have been highlighted
as having an impact on PRRSv infection duration [26–28] :
• the macrophage permissiveness and excretion rate ;
• the levels of antiviral and immuno-modulatory cytokines ;
• the balance between the cellular, humoral and regulatory responses.
It is well established that PRRSv infection usually induces low levels of innate antiviral cytokines,
in particular IFNα and TNFα, as well as a delayed and inefficient adaptive immune response [26–
28]. In particular, PRRSv infection in pigs leads to a weak and delayed production of neutralising
antibodies [34], as well as a weak cellular adaptive immune response [51].
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I.1.3 Interactions between the pathogen and its target cells
The pathogen recognition through the toll-like receptors (TLR) of APC, which are pattern
recognition receptors directed against key pathogen-associated molecules, initiate the innate
response. When a TLR ligand binds to the receptor, an intracellular signal transduction cascade
is triggered, altering the pattern of gene expression in the cell. Activation of the TLR leads not
only to the induction of inflammatory responses, but also to the development of the adaptive
immunity [9, 10, 52]. The TLR family is known to consist of 10 members (TLR1–TLR10), which
can be divided into five subfamilies : TLR3, TLR4, TLR5, TLR2 (including TLR1, TLR2, TLR6,
and TLR10) and TLR9 (including TLR7, TLR8, and TLR9) [9, 10, 52]. Microbial products such
as peptidoglycan, LPS or flagellin are known to be the ligands of TLR2, TLR4, TLR5 and TLR9
subfamilies, while TLR3, TLR7 and TLR8 subfamilies are related on recognition of viral nucleic
acids [9, 10, 52, 53]. TLR family members are expressed differentially among immune cells and
appear to respond to different stimuli [9, 10, 52].
The interaction between the pathogen and APC involves either internalisation receptors
resulting in the APC infection or TLR resulting in the APC activation. These interactions result
in cascaded reactions within the cell which allow to either induce/promote or block/limit each
immune function. Obviously, from the virus (APC) point of view, the target cell binding should
result in promoting (limiting) the cell permissiveness and the viral replication, while limiting
(promoting) the antiviral immune functions. Pathogens develop numerous strategies to evade
the immune system. For instance, the pathogen internalisation could result in the regulation
of the TLR expression and so modify the APC immune functions, such as cytokine synthesis
or MHC expression, which consequently hamper the whole immune response. Moreover, the
internalisation induces the expression of viral epitopes by APC whithin the MHC, which induce
an adaptive immune response specific to the pathogen, expressing in turn the viral epitopes.
These epitopes can also alter the adaptive immune functions.
When a pathogen encounters a susceptible antigen presenting cell, it activates the cell : the
pathogen is either phagocyted (APC activation through TLR receptors), resulting in pathogen
destruction, or it infects the cell (APC activation through internalisation receptors), resulting in
pathogen replication. Activated APC display a fragment of the pathogen antigen (called epitope)
bound to a major histocompatibility complex (MHC) molecule on their membrane, which can
be recognised and can activate helper T cells. Unless they are infected, activated APC can lose
their activation and revert to a susceptible status. However, infected cells remain infected, i.e.
they cannot eliminate the pathogen.
The dynamics of the pathogen, its target APC and their interactions are regulated by cyto-
kines and immune cells :
• pathogens can be neutralised by antibodies, which prevent cell infection ;
• infected cells can be destroyed by cytolytic cells, i.e. natural killers and cytotoxic lympho-
cytes ;
• APC are subject to apoptosis induced by TNFα [27, 54] ;
• the recruitment of APC to the infection site is amplified by pro-inflammatory cytokines
[1, 10, 55, 56] ;
• the activation of APC through TLR receptors is amplified by antiviral cytokines (TNFα,
IFNα and IFNγ) and inhibited by immuno-modulatory cytokines (IL10 and TGFβ) [52] ;
• the infection of APC, linked to their permissiveness, can be modulated by cytokines. For
instence, APC infection by PRRSv is amplified by IL10 and inhibited by innate antiviral
cytokines (IFNα,TNFα) and TGFβ [13, 41].
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Whatever the pathogen, the infection of APC necessarily impacts their immune functions,
and hence the innate immune response. As APC are responsible for the activation of the adaptive
immune response, their infection has consequences on the adaptive immune response.
I.1.3.1 PRRSv specificities
PRRSv (Arteriviridae family within the genus Arterivirus, order Nidovirales) developed various
strategies to evade the innate immune systems by the regulation of Toll-like receptor expression.
Immune functions of APC PRRSv mainly targets macrophages and so reduces the phagocy-
tosis activity, since infected macrophages cannot phagocyte anymore [57]. PRRSv also increases
the permissiveness of non-infected APC [58]. Moreover, PRRSv replication in infected APC has
multiple effects [13, 26–28, 59–61] :
• it induces apoptosis ;
• it down-regulates the expression of major histocompatibility complex (MHC) ;
• it up-regulates the synthesis of IL10 and IL12 ;
• it down- or up-regulates the synthesis of pro-inflammatory and innate antiviral (TNFα
and IFNα) cytokines depending on experimental results.
However, PRSSv influence on the host ability to synthesise the various cytokines must be inter-
preted with caution, since the absence of one cytokine may influence the production and action
of another.
TLR involved in PRRSv-APC binding Published information about the involvement
or regulation of TLR in PRRSv is limited [13]. TLR3 recognises double stranded RNA and
Nidovirales are known to produce dsRNA which accumulate in the cell during the replication
cycle [13]. In consequence, interactions between TLR3 and PRRSv could be expected. Published
data are divided on the interactions between the various TLR and PRRSv [13]. Some reported
a transient inhibition of TLR3 and TLR7 expression by macrophages and dendritic cells after
in vitro PRRSv infection, whereas in vivo PRRSv infection results suggested the opposite [13].
Liu et al. [62] reported an increase in the expression of TLR3 -– as well as TLR2, TLR4, TLR7
and TLR8 -– in lymphoid tissues of infected pigs and Miguel et al. [63] showed that TL3, TLR4
and TLR7 expression increased in the lymph nodes.
Several TLR including TLR3, TLR7/8 and TLR9 are involved in antiviral responses by
triggering the production of cytokines such as type I interferons (IFN) [64]. PRRSv seems able
to regulate the expression of these TLR, which can explain the observed down- or up-regulation
of innate antiviral cytokines. Moreover, the non-structural proteins (nsp) of the virus is a strong
inhibitor of IFNα production, by inhibiting one part of the pathway of IFNα induction upon
TLR3 activation [13, 26]. As the non-structural proteins are the most variable parts of the viral
genome among PRRSv strains, different PRRSV isolates might interfere differently with TLR3
and may account for the up or down-regulation of the innate antiviral responses [13].
TLR3 seems to be an important element in controlling viral replication : the activation
of TLR3 resulted in a lower PRRSv viral multiplication and conversely, low TLR3 expression
increased the viral replication [13]. Finally, Calzada-Nova et al. [65] indicated that PRRSV failed
to induce secretion of a number of cytokines in plasmocytoid dendritic cells, suggesting some
interference with TLR7 and TLR9 signalling.
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Synthesis To summarise, PRRSv dynamics directly depends on its interactions with the target
cells, but is also impacted by other immune components (antibodies, cells and cytokines) and
impacts other immune components (cells, cytokines). Consequently, PRRSv is linked to the
dynamics of the immune components in a complex way, involving many interactions.
I.1.4 Innate immune response
The host innate immune response plays a key role against early viral infection [61]. The innate
immune response (i) is the first line of defence against a pathogen, (ii) is activated within a few
hours and (iii) is not pathogen-specific. Apart from the physical barriers, the innate response
consists of :
• the pathogen destruction by phagocyting cells, the macrophages and dendritic cells ;
• the infected cell destruction by non specific cytolytic cells, the natural killers ;
• the inflammation induction by the synthesis of pro-inflammatory cytokines and chemo-
kines, which amplify the recruitment of innate cells to the infection site ;
• the inhibition of the target cell permissiveness (i.e. the virus ability to circumvent the
host defences and to replicate) and the pathogen replication by the synthesis of antiviral
cytokines ;
• the complement system, which helps or “complements” antibodies and phagocytic cells to
clear pathogens from the host ;
• the adaptive response activation by the expression of MHC on the APC surface.
The major innate cells are the macrophages, the dendritic cells and the natural killers. Their
functions are detailed below.
Macrophages Macrophages phagocyte and destroy the pathogen. Activated macrophages (ei-
ther phagocyting or infected) synthesise innate cytokines : pro-inflammatory (Pi : IL1β, IL6, IL8),
antiviral (Ai : IFNα,TNFα) and immuno-regulatory (IL12, IL10,TGFβ) cytokines [1].
Dendritic cells The mature dendritic cells polarise the adaptive response via the synthesis
of various cytokines. Their ability to synthesise cytokines differs depending on their sub-types,
the cytokine environment, their activation way (internalisation receptors or TLR), but also
the pathogen strains and the hosts. The conventional Dc and the plasmocytoid Dp dendritic
cells are two major sub-types. The main immune functions of Dc dendritic cells are the an-
tigen presentation to the naive adaptive helper T cells and the synthesis of various cytokines
(IL1β, IL6, IL8, IFNα,TNFα, IL12, IFNγ , IL10,TGFβ). The main immune function of the D
p den-
dritic cells is the synthesis of innate antiviral cytokines (IFNα,TNFα).
Natural killers Natural killers are effectors of the innate response. Their main immune func-
tions are the destruction of infected cells and IFNγ synthesis [1, 10, 11, 66]. These cytotoxic cells
are recruited to the infection site by pro-inflammatory cytokines. Their proliferation and im-
mune functions are activated by several cytokines (IFNγ , IL12, IL15, IL18, IL21, IFNαβ), whereas
IL10 inhibits the natural killer differentiation and their immune functions [66].
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I.1.4.1 PRRSv specificities
An hypothesis to explain the prolonged infection induced by PRRSv is that the viral dynamics is
more determined by the target cell permissiveness and the early events of the immune response
than by the adaptive response mechanisms [51, 67]. The dynamics and mechanisms of virus–host
interactions during the first two weeks post infection are indeed critical for the subsequent
immunological and clinical outcomes. However, our knowledge on virus–host interactions during
this acute infection period is sparse [60]. Previous reports demonstrated various negative effects
of PRRSv on innate immune functions : alteration of the cytolysis function by natural killers,
suppression of phagocytic and antigen presentation activities and alteration of the cytokine
patterns [13, 14, 26–28, 59–61, 68].
Down-regulation of pro-inflammatory cytokine synthesis Pro-inflammatory cytokines
(IL1β, IL6 and IL8) peak around 14 days after PRRSv infection [69]. Pro-inflammatory cytokines
amplify the recruitment of APC to the infection site [12, 70]. In contrast to other viral respiratory
diseases of pigs, production of pro-inflammatory cytokines is limited with PRRSv [71]. Infected
pigs fail to elicit any significant IL1β synthesis in the lung. Most studies found that PRRSv
induces IL8 synthesis. Regarding IL6, some studies indicated production [13, 62, 70], while
others did not [13, 67, 72]. Low expression of pro-inflammatory cytokines has been reported in
pigs infected with type 1 (European genotype) and type 2 (American genotype) PRRSv strains.
Increases in expression of IL1β, IL6 and TNFα in the lungs of pigs infected with type 1 PRRSv
strain are correlated with the development of interstitial pneumonia [69]. There appears to be
a correlation between the virulence of the PRRSv strain, the severity of clinical signs and the
expression of pro-inflammatory cytokines. The ability to synthesise IL8 is highly variable among
hosts ; high abilities have been associated with high host resistances to PRRSv [73].
Down-regulation of IFNα and TNFα PRRSv replication seems to be highly susceptible
to both IFNα and TNFα, but their synthesis by PRRSv-infected pigs is not adequate [12, 13,
70, 74–76]. The down-regulation of IFNα and TNFα is assumed to be a crucial step of PRRSv
pathogenesis [27]. It is postulated that at least one of the mechanisms for viral persistence may
be related to the modulation of IFNα production by PRRSv [77].
IFNα significantly inhibits PRRSv replication [30] and is important for the induction of IFNγ-
producing adaptive immune cells [78]. Interestingly, the expression of IFNα in PRRSv infected
pigs reaches its maximum expression after the viremic phase [69], suggesting an inhibitory effect
of PRRSv on IFNα production. In some studies, IFNα was not detected in the lungs of pigs where
PRRSv is actively replicating. In addition, PRRSv-exposed plasmocytoid dendritic cells (Dp),
the major IFNα producer following viral infection, fail to induce IFNα production. Different
PRRSv isolates appear to have different abilities to induce or inhibit IFNα synthesis by D
p [79].
Most PRRSv strains are weak inducers of TNFα [28]. Some PRRSv strains induce the syn-
thesis of TNFα at variable levels, whereas others fail to induce TNFα synthesis [80]. TNFα
plays an important role in the inflammatory and antiviral responses, protecting cells from infec-
tion against viruses or enhancing selective elimination of virus-infected cell. In vitro infections
showed that TNFα inhibited PRRSv replication and that PRRSv-infected macrophages had
reduced expressions of TNFα. Moreover, the percentage of macrophages was reduced by 40% 48
hours post infection [81] and most apoptotic cells (induced by TNFα) were non-infected macro-
phages [82, 83]. Even if low levels of apoptosis are encountered in in vivo experiments, it plays
an important role in the PRRSv infection [82].
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Up-regulation of IL10 Most studies indicate that PRRSv up-regulates the synthesis of IL10
[13, 21, 22, 70, 77, 84, 85]. However, some studies found no significant IL10 response to PRRSv
infection [25, 86]. The host ability to synthesise IL10 is highly variable between hosts and PRRSv
strains : highly virulent strains and highly susceptible pigs exhibited high levels of IL10 [28, 49,
59, 80]. A transcriptional analysis of PRRSv-infected macrophages [87] and dendritic cells [21]
revealed IL10 up-regulation only few hours post infection. Different viral strains were able to
induce different IL10 responses in macrophages of PRRSv-naive pigs [67] and the stimulation of
dendritic cells with different type 1 strains (European genotype) induced different IL10 syntheses
[24].
Most papers suggest that IL10 plays a crucial role in PRRSv infection. IL10 is responsible
for the inhibition of pro-inflammatory and antiviral cytokines [69], it inhibits the phagocytosis
by macrophages and the dendritic cell activation and it amplifies the APC permissiveness to
PRRSv [13, 60, 88]. IL10 concentration and PRRSv replication rate are strongly correlated [69].
IL10 may be involved in the inhibition of TNFα gene expression in PRRSv-infected pulmonary
macrophages [87]. In an in vitro experiment, the neutralisation of IL10 resulted in an enhanced
production of TNFα by macrophages co-cultured with PRRSv [85]. However, another in vivo
experimental study found that, depending on the PRRSv strain, infected pigs were able to
synthesise IL10, TNFα or both [80]. These experiments suggest that low levels of TNFα synthesis
are not always due to IL10.
Down-regulation of natural killers The modulation of the innate immune response in
PRRSv-infected pigs under field conditions is associated with a decrease in the cytotoxicity, but
not in the percentage of natural killers (NK) [12, 89]. Their concentration starts increasing five
days post infection [12]. The reduced cytotoxic function of NK cells is associated with increased
plasma concentrations of IL4, IL10 and IL12, suggesting a role for these cytokines in modulating
the host immune response [89].
Down-regulation of MHC expression MHC are required for the adaptive response acti-
vation. The effects of PRRSv on the expression of MHC are far from being clearly understood.
Dendritic cells are the best cell type for examining such effects, since they are the major an-
tigen presenting cells. PRRSv replication in dendritic cells down-regulates the expression of
MHC [21, 22, 25]. As a consequence, the adaptive response to PRRSv is likely to be delayed
or even deficient. It has been previously shown the IFNα together with TNFα induce an ef-
fective up-regulation of MHC expression [90]. The presence of exogenous recombinant porcine
IFNα could reverse the down-regulation of MHC by PRRSv infection [32]. The secretion of IL10
down-regulates MHC expression, as do costimulatory and other surface molecules that induce
depressed antigen presentation and a suppressed immune response [22].
I.1.5 Adaptive immune response
The adaptive immune system is considered as determining for the infection resolution against
numerous pathogens. The adaptive immune response (i) is triggered when a pathogen evades the
innate immune system, (ii) is delayed compared to the innate response and (iii) is composed of
highly specialised cells and processes that eliminate or prevent pathogen growth. The adaptive
response consists of :
• the helper T cells, which orientate the adaptive system towards the cellular, humoral or
regulatory responses (detailed below) ;
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• the cellular response, characterised by cytotoxic T cells, which destroy infected cells (de-
tailed below), and by the antiviral cytokine IFNγ ;
• the humoral response, characterised by antibodies, which either mark the pathogen and
infected cells or neutralise the pathogen (detailed below), and by the immuno-modulatory
cytokine IL10 ;
• the regulatory response, characterised by TGFβ, an immuno-modulatory cytokine which
inhibits numerous immune functions ; the regulatory response down-regulates the functions
of immune effector cells and hence suppresses excessive responses that could harm the host
more than the pathogen itself.
The major adaptive cells are the helper T cells, the cytotoxic T cells and the B lymphocytes.
Their functions are detailed below, as well as the role of memory cells and immunity.
Helper T cells [1–8, 91, 92]
Naive helper T cells are activated by mature dendritic cells via a major histocompatibility
complex, resulting in the expression of T CD4 membrane proteins and the synthesis of IL12. Then
helper T cells proliferate and this proliferation is amplified by IL12 and inhibited by TGFβ. CD
+
4
T cells differentiate into effectors or memory cells. The three main effectors are the type 1 helper
(Th1), type 2 helper (Th2) and the regulatory (Treg) T cells. TNFα induce Th apoptosis.
The mechanisms determining the differentiation towards the various effectors are not yet
fully identified, but differentiation was shown to depend on the cytokine environment [3, 6, 8].
• Differentiation towards Th2 seems to be the default and is amplified by IL4 [3]. IL6 blocks
the differentiation towards the other two orientations. Th2 synthesise IL4 and IL10 cytokines
and induce the synthesis of IgG, IgE and IgM antibodies by B lymphocytes.
• Differentiation towards Th1 is induced by IL12 and amplified by IFNγ . IL12 synthesis by
dendritic cells is amplified by IFNγ and inhibited by IL10. Th1 synthesise IFNγ and IL2,
induce the activation of cytotoxic lymphocytes Tc and the synthesis of IgG antibodies by
B lymphocytes.
• Differentiation towards Treg is induced by TGFβ. Treg are responsible for the synthesis of
two immuno-modulatory cytokines, IL10 and TGFβ and the synthesis of IgA antibodies
by B lymphocytes.
Differentiation was also shown to depend on dendritic cell subsets CD8α+ or CD8α− [3]. CD8α+
dendritic cells induce the activation of cells secreting IL12 and IFNγ and so polarise Th towards
Th1, whereas the other subset CD8α
− induce the activation of cells secreting high levels of IL10,
IL4 and IL5 and so polarise Th towards Th2. CD8α
+ drive the development of Th1 through the
production of IL12. However, whatever the dendritic cell subset, the cytokine environment can
determine the Th differentiation [3]. For instance, the absence of IFNγ or IL12 results in the
induction of Th2 by the CD8α
+ subset and the absence of IL10 results in the induction of Th1by
the CD8α− subset. Consequently, the differentiation of Th induced by the dendritic cell subsets
depends on their ability to synthesise the various cytokines, which is in turn influenced by the
cytokine environment.
Another helper T cell, Th17, was identified more recently [93, 94]. Th17 cells, which produce
proinflammatory cytokine IL17, play an important role in the induction of inflammation [94].
Th17 and Treg differentiation are interconnected [93]. The differentiation towards Treg requires
the presence of TGFβ. However, in the presence of TGFβ plus IL6, the helper differentiation
switches to Th17 [93]. Moreover, high levels of TGFβ seem to inhibit the differentiation towards
Th17, which then requires IL1β and IL6 cytokines [94]. Th17 were proposed as a pathogenetic
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mechanism in autoimmune diseases and acute transplant rejection. In contrast, Treg cells play
central roles for immunoregulation and induction of tolerance [94]. Treg cells are now known to
inhibit proliferation and cytokine production in both CD4+ and CD8+ T cells, antibody produc-
tion by B cells, cytotoxic activity of natural killers and maturation of dendritic cells, resulting
in the induction of tolerance [94]. Various pathogens, including Mycobacterium tuberculosis, can
trigger a strong Th17 response [93].
Cytotoxic T cells [6–8]
Cytotoxic T cells (Tc) express the CD8 glycoprotein at their surface and are a also known
as CD8+ T cells. The naive Tc are activated by licensed dendritic cells. The dendritic cell
licensing is a preliminary step consisting in the binding of an activated dendritic cell and a
Th1 ; it results in the expression of dendritic cell membrane proteins which allow the binding
of licensed dendritic cells to naive Tc. Then Tc proliferate, amplified by IL12 and inhibited by
TGFβ. Tc are responsible for the synthesis of two antiviral cytokines, IFNγ and TNFα, and for
the destruction of infected cells by cytolysis. TNFα induces Tc apoptosis.
B lymphocytes and antibodies [6–8]
The preliminary step for the activation of a naive B lymphocyte is the binding with a free
viral particle, inducing the expression of MHC by the B lymphocyte. The B lymphocyte then
becomes a plasmocyte by binding to a Th cell, which induces cytokine syntheses by the Th cell.
Plasmocytes proliferate and differentiate into effector or memory plasmocytes. The proliferation
of effector plasmocytes is inhibited by TGFβ. Effector plasmocytes first secrete IgM antibodies
(Ig for immunoglobulin). Depending on the cytokines synthesised by Th (i.e. depending on
the Th sub-type : Th1, Th2 or Treg), the effector plasmocytes then switch to secrete one of the
following antibody isotypes : IgG, IgA or IgE. IgM-secreting plasmocytes (BM ) require IL2 or IL4
, produced by Th1 or Th2 lymphocytes. Switching to IgG-secreting plasmocytes (BG) requires
IFNγ , IL4 or TGFβ, produced by Th1, Th2 or Treg lymphocytes. Switching to IgA-secreting
plasmocytes (BA) requires TGFβ, produced by Treg lymphocytes. Switching to IgE-secreting
plasmocytes (BE) requires IL4, produced by Th2 lymphocytes.
Antibodies can have either a neutralising or a marking function. Firstly, antibodies can
directly neutralise the pathogen and prevent cell infection. For instance, by binding to the virus,
they can block the uptake into cells or cause aggregation of virus particles. Secondly, antibodies
can mark the pathogen : by binding to surface antigens, they facilitate the pathogen phagocytosis
by APC (opsonization) ; marker antibodies can also activate the complement system and directly
cytolyse the pathogen . Finally, antibodies can mark infected cells : they facilitate the binding
of cytotoxic cells to infected cells and hence amplify the cytolysis (ADCC : antibody-dependent
cell-mediated cytotoxicity).
• IgM appear at an early stage of the humoral response and circulate in blood serum. They
mainly activate the complement system as marker antibodies, but they can also clump
and hence neutralise pathogens (agglutination).
• IgG are the most abundant antibodies, found in serum and other extra-cellular fluids. They
are versatile immunoglobulins, as they have neutralising and marking functions.
• IgA are found in mucosal areas such as the gut, the respiratory tract and the urogenital
tract, as well as in mucous secretions such as tears, saliva, sweat and colostrum. Their
main function is to neutralise the pathogen, but they are also involved in ADCC.
• IgE are the least abundant antibodies and are mainly involved in allergic reactions.
• Little IgD is produced at any time. The role of IgD is uncertain.
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Memory, vaccination and immunity During their proliferation phase, activated T cells
and B lymphocytes differentiate into effector and memory cells. These memory cells are long-
lived and pathogen-specific. They confer active long-term immunity to the host. When the host
is re-infected by the pathogen, due to these memory cells, the adaptive response is stronger and
builds up faster.
Active immunity can also be induced by vaccination. Vaccines challenge the host with the
pathogen antigen and so trigger the immune response to the pathogen, but they do not cause the
disease. Most vaccines are based on live attenuated pathogens (especially for viruses), inactivated
pathogens or fragments of the pathogens. Vaccines do not always induce a strong adaptive
immune response. Their efficiency may be improved by the addition of adjuvants, which activate
the APC.
Passive short-time immunity is acquired from the transfer of maternal antibodies across the
placenta (IgG) or by colostrum intake (IgG and IgA) for humans. Concerning pigs, the transfer
of maternal antibodies occurs only by colostrum intake and mainly consists of IgA and in a
lesser extend IgG antibodies. Passive immunity protects the young host against infection until
its immune system can produce its own antibodies. It lasts up to a few months.
I.1.5.1 PRRSv specificities
A dominating concept of the immunopathogenesis of PRRSv infection is the immunosuppression
or dysregulation of the adaptive immune response. PRRSv infection in pigs leads to a weak
cellular immune response, as well as a delayed production and low titers of neutralising antibodies
while the humoral response is highly activated [13, 14, 26–28, 59–61, 68]. While neutralising
antibodies can control the spread of the free viral particles, Tc are needed to eliminate virus-
infected cells. Overall, there is insufficient information as to whether and to which extent the B
cell or the T cell systems are affected by PRRSv [61].
The characteristics of the adaptive response to PRRSv and the hypotheses proposed to
explain the prolonged viremia are detailed below, based on the most recent reviews [13, 14, 26–
28, 59–61, 68].
Weak and delayed cellular response activation The induction of virus-specific cytotoxic
T lymphocytes Tc in PRRSv-infected pigs is very weak and slow to develop. A transient T cell
response is detected between 4 and 12 weeks post infection and lasts two to three additional
months. However, the long-term persistence of the virus in the host suggests that the cellular
response is ineffective. Moreover, a live attenuated PRRSv vaccine that induced high titers of
cytotoxic T cells protected pigs against viremia [27]. Consequently, it appears that the cellular
response could be protective against PRRSv, but it is too weakly activated.
In general, the cellular response is the most efficient response against viruses because (i) IFNγ
reduces the target cell permissiveness and the viral replication and (ii) Tc kill infected cells and
stop the generation of new viral particles. However, increasing the Tc level may not significantly
improve PRRSv infection resolution [61]. Furthermore, Tc cells are difficult to track, in vitro and
in vivo [61]. In practice, the activation level of the cellular response is deduced from the levels
of IFNγ , as Tc and Th1 are the major IFNγ-producing cells. Reported IFNγ levels induced by
PRRSv infection are usually low, whereas IL10 levels are high. IL10, synthetised by APC, Th2
and Treg, is a potent immunosuppressive cytokine that interacts with numerous immune cells,
resulting in the inhibition of the innate and adaptive responses and most particularly of the
cellular adaptive response. This suggests that PRRSv is capable of shifting the immune response
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towards a less effective Th2-mediated immune response, explaining the low cellular response and
hence the prolonged infection. However, this conclusion may not always hold, since the synthesis
of IFNγ is highly variable between hosts : a high IFNγ synthesis ability is associated with a high
pig resistance to PRRSv. Moreover, the different capacity of PRRSV strains to induce protective
immunity is assumed to depend on their different capacity to induce a strong cellular immune
response [72]. Among the structural proteins of the virus, M and N proteins followed by GP4
are the stronger inducers of IFNγ responses [13].
Significant but inefficient humoral response PRRSv infection produces abundant antibo-
dies in the infected animal, detectable from day 5 post infection (pi). Initially, antibodies mostly
belong to the IgM class. Day 21 pi, a switch towards a predominance of IgG is noticeable. Howe-
ver, PRRSv antibodies are mostly marker antibodies. Neutralising antibodies appear between 2
and 4 weeks pi, persist at low levels and may not peak until 10 to 18 weeks pi [12, 13, 68]. PRRSv
neutralising antibodies block the infection by preventing the interaction of the virus with the
sialoadhesin internalisation receptor on macrophages [95]. Failure to produce neutralising anti-
bodies is not a direct consequence neither of the low adaptive response activation (antibodies are
abundant), nor of its orientation towards the humoral response (which favours antibody produc-
tion), so it is probably due to the virus itself. Indeed, delay in the neutralising antibody response
to PRRSV has been postulated to be due to the presence of a nearby immunodominant decoy
epitope [96], which may evoke a robust, early, and non-protective immune response that masks
or impairs the response to the major neutralising epitope [27]. Early antibodies (which are de-
void of neutralising capacity) are directed against the nucleocapsid and non-structural proteins
(nsps), whereas antibodies against M protein and GP5 develop later [27]. Because each of the
PRRSV structural proteins carries common and type-specific antigenic determinants, European
and North American strains can be differentiated from each other [27].
Neutralising antibodies play a critical role in immunological control of a wide variety of viral
infections in general and are believed to be crucial for PRRSv as well [97, 98]. However, a variety
of studies show that PRRSv viremia is often resolved before neutralising antibodies are detected
[68]. Moreover, PRRSv can be isolated from blood of pigs which have neutralising antibodies
[27, 72]. Animals lacking neutralising antibodies are sometimes resistant to re-infection [67]. It
is clear that porcine neutralising antibodies are not essential for PRRSv immunity and their
precise role in the clearance of the primary infection and in the prevention of reinfection is
uncertain [26, 27].
Furthermore, antibodies could be responsible for an antibody-dependent enhancement (ADE)
of viral replication [99] : non-neutralising antibodies mark the virus and facilitate its internalisa-
tion into the macrophages, where it replicates. The epitopes responsible for inducing antibodies
participating in ADE would be located in the N protein and in GP5 [13].
Regulatory response Studies looking into the role of Treg in PRRSv infection were recently
published, but they are still few results [13, 20, 24, 26, 41, 60, 61, 100]. TGFβ-dependent induc-
tion of Treg by PRRSv-infected dendritic cells was reported and the infection of dendritic cells
seemed sufficient to induce Treg [24]. PRRSv prolonged infection duration, the weak activation
of the immune response and the fact that the infection can be extremely persistent in very young
pigs have been considered as indirect evidences of an active regulatory response [13]. Indeed,
Treg inhibits numerous immune functions and hence contribute to delaying the clearance of the
infection.
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An experimental infection by an American PRRSv strain induced Treg starting 28 days post
infection [100]. Interestingly, the Treg concentration and the viremia were positively correlated.
This suggests that Treg could be involved in the persistence of the infection. However, regulatory
T cells induced by genotype 2, but not genotype 1, impair the host immune response [20, 24, 100].
Although genotype 2 increases the percentage of Treg, its effect on the immune response in vivo
is not yet clear [41]. Differences were in the ability of genotype 1 (European) and genotype 2
(American) strains to generate Treg. This suggests that different PRRSv strains induce various
regulatory responses.
Infection by an American PRRSv strain induced the synthesis of TGFβ and IL10 by Treg
[100]. The capacity of PRRSv to modulate the immune response through the infection of APC,
in particular the enhanced synthesis of immuno-modulatory cytokines (IL10 and TGFβ), can
promote the induction and maintenance of Treg. Whereas no increase in TGFβ expression was
reported after vaccination or infection with European PRRSv genotypes [20, 67], an increase in
TGFβ expression was observed in infections with North American genotypes [24]. The expression
of TGFβ may either favour or hinder the onset of an efficient host immune response [41]. On the
one hand, TGFβ may be able both to avoid over-production of pro-inflammatory cytokines at
the tissue level and to hinder PRRSv replication by down-regulating the expression of PRRSv
internalisation receptors. The late regulatory response would then be responsible for limiting
the inflammation and hence protecting the host against severe PRRSv infection. On the other
hand, TGFβ may impair the host immune response by (i) inhibiting an efficient expression of
antiviral cytokines, and/or (ii) inducing the differentiation of Th towards Treg. Experimental
results suggest that that PRRSv-infected APC promote the synthesis of IL10 and/or TGFβ
[41]. Consequently, the early immune mechanisms would be responsible for the inefficient host
immune response and the induction of Treg cells, which in turn maintain the immuno-modulatory
cytokine environment.
Concerning Th17, the presence of IL17 secreting lymphocytes in the lung and peripheral blood
of pigs was reported [101]. However, we found no information about Th17 during PRRSv infection
so we neglected them.
I.1.6 Synthesis of the immune response to PRRSv
Immune response to PRRSv is characterised by a weak innate response associated with (i)
a high inflammation, (ii) a low phagocytosis activity, (iii) a down(up)-regulation of antiviral
(immuno-modulatory) cytokines, (iv) a high PRRSv replication rate, (iv) a down-regulation
of natural killer functions and (vi) a down-regulation of MHC expression in APC. All these
regulations result in an inefficient adaptive response associated with (i) a weak and delayed
cellular response, (ii) a high but inefficient humoral response with low neutralising antibodies
and (iii) the regulatory response activation, which maintains low levels of antiviral cytokines
and high levels immuno-modulatory cytokines. A synthetic summary is provided in Table I.3.
The impairment of the immune response evoked during PRRSv infection is one of the major
paradigms of the immunology in the modern research of porcine diseases. Several efforts are being
conducted to elucidate the mechanisms used by the virus to evade the host immune response.
Some published studies assume that neutralising antibodies and the antiviral cytokine IFNγ
have protective functions [13]. However, the vaccine efficiency against PRRSv does not seem to
depend on its ability to induce either neutralising antibodies or IFNγ [68]. Vaccines promoting
the IFNγ synthesis allow to increase the activation of the adaptive response [12]. Nonetheless,
these assumptions remain controversial, partly due to the high variability of the immune response
depending on the PRRSv strains and hosts.
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Table I.3 Synthesis of the within-host infection and immune response induced by PRSSv,
focused on PRRSv specificities.
Porcine Respiratory and Reproductive Syndrome virus (PRSSv)
Infection long and variable, persistence of the virus in the lungs and lymph nodes
Duration between 28 to 42 days in the blood, around 56 days in the lungs
Variability in host susceptibility, depending on the host genotype and housing conditions ;
in pathogen virulence, with generally moderately virulent genotype 1 strains (Euro-
pean) and highly virulent genotype 2 strains (American)
Target cells pulmonary macrophages (M) & conventional dendritic cells (Dc), which are antigen
presenting cells (APC)
Innate response impaired by the infection of APC
High levels of pro-inflammatory cytokines (IL1β, IL6 and IL8) → high severity of clinical si-
gns
Low levels of innate antiviral cytokines (IFNα and TNFα) → high target cell permissiveness,
high replication rate, low target cell apoptosis and MHC expression
High levels of immuno-modulatory cytokine IL10 → low levels of antiviral and pro-
inflammatory cytokines, low phagocytosis rate, high target cell permissiveness
Low MHC expression in APC → low activation of the adaptive response
Adaptive response weakly activated by the innate response, whose low (high) levels of antiviral
(immuno-modulatory) cytokines promote the humoral response
Weak and delayed cellular response activation → low infected cell destruction & low levels
of adaptive antiviral cytokines
Significant but inefficient humoral response → low neutralisation of PRRSv, high levels of
adaptive immuno-modulatory cytokines, antibody-dependent enhancement (ADE) of
viral replication
Regulatory response activation → limitation of inflammation, cell permissiveness, antiviral
cytokines, adaptive cell proliferation, amplification of immuno-modulatory cytokines
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I.2 Immunological models for respiratory pathogens targeting
APC
We singled out three main issues to be addressed in this thesis by a modelling approach (Sec-
tion 3), i.e. identify the immune mechanisms that determine the infection duration (Chapter II),
study the exposure impact (Chapter II) and explore vaccine efficiency (Chapter IV), in a host
and strain variability context. So we scanned the literature to find models on which we could
base our studies.
We first describe the criteria we used to determine the most relevant models to meet our
goals (Section I.2) and present the models hence identified in the literature (Table I.2). Then
we synthesise the immune components and mechanisms included in the selected models. To this
end, a series of synthetic tables are provided and commented. They describe the interactions
between the pathogen and its target cells (Section I.2.2 and Table I.5), the regulations by
immune cells (Section I.2.3 and Table I.6) and the cytokine regulations (Section I.2.4 and
Table I.7). Finally, we present the broad lines and characteristics of the three models we
developed (Section I.2.5) : the lung-based model published in [102], presented in Chapter II
(denoted by Ê), the simplified lung-based model presented in Chapter III (denoted by Ë) and
the within-host model presented in Chapter IV (denoted by Ì). These three models are described
in the above-mentioned synthetic tables, along with the selected models, so as to situate them
among the literature.
We based our model review on immune components and mechanisms that characterise
PRRSv within-host infection and immune dynamics (Section I.1.6) and that we deemed re-
levant to meet our goals. However, the models we selected from the literature were developed
to address different issues. When discussing their features in terms of immune components and
mechanisms represented, we do not assess the relevance of the models to address their issues,
but their relevance to achieve our goals.
I.2.1 Model selection
There are numerous dynamic immunological models in the literature, which describe the evolu-
tion over time, and possibly space, of immune variables and their interactions. We are interested
in developing models that describe the host immune response in a rather comprehensive manner
to account for its complex regulations, at the between-cell scale, in the lung and the lymph
nodes. The criteria we used to select the most relevant models in the literature are, i.e. : (i) the
biological scale, (ii) the immune processes represented and (iii) the mathematical formalism. We
had to add an extra criterion, (iv) the pathogen, to identify a reasonable number of models.
Biological scale The spectrum of mathematical models representing host–pathogen interac-
tions, in particular immunological processes, is extremely rich [103–107]. Narang et al. [107] give
a global and comprehensive overview of the immunological modelling field. Published immuno-
logical models proceed from a fine view, representing immune mechanisms at the molecular and
gene/protein scales, to a large and integrative view, representing the immune response at the or-
ganism or population scale [107]. Finer scales are adapted to explore intra-cellular mechanisms,
such as the recognition of pathogen molecular patterns by immune cells or the phagocytosis of
the pathogen by macrophages. Larger scales are adapted to explore the immune mechanisms
determining the infection resolution at the within-host scale or the pathogen spread in the host
population, considering different strains and host conditions.
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Our approach is clearly at an intermediate scale, considering the immune mechanisms at the
between-cell scale. Integrative model at the within-host scale would include too many processes
and an integrative model at the immune function scale would be too simplified to meet our goals.
However, representing the immune response at the between-cell scale may require the integration
of phenomena at finer scales, for instance for the up- and down-regulations by cytokines. At the
finer scale, gene expression in response to activators and inhibitors is described using Michaelis–
Menten enzyme kinetics and the Hill function. These equations reproduce the characteristic
sigmoid-shaped dynamics of gene transcription. At a larger but cell-based scale, models do not
represent these mechanisms explicitly, but usually consider sigmoid-shaped cytokine regulation
functions based on a Michaelis–Menten formalism [108–110].
Processes represented The most basic model of the immune response to a pathogen repre-
sents the interaction between free pathogen particles and their target cells [111] : susceptible
cells (target cells) become infected when they encounter the pathogen ; infected cells produce
new pathogen particles and die. Such a model is too simplified to meet our goals.
Indeed, PRRSv mainly targets pulmonary macrophages, a key component of the innate
immune response, and hence alters the innate and subsequent adaptive immune responses in
complex ways (Section I.1.6). Moreover, immune mechanisms responsible for the infection reso-
lution and host protection are strongly variable between hosts and PRRSv strains. To identify
the mechanisms that determine the infection duration or to explore vaccine efficiency in a host
and strain variability context, components of the innate and adaptive responses need to be
included in the models.
Mathematical formalism Some immunological models explicitly represent the space and
follow the evolution over time and space of the immune variables [112]. These model usually
require the use of partial differential equations [113]. PRRSv infection is mainly localised in
the lungs and lymph nodes. The bloodstream links the two infection sites. We assume that the
lungs and lymph nodes are both rather homogeneous environments, in terms of immune cells,
antibodies and cytokines. Moreover, the circulation in the bloodstream is fast. Therefore, we can
neglect PRRSv within-host spatial dynamics and focus on the temporal dynamics to address
our issues.
Some immunological models are individual-based models (IBM, i.e. agent-based models,
cellular automata). These computer science models consist of a set of individuals, each individual
being characterised by a number of variables. Individuals interact and their characteristics evolve
over time (and space) according to given rules. These models are quite intuitive but would
require intensive computation at the between-cell scale, as each cell or free viral particle would
be considered as an individual. These models could fit our criteria in terms of biological scale
and processes represented, but their formalism is too far from our modelling choice.
IBM generally are stochastic discrete time models, but most immunological models are conti-
nuous time deterministic models. We assume that the immune response to PRRSv infection at
the within-host scale is determined for a given strain virulence, host susceptibility and viral
exposure. Consequently, we selected continuous time deterministic models.
Such models consist of a set of ordinary differential equations (ODE). Each ODE describes
the evolution of an entity, called state variable, over time (e.g. the concentration of pathogen
particles during the infection duration). The equation represents the processes that affect the
state variable in the course of time, such as production and decay processes of the state variable,
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as well as interactions with the other state variables. Equations include parameters, which are
usually constant over time (e.g. the viral excretion rate).
Pathogen As we only identified one PRRSv model meeting the criteria described above [114],
we broadened our search to similar pathogens, i.e. respiratory pathogens targeting antigen pre-
senting cells. So we also considered models representing the infection and immune dynamics
induced by Mycobacterium tuberculosis, the usual bacteria that causes TB, and influenza vi-
ruses. As a sideline, this allows us to gain on genericity in our modelling approach.
Models selected We identified six models on Mycobacterium tuberculosis infection [109, 110,
115–118], reviewed in [108, 112] ; eight models on influenza virus infection [119–126], reviewed
in [113, 127–129] ; and only one study on PRRSv infection (our models excepted) [114]. These
models, plus our three PRRSv models, are presented in Table I.4.
I.2.2 Pathogen-target cell interactions
In Section I.1.3, we pointed out the importance of the interactions PRRSv and antigen presenting
cells for the infection dynamics. Among the selected published models, the level of detail of the
immune mechanisms involved in these interactions is highly variable (Table I.5).
Epithelial and antigen presenting cells are target cells for influenza viruses [130]. However,
among the selected models, the infection of APC is not represented and only three out of
eight models incorporate these cells [119, 120, 122]. Macrophages are the only target cell for
Mycobacterium tuberculosis, so all six Tb models represent macrophage infection and three
of them also consider dendritic cells [109, 116, 118]. The only PRRSv model (ours excepted)
represents macrophages but not dendritic cells [114].
Almost all models represent pathogen replication. Among the ten models that incorporate
APC (ours excepted) [109, 110, 114–120, 122], the immune functions represented vary, with slight
differences in the status of the immune cells involved. Eight out of ten models represent antigen
presentation, but only five phagocytosis (Tb models). All ten models consider the production
of antiviral cytokines, six only the production of immuno-regulatory cytokines (Tb models) and
none the production of pro-inflammatory cytokines.
Consequently, from the pathogen–APC point of view, the selected Tb models globally fit our
needs, except for the inflammation process which could play a key role during PRRSv infection
(Section I.1.4).
From this same point of view, our three models are understandably quite comprehensive.
They dot not include a resistant status for APC as found in [114], but they allow to regulate their
permissiveness according to the host susceptibility or PRRSv strain virulence. Our lung-based
models (Êand Ë) do not represent the dendritic cell dynamics, but their functions are globally
represented. This particular point is discussed in more details in Section II.4.
I.2.3 Regulations by immune cells
PRRSv and APC dynamics are regulated by cellular innate effectors (natural killers), by cellular
and humoral adaptive effectors and by antibodies, which are assumed to play a key role in PRRSv
infection resolution (Section I.1.3). The inclusion of these immune cells and antibodies is highly
variable among selected published models (Table I.6).
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Table I.4 Selected immunological models at the between-cell scale for influenza viruses
(Iv), Mycobacterium tuberculosis (Tb) and Porcine Reproductive and Respiratory Syndrome virus
(PRRSv). The biological scale, the number of variables and the number of parameters are indicated
for each model.
References Biological scale # Variables # Parameters
Human, mice or horse infection with influenza viruses (Iv)
Bocharov and Romanyukha, 1994 [119] Whole organism 13 54
Hancioglu et al. 2007 [120] Whole organism 10 27
Lee et al. 2009 [122] Lung + lymph nodes 15(5+10) 48
Handel et al. 2010 [121] Whole organism 7 13
Tridane and Kuang, 2010 [124] Epithelium 5 10
Miao et al. 2010 [123] Lung 3 9
Saenz et al. 2010 [125] Whole organism 8 11
Palwelek et al. 2012 [126] Whole organism 5 9
Human infection with Mycobacterium tuberculosis (Tb)
Wigginton and Kirschner, 2001 [110] Lung 12 66
Sud et al., 2006 [117]
(based on [110])
Lung 16 103
Marino et al. 2007 [115]
(based on [117])
Granuloma 16 122
Day et al. 2009 [118]
(based on [110, 116, 117])
Lung 11 58
Marino and Kirschner, 2004 [116]
(based on [110])
Lung + lymph nodes 17 (13+4) 76
Marino et al. 2010 [109]
(based on [116])
Lung + lymph nodes 32 (18+20) 210
Pig infection with the Porcine Reproductive and Respiratory Syndrome virus (PRRSv)
Doelsch-Wilson and
Galina-Pantoja, 2010 [114]
Whole organism [4 ;3 ;5] [8 ;9 ;15]
Ê Go et al. [102] Lung 18 30
Ë Go et al. 2014 [submitted]
(based on [102])
Lung 14 29
Ì Go et al. 2014 [in preparation]
(based on [102])
Whole organism 28 78
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Concerning the innate effectors, no model represents the dynamics of natural killers. [120]
take the into account the cytolysis of infected cells by natural killers by way of an increased
mortality rate.
Concerning the adaptive effectors, the cellular response is globally more detailed than the
humoral response. The level of detail for the activation and differentiation steps varied among the
models. Some models use qualitative components to represent immune functions (Unspecified
columns in Table I.6), others only include certain T cells and others distinguish each adaptive
component.
The cellular response is represented in ten models out of fifteen reviewed (ours excepted).
Most of these ten models include both the helper and cytotoxic T cells. Most represent cytolysis.
However, the synthesis of adaptive antiviral cytokines, particularly IFNγ , is only included in the
six Tb models (TNFα only in three).
The humoral response is represented in eight models out of fifteen reviewed (ours excepted).
All include helper T cells, but half of them only include B lymphocytes and antibodies (influenza
models). Five influenza models represent viral neutralisation, the major immune function of the
humoral response. Tb models do not, which is logical as tuberculosis is induced by a bacte-
ria. Four models only (Tb models) represent the synthesis of IL10, a key immuno-modulatory
cytokine, by the adaptive humoral effectors.
As a result, the representation of the adaptive humoral response is partial in all selected
models, so they do not fit our needs.
Our lung-based models (Ê and Ë) propose a simplified adaptive response, with qualitative
adaptive effectors fulfilling the cytolysis and neutralisation functions and producing the two
major cytokines, IFNγ and IL10. As adaptive effector dynamics are mostly active in the lymph
nodes, this simplification is valid. This point is discussed in Section II.4. In our within-host model
(Ì), we detail the dynamics of each adaptive effector. We do not include the naive status of
these effectors, but we take into account the cytokine regulations that control their recruitment
and activation.
I.2.4 Regulations by cytokines
PRRSv and APC dynamics are also regulated by innate and adaptive cytokines. The cytokine
environment is not static during the infection. Cytokines are produced by activated immune
cells. In turn, they modulate the cellular functions through their recognition by specific recep-
tors, inducing cascade reactions within the cells. Consequently, they play a major role in the
regulation of the immune response. They are classified according to their immune functions :
pro-inflammatory, antiviral and immuno-regulatory cytokines. During PRRSv infection, several
cytokines are assumed to play a key role : IL1β, IL6 and IL8 for the inflammation process, IFNα,
TNFα and IFNγ for their antiviral functions and IL12, IFNγ , IL10 and TGFβ for the orientation
of the adaptive response towards the cellular, humoral and regulatory responses (Section I.1.6).
The cytokines and functions included in the selected models are contrasted according to the
pathogen (Table I.7). None of the selected models represent the pro-inflammatory cytokines.
The PRRSv model [114] (ours excepted) does not include cytokines.
The antiviral cytokine TNFα and its impact on the cell permissiveness are only represented
in four to five influenza models. In contrast, most Tb models represent TNFα and IFNγ and
their impact on antigen presentation, as well as the impact of TNFα on cell apoptosis.
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Immuno-regulatory cytokines are included in almost all Tb models, except for TGFβ, which
is found in none of the selected models. TGFβ plays a major role in the regulatory response,
which is not represented in selected models.
Consequently, the cytokine regulations are only partially represented in the selected models,
so they do not fit our needs from this point of view.
In our three models, the cytokine regulations are represented in a comprehensive way.
I.2.5 Our modelling approach
Table I.8 Synthesis of our modelling approach for PRRSv within-host infection and immune dynamics
Our PRRSv immunological models
Aims : identify the immune mechanisms that determine the infection duration (Chapter II),
study the exposure impact (Chapter III) and explore vaccine efficiency (Chapter IV), in a
host and strain variability context.
Biological scale : within-host and between-cell scale, in the lung or lung + lymph nodes.
Focus : host-pathogen interactions, i.e. interactions between PRRSv and its target cells (ma-
crophages and dendritic cells).
Main processes : target cell infection and virus excretion ; innate response ; adaptive response
and its orientation towards the cellular, humoral and regulatory responses ; cytokine syn-
theses and regulations.
Outputs : evolution over time of the concentrations in free viral particles, innate and adaptive
effectors, cytokines.
Formalism : deterministic, non spatial, continuous time dynamic model→ ordinary differential
equations (ODE).
We set our modelling framework in accordance with the issues we raised (Table I.8). As
published models did not fit our needs (Sections I.2.2, I.2.3 and I.2.4), we developed our own
PRRSv immunological models. Compared to the immunological models developed for PRRSv or
similar pathogens targeting pulmonary macrophages, such as influenza viruses or tuberculosis
(Table I.4), the strengths of our models are : (i) the explicit and detailed representation of
the innate immune mechanisms (in particular, the interactions between the virus and its target
cells) ; (ii) the orientation of the adaptive response towards the cellular, humoral and regulatory
responses, whereas no published immunological models represent the regulatory response and
only few represent both the cellular and the humoral responses ; (iii) the explicit representation
of the main innate and adaptive cytokine syntheses and their complex regulations of the immune
mechanisms.
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Ê The lung-based model This model represents PRRSv infection and immune dynamics in
the lungs. The interactions between the pathogen and its target cells, the cytokine regulations
and the innate response are fairly detailed. The dendritic cells are not included. Moreover, the
adaptive response is simplified : it is represented by qualitative effectors (one for each adaptive
response orientation), which perform the basic adaptive functions : cytolysis of infected cells,
neutralisation of free viral particles and cytokine synthesis.
The model is characterised by 18 state variables (illustrated in Figure I.1) : the free viral
particles (V ) ; five effectors of the innate response : four macrophage states and the natural
killers (NK) ; three effectors of the adaptive response and nine cytokines. A macrophage can
either be susceptible (Ms), phagocyting (Mp), or infected ; in this latter case, it is either latent
(Ml) or excreting the virus (Me). For the adaptive response, the effectors represent the regulatory
(Rr), humoral (Rh) and cellular (Rc) responses. The nine cytokines included are the major pro-
inflammatory (IL1β, IL6, IL8), the innate antiviral (TNFα, IFNα) and the immuno-regulatory
(IFNγ , IL10, TGFβ, IL12) cytokines.
Ë The simplified lung-based model This model is based on Ê with the following sim-
plifications on the state variables : the latent infected macrophage state is neglected ; the pro-
inflammatory cytokines IL1β, IL6 and IL8 are grouped in Pi ; the innate antiviral cytokines IFNα
and TNFα are grouped in Ai. Moreover the functions used for the cytokine regulations are also
simplified. Despite these simplifications both lung-based models exhibit comparable behaviours
and outputs.
The model is hence characterised by 14 state variables instead of 18 (illustrated in Fi-
gure I.2).
Ì The within-host (or individual) model This model represents PRRSv infection and
immune dynamics in the lungs and the lymph nodes. It extends the lung-based model by inte-
grating a detailed adaptive response. Instead of qualitative effectors, the actual adaptive effectors
(T cells and antibodies) are included. The dendritic cells are included. The simplifications made
for Ì are partially retained : the latent infected macrophage state is neglected and the functions
used for the cytokine regulations are simplified, but the cytokines are not grouped.
The model is characterised by 28 state variables (illustrated in Figure I.3) :
• the free viral particles V ;
• nine effectors of the innate response composed of three macrophage states M (susceptible
Ms, phagocyting Mp and infected Mi) ; three states for conventional dendritic cells D
c
(susceptible Dcs, mature D
c
m and infected D
c
i ) ; two states for plasmocytoid dendritic cells
Dp (susceptible Dps and mature D
p
m) ; the activated natural killers NK ;
• six effectors of the adaptive response composed of three T CD+4 lymphocyte states (type 1
helper Th1, type 2 helper Th2 and regulatory Treg T cells) ; the cytotoxic lymphocytes Tc ;
two B lymphocyte states (producing IgM and IgG antibodies BMG and producing IgA
antibodies BA) ;
two functional types of antibodies composed of the neutralising (AN : IgM or IgG) and
the marking antibodies (AM : IgM, IgG or IgA) ;
• ten cytokines composed of the major pro-inflammatory (Pi : IL1β, IL6, IL8) ; antiviral
(innate Ai : TNFα, IFNα and adaptive IFNγ) ; and immuno-regulatory (IL12, IFNγ , IL10,
IL4, TGFβ) cytokines.
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Figure I.1 Conceptual model : state variables and flows without regulations. The state
variables consist of : the free viral particles (V ) ; the susceptible (Ms), phagocyting (Mp), latent
(Ml) and excreting (Me) macrophages ; the natural killers (NK) ; the cellular (Rc), humoral (Rh)
and regulatory (Rr) adaptive cells ; the pro-inflammatory cytokines (IL1β, IL6 & IL8 ; grouped in
the box), the innate antiviral cytokines (IFNα & TNFα) and the immuno-regulatory cytokines
(IL12, IFNγ , IL10 & TGFβ). The flows represented are : the inoculation of free viral particles (V0) ;
the recruitment of susceptible macrophages (Am) ; the activation of natural killers (αN ) and cells
of the adaptive response (αR) ; the decay of the free viral particles (µv), the macrophages (µM*),
the natural killers (µN ), the adaptive cells (µR) and the cytokines (µC) ; the macrophage state
changes,i.e. phagocytosis (η and γ), infection (β) and transient excretion (λ and ν) ; the excretion
of free viral particles by infected macrophages (e) and the cytokine syntheses by activated immune
cells (ρ*). For the sake of readability, the cytokine and cell regulations and not drawn and some
parameter notations (marked with *) are simplified.
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Figure I.2 Conceptual model : state variables and flows without regulations. The state
variables consist of : the free viral particles (V ) ; the susceptible (Ms), phagocyting (Mp) and
infected (Mi) macrophages ; the natural killers (NK) ; the cellular (Rc), humoral (Rh) and regu-
latory (Rr) adaptive effectors ; the pro-inflammatory cytokines (Pi), the innate antiviral cytokines
(Ai) and the immuno-regulatory cytokines (IL12, IFNγ , IL10 & TGFβ). The flows represented
are : the viral exposure E(t) ; the recruitment of susceptible macrophages (Am) ; the activation
of natural killers (αR) and cells of the adaptive response (αR) ; the decay of the free viral par-
ticles (µV ), the macrophages (µM*), the natural killers (µN ), the adaptive cells (µR) and the
cytokines (µC) ; the macrophage state changes, i.e. phagocytosis (η and γ) and the infection
(β) ; the excretion of free viral particles by infected macrophages (e) and the cytokine syntheses
by activated immune cells (ρ*). For the sake of readability, the cytokine and cell regulations and
not drawn and some parameter notations (marked with ∗) are simplified.
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Figure I.3 Simplified scheme of the within-host model focused on the adaptive response.
The dynamics of the APC in this model are very similar to those in the lung-based models (Fi-
gure I.1 and I.2).
State variables of the model : free viral particles (V ) ; susceptible APC (macrophages Ms, conven-
tional dendritic cells Dcs and plasmacytoid dendritic cells D
p
s) ; activated and non-infected APC
(phagocyting macrophages Mp, mature conventional dendritic cells D
c
m plasmacytoid dendritic
cells Dpm) ; infected APC (macrophages Mi and conventional dendritic cells D
c
i ) ; natural killers
(NK) ; activated helper T-cells (type 1 Th1, type 2 Th2 and regulatory T cells Treg) ; activated
cytotoxic T cells (Tc) ; activated plasmocytes (derivated from the B lymphocytes, either BMG
which synthesise IgM and IgG antibodies or BA which synthesise IgA antibodies) ; antibodies
(neutralising AN or marking AM ) ; and cytokines : pro-inflammatory (IL1β, IL6, IL8), antiviral
(TNFα, IFNα, IFNγ) and the immunoregulatory (pro-Th1 : IL12 and IFNγ , pro-Th2 : IL4 and IL6
and pro-Treg : TGFβ).
Immune interaction represented. Interactions between the APC and the PRRSv consist of either
the phagocytosis (resulting in the viral destruction and APC activation) or the APC infection
(resulting in the excretion of new viral particles and APC activation) ; the antigen presentation
by Dcm and D
c
i which activate the helper T cells. The subsequent orientation of the adaptive res-
ponse towards the cellular (Th1 which synthesise IL12 and IFNγ) or humoral (Th2 wich synthesise
IL4) or regulatory (Treg which synthesise TGFβ) depends on the immuno-modulatory cytokine
environment. The activation of the cytotoxic lymphocytes and plasmocytes and the antibodiy
synthesis by the last one. The natural killers and the cytotoxic lymphocytes destroy the infected
APC by cytolysis. The marking antibodies promote the APC phagocytosis while inhibit their
infection and the neutralising antibodies inhibit new interactions between the PRRSv and the
immune cells.
Colour code : virus in green, innate components in red, adaptive components in blue and
components from both innate and adaptive responses in purple.
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Abstract
The immune mechanisms which determine the infection duration induced by pathogens targeting
pulmonary macrophages are poorly known. To explore the impact of such pathogens, it is indis-
pensable to integrate the various immune mechanisms and to take into account the variability
in pathogen virulence and host susceptibility. In this context, mathematical models complement
experimentation and are powerful tools to represent and explore the complex mechanisms in-
volved in the infection and immune dynamics. We developed an original mathematical model in
which we detailed the interactions between the macrophages and the pathogen, the orientation
of the adaptive response and the cytokine regulations. We applied our model to the Porcine Res-
piratory and Reproductive Syndrome virus (PRRSv), a major concern for the swine industry.
We extracted value ranges for the model parameters from modelling and experimental studies on
respiratory pathogens. We identified the most influential parameters through a sensitivity analy-
sis. We defined a parameter set, the reference scenario, resulting in a realistic and representative
immune response to PRRSv infection. We then defined scenarios corresponding to graduated
levels of strain virulence and host susceptibility around the reference scenario. We observed that
high levels of antiviral cytokines and a dominant cellular response were associated with either
short, the usual assumption, or long infection durations, depending on the immune mechanisms
involved. To identify these mechanisms, we need to combine the levels of antiviral cytokines,
including IFNγ , and IL10. The latter is a good indicator of the infected macrophage level, both
combined provide the adaptive response orientation. Available PRRSv vaccines lack efficiency.
By integrating the main interactions between the complex immune mechanisms, this modelling
framework could be used to help designing more efficient vaccination strategies.
Author Summary
Some respiratory pathogens infect immune cells and consequently hamper the immune system
through complex mechanisms compromising the vaccine efficiency. The development of more
efficient vaccines requires a better understanding of the interactions between pathogens and im-
mune cells. The immune response exhibits a high variability between hosts and pathogen strains.
In this context, a global exploration by experimentation is even more difficult. We proposed an
alternative approach : an integrative mathematical model of the immune and infection dyna-
mics. Having chosen the example of an animal virus, we identified the immune components that
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determine the infection duration. First, we found that promoting an efficient innate response
reduces the infection duration. This had already been suggested, but not proved. Second, we
found that, depending on the host and the viral strain, various immune mechanisms can result
in the same infection duration. These results provide explanations for the apparent contradic-
tions between experimental results and point out the interest of such an integrative approach.
Consequently, our model constitutes (i) a framework to explore the efficiency of current vaccines
as well as (ii) a tool to design new and more efficient vaccines.
II.1 Introduction
Respiratory pathogens, which enter the body through the mucosal surfaces of the respiratory
tract, are responsible for local inflammation and tissue damages [1, 2]. They initiate the infection
and the immune response. The first interaction between the pathogen and the immune system
involves the innate immune system. This first line of defence, which includes epithelial surfaces,
inflammation process, complement system and innate cells, provides an immediate but non-
specific response. The innate cells mainly consist of the pulmonary macrophages, the dendritic
cells and the natural killers. Macrophages and dendritic cells phagocyte the pathogens, whereas
the natural killers destroy the host infected cells. If pathogens successfully evade the innate
response, a second layer of protection is provided by the adaptive immune system, which is
activated by the innate response and confers specific long-lasting protective immunity to the
host. The adaptive immune system mainly involves the cellular, the humoral and the regulatory
responses. The cellular effectors destroy the infected cells, whereas the humoral effectors release
antibodies, which are responsible for the neutralisation of free viral particles. The regulatory
response mainly inhibits the adaptive response. Innate and adaptive immune cells synthesise
cytokines, small proteins which regulate the immune mechanisms in complex ways.
The best strategy to control the severity of respiratory pathogens is to limit the inflammation
while maintaining an efficient immune response. Some pathogens, such as influenza viruses, My-
cobacterium tuberculosis or the Porcine Reproductive and Respiratory Syndrome virus, replicate
in the cells of the respiratory tract, including pulmonary macrophages. They hinder the immune
functions of the macrophages and consequently reduce the efficacy of the immune response. With
these pathogens, activated macrophages (i) either phagocyte and destroy the pathogen, or are
infected and excrete the pathogen ; (ii) produce cytokines that promote the migration of immune
cells to the infection site ; (iii) synthesise cytokines that regulate the adaptive immunity ; (iv)
express antigen proteins on their cell surface that activate the adaptive response. In turn, the
adaptive cell effectors and cytokines regulate the immune functions of macrophages. However,
the influence of macrophage–pathogen interactions on the immune response has been poorly
studied and needs more insight [1–4]. The two major reasons are that the innate mechanisms
are very difficult to explore by experimentation in vivo and that they have been considered as
having little impact compared to the adaptive response.
Here, we were interested in identifying the immune mechanisms which determine the infec-
tion duration induced by pathogens targeting pulmonary macrophages. The immune response
is a highly complex system involving numerous interactions between cells and cytokines. An
additional level of complexity is due to the between-host and between-pathogen variability. Pa-
thogens use multiple strategies, that vary among pathogens but also among strains, resulting in
various virulence levels. The host response depends on the host genotype or housing conditions,
resulting in various susceptibility levels to a given pathogen. Consequently, to explore the im-
pact of pathogens targeting pulmonary macrophages, it is indispensable to integrate the various
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immune mechanisms and to take into account the variability in pathogen virulence and host
susceptibility.
In this context, mathematical models are powerful tools to represent and explore the complex
mechanisms involved in the infection and immune dynamics [3, 5]. They complement experimen-
tation. On the one hand, they are based on experimental data. On the other hand, they can be
used to test biological hypotheses or assess the impact of control strategies, which would not
be feasible or would be too expensive by experimentation. They can also guide experimenta-
tion by identifying key parameters or mechanisms that need further exploration. Mathematical
models have been developed to explore the immune and infection dynamics for various human
and animal diseases. However, very few models represent the innate mechanisms explicitly and
macrophage–pathogen interactions need to be better represented in models [6]. Several models
describe pathogens targeting macrophages, such as influenza viruses [5–7], Mycobacterium tu-
berculosis [8, 9], or Porcine Respiratory and Reproductive Syndrome virus [10]. These models
focused more on the adaptive than on the innate response, which was fairly simplified or even
missing. In particular, none of these models included the macrophage and natural killer immune
functions explicitly and innate the cytokine regulations were simplified. Moreover, none took
into account the regulatory adaptive response.
So we proposed an original model of the immune response to a virus infecting pulmonary
macrophages in the lung. We considered with particular attention the macrophage–virus inter-
actions. We highly detailed the mechanisms of the innate response and the cytokine regulations.
We included the cellular, the humoral and the regulatory orientation of the adaptive response,
as well as their main functions. We represented the interactions between innate and adaptive
components. We applied our model to the Porcine Respiratory and Reproductive Syndrome
virus (PRRSv). PRRSv is a major concern for the swine industry, as it is responsible for signi-
ficant economic losses worldwide [11, 12]. This pathogen is of particular interest because : (i)
it exhibits a strong tropism for the pulmonary macrophages [11–14] ; (ii) it induces a prolonged
viremia due to its ability to hamper the immune response [11, 12, 15] ; and (iii) the infection
and immune dynamics are highly variable between hosts and viral strains. Depending on the
studies, various components of the immune response have been highlighted as having an impact
on PRRSv infection duration : (i) the macrophage permissiveness and excretion rate ; (ii) the
levels of antiviral and immuno-modulatory cytokines ; and (iii) the balance between the cellular,
humoral and regulatory responses [16]. We used our integrative model to identify the immune
mechanisms determining the infection duration and to explore the relevance of these three as-
sumptions, taking into account the variability in pathogen virulence and host susceptibility.
First, we built our model by synthesising knowledge on the immune mechanisms from pu-
blished studies on PRRSv. Experimental studies on PRRSv are numerous, but cannot provide
all our model parameter values. So we compiled data from the literature by reviewing expe-
rimental and modelling studies on pathogens targeting pulmonary macrophages and obtained
large value ranges for our model parameters. We explored the influence of these parameters on
the viral and macrophage dynamics by a sensitivity analysis. We then identified a parameter
set resulting in realistic infection and immune dynamics. Finally, we explored the influence of
host susceptibility and viral virulence on the infection outcome and we identified the associated
immune mechanisms.
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II.2 Methods
In this section, we first present the dynamic model and its calibration, based on literature
data. We then describe the sensitivity analysis method used to quantify the influence of model
parameters on outputs of interest, among which the viral titer. Finally, we define scenarios which
represent the variability in host susceptibility and strain virulence, in order to assess the impact
of this variability on the model outputs.
II.2.1 Model description
We built a deterministic dynamic model of ordinary differential equations to simulate the in-
fection and immune dynamics induced by a pathogen targeting pulmonary macrophages in the
lung. The functional diagram of the model appears in Figure II.1. We selected the immune
components and their interactions from current knowledge on the immune mechanisms induced
by pathogens targeting pulmonary macrophages. Our modelling assumptions are detailed and
justified in the complete model description given in Appendix A. In particular, the cytokine
regulations and syntheses represented in our model, as well as the related literature references,
are summarised in Table A.1 and Table A.2 respectively.
The model is characterised by 18 state variables : the free viral particles (V ) ; five effectors of
the innate response : four macrophage states and the natural killers (NK) ; three effectors of the
adaptive response and nine cytokines. A macrophage can either be susceptible (Ms), phagocyting
(Mp), or infected ; in this latter case, it is either latent (Ml) or excreting the virus (Me). For the
adaptive response, the effectors represent the regulatory (Rr), humoral (Rh) and cellular (Rc)
responses. The nine cytokines included are the major pro-inflammatory (IL1β, IL6, IL8), the
innate antiviral (TNFα, IFNα) and the immuno-regulatory (IFNγ , IL10, TGFβ, IL12) cytokines.
IFNγ also exhibits an antiviral function. TNFα is generally considered as a pro-inflammatory
cytokine, but we were here more interested is its antiviral function. The model describes the
evolution over time of the state variable concentrations in the lung.
The main processes that drive the evolution of these state variables and that are integrated
in the model are : the phagocytosis of the viral particles by the macrophages (rate η) ; the
macrophage infection by the virus (rate β) ; the excretion of free viral particles by the infected
macrophages (rate e) ; the recruitment (rate Am) and decay/migration of the macrophages (rates
µM ) ; the activation (rates α) and decay/migration of the other effectors (rates µ) ; the cytokine
productions by the immune cells (rates ρ) and their decay (rates µC) ; the cytokine regulations
(functions κ). Figure II.2 gives a schematic representation of the model (without regulations).
Parameter descriptions and values are synthesised in Table II.1. A complete description of the
model and the corresponding equations is given in Appendix A. Here we describe the main
components of the model, illustrated by a few representative equations.
When a free viral particle encounters a susceptible macrophage (1 in Figure II.1), it can ei-
ther be phagocyted (rate η, 2a in Figure II.1), resulting in viral destruction (3a in Figure II.1),
or it can infect the cell (rate β, 2b in Figure II.1), resulting in viral replication (3b in Fi-
gure II.1). The phagocytosis is amplified by antiviral cytokines (TNFα, IFNα and IFNγ) and
inhibited by immuno-modulatory cytokines (IL10 and TGFβ, 2a in Figure II.1). The infection
(linked to the macrophage permissiveness) is amplified by IL10 and inhibited by innate antiviral
cytokines (IFNα,TNFα) and TGFβ (2b in Figure II.1). Phagocyting macrophages revert to a
susceptible status after viral destruction (rate γ) ; it is amplified by the antiviral cytokines and
inhibited by IL10 (2a in Figure II.1). Activated macrophages (infected or phagocyting macro-
phages) produce pro-inflammatory cytokines (3d in Figure II.1), which amplify the recruitment
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Figure II.1 Functional diagram of the immune response to a virus targeting ma-
crophages. Interactions between macrophages and virus (1) result in macrophage activation
by either phagocytosis (2a, amplified by antiviral cytokines and inhibited by immuno-modulatory
cytokines) or macrophage infection (2b, amplified by immuno-modulatory cytokines and inhi-
bited by antiviral cytokines) releasing viral particles (3b). The activated macrophages initiate
the adaptive response (4a–c). IFNγ and IL12 orient the adaptive response towards the cellular
response (4a), whereas immuno-modulatory cytokines orient the response towards the humoral
and regulatory responses (4b–c). The cellular response and the natural killers are responsible
for the destruction of infected cells by cytolysis (7 & 10, respectively). The humoral response
is responsible for the viral neutralisation through antibodies (6). The recruitment of susceptible
macrophages and natural killers is amplified by the pro-inflammatory cytokines (8a & 8b, respec-
tively). Cytokines are produced by activated macrophages (3d), natural killers (9) and adaptive
cells (5a–c). These syntheses are regulated by various cytokines
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Figure II.2 Conceptual model : state variables and flows without regulations.
The state variables consist of : the free viral particles (V ) ; the susceptible (Ms), phagocyting
(Mp), latent (Ml) and excreting (Me) macrophages ; the natural killers (NK) ; the cellular (Rc),
humoral (Rh) and regulatory (Rr) adaptive cells ; the pro-inflammatory cytokines (IL1β, IL6
& IL8 ; grouped in the box), the innate antiviral cytokines (IFNα & TNFα) and the immuno-
regulatory cytokines (IL12, IFNγ , IL10 & TGFβ). The flows represented are : the inoculation of free
viral particles (V0) ; the recruitment of susceptible macrophages (Am) ; the activation of natural
killers (αN ) and cells of the adaptive response (αR) ; the decay of the free viral particles (µv),
the macrophages (µM*), the natural killers (µN ), the adaptive cells (µR) and the cytokines
(µC) ; the macrophage state changes,i.e. phagocytosis (η and γ), infection (β) and transient
excretion (λ and ν) ; the excretion of free viral particles by infected macrophages (e) and the
cytokine syntheses by activated immune cells (ρ*). For the sake of readability, the cytokine and
cell regulations and not drawn and some parameter notations (marked with *) are simplified.
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of susceptible macrophages (inflow Am, 8a in Figure II.1) [4, 17–19]. Finally, susceptible ma-
crophages undergo natural decay (rate µnatM ) and TNFα-induced apoptosis (rate µ
inf
M ) [20]. The
resulting susceptible macrophage dynamics is shown in Equation (II.1) and Figure II.3.
M˙s = Am [1 + κ(IL12, IL6)] [1 + κ(IL8)] ←− recruitment
− η Ms V [1 + κ(TNFα)] [1 + κ(IFNα)] [1 + κ(IFNγ)]
[1 + κ(IL10)] [1 + κ(TGFβ)]
←− phagocytosis
+ γ Mp
[1 + κ(TNFα)] [1 + κ(IFNα)] [1 + κ(IFNγ)]
1 + κ(IL10)
←− phagocytosis ending
− β Ms V 1 + κ(IL10)
[1 + κ(TNFα)] [1 + κ(IFNα)] [1 + κ(TGFβ)]
←− infection
−Ms (µnatM + µinfM TNFα) ←− decay
(II.1)
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Figure II.3 Susceptible macrophage dynamics with cytokine regulations. The state
variables represented are : the free viral particles (V ) ; the susceptible (Ms), phagocyting (Mp)
and latent (Ml) macrophages ; the pro-inflammatory cytokines (IL6 & IL8), the innate antiviral
cytokines (IFNα & TNFα) and the immuno-regulatory cytokines (IL12, IFNγ , IL10 & TGFβ).
All processes that impact the susceptible macrophages are included : recruitment (Am), decay
(µM , simplified notation), phagocytosis (η and γ) and infection (β) ; their positive and negative
regulations by cytokines are also drawn.
The cytokine environment is not static in our model, as we explicitely represented the evo-
lution of the cytokine concentrations over time. Cytokines are produced by activated immune
cells. In turn, they modulate the cellular functions through their recognition by specific recep-
tors, inducing cascaded reactions within the cells. The higher the cytokine concentration, the
stronger the effect. However, there is a limited number of cytokine receptors on the cell surface,
so the effect saturates above a given cytokine concentration. We formalised the cytokine effects
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by a Michaelis–Menten function (κ) of the cytokine concentration (Ci) [8, 21, 22] as follows :
κ(Ci) =
K Ci
Ci + k
,
where K represents the saturation factor and k the half-saturation concentration. A cytokine
can have three possible effects listed below on a given flow (R).
• Activation : R κ(Ci). The flow is only possible in the presence of the cytokine and it
increases with the cytokine concentration.
• Amplification : R [1 + κ(Ci)]. The flow increases with the cytokine concentration.
• Inhibition : R/[1 + κ(Ci)]. The flow decreases with the cytokine concentration.
Regulations often involve several cytokines (Ci and Cj), which can act
• either independently : R [κ(Ci) + κ(Ci)] for an activation, R [1 + κ(Ci)] [1 + κ(Cj)] for an
amplification, or R/([1 + κ(Ci)] [1 + κ(Cj)]) for an inhibition ;
• or in synergy : R κ(Ci, Cj) = R κ(Ci) κ(Cj) for an activation, R [1 + κ(Ci, Cj)] for an
amplification, or R[1 + κ(Ci, Cj)] for an inhibition.
For example, the recruitment of susceptible macrophages (8a in Figure II.1) is amplified by
three cytokines, as shown in Equation (II.1) : two act in synergy (IL12 and IL6) and the third
one acts independently (IL8).
The dynamics of natural killers, given by Equation (II.2), offers a more complex example of
cytokines acting independently and in synergy. We represented the dynamics of activated natural
killers and only included the regulations by the most influential cytokines [4, 19, 23, 24]. The
recruitment of natural killers from the bloodstream (rate αN , 8b in Figure II.1) is activated
by pro-inflammatory cytokines : IL12 and IL6 co-activate the recruitment, whereas IL8 acts
independently. Natural killers are then activated by IFNγ and IL12, whereas IL10 inhibits the
activation. They are subject to natural death or/and migration (rate µR). Activated natural
killers destroy infected cells (10 in Figure II.1) and synthesise IFNγ (9 in Figure II.1) [4, 19,
23, 24].
N˙K = αN
[κ(IL12, IL6) + κ(IL8)] [κ(IFNγ) + κ(IL12)]
[1 + κ(IL10)]
←− recruitment & activation
− µR NK ←− decay
(II.2)
Activated macrophages present the viral antigens to the adaptive cells (3c in Figure II.1).
The subsequent orientation of the adaptive response depends on the immuno-regulatory cyto-
kines (4a – c in Figure II.1). We represented the adaptive response by three effectors correspon-
ding to the three main orientations : cellular, humoral and regulatory responses [1, 4, 13, 25–31].
As for the natural killers, we only represented the dynamics of the activated effectors. Based
on the model proposed by Yates et al. for the regulation of T helper cell populations [31], we
synthesised the dynamics of each adaptive effector by three steps : activation by activated ma-
crophages (rate αR), proliferation (rate pR) and decay. We represented the regulations of the
activation and proliferation steps by the most influential cytokines : IFNγ , IL12, IL10 and TGFβ
(assumptions and references detailed in Appendix A). The decay includes the natural decay
(rate µR) and the Activation Induced Cell Death (AICD) induced by the interaction with a
type 1 T helper cell from the Rc compartment (basic rate δRc) [31].
• Cellular response : Rc represents the type 1 T helper cells and the cytotoxic lymphocytes.
Its dynamics is described in Equation (II.3). Activation is amplified by IFNγ and IL12 and
inhibited by IL10 ; proliferation is activated by IFNγ and IL12 and inhibited by IL10 and
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TGFβ (4a in Figure II.1). Rc synthesises IFNγ (5a in Figure II.1) and destroys infected
macrophages (7 in Figure II.1).
R˙c = αR [Mp +Ml +Me]
[1 + κ(IFNγ)] [1 + κ(IL12)]
1 + κ(IL10)
←− activation
+ pR Rc
[κ(IFNγ) + κ(IL12)]
[1 + κ(IL10)] [1 + κ(TGFβ)]
←− proliferation
− µR Rc − δRc Rc2 ←− decay
(II.3)
• Humoral response : Rh represents the type 2 T helper cells, the B lymphocytes and the
antibodies. Activation is amplified by IL10 and inhibited by IFNγ and IL12 ; proliferation
is activated by IL10 and inhibited by IFNγ , IL12 and TGFβ (4b in Figure II.1). Rh
synthesises IL10 (5b in Figure II.1) and neutralises free viral particles through antibodies
(6 in Figure II.1).
• Regulatory response : Rr represents the regulatory T cells. Activation is amplified by
IL10 and TGFβ and inhibited by IFNγ and IL12 ; proliferation is activated by TGFβ and
inhibited by IL10, IFNγ and IL12 (4c in Figure II.1). Rr synthesises IL10 and TGFβ (5c
in Figure II.1).
Simulations The model was implemented in Scilab 5.3.3 1. For all simulations, the initial
conditions were set to represent an initial viral inoculation in a PRRSv-naive host and were
chosen as follows : V (0) = V0 ∈ [104, 107]TCID50/ml for the viral titer ; Ms(0) = 5 105cells/ml
for the susceptible macrophages ; all remaining variables were set to zero. The model parameters
are summarised in Table II.1.
II.2.2 Model calibration
Published experimental data on PRRSv infection (reviewed in [11, 12, 16, 32–37]) are highly
heterogeneous and differ on : (i) the monitoring duration, (ii) the measured immune components,
(iii) the viral strain, (iv) the pig genotype. Moreover, among the variables included in our model,
only a few were monitored in each experimental study and there were few measures over time.
Consequently, based on these data, classical parameter estimation methods were not suitable to
calibrate our model and we had to design an ad hoc procedure.
The first step of the calibration procedure was to synthesise data from experimental in-
fections to identify the variation ranges of our model parameters. When PRRSv studies could
not provide parameter values, we reviewed models applied to tuberculosis and influenza. The
value ranges obtained for the model parameters and the corresponding references are given in
Table II.1 (ranges defined by the minimum and maximum tested values). The second step was
to explore the parameter space defined by these value ranges. We used a design of experiments
which is described in the Sensitivity analysis section below. The simulations resulting from this
exploration exhibited very contrasted outputs (Figures S2–S4). So the third step was to define
the characteristics of the infection and immune dynamics corresponding to a realistic response
to PRRSv infection. We chose to represent an average response as our reference scenario (S0).
This step is detailed below. Finally, the fourth step was to select a parameter set corresponding
to this reference scenario. We used the sensitivity analyses presented below to focus first on the
most sensitive parameters, i.e. parameters which had the greatest impact on the model outputs.
1Scilab : http ://www.scilab.org/
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Table II.1 Model parameters. The minimal and maximal values tested were issued from the litera-
ture when we found some information, otherwise they were assumed (–). Macrophages : susceptible
(MS), latent (ML), excreting (ME), infected (MI = ML + ME), phagocyting (MP ), activated
(Ma = ML +ME +MP ). Adaptive cells R : cellular (Rc), humoral (Rh) and regulatory (Rr) effec-
tors.
* The unit of η and β is given for the macrophage equation and is different in the virus equation
(ml/(d.TCID50)) ; nevertheless, the parameter values are the same since we considered that the
phagocytosis and macrophage infection consume one TCID50 of virus per macrophage.
Parameter Description Tested values Reference value Unit References
Macrophage dynamics
Am recruitment rate of Ms 5 10
4 105 1.5 105 5 104 (ml.d)
−1
[21, 38]
η phagocytosis rate 10−10 10−8 10−6 5 10−7 ml/d* [39]
β infection rate 10−10 10−8 10−6 10−6 ml/d* [14]
γ 1/ phagocytosis duration 24 48 96 96 d−1 [23]
λ 1/ duration of Ml state 6 12 24 6 d
−1 [14]
ν 1/ duration of Me state 6 12 24 6 d
−1 –
µnatM natural death rate 0.1 0.2 0.3 0.2 d
−1 [22]
δµ over-mortality rate of Mi 0.9 1 1.1 1.1 no unit –
µapM apoptosis rate by TNFα 10
−7 10−4.5 10−2 10−2 ml/(pg.d) [40]
µinnM cytolysis rate of Mi by NK 10
−8 10−5.5 10−3 10−3 ml/d [40]
µadM cytolysis rate of Mi by Rc 10
−8 10−5.5 10−3 10−3 ml/d [40]
Virus dynamics
V0 initial viral inoculation 10
4 105 107 2 106 TCID50/ml [41, 42]
e excretion rate 0.1 1 10 0.2 TCID50/d –
µnatV natural death rate 0.1 0.2 0.3 0.2 d
−1 –
µadV neutralisation rate by Rh 10
−4 10−3 10−2 10−4 ml/d –
Adaptive cell (R) and natural killer (NK) dynamics
αR activation rate of R by Ma 10
−6 10−5 10−4 10−5 d−1 [21]
αN activation rate of NK 0.1 1 10 10 (ml.d)
−1
[21]
pR proliferation rate of R 0.05 0.05 d
−1 –
δRc death rate of R by AICD 10
−3 10−2 10−1 10−1 ml/d –
µR natural death rate 0.01 0.03 0.05 0.05 d
−1 –
Cytokine dynamics
ρPi synthesis rate of Pi by Ma 10
−2 10 102 10−2 pg/d –
ρIL12 synthesis rate of IL12 by Ma 10
−2 10 102 10−2 pg/d –
ρAi synthesis rate of Ai by Ma 10
−2 10 102 5 10−2 pg/d –
ρinnIL10 synthesis rate of IL10 by Ma 10
−2 10 102 2 10−2 pg/d –
ρadIL10 synthesis rate of IL10 by R 10
−2 10 102 2 pg/d –
ρinnIFNγ synthesis rate of IFNγ by NK 10
−2 10 102 10 pg/d –
ρadIFNγ synthesis rate of IFNγ by R 10
−2 10 102 10 pg/d –
ρTGFβ synthesis rate of TGFβ by R 10
−2 10 102 10 pg/d –
µC natural death rate 10 20 40 20 d
−1 [22]
k half-saturation concentration 5 102 1.5 103 30 pg/ml [22]
K saturation factor 0.5 1 1.5 1.5 no unit –
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For the reference scenario, we chose to represent the infection of a weaned pig by a single
PRRSv inoculation. Weaned pigs are supposed to be naive to PRRSv and to have lost their
maternal immunity. In experimental PRRSv infection studies, the inoculation dose ranged bet-
ween 4 and 7 log10(TCID50/ml) [41, 42] ; we chose an inoculation dose of 6.3 log10(TCID50/ml).
PRRSv infection usually lasts between 28 to 42 days in the blood [12, 16, 43] and around 56
days in the lung [12]. However, the infection duration is highly variable between pigs and viral
strains and can be higher than 200 days [16, 44]. So we chose an infection duration in the lung
of around 70 days. Few quantitative data are available for the immune dynamics. The cytokine
levels are highly variable between studies [11, 13] and poorly documented in the lung. Their
magnitude ranges between 10−1 and 103 pg/ml. IL10 levels in response to PRRSv infection and
other respiratory pathogens are similar. They are higher than the levels of pro-inflammatory,
antiviral (innate and adaptive) and other immuno-regulatory (IL12, IFNγ and TGFβ) cytokines.
Without infection, macrophage concentrations in the lung were observed around 105 cells/ml. To
our knowledge, only one experimental study tracked infected macrophages, which peaked during
the first days of PRRSv infection at around 40% among all macrophages [42]. Little is known
about the phagocyting macrophages, except that the phagocyting state is transient and that
PRRSv promotes macrophage infection over phagocytosis [45, 46]. Reported levels of natural
killers during PRRSv infection were low compared to other respiratory pathogens [15, 33]. The
humoral response to PRRSv infection is similar to other respiratory pathogens, whereas the cell-
mediated immunity is delayed and weak. The regulatory response has been poorly studied and
results are controversial [13, 47–49]. Moreover, the orientation of the adaptive response varied
considerably between studies. Consequently, we chose a balanced adaptive response orientation
for our reference scenario.
II.2.3 Sensitivity analysis
We were interested in identifying the most influential parameters on the infection dynamics
using a global sensitivity analysis. Consequently, the first two outputs selected were the viral
titer (V ) and the percentage of infected macrophages among the total concentration of ma-
crophages (%Mi = %(Ml + Me)). We were also interested in characterising the phagocytosis
activity, which directly limits the macrophage infection. The phagocytosis is a transient macro-
phage state, which explains why, whatever the parameter combination selected in the parameter
ranges, the percentage of phagocyting macrophages (%Mp) was low compared to the percen-
tage of infected macrophages (%Mi) at any time during the course of infection (Figure A.1).
However, it does not mean that the phagocytosis activity was necessarily low. We compared
the phagocytosis flow (susceptible macrophages becoming phagocyting macrophages per unit of
time) and the infection flow (susceptible macrophages becoming infected macrophages per unit
of time) during the course of infection. Depending on the parameter values, the phagocytosis
inflow was higher or lower than the infection inflow (Figure A.1). Consequently, the cumulative
number of phagocyting macrophages (cMP ), which corresponds to the phagocytosis flow integra-
ted over time, is a good representation of the phagocytosis activity. So we selected this variable
as the third output of interest. We used a design of experiments to define which simulations to
run. The resulting outputs were analysed to produce the sensitivity indices, which quantify the
influence of the parameters on the model outputs. We used the R software2, version 3.0.2, for
these analyses.
2http ://www.r-project.org/
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We selected 30 among the 31 model parameters for the sensitivity analysis. We did not in-
clude the proliferation rate of the adaptive effectors (pR), because the combination of high pR
and high IL10 synthesis rates led to the explosion of the Rh and Rr dynamics, which resulted
in a numerical integration failure of the model. For each of the 30 parameters, we chose to test
three values among the value range identified in the calibration procedure : the lower and up-
per bounds of the range, as well as an intermediate value (Table II.1). Testing all parameter
combinations, i.e. a complete factorial design, would have required 330 simulations, which was
not feasible. Consequently, fractional factorial designs were used instead. A preliminary analysis
was conducted to estimate the main effects of the 30 parameters on the model outputs, without
taking into account the interactions between parameters. A fractional design of size 243, de-
termined as the minimum size to correctly estimate the main effects, was implemented : 243
parameter combinations were defined and the corresponding simulations were performed and
analysed. From this preliminary analysis, the ten most influential parameters on each of the
three outputs were identified. We then performed a sensitivity analysis on each output, aiming
at estimating the main effects and two-parameter interactions of the corresponding ten most in-
fluential parameters, to which we potentially added extra parameters assumed to have an impact
on the corresponding output. For instance, we added the macrophage mortality rates for the
%Mi output. We selected 17 parameters for the viral titer, 10 parameters for the cumulative Mp
and 21 parameters for the percentage of infected macrophages (Figure II.4). The smallest de-
sign that correctly estimates the main effects and two-parameter interactions for 21 parameters
(%Mi output) requires 3
8 = 6561 parameter combinations. We chose to use the same design size
for all outputs, so 6561 simulations were performed and analysed for each of the three outputs.
The Planor R package3 was used to construct the fractional designs.
Sensitivity indices were calculated for each parameter on each output in the preliminary
analysis (30 parameters × 3 outputs) and the subsequent analyses taking into account two-
factor interactions. Sensitivity indices quantify the fraction of output variance among simulations
explained by the variation of each parameter within its value range [50]. Our model outputs
being time-dependent variables, we used a method adapted to multivariate outputs, which is
based on a decomposition of the variable using a principal component analysis (PCA) [51]. As
a result of the PCA, an inertia proportion is attributed to each component. It represents the
variability among simulations carried by the component. Moreover, each simulation is given a
“score” on each component, a scalar which represents the projection of the simulation on the
component. Then, for each component, an ANOVA is performed on these scores to estimate
the influence of each parameter on the output. The sensitivity index associated with each term,
main effect of a parameter or interaction between parameters, is defined as the ratio between the
sum of squares corresponding to that term and the total sum of squares. Finally, a generalised
sensitivity index (GSI) is calculated for each term (main effect or interaction) as the the sum
of the sensitivity indices corresponding to that term on each PCA component, weighted by the
inertia of the component. The total generalised sensitivity index (tGSI) of a parameter is defined
as the sum of the sensitivity indices corresponding to this parameter (main effect mGSI plus
sum of interactions involving the parameter iGSI). We used the Multisensi R package 4 for this
analysis.
GSI results are presented below. For each output, key parameters are defined as the most
influential parameters for which the cumulative total GSI is higher than 75%.
3Planor R package : http ://cran.r-project.org/web/packages/planor/index.html
4Multisensi R package : http ://cran.r-project.org/web/packages/multisensi/index.html
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II.2.4 Variability in host susceptibility and strain virulence
PRRSv exhibits an important genotypic diversity associated with various virulence levels [13].
The European genotype is less virulent than the American genotype [35], but the virulence also
differs among strains within a genotype [52]. The highly virulent strains are associated with a
prolonged viremia, a high viral replication rate and a high humoral response [53]. Moreover,
the genetic component of the host susceptibility to PRRSv has been demonstrated [54, 55]. Pig
susceptibility can also depend on other factors such as herd management. The more susceptible
pigs develop prolonged viremia, with low titers of neutralising antibodies [10, 55], probably
linked to a high macrophage permissiveness and/or specific cytokine profiles [54].
Both viral virulence and pig susceptibility seem linked to : (i) the virus capacity to infect
the cell and replicate, (ii) the host capacity to synthesise antiviral vs immuno-modulatory cy-
tokines in response to PRRSv infection, and (iii) the activation and orientation of the adaptive
response. Recent studies hypothesise that these variations of the immune dynamics are due to
cascaded reactions initiated by the macrophage–virus interactions [33, 34, 52, 54]. Consequently,
we focused on the macrophage infection and cytokine synthesis capacities. Both macrophage per-
missiveness and viral replication impact the cytokine synthesis, which in turn regulates them.
Discriminating the respective influence of the macrophage permissiveness and the cytokine syn-
thesis rate is very difficult experimentally, but it can be achieved by a modelling approach.
To explore the influence of both mechanisms, scenarios were defined by varying a selection of
parameters chosen according to the sensitivity analysis results and to the hypotheses presented
above. We tested 19 graduated values of : (i) the macrophage permissiveness, promoting either
the phagocytosis (scenarios S0 to S1 : S0→S1), or the macrophage infection and viral excretion
(scenarios S0→S2) ; and (ii) the cytokine synthesis rates, promoting either the antiviral cytokine
synthesis (scenarios S0→SB), or the immuno-modulatory cytokine synthesis (scenarios S0→SA).
Scenarios are defined in Table II.2. Compared to the reference scenario (S0), scenarios S0→S1
and S0→SB correspond to low host susceptibility and strain virulence, whereas scenarios S0→S2
and S0→SA correspond to high susceptibility and virulence. The parameter ranges were set to
cover the variation range of the viral titer reported in the literature.
We used the area under the curve (AUC) to synthesise our model outputs. As the shapes of
the immune and viral output curves were similar across the scenarios, characterising each curve
by a well-chosen number was appropriate and facilitated the comparisons between scenarios.
Choosing the AUC was relevant, as it reflects the entire curve [56]. Relative AUC were defined
as percentages of output AUC among a group of outputs.
Several linear regressions were performed to extract trends from our results and facilitate the
interpretations. In particular, to highlight the links between immuno-regulatory cytokines and
the orientation of the adaptive response, we performed linear regressions between (i) the relative
AUC of relevant cytokines and (ii) the relative AUC of the adaptive response effectors (Rc, Rh
& Rr). To highlight the immune mechanisms determining the infection duration, we performed
linear regressions between (i) the AUC of relevant immune components, which are assumed to
have a strong influence on the infection duration in the literature and (ii) the infection duration.
We used the R software, version 3.0.2, for these analyses.
The infection duration is defined as the time elapsed between the initial viral inoculation
and the virus clearance. In our model, we assumed that there was no more infection when the
virus titer was below 0.01 TCID50/ml.
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Table II.2 Definition of the host susceptibility and strain virulence scenarios.Scenarios S1 and
S2 differ from the reference scenario S0 by their respectively low and high macrophage permissive-
ness. Scenarios S1→S2 correspond to 19 intermediate scenarios (including S0) obtained by gradually
varying the following parameter values : excretion rate (e), macrophage infection rate (β) and pha-
gocytosis rate (η). Scenarios SB and SA differ from the reference scenario S0 by their cytokine
synthesis capacities : scenario SB promotes antiviral over immuno-modulatory cytokine synthesis,
and vice versa for scenario SA. Scenarios SB→SA correspond to 19 intermediate scenarios (inclu-
ding S0) obtained by varying gradually the synthesis rates of the following cytokines : the innate
antiviral cytokines IFNα and TNFα (both ρAi) ; the immuno-regulatory cytokines IFNγ (ρ
inn
IFNγ
&
ρadIFNγ ), IL10 (ρ
inn
IL10
& ρadIL10) and TGFβ (ρTGFβ ). Low/high susceptibility and virulence levels corres-
pond to scenarios with low/high macrophage permissiveness (S1/S2) and scenarios which promote
the antiviral/immuno-modulatory cytokine synthesis (SB/SA). The parameter values corresponding
to the reference scenario are in boldface.
Macrophage permissiveness Cytokine synthesis capacities
Scenarios e β η ρAi ρ
inn
IFNγ
ρadIFNγ ρ
inn
IL10
ρadIL10 ρTGFβ
S1 0.15 5 10−7 10−6 0.05 10 10 0.02 2 10
SB 0.2 10−6 5 10−7 0.5 100 100 0.005 0.5 2.5
S0 0.2 10−6 5 10−7 0.05 10 10 0.02 2 10
SA 0.2 10−6 5 10−7 0.005 0.1 0.1 0.08 8 40
S2 0.25 2 10−6 2.5 10−7 0.05 10 10 0.02 2 10
II.3 Results
II.3.1 Model calibration and sensitivity analysis
The reference scenario (S0) was characterised by a 72-day infection duration, an infected ma-
crophage peak at 40% of the total macrophage concentration, a balanced adaptive response
orientation and high IL10 levels compared to antiviral and pro-inflammatory cytokine levels. Its
parameter values are given in Table II.1 and it is represented in Figure II.5 (black curves).
In the preliminary sensitivity analysis, with all 30 parameters but no interactions between
parameters, the variance explained by the parameters retained for the main sensitivity analysis
on each output was 89% for the viral titer, 89% for the cumulative number of phagocyting
macrophages and 70% for the percentage of infected macrophages. The results of the main
sensitivity analyses with two-parameters interactions are shown in Figure II.4 ; for each output,
the total global sensitivity index defined for each parameter is split into the parameter main effect
and its interactions. At least 92% of the total output variance was explained by the parameters
and two-parameter interactions for all three outputs. Three key parameters (explaining together
more than 75% of the variance) were identified for each output. Their impact is detailed in
Table II.3. Most of them were involved in macrophage–virus interactions. The infection rate β
was a key parameter for the three outputs of interest. The excretion rate e was a key parameter
for the viral titer and the percentage of infected macrophages. The phagocytosis rate η was a
key parameter for the viral titer and the cumulative number of phagocyting macrophages. The
remaining key parameters were the inoculation dose V0 for the cumulative number of phagocyting
macrophages and the synthesis rate of innate antiviral cytokines ρAi for the percentage of infected
macrophages. The main effects of the key parameters ranged between 0.4% (β on the viral titer)
and 28% (η on the viral titer). Key parameters also exhibited high interactions (e.g. 27% for
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Figure II.4 Generalised sensitivity indices (GSI) for the three outputs of interest.
A : Viral titer V (R2 = 0.93). B : Cumulative number of phagocyting macrophages cMP
(R2 = 0.92). C : Percentage of infected macrophages among all macrophages %Mi (R2 = 0.96).
Total GSI (bars) are represented for an output-dependent selection of influential parameters. For
each parameter, the total GSI is split into main parameter effect (black bar) and the sum of
two-parameter interactions involving the parameter (grey bar). R2 corresponds to the fraction of
output variance explained by the parameters. NB : As the two-parameter interactions are counted
for both parameters, the sum of the total GSI is higher than 100%.
Table II.3 Generalised sensitivity indices and influence of the key parameters on the three
outputs of interest. The outputs are the viral titer (V ), the cumulative number of phagocyting
macrophages (cMP ), and the percentage of infected macrophages among all macrophages (%Mi).
Three key parameters were identified for each output (corresponding GSI in bold). For each parameter
and each output, the generalised sensitivity index of the parameter main effect (mGSI, in %) and of
the sum of two-parameter interactions involving the parameter (iGSI, in %) are given. Increasing the
parameter value can induce an increase (↑) or decrease (↓) of the output.
V cMP %Mi
Key parameters mGSI iGSI Influence mGSI iGSI Influence mGSI iGSI Influence
Initial inoculation V0 8 3 ↑ 12 23 ↑ 2 3 ↑
Excretion rate e 10 12 ↑ 1 11 ↑ 7 20 ↑
Infection rate β 0.4 19 ↑ 0.6 12 ↓ 14 27 ↑
Phagocytosis rate η 28 11 ↓ 9 23 ↑ 1 6 ↓
Ai synthesis rate ρAi 3 4 ↑ – – ↑ 8 19 ↓
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interactions involving β on the percentage of infected macrophages), in particular between two
key parameters (results not shown).
The initial inoculation dose V0 was a key parameter for the cumulative number of phagocyting
macrophages (tGSI=35%), but neither for the viral titer (tGSI=11%), nor for the percentage
of infected macrophages (tGSI=5%). This result can be explained by the fact that the phago-
cytosis activity mostly occurs during the first days of the infection, whereas the viral titer and
infected macrophages are impacted all along the infection course (Figure A.2, Figure A.3 and
figurename A.4).
The infection rate β had less impact on the viral titer variability (tGSI=19.4%, mGSI=0.4%)
than the phagocytosis rate η (tGSI=39%, mGSI=28%) and the excretion rate e (tGSI=22%,
mGSI=10%). Macrophage infection results in viral excretion and has a positive impact on the
free viral particles, but it is attenuated by the virus mobilisation by infected macrophages.
The infection rate β and the excretion rate e exhibited a strong interaction on the viral
titer and the percentage of infected macrophages (GSI around 8%). Indeed, the viral replication
needs macrophages to be infected and conversely, macrophage infection is induced by free viral
particles which are released through viral excretion.
II.3.2 Impact of host susceptibility and strain virulence on the infection re-
solution and associated immune mechanisms
The 37 scenarios corresponding to graduated levels of host susceptibility and strain virulence
were simulated. The results are illustrated in Figure II.5 and summarised in Table II.4. The
infection durations (52–118 days according to the scenario) were consistent with literature data
[12, 16, 43, 44]. All scenarios had a notable impact on the infection duration. The scenarios rela-
ted to macrophage permissiveness (S1→S2) induced higher differences in infection duration than
the scenarios related to the cytokine synthesis (SB→SA), even if the parameter variations were
lower for scenarios S1→S2 than for scenarios SB→SA (Table II.2). Consequently, the infection
duration seems more sensitive to the parameters involved in the macrophage permissiveness
than the antiviral cytokine synthesis rate.
The dynamics of immune components were similarly bell-shaped but differed quantitatively.
More severe and longer infections were overall associated with higher levels of immune responses
(Figure II.5), but the relative proportions of the immune components varied (Table II.4).
Concerning the innate response, we found a significant and positive correlation (R2 = 0.97)
between the levels of infected macrophages and IL10, a cytokine which amplifies macrophage
permissiveness and viral replication (results not shown).
There was no evidence of a link between the proportions of IL12 and TGFβ and the orientation
of the adaptive response. The proportions of IL10 and IFNγ , however, were linked to the adaptive
response orientation (Table II.4 & Figure II.5). The proportion of IL10 among IL10 and IFNγ
was negatively correlated with the percentage of cellular response (R2 = 0.91) and positively
correlated with both the humoral (R2 = 0.94) and regulatory responses (R2 = 0.84).
Scenarios S1→S2 resulted in immune dynamics rather close to the reference scenario, except
for IFNγ levels (Figure II.5). On the one hand, high infection capacities (S0→S2) resulted in
long infection durations despite high levels of IFNγ (Figure II.5) and the adaptive response was
oriented towards the cellular response (%Rc = 40%, Table II.4). However, IFNγ percentages
were similar to the reference scenario. On the other hand, low infection capacities (S1→S0)
resulted in short infection durations despite high percentages of IL10 and the adaptive response
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Figure II.5 Immune and infection dynamics for variable host susceptibility and
strain virulence. Evolution of twelve variables (panels A to L) during the first 30 days of
infection (unless specified). A : Viral titer (V , during 120 days). B : Phagocyting macrophages
(Mp). C : Infected macrophages (Mi = Ml + Me). D : Pro-inflammatory cytokines (Pi =
IL1β + IL6 + IL8). E : Innate antiviral cytokines (Ai = TNFα + IFNα). F–I : Immuno-regulatory
cytokines (F : IL12, G : IFNγ , H : IL10 and I : TGFβ). J : Adaptive cellular effectors (Rc). K :
Adaptive humoral effectors (Rh). L : Adaptive regulatory effectors (Rr). For each variable, the
left plot corresponds to scenarios SB→SA, in which the antiviral cytokine synthesis is higher
(S0→SB, red) or lower (S0→SA, magenta) than in the reference scenario (S0, black). The right
plot corresponds to scenarios S1→S2, in which the macrophage permissiveness is lower (S0→S1,
green) or higher (S0→S2, blue) than in the reference scenario (S0, black). Low susceptibility and
virulence levels correspond to scenarios which promote the antiviral cytokine synthesis (red) and
scenarios with low macrophage permissiveness (green). High susceptibility and virulence levels
correspond to scenarios which promote the immuno-modulatory cytokine synthesis (magenta)
and scenarios with high macrophage permissiveness (blue) Scenarios are defined in Table II.2.
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Table II.4 Summary of the virus and immune dynamics for variable host susceptibility and
strain virulence. Scenarios S1 : low macrophage permissiveness ; SB : high antiviral and low immuno-
modulatory cytokine synthesis ; S0 : reference ; SA : high macrophage permissiveness ; S2 : low antivi-
ral and high immuno-modulatory cytokine synthesis. AUC (area under the curve) units : macrophages
[105 d/ml], other cells [d/ml], cytokines [102 pg.d/ml]. Macrophages : infected (MI), phagocyting
(MP ). Adaptive effectors : cellular (Rc), humoral (Rh) and regulatory (Rr) orientations.
∗ Relative AUC are defined within a group of outputs (e.g. the four cytokines IL12, IFNγ , IL10 and
TGFβ) as the AUC of the outputs expressed as percentages of the sum of the AUC within the group.
Susceptibility and virulence :
low reference high
S1 SB S0 SA S2
Virus – Infection duration [d] 52 57 72 93 118
Innate response – AUC
Mp/(Mi +Mp) [%] 1.4 1.6 0.5 0.2 0.2
Mp 0.030 0.008 0.009 0.030 0.008
Mi 2.1 0.48 3.5 18 5.1
NK 71 15 225 866 559
Pi = IL1β + IL6 + IL8 1.2 0.28 2.4 10.8 3.6
Ai = IFNα + TNFα 9 26 16 7 23
Adaptive response – AUC
IL12 + IFNγ + IL10 + TGFβ 3.2 2.5 6.6 107 10.3
Rc +Rh +Rr 108 36 124 455 146
Cytokines – relative AUC [%]∗
IL12 21 9 16 2.8 14
IFNγ 1 85 22 0.2 30
IL10 71 4.5 59 93 54
TGFβ 7 0.5 3 4 2
Orientation – relative AUC [%]∗
Rc 23 54 32 14 40
Rh 41 23 36 43 32
Rr 36 23 32 43 28
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was oriented towards the humoral response (%Rh = 41%, Table II.4). IL10 levels were similar
to the reference scenario (Figure II.5).
Scenarios SB→SA resulted in more contrasted immune dynamics (Figure II.5) and influen-
ced the adaptive response orientation more than scenarios S1→S2 (Table II.4). Low antiviral
capacities (S0→SA) resulted in long infection durations associated with high levels (Figure II.5)
and percentages of IL10, and co-dominant humoral and regulatory responses (Table II.4).
High antiviral capacities (SB→S0) resulted in short infection durations associated with high
levels (Figure II.5) and percentages of IFNγ , and an orientation towards the cellular response
(Table II.4).
To extract trends more easily from these results, we investigated the correlations between
the infection duration and the levels of seven key immune components of interest : infected and
phagocyting macrophages, innate antiviral and pro-inflammatory cytokines and percentages of
IL10 and IFNγ (Figure II.6). Considering all scenarios together, no significant correlations could
be extracted. Consequently, we split the scenarios in two groups : those with varying macro-
phage capacities (S1→S2) and those with varying cytokine synthesis capacities (SB→SA). All
correlations were significant. The AUC of infected macrophages and pro-inflammatory cytokines
were positively correlated with the infection duration for both groups. Otherwise, both groups
exhibited opposite correlations.
In summary, low virulence and susceptibility scenarios induced short infection durations by
promoting the phagocytosis or the synthesis of antiviral cytokines. On the contrary, high viru-
lence and susceptibility scenarios resulted in long infection durations by promoting the infection
and viral excretion or the synthesis of immuno-modulatory cytokines. Infection durations were
always positively correlated with the levels of infected macrophages and pro-inflammatory cy-
tokines. We observed that longer durations were associated with higher percentages of infected
macrophages among activated macrophages. However, high levels of antiviral cytokines compa-
red to immuno-regulatory cytokines, inducing a dominant cellular response, can be associated
with either (i) long (scenarios related to macrophage permissiveness) or (ii) short infection du-
rations (scenarios related to cytokine synthesis capacities).
II.4 Discussion
II.4.1 Modelling approach
In this paper, we presented an integrative dynamic model of the immune response in the lung
to a virus targeting pulmonary macrophages : the PRRSv. The complexity level of the model
is a good compromise between detailed intra-cellular models which focus on specific immune
mechanisms and global models which give general trends [8]. Our model offers a comprehensive
representation of the interactions between the virus and the immune response, which is necessary
to explore the influence of the immune mechanisms on the infection duration. It is an original
approach that takes into account the innate mechanisms, the adaptive response orientation and
their complex interactions and regulations involving cytokines. We chose to represent the acti-
vation and orientation of the adaptive response, even if they occur outside the lung, because
they interact with the immune and infection dynamics. Therefore, we did not detail the inter-
mediate differentiation and proliferation steps of the adaptive response, but we represented its
main immune functions and regulations. We hence obtained a realistic qualitative dynamic of
the adaptive response. We did not represent the dendritic cells, major antigen presenting cells
which influence the adaptive response activation and orientation. These cells maturate during
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Figure II.6 Linear regressions between the infection duration and immune com-
ponents of interest. The immune components selected are the area under the curve (AUC) of
A : infected macrophages (Mi = Ml+Me), B : innate antiviral cytokines (Ai = TNFα+ IFNα),
D : pro-inflammatory cytokines (Pi = IL1β + IL6 + IL8), and E : phagocyting macrophages
(Mp) ; and the relative AUC of C : IFNγ and F : IL10. Two regressions were performed for each
component : (i) for scenarios SB→SA (dark red), in which the antiviral cytokine synthesis is
higher (S0→SB, red dots) or lower (S0→SA, magenta dots) than in the reference scenario ; (ii)
for scenarios S1→S2 (dark blue), in which the macrophage permissiveness is lower (S0→S1,
green dots) or higher (S0→S2, blue dots) than in the reference scenario. Scenarios are defined
in Table II.2.
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their migration from the infection site to the lymph nodes, where they synthesise cytokines.
They influence the infection dynamics through the cytokines they synthesise, which is conse-
quently negligible in the lung. Moreover, dendritic cells and macrophages drive the adaptive
response orientation in a similar way. As our model does intend to represent the orientation of
the adaptive response between the different types and not the quantitative levels of adaptive
cells, we trust that our simplification did not distort the results. This simplification is even
more appropriate when dealing with PRRSv, as the virus also infects dendritic cells. Dendritic
cells and macrophages hence have very similar dynamics and impacts during PRRSv infection
[57, 58].
The model was built to describe a single infection by a stable pathogen at the within-host
scale. We used it to study the impact of PRRSv strains, which exhibit various virulence levels.
Our model could be easily adapted to other pathogens targeting pulmonary macrophages, such
as influenza viruses. As influenza also infects epithelial cells, these target cells would have to
be included in the model. As for other pathogens, the immune dynamic part of our model
constitutes a good basis to study the innate response, given the fact that it is strongly simplify
in most of the published models.
II.4.2 Model calibration and scenario definition
The variation range of our model parameters were based on literature data. To complement these
data and deal with the high variability on the parameter values and output levels, we developed
an ad hoc method based on large parameter space exploration and sensitivity analysis. We
defined a reference scenario, which corresponds to an average dynamics within the observed
immune and infection dynamics. To study the impact of host and strain variability, we also
defined parameter sets based on published assumptions and resulting in infection durations
which were consistent with the literature [12, 16, 43, 44]. However, a quantitative calibration
based on the viral dynamics and immune response data was not feasible. The levels of strain
virulence and susceptibility of pigs are not quantified, the viral strains and pig breeds are not
always informed and only few combinations of breeds and strains have been tested, so the
comparisons between our scenarios and the literature are limited, especially for the immune
response.
The sensitivity analysis highlighted five key parameters with a strong influence on the ma-
crophage and virus dynamics : the viral inoculation dose V0, the viral excretion rate e, the
macrophage infection rate β, the phagocytosis rate η and the antiviral cytokine synthesis rate
ρAi . The inoculation dose is measured in experimental studies but is difficult to assess in field
conditions. The other three key parameters are not easy to inform. Distinguishing between in-
fected and phagocyting macrophages is an experimental challenge, so their dynamics are rarely
observed and the related parameter values are not measured in the literature. Further experi-
mentation would be needed to track the dynamics of our outputs of interest, especially viral titer
and ideally both infected and phagocyting macrophages, or at least activated macrophages. The
sensitivity analysis also exhibited high interactions between parameters, which partly explain
the difficulties encountered to calibrate the model.
In terms of viral dynamics, the simulated infection durations ranged between 52 and 118
days according to the scenarios. Experimental studies show that the resolution generally occurs
in the serum between 28 and 42 days after a PRRSv infection [12, 16, 43] and in the lung
after 56 days on average [12, 59–62]. Infections longer than 240 days have been observed [16].
Consequently, the variation range of the simulated infection durations is realistic. Few studies
measure the infection duration in the sera and in the lung simultaneously [43, 63, 64]. Combining
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these studies, we estimated that the infection duration in the lung is around 1.6 times longer
than in the sera. This approximation allowed us to compare the infection duration in the lung
from our simulation results to the infection duration in the blood (viremia) from experimental
results. Few experimental studies focus on the response variability due to the viral strain or
pig breed susceptibility. In a resistant pig breed, the viral load was around 35 days in the sera
(estimated around 56 days in the lung) [55] and around 52 days in the lung with a low virulent
strain [38]. Conversely, a more susceptible pig breed showed a 72-day viremia (estimated around
115 days in the lung) [55]. Infections by a highly virulent strain resulted in a viremia of 36 days
(estimated around 58 days in the lung) [62] or the presence of viral particles in the lung for more
than 67 days [65]. Our results were consistent with these data, but exhibited a larger range of
infection durations.
In terms of immune response, the main trends found in the literature are the following : high
virulence and susceptibility are associated with (i) a high activation of the immune response [66] ;
(ii) a dominant humoral response [41] with high levels of IL10 ; (iii) a lower cellular response with
low levels antiviral cytokines [33, 34, 53, 66, 67]. However, trends (ii) and (iii) do not always hold.
Some reviews point out that levels of antiviral and IL10 cytokines are highly variable between
hosts and viral strains [11, 13]. An infection by a highly virulent strain can result in high levels of
IFNγ [62]. A strong cellular response is not necessarily correlated with a short infection duration
[60]. Our results are qualitatively consistent with these data : high virulence and susceptibility
scenarios were associated with high levels of the immune response and various orientations of
the adaptive response. A common trend detected throughout all scenarios was the correlation
between IL10 and the infected macrophages. Unlike the infected macrophages, IL10 can be easily
be measured. However, this result should be confirmed by experimentation before using IL10 as
a proxy for infected macrophages. We also found that high levels of pro-inflammatory cytokines
were associated with longer infections. It has been suggested that inflammatory responses in
the lung are an indicator of the severity and duration of the PRRSv infection rather than an
indicator of the immune response efficacy [17].
II.4.3 Assessing the impact of variability in host susceptibility and strain
virulence
The strain virulence and pig susceptibility variability impact the infection duration, but the
underlying mechanisms are still incompletely understood. Several hypotheses are formulated to
explain PRRSv infection duration. Early immunological findings link prolonged viremia with
(i) a weak innate antiviral response, (ii) high levels of immuno-modulatory cytokines (IL10 and
TGFβ) and (iii) low levels of IFNγ , resulting in the orientation towards an inefficient humoral
response ; in contrast the cellular response could be protective. These results are challenged in
more recent studies. All this knowledge is synthesised and discussed in terms of between-host and
between-strain variability in recent reviews [16, 33, 34, 37]. In the following discussion sections,
we confront our simulation results to the above-mentioned hypotheses.
II.4.3.1 Innate response
PRRSv has been reported to have various negative effects on innate immune functions, which
probably contribute to the long survival of the virus in infected pigs. It suppresses the phagocy-
ting activity, it fails to elicit any significant innate antiviral cytokines and it alters of the innate
cytokine patterns compared to other respiratory pathogens [33, 37]. Consequently, we could ex-
pect negative correlations between the infection duration and both innate antiviral cytokines
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(Ai) and phagocyting macrophages (Mp). However, we found that long PRRSv infections were
correlated as follows : either positively with Ai and negatively with Mp, or positively with Mp
and negatively Ai. To explain these puzzling results, we need to consider the levels of the other
immune components and the parameter values used.
For scenarios S1→S2, we gradually promoted the infection and excretion while limiting the
phagocytosis. It resulted in longer infection durations, a high increase of Ai, a decrease of Mp
and a moderate increase of infected macrophages (Mi). As Ai are mainly synthesised by Mi,
promoting infection results in increasing Ai. In turn, Ai inhibits the infection and should reduce
Mi. However, promoting the excretion and limiting the phagocytosis increase the free viral
particles (V ) and Mi. This last mechanism was dominant in these scenarios and countered the
effect of Ai.
For scenarios SB→SA, we gradually promoted the synthesis of immuno-modulatory cytokines
(IL10 and TGFβ) and limited the synthesis of Ai and IFNγ . It resulted in longer infection
durations, an increase of Mp and a high increase of Mi and IL10. Promoting IL10 and TGFβ
should increase the infection and reduce the phagocytosis, both contributing to an increase of
V . In turn, V activates the phagocytosis and infection. This last mechanism was dominant in
these scenarios and countered the cytokine effect. As a net result, Mp increased.
Our results suggest that despite high correlations between components of the innate response
and the infection duration, measuring the innate response alone is insufficient to explain and
predict the infection duration.
II.4.3.2 Adaptive response
The orientation towards the cellular, humoral or regulatory responses is supposed to have a high
influence on the infection duration, but the mechanisms governing the orientation still need more
insight. In experimental studies, the orientation towards the humoral and cellular responses is
usually approximated by the levels of IL10 and IFNγ respectively. However, few studies consider
the cellular and humoral responses simultaneously, as well as the associated cytokines, and most
studies neglect the regulatory response. Reviews on PRRSv infection suggest that high levels of
IL10 are capable of shifting the immune response towards a humoral response and that in the
absence of IFNγ , there is no cellular response [16, 33]. As the neutralisation of IL10 inhibits the
regulatory response [37], levels of IL10 and regulatory response are assumed to be linked. In our
model, the three orientations were represented, as well as their regulations and interactions. We
found that the orientation of the adaptive response did not depend on specific cytokine levels,
but on the proportions of IFNγ and IL10. This result is consistent with the literature, as it
points out the crucial role of IFNγ and IL10 on the adaptive response orientation. However, it
also points out the limits of the usual approximation of the adaptive response orientation by
IFNγ or IL10 levels.
The cellular response is considered as protective against a wide variety of viral infections
but its influence is controversial in the case of PRRSv infections [16, 33]. Reviews suggest that
the suppression of IFNγ may have little influence on the in vivo disease progression [16, 68].
Moreover, long-term persistence of the virus in the host associated with a strong cellular response
has been observed [33]. Both findings suggest that the cellular response alone cannot curtail the
infection. Correlations between the strength of the cellular response and the PRRSv infection
duration are highly variable between hosts and strains [34]. We also found that a dominant
cellular response and high percentages of IFNγ can be associated with either long or short
infection durations. Scenarios SB→SA are consistent with the usual assumption that confers a
protective role to the cellular response. However, in scenarios S1→S2, long infection durations
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were associated with a dominant cellular response. To explain this result, we need to consider
simultaneously the levels of the other immune components and the parameter values used. Long
infection durations were associated with high levels of IFNγ and Ai, moderate levels of IL10 and
infected macrophages, as well as an orientation towards the cellular response. We previously
explained the high increase of Ai and the moderate increase of Mi (see Innate response above).
Being produced by Mi, IL10 also increases, but less than Ai (lower production rate). As Mi
increases, the activation of the immune response also increases. In particular, the natural killers
increase. They synthesise IFNγ , which promotes the cellular response, whose effectors synthesise
IFNγ , resulting in the orientation towards the cellular response. IL10 does not increase enough
to prevent this orientation. As Ai, the cellular response and IFNγ inhibit the infection, but not
enough to compensate the high excretion and infection rates.
The high influence of the excretion rate on the infection duration is consistent with the results
of the sensitivity analysis. The scenarios explored could correspond to real conditions. Indeed, an
experimental study showed that pig genotypes can influence the alveolar macrophage abilityto
suppress the viral replication [69]. Moreover, virulent strains vary in their ability to induce the
synthesis of antiviral [16] and IL10 [37] cytokines. So scenarios S0→S2 could correspond to a pig
that is not able to inhibit the viral replication and that is infected by a highly virulent type 2
PRRSv field strain, inducing a strong antiviral response and a moderate IL10 production.
Neutralising antibodies play a key role in the immunological control of a wide variety of viral
infections [16, 33]. Consequently, a strong humoral response, should result in a short infection
duration. PRRSv infections induce high levels of IL10 compared to the other cytokines and the
humoral response levels are similar to the levels encountered in other viral infection. However,
the levels of neutralising antibodies remain low. The combination of high levels of IL10 and a
strong but inefficient humoral response is often proposed to explain the long infection duration
[11]. Indeed, IL10 is a major regulator of the immune response and its inhibitory effects on nu-
merous immune functions could explain several immunological phenomena observed in PRRSv
infection [33, 34, 37]. However, the variability in host susceptibility and viral virulence challenges
this hypothesis. PRRSv infections by virulent or attenuated strains showed no correlation bet-
ween the IL10 levels and the infection duration [16]. In a variety of studies, PRRSv infection
resolution was observed without the development of neutralising antibodies [16]. We found that
a dominant humoral response and high percentages of IL10 can be associated with either long or
short infection durations. Scenarios SB→SA are consistent with the usual assumption of the in-
effective humoral response. However, scenarios S1→S0 associated short infection durations with
a dominant humoral response. This result is due to the low excretion and macrophage infection
rates, despite the low levels of innate and adaptive antiviral cytokines.
Concerning TGFβ and the regulatory response, few studies explored their influences on
the immune dynamics and the subsequent infection resolution. The induction of regulatory T
lymphocytes (Treg) during the early stages of infection is considered as one of the mechanisms
that establish chronic or persistent viral infections [16, 33]. According to this hypothesis, our
results showed that a strong regulatory response was associated with very high levels of IL10 and
that it resulted in a prolonged infection (scenarios S0→SA). Further experimentation considering
the Treg cells and TGFβ cytokines are needed to validate our model results.
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II.4.4 Conclusion
We built an original and integrative model of the immune response in the lung to a pathogen
targeting pulmonary macrophages, applied here to PRRSv. This model provides an interesting
framework to explore the macrophage–pathogen interactions while representing the adaptive
response. We used the model to explore the influence of macrophage permissiveness and cytokine
synthesis capacities on the infection duration and immune dynamics. A recent review suggests
that the concepts proposed to explain prolonged PRRSv infection have not been experimentally
proved ; in particular, the roles of the cytokines and the orientation of the adaptive response
need to be more clearly elucidated [16]. Our integrative model allowed to simulate contrasted
dynamics in terms of immune response and infection duration, suggesting hypotheses to explain
the apparent contradictions between published results.
In addition, we extracted some synthetic and original elements from our work.
1. Among the immune variables that can be easily measured, some were found to characterise
immune mechanisms : (a) the proportions of IL10 and IFNγ were good indicators of the
adaptive response orientation ; and (b) the level of IL10 was a good indicator of the level
of infected macrophages.
2. Whatever the strain virulence and host susceptibility, the infection duration was linked to
some immune variables : (a) the level of pro-inflammatory cytokines was a good indicator
of the infection duration ; and (b) a dominant regulatory response was associated with a
prolonged infection.
However, to identify and understand the immune mechanisms responsible for the infection dura-
tion, the entire immune response had to be considered. At least (i) the levels of innate antiviral
cytokines, (ii) the level of IL10, and (iii) the relative levels of IL10 and IFNγ were needed.
We found that the macrophage permissiveness and the cytokine synthesis capacities both
influence the infection duration through various immune mechanisms. Promoting antiviral cy-
tokines or limiting the macrophage permissiveness and viral replication in order to reduce the
infection duration has only been suggested [33, 34, 60]. Classically, two main approaches are
associated to limit the infection : (i) appropriate housing conditions to reduce the pig suscep-
tibility and (ii) vaccination to improve the immune response efficiency. Moreover, it has been
shown that pig genotypes can influence the alveolar macrophage ability to suppress viral replica-
tion [54]. Our results suggest that the viral replication rate is highly influential on the infection
duration. So selecting resistant pigs should be efficient to prevent severe infections. Concerning
the vaccination strategies, vaccines capable of promoting the synthesis of antiviral cytokines or
minimising IL10 production have been considered in the literature and numerous experimenta-
tion have been carried out, but the current results are not convincing (reviewed in [16, 37]).
Obviously, vaccination strategies need more insight. Our integrative model provides a powerful
framework to go beyond experimental constraints. In particular, such an approach could be used
to help designing efficient vaccination strategies.
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Abstract
Understanding the impact of exposure on the within-host dynamics and its outcome in terms
of infectiousness is a key issue to better understand and control the infection spread. It has not
been fully explored yet, neither in experimental infections, nor in modelling studies, which mostly
represent exposure by a punctual dose. We tackled this issue by a modelling approach focused
on the Porcine Reproductive and Respiratory Syndrome virus (PRRSv), a major concern for the
swine industry. PRRSv immune response is partially understood and highly variable depending
on viral strains and host susceptibilities.
We used a mathematical model representing PRRSv immune and infection dynamics in the
lung ; we built designs of numerical experiments to explore the impact of exposure intensity, du-
ration and peak, as well as strain virulence, on characteristics of the viral and immune dynamics ;
we then quantified their impact by sensitivity analyses and descriptive statistics.
We found that the infection severity was fully determined by the exposure intensity. The
infection duration increased with the strain virulence and, for a given strain, exhibited a positive
linear correlation with the exposure intensity logarithm and the exposure duration.
Exposure simplifications should hence at least preserve the exposure intensity. Besides, re-
presenting the exposure due to contacts by short or even punctual exposures would tend to
underestimate the infection duration. As the infection severity and duration both contribute to
the pig infectiousness, a prolonged exposure of the adequate intensity would be recommended
in an immuno-epidemiological context.
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III.1 Introduction
Understanding the pathogen spread in a population is essential to develop effective prevention
and control strategies. In this context, modelling approaches coupling between and within-host
dynamics offer new perspectives [1, 2]. At the between-host scale, the infection spread, the
infectiousness of infected individuals and the host contact structure determine the exposure of
susceptible individuals, which can trigger new infections. At the within-host scale, the exposure,
the individual susceptibility and the pathogen virulence drive the immune dynamics, which
dictates the infection duration and severity, as well as the infectiousness of infected individuals.
Exposure hence links the between-host to the within-host dynamics, whereas infectiousness
links the within-host to the between-host dynamics. In this paper, we focused on the impact of
exposure on the within-host dynamics, which is regarded as a key issue [1, 3, 4].
We based our study on the Porcine Reproductive and Respiratory Syndrome virus (PRRSv),
a major concern for the swine industry, responsible for significant economic losses worldwide
[5, 6]. There is no specific treatment and the vaccines are not efficient enough to eradicate the
infection [7, 8]. PRRSv is mainly transmitted by close contact with an infected pig [6]. Some epi-
demiological studies pointed out that the spread of PRRSv depends on the pig contact network,
the pig infectiousness and the pig susceptibility [9, 10]. The infectiousness and susceptibility
are influenced by several factors, which probably interact in a complex way [11] : the PRRSv
strain virulence [7, 8, 12, 13], the pig genetic resistance to PRRSv infection [8, 14, 15], as well as
the exposure intensities and inoculation routes [16–18]. Experimental studies found that (i) the
infectiousness is a log-normal-like function of the time post-infection [16] and that (ii) PRRSv
infection probability is a logistic function of the initial inoculum dose [17]. Studies on other
viruses showed that the initial inoculum dose determines the within-host immune dynamics and
course of infection [3, 4]. However, no such studies were conducted for PRRSv.
A modelling approach is a relevant tool to study the exposure impact on the within-host
dynamics for two main reasons. Firstly, experimental infections by inoculation, considered as
proxies for natural infections, usually allow to explore the influence of a single and short exposure.
Varying the exposure duration and intensity, as well as the strain virulence, would be difficult
and costly by experimental infection. Secondly, PRRSv mainly targets pulmonary macrophages,
a key component of the innate immune response, and hence alters the innate and the subsequent
adaptive immune responses in complex ways. Moreover, immune mechanisms responsible for the
infection resolution and host protection are strongly variable between hosts and PRRSv strains
[7, 8, 12, 14]. So we used a model which details the interactions between the virus and the immune
mechanisms, based on a previous study [19]. Compared to immunological models developed for
PRRSv [20] or similar pathogens targeting pulmonary macrophages, such as influenza viruses
[21–23], or tuberculosis [24, 25], the strengths of this model are : (i) the explicit and detailed
representation of the innate immune mechanisms (in particular, the interactions between the
virus and its target cells) ; (ii) the orientation of the adaptive response towards the cellular,
humoral and regulatory responses, whereas no published immunological models represent the
regulatory response and only few represent both the cellular and the humoral responses ; (iii) the
explicit representation of the main innate and adaptive cytokine syntheses and their complex
regulations of the immune mechanisms.
Using such a modelling approach to explore PRRSv exposure influence on the within-host
infection and immune dynamics for various strain virulence levels should fill in some gaps in
current knowledge. Moreover, it should help us apprehend the pig response to a given exposure
and its subsequent infectiousness, which are needed to better understand, predict and control
PRRSv spread at the between-host scale.
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In this paper, we first gave an overview of the immunological model used and defined the
designs of numerical experiments built to explore the impact of virulence level, exposure in-
tensity and duration on characteristics of the viral and immune dynamics. We then quantified
their impact by sensitivity analyses and descriptive statistics. We compared our results with
the literature and assessed the errors made on the various characteristics when approximating
exposure by simplified functions. Finally, we discussed our results, highlighting the impact of
exposure on the between-host dynamics and suggesting when and how to take exposure into
account.
III.2 Materials and methods
III.2.1 Model overview
We used a deterministic dynamic model of ordinary differential equations to simulate the infec-
tion and immune dynamics induced by PRRSv in the lung. It is a simplified version of a recently
developed model [19], in which we grouped some state variables and simplified the cytokine re-
gulation functions. The functional diagram of the model appears in Figure III.1. The model
describes the evolution over time of 14 state variable concentrations : the free viral particles (V ) ;
four effectors of the innate response : three macrophage states and the natural killers (NK) ; three
effectors of the adaptive response and six cytokines. A macrophage can either be susceptible
(Ms), phagocyting (Mp), or infected (Mi). For the adaptive response, the effectors represent the
regulatory (Rr), humoral (Rh) and cellular (Rc) responses. The six cytokines included are the
pro-inflammatory (Pi, grouping IL1β, IL6 and IL8), the innate antiviral (Ai, grouping IFNα and
TNFα) and the immuno-regulatory (IL12, antiviral IFNγ , immuno-modulatory IL10 and TGFβ)
cytokines. Our modelling assumptions are detailed and justified in Appendix B, which gives a
complete description of the model and the corresponding equations. Here we describe the main
components of the model, illustrated by a few representative equations.
Exposure to PRRSv results in free viral particles entering the lung (function E(t)). When
a free viral particle encounters a susceptible macrophage, it can either be phagocyted (rate
η), resulting in viral destruction, or it can infect the cell (rate β), resulting in viral replica-
tion (rate e). The phagocytosis is amplified by antiviral cytokines (Ai and IFNγ) and inhibited
by immuno-modulatory cytokines. The infection is amplified by IL10 and inhibited by Ai and
TGFβ. Phagocyting macrophages revert to a susceptible status after viral destruction (rate γ) ;
it is amplified by the antiviral cytokines and inhibited by IL10. The excretion (rate e) is inhi-
bited by antiviral cytokines. Pro-inflammatory cytokines amplify the recruitment of susceptible
macrophages (inflow Am) and natural killers. Macrophages undergo natural decay (rate µ
nat
M )
and TNFα-induced apoptosis (rate µ
inf
M ). Infected macrophages are cytolysed by natural killers
(rate µinnM ) and cellular effectors (rate µ
ad
M ). The viral particles undergo natural decay (rate µ
nat
V )
and are neutralised by the humoral response (rate µadV ). Corresponding equations are (III.1) &
(III.2).
III.2 Materials and methods 99
Blood vessel
Phagocytosis
IL10
IL12
Infection
TGF
γIFN
β
AiPi
Viral replication
Positive
Negative
Antibodies
Macrophage
Natural killers
Recruitment
Virus
Regulations: 
Flows: 
Viral destruction
Epithelial cellsExposure
Rc
Rh
Rr
MS
MP
MI
NK
NK
Humoral response
activation
Activation
Unactivated
effectors
MP
MI
Activated
Macrophages
Viral neutralisation
Cytolyse
Cellular response
activation
Regulatory response
activation
Cytokines:  
Cells: MS susceptible
MP Phagocyting
MI Infected
Macrophage: 
Natural killers:
NK
Adaptive effectors:
Rc Cellular
Rh Humoral
Rr Regulatory
Pro-inflammatory: Innate antiviral: Immuno-regulatory:
Production
Change of state
Adaptive effector
activation
Figure III.1 Functional diagram of the immune response to PRRSv infection in the lung.
Exposure to the virus initiates the within-host dynamics. Interactions between macrophages and
virus result in macrophage activation by either phagocytosis (amplified by antiviral cytokines
and inhibited by immuno-modulatory cytokines) or macrophage infection (amplified by immuno-
modulatory cytokines and inhibited by antiviral cytokines) resulting in the viral replication. The
activated macrophages initiate the adaptive response. The adaptive response orientation depends
on the cytokine environment : IFNγ and IL12 promote the cellular response, whereas immuno-
modulatory cytokines promote the humoral and regulatory responses. The cellular response and
the natural killers are responsible for the destruction of infected cells by cytolysis. The humo-
ral response is responsible for the viral neutralisation through antibodies. The recruitment of
susceptible macrophages and natural killers is amplified by the pro-inflammatory cytokines. Co-
lour code : virus in green, innate components in red, adaptive components in blue, components
belonging both to the innate and adaptive responses in purple.
100 Impact of exposure on the within-host dynamics
M˙s = Am [1 + κ
+(Pi IL12)] ←− recruitment
− η Ms V κ−(IL10 + TGFβ) [1 + κ+(Ai + IFNγ)] ←− phagocytosis
+ γ Mp κ
−(IL10) [1 + κ+(Ai + IFNγ)] ←− end of phag.
− β Ms V κ−(Ai + TGFβ) [1 + κ+(IL10)] ←− infection
−Ms [µnatM + µinfM κ+(Ai)] ←− decay
(III.1)
V˙ = E(t) ←− exposure
− η Ms V κ−(IL10 + TGFβ) [1 + κ+(Ai + IFNγ)] ←− phagocytosis
− u β Ms V κ−(Ai + TGFβ) [1 + κ+(IL10)] ←− infection
+ e Mi κ
−(Ai + IFNγ) ←− excretion
− V [µnatV + µadapV Rh] ←− decay/migration
(III.2)
Cytokines drive the model dynamics by a complex feedback system, as illustrated in Fi-
gure III.1. We selected the cytokines that better represent the pro-inflammatory, antiviral and
immuno-regulatory functions. The cytokine dynamics consist of two steps : synthesis by activa-
ted innate and adaptive cells and decay. The synthesis can be regulated by cytokines. Cytokine
regulations (up κ+ and down κ−) are based on the Michaelis–Menten function [24, 26, 27]. The
higher the cytokine concentration (Ci), the stronger the effect, which saturates above a threshold
concentration :
κ+(Ci) =
vm Ci
km + Ci
; κ−(Ci) =
km
km + Ci
.
A given rate (r) can either be activated (r κ+(Ci)), amplified (r [1 + κ
+(Ci)]) or inhibited
(r κ−(Ci)) by a cytokine. Regulations often involve several cytokines (Ci and Cj), which can act
independently (κ(Ci + Cj)) or in synergy (κ(Ci Cj)).
We represented the adaptive response by three effectors corresponding to the cellular Rc,
humoral Rh and regulatory Rr responses (Figure III.1). The adaptive response orientation
depends on the immuno-regulatory cytokines. The dynamics of each effector consists of three
steps : activation by activated macrophages (phagocyting or infected), proliferation and decay.
Rc synthesises IFNγ and destroys infected macrophages. Rh synthesises IL10 and neutralises free
viral particles through antibodies. Rr synthesises IL10 and TGFβ.
We previously calibrated the model to simulate an average response of an experimentally in-
fected and isolated pig to a moderately virulent PRRSv strain [19]. In published PRRSv studies,
experimental conditions are highly heterogeneous. Moreover, among the variables included in our
model, few were monitored in each study and there were few measures over time. Consequently,
based on these data, we had to design an ad hoc procedure to estimate the model parameters :
(i) definition of parameter ranges from experimental and modelling studies on pathogens tar-
geting pulmonary macrophages ; (ii) exploration of the hence defined parameter space based on
sensitivity analysis methods ; (iii) definition and selection of a relevant parameter set. The model
parameters are summarised in Table III.1.
We simulated the infection of a PRRSv-naive pig at the post-weaning stage, i.e. with no
maternal antibodies, during 300 days. The initial conditions were set as follows : Ms(0) =
5 105cells/ml for the susceptible macrophages and all remaining variables were set to zero. The
model was implemented in Scilab 5.3.3 [28].
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Table III.1 Model parameters.
Parameter Description Value Unit*
Macrophages : susceptible (Ms), infected (Mi), phagocyting (Mp)
Am recruitment rate of Ms 5 10
4 [Ce]day−1
η phagocytosis rate 5 10−7 [V]−1day−1
β infection rate 10−6 [V]−1day−1
γ 1/phagocytosis duration 96 day−1
µnatM natural decay rate 0.2 day
−1
δµ over-mortality rate of Mi 1.1 no unit
µapM apoptosis rate by TNFα 0.8 day
−1
µinnM cytolysis rate of Mi by NK 10
−3 [Ce]−1day−1
µadM cytolysis rate of Mi by Rc 10
−3 [Ce]−1day−1
Free viral particles (V )
u macrophage-virus interaction rate 1 [V][Ce]−1
e excretion rate 0.2 [V][Ce]−1day−1
µnatV natural decay rate 0.2 day
−1
µadV neutralisation rate by Rh 10
−4 [Ce]−1day−1
Adaptive effectors : cellular (Rc), humoral (Rh), regulatory (Rr) & natural killers (NK)
αR activation rate of Rc, Rh and Rr by Mp and Mi 10
−5 day−1
αN activation rate of NK 10 [Ce]day
−1
pR proliferation rate of Rc, Rh and Rr 0.05 day
−1
δRc decay rate of Rc, Rh and Rr by AICD 10
−1 [Ce]−1day−1
µR natural decay rate 0.05 day
−1
Cytokines : pro-inflammatory (Pi = IL1β + IL6 + IL8), innate antiviral (Ai = TNFα + IFNα),
immuno-regulatory (IL12, IFNγ , IL10, TGFβ)
ρPi synthesis rate of Pi by Mp and Mi 10
−2 [Cy][Ce]−1day−1
ρIL12 synthesis rate of IL12 by Mp and Mi 0.02 [Cy][Ce]
−1day−1
ρAi synthesis rate of Ai by Mp and Mi 0.05 [Cy][Ce]
−1day−1
ρinnIL10 synthesis rate of IL10 by Mp and Mi 0.02 [Cy][Ce]
−1day−1
ρadIL10 synthesis rate of IL10 by Rh and Rr 2 [Cy][Ce]
−1day−1
ρinnIFNγ synthesis rate of IFNγ by NK 10 [Cy][Ce]
−1day−1
ρadIFNγ synthesis rate of IFNγ by Rc 10 [Cy][Ce]
−1day−1
ρTGFβ synthesis rate of TGFβ by Rr 10 [Cy][Ce]
−1day−1
µC natural decay rate among the 54 scenarios 20 day
−1
km half-saturation concentration 30 [Cy]
vm saturation factor 1.5 no unit
*cell unit [Ce] = cells/ml, virus unit [V] = TCID50/ml, cytokine unit [Cy] = pg/ml
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III.2.2 Exposure functions
To represent natural and experimental infections of a naive weaner without passive immunity, we
identified three kinds of exposure : a short (Es), a prolonged (Ep) and a combination of the two
exposures (Es+p). Es represents an experimental infection by a single inoculation of an isolated
pig and could also correspond to a single contact with an infected pig under natural conditions.
Ep represents repeated contacts with infected pigs and corresponds to natural infection of a
susceptible pig in an infected herd or in an experimental batch. Es+p represents an experimental
infection of non-isolated pigs.
It has been shown that lymphoid tissues and lungs became infected 12 to 24 hours post
experimental inoculation by both intranasal and intramuscular routes [6, 29]. Natural infections
occur mainly through the nasal and oral routes. Viral particles then have to migrate to the lungs
and are exposed to the first line of defence of the organism (physical barriers and epithelial cells),
which slow down the progression. So we supposed that Es corresponds to a narrow bell-shaped
input of viral particles in the lung that lasts one day.
The first case of prolonged exposure Ep corresponds to contacts in a herd. When PRRSv is
introduced in a batch of susceptible post-weaner pigs, it spreads rapidly. The resulting outbreak
is often associated with a bell-shaped prevalence curve in the batch [6]. Furthermore, pigs have
frequent contacts with other animals in their batch, so their exposure can be approximated
by a bell-shaped curve. Depending on the pig susceptibility, strain virulence and management
conditions, the infection can have variable lengths [10]. The post-weaning stage usually lasts 40
to 50 days, so the exposure duration should not exceed 50 days. The second case of prolonged
exposure corresponds to an experimental batch, in which a susceptible pig usually has close
contacts with a single inoculated pig. The infectiousness curve of a PRRSv-infected pig is very
close to the viral titer from nasal swabs and is strongly correlated with the viremia, which follows
bell-shaped curves throughout the infection duration [16]. The infectiousness is shorter than the
infection duration. For instance, infection durations around 77 days and infectiousness duration
around 56 days were reported [16]. PRRSv mean infection duration in the lung is 56 days [6].
So in both cases, we approximated the exposure Ep by a bell-shaped curve, which we assumed
to last between 10 and 50 days.
Experimental data showed that the viral peak occurs between 7 and 14 days post-inoculation
[6]. Infection dates are difficult to monitor in natural conditions. To our knowledge, there are
no data on viral peak for natural infections. We assumed that the viral peak dates from natural
and experimental infections were fairly similar. The exposure peak should not occur after the
viral peak, so we set the former at 7 days. It is consistent with the infectiousness peak and the
peak of viral particles from nasal swabs reported in the literature for inoculated pigs as well as
pigs infected by contacts [16].
To represent the simple exposures (short and prolonged), we chose a function of time E(t)
based on the Beta distribution (Figure III.2) :
E(t) =
NE
ta−1 (DE−t)b−1∫DE
0 t
a−1 (DE−t)b−1 dt
if 0 < t < DE
0 else
(III.3)
with 1 < a < b shape parameters (no unit) for a left-shifted bell-shaped curve,
NE exposure intensity (in TCID50/ml),
DE exposure duration (in days).
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Figure III.2 Simple exposure function (semi-log graph) and its characteristics. Exposure
to the virus is a function of time E(t) defined in Equation (III.3). It is characterised by the
exposure peak Emax, the exposure peak date PE , the exposure duration DE and the exposure
intensity NE (AUC).
The curve peaks at : PE =
DE(a−1)
a+b−2 , which was set to 0.35 day for Es and 7 days for Ep.
The higher the b (resp. a), the flatter the curve at the end (resp. at the beginning) of the
exposure. We set b in order to obtain a rather flat curve at the end : for prolonged exposures,
we set E(DE − 1) ' 0.01 TCID50/ml day−1 ; for the short one-day exposure, we chose b = 5.
We deduced a from PE and b : a =
PE (b−2)+DE
DE−PE . The exposure intensity NE corresponds to the
total number of viral particles received through exposure i.e. the area under the curve (AUC).
It varied between 104.3 and 109.3 TCID50/ml as reported in experimental inoculations [13].
The combined exposure is the sum of the corresponding simple exposure functions : Es+p =
Es+Ep. It is therefore characterised by an exposure duration DEs+p = DEp and by an exposure
intensity NEs+p = NEs +NEp that also corresponds to the total exposure intensity received.
III.2.3 Designs of numerical experiments
Highly virulent strains are assumed to (i) efficiently infect the cells and replicate, (ii) promote
the host capacity to synthesise immuno-modulatory over antiviral cytokines and (iii) reduce
the activation of the adaptive response [8, 30, 31]. So we defined three virulence levels Svir
by varying ±35% the reference values in Table III.1 for (i) the parameters related to the
macrophage permissiveness (e, η and β), (ii) the cytokine synthesis rates (ρinnIFNγ , ρ
ad
IFNγ
, ρinnIL10 ,
ρadIL10 , ρTGFβ ) and (iii) the rate of adaptive response activation (αR). The low (S1), reference
(S2) and high (S3) virulence levels and their parameter values are given in Table III.2.
We tested six exposure durations DE (one short s and five prolonged p1, . . . , p5) and six gra-
duated levels of exposure intensity NE (L1, . . . , L6) given in Table III.3. Each simple exposure
function is denoted by ENEDE . We defined a first complete design D1 for the simple exposures
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crossing the six exposure durations DE , the six exposure intensities and the three virulence
levels Svir (Figure III.4).
For the combined exposures Es+p, we defined a second complete design D2 (Figure III.4) :
first we crossed two DEp durations (p1 and p5) with three exposure intensities NEp (L1, L4,
L6) ; then we combined them with the same three intensities NEs for the short exposure ; finally
we crossed these 18 exposure scenarios with the three virulence levels. Each combined exposure
function is denoted by E
NEs+NEp
DEs+DEp
. Values of the combined exposure intensity NEs+p are shown in
Table III.4. They can be approximated by the highest intensity of the combination : NEs+p '
max(NEs ,NEp).
Illustrations of simple and combined exposure functions are shown in Figure III.3.
Table III.2 Model parameter values for the three virulence levels used in designs D1 and
D2. The reference value (ref.) corresponds to Table III.1, in which the parameters are defined.
e η β ρAi ρ
inn
IFNγ
ρadIFNγ ρ
inn
IL10
ρadIL10 ρTGFβ αR
low S1 0.13 6.75 10
−7 0.35 10−6 0.0675 13.5 13.5 0.013 1.3 6.5 1.35 10−5
ref. S2 0.2 5 10
−7 10−6 0.05 10 10 0.02 2 10 10−5
high S3 0.27 3.25 10
−7 1.35 10−6 0.0325 6.5 6.5 0.027 2.7 13.5 0.35 10−5
units e : [V][Ce]−1day−1 η, β : [Ce]−1day−1 ρ.. : [Cy][Ce]−1day
−1 αR : day−1
Table III.3 Exposure parameter values for the simple
exposures used in design D1. Parameters, defined in Equa-
tion (III.3), are the exposure intensity NE , the exposure du-
ration DE and the shape parameters a and b. a is deduced
from the three other parameters and the exposure peak date
PE by : a =
PE(b−2)+DE
DE−PE .
L1 L2 L3 L4 L5 L6
NE 104.3 105.3 106.3 107.3 108.3 109.3
DE PE b
s 1 0.35 5 5 5 5 5 5
p1 10 7 1.4 1.9 2.3 2.7 3.1 3.6
p2 20 7 2.9 4.7 6.6 8.4 10.3 12.1
p3 30 7 4.3 7.6 11 14 17 21
p4 40 7 5.7 5.7 5.7 8.1 8.1 8.1
p5 50 7 7.1 7.1 7.1 7.1 7.1 7.1
units NE : TCID50/ml DE , PE : day a, b : no unit
Table III.4 Exposure intensity
values for the combined ex-
posures used in design D2.
A combined exposure being de-
fined as the sum of a short and a
prolonged exposure, its exposure
intensity is the sum of the cor-
responding two simple exposure
intensities :
NEs+p = NEs +NEp .
NEs
+ L1 L4 L6
L1 10
4.6 107.3 109.3
NEp L4 107.3 107.6 109.3
L6 10
9.3 109.3 109.6
unit NE : TCID50/ml
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Figure III.3 Exposure functions (semi-log graphs) used in designs D1 and D2 (selection).
The whole exposure intensity range NE ∈ {L1, L2, L3, L4, L5, L6} and a selection of exposure
durations are represented. Panels A–C correspond to simple exposures (design D1) for various
durations : A short DE = s, B prolonged DE = p1 and C prolonged DE = p5. Panel D
corresponds to combined exposures (design D2) for DE = p5 and NEs = NEp . The ∗ and the
dashed line mark the exposure peak date.
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Figure III.4 Designs of numerical experiments for the simple (design D1) and combined
(design D2) exposure scenarios. The scenarios are defined by the following parameters, consi-
dered as inputs for the sensitivity analyses : the exposure duration DE ∈ {s, p1, p2, p3, p4, p5} ;
the exposure intensity NE ∈ {L1, L2, L3, L4, L5, L6} ; the virulence level Svir ∈ {S1, S2, S3}.
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III.2.4 Characteristics of the viral and immune dynamics
To illustrate the within-host dynamics, we looked at the viral titer V and selected seven key
immune outputs relevant to PRRSv infection : the infected macrophages Mi, the cellular Rc and
humoral Rh effectors, the pro-inflammatory cytokines Pi, the innate antiviral cytokines Ai and
two immuno-regulatory cytokines IFNγ and IL10 [6, 30, 32, 33].
To characterise the viral titer curve over time, we considered five scalar descriptors based on
[3]. They are listed below and illustrated in Figure III.5 :
• ΣV : the total viral dose, defined as the cumulative number of viral particles over the
simulation duration (AUC), an indicator of the infection severity ;
• Vmax : the viral peak ;
• Tmax : the viral peak date ;
• DI : the infection duration ; DI is defined as the time during which the viral titer is higher
than 10−2 TCID50/ml ;
as we used a continuous time formalism in our model, the variables may tend to zero but
cannot reach the zero value in finite time. So we fixed a threshold at 10−2 TCID50/ml
below which we assumed that the infection was resolved ;
• DD : the detection duration, defined as the time during which the viral titer is higher than
the detection limit set at 102 TCID50/ml, as in [3].
The viral peak and infection duration more or less determine the total viral dose and are hence
two components of the infection severity.
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Figure III.5 Shape of the viral titer curve over time (semi-log graph) and its characteris-
tics. The latter consist of the viral peak Vmax, the viral peak date Tmax, the infection duration
DI , the detection duration DD and the total viral dose ΣV (AUC).
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To characterise the immune response, we first chose four basic descriptors that can be mea-
sured experimentally and are relevant for PRRSv global immune response [6, 30, 32, 33]. They
are based on the AUC of cytokines and adaptive effectors :
• ΣPi : the total pro-inflammatory cytokines (AUC), shown to be a good proxy of the
activation level of the immune response [19] and related to the clinical status of the pig ;
• %(Ai+IFNγ) = 100 ΣAi+ΣIFNγΣAi+ΣIFNγ+ΣTGFβ+ΣIL10 : the percentage of anti-viral cytokines, sup-
posed to play a key role in PRRSv infection resolution ;
• %Rc = 100 ΣRcΣRc+ΣRh+ΣRr : the percentage of cellular response, supposed to play a key role
in PRRSv infection resolution ;
• %Rh = 100 ΣRhΣRc+ΣRh+ΣRr : the percentage of humoral response, supposed to play a key
role in PRRSv infection persistence.
We also defined another set of five descriptors related to the viral destruction or replication
mechanisms : the phagocytosis, neutralisation and excretion of viral particles, the infection by
viral particles and the cytolysis of infected macrophages. For each mechanism, the descriptor is
defined as the ratio between the total number (AUC) of viral particles or macrophages involved
and the exposure intensity (NE). This normalisation allowed us to compare the activation levels
of the mechanisms independently from the exposure intensity. For instance, the normalised
number of viral particles having infected macrophages is defined from Equation (III.2) as follows :
Ninf/E =
∫ DI
t=0 u β Ms(t) V (t) κ
−(Ai(t) + TGFβ(t)) [1 + κ+(IL10(t))] dt
NE .
The other descriptors are similarly defined. All five are listed below :
• Npha/E : the normalised number of viral particles phagocyted by macrophages ;
• Ninf/E : the normalised number of viral particles having infected macrophages ;
• Nneutr/E : the normalised number of viral particles neutralised by the humoral response ;
• Ncyt/E : the normalised number of cytolysed infected macrophages ;
• Nexcr/E : the normalised number of viral particles excreted by infected macrophages.
III.2.5 Analyses
To analyse design D1 based on simple exposure scenarios, we performed sensitivity analyses.
The first set of analyses aimed at exploring the influence of the scenario parameters (DE , NE
and Svir), considered as inputs, on the 14 scalar descriptors of the within-host dynamics defined
above, considered as outputs. We identified the main effect of each input and the effects of the
two-input interactions. For each scalar output, we used a classical univariate method : for a
given design – defining the input combinations tested, or scenarios – sensitivity indices quantify
the fraction of variance among simulations explained by each input. An ANOVA is performed
to estimate the influence of the main effect of each input and the effects of the multi-input
interactions on the output. The sensitivity index associated with each term (main effect or
interaction) is defined as the ratio between the sum of squares corresponding to that term and
the total sum of squares [34].
We also performed a sensitivity analysis to explore the influence of the scenario parameters
on the viral titer curve over time, which is non scalar output. We used a multivariate method
based on a decomposition of the output by a principal component analysis (PCA) [35]. As a
result of the PCA, an inertia proportion is attributed to each component. It represents the
variability among simulations carried by the component. Moreover, each simulation is given a
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“score” on each component, a scalar which represents the projection of the simulation on the
component. Sensitivity indices are computed for each component using these scores as outputs.
Finally, a generalised sensitivity index (GSI) is calculated for each term as the sum of the
sensitivity indices corresponding to that term on each PCA component, weighted by the inertia
of the component. We used the multisensi R package [36] for these analyses.
We did a focus on an output of particular interest, the infection duration (DI), which is one
component of the infectiousness. In order to quantify the influence of the scenario parameters on
the infection duration, for both designs D1 and D2, we fitted a linear model defined as follows :
DI = ξ0 + ξSvir + ξNE log(NE) + ξDE DE + ε
with ξ0 the constant term and ε the residual variance. Svir was considered as a qualitative factor,
log(NE) and DE as quantitative covariables. The parameters that were estimated were the three
ξSvir for Svir ∈ {S1, S2, S3}, ξNE and ξDE .
We used design D2 to investigate whether combined exposures could be approximated by
simpler exposure functions. For instance, we wanted to assess the error made if we neglected
the exposure due to contacts in an experimental infection. We chose two approximation types :
(a) we neglected either the short or the prolonged simple exposure of the combination ; and (b)
we approximated the combination by a simple scenario with a similar exposure intensity and
either a short or the same exposure duration. The exposure intensity of the combined scenario is
close to the highest intensity of the combination (see Table III.4), so this is the value used for
the simple scenario in type (ii) approximations. The relative error for each viral characteristic
C ∈ {ΣV , Vmax, Tmax, DI} was denoted by :
∆Ci+jk (E
l
m) =
C(Ei+js+k)− C(Elm)
C(Ei+js+k)
with Elm ∈
{
Eis, E
j
k, E
max(i,j)
s , E
max(i,j)
k
}
∀ i, j ∈ {L1, L4, L6} & ∀ k ∈ {p1, p5}.
(III.4)
Comparisons involved the same Svir level for both scenarios.
For the 18 homogeneous scenarios (i = j), simple scenarios used in (a) and (b) approxi-
mations were the same (Eis = E
max(i,j)
s and E
j
k = E
max(i,j)
k ), leading to 18 × 2 = 36 compari-
sons. For the 36 heterogeneous scenarios (i 6= j), one of the four simple scenarios (Emax(i,j)s if
max(i, j) = i, or E
max(i,j)
k if max(i, j) = j) corresponded to both (a) and (b) approximations,
leading to 36× 3 = 108 comparisons. So a total of 144 comparisons was performed. Besides, we
used type (c) approximations to designate approximations of both types (a) and (b).
We performed all our analysis using R software, version 3.0.2. [37].
III.3 Results
Overview of the within-host dynamics among all scenarios
The viral titer and the seven key immune outputs for the 162 scenarios of designs D1 and D2
are represented in Figure III.6.
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Firstly, we compared our results with the literature (Table III.5). Results related to the viral
titer dynamics are in good agreement with the literature data. We compared the detection dura-
tions DD with the experimental infection durations reported in the literature, as measurement
techniques have a detection threshold a priori close to the value we chose (102 TCID50/ml).
The DD range (15–94 days) is narrower than the infection durations reported in the literature
(ca 28–251 days). However, the mean DD (54 days) is close to the mean infection duration in
the lung reported in experimental studies (56 days) [6].
The viral titer dynamics is widely informed in the literature, but we found few data on the
immune dynamics. So we looked at the qualitative behaviour rather than quantitative values of
the immune response. Our results exhibited realistic qualitative behaviours and variation ranges
(Table III.5). The innate variables (Ai, Pi,Mi, IL10 in Figure III.6) peaked in the first infection
days, whereas the adaptive variables (IFNγ , Rc, Rh in Figure III.6) peaked later, around two
to three weeks, in agreement with the literature [5, 30, 32]. As reported in the literature, our
results exhibited lower percentages of cellular response than of humoral response (Table III.5).
Secondly, we looked at the impact of exposure on the model outputs. Globally, the higher
the exposure intensity (log(NE)), the higher the viral titer and the key immune outputs (Fi-
gure III.6), in agreement with the literature [16–18]. For a given level of exposure intensity,
we identified the impact of the other inputs (exposure duration and virulence level). In parti-
cular, scenarios with short exposure durations (DE) resulted in an early peak (for example, the
viral titer peaked at 1 day), whereas scenarios with prolonged exposure durations resulted in a
delayed peak (for example, the viral titer peaked between 9 and 12 days).
Thirdly, we focused on the infection duration (DI), an output related to the infectiousness.
The impact of exposure on this output was further investigated by fitting linear models. They
exhibited a good fit (R2 > 0.98) for the simple and combined exposure scenarios. The effects of
exposure intensity (log(NE)), exposure duration (DE) and virulence (Svir) were significant for
both designs : DI showed a linear relation with log(NE) and with DE for each virulence level
Svir (Figure III.7). For virulence levels Svir ∈ [S1, S3] (a realistic range), we found that, after a
simple exposure DI = [31.67, 140.82] + 9.21 log(NE) + 0.33DE and after a combined exposure
DI = [29.62, 141.12] + 9.42 log(NE) + 0.17DE .
We used the four basic immune descriptors (ΣPi , %(Ai+IFNγ), %Rc and %Rh) to assess
the impact of the immune response on the infection duration among all exposure and viru-
lence scenarios (Figure III.8). DI always decreased as %(Ai+IFNγ), the percentage of antiviral
cytokines, increased. No such trends were identified for the other descriptors. However, for a
given virulence level, increasing levels of the total pro-inflammatory cytokines (ΣPi) and per-
centage of humoral response (%Rh) and decreasing levels of the percentage of cellular response
(%Rc) tended to increase the infection duration. These results are consistent with the literature
[7, 8, 12, 14, 19].
We highlighted two scenarios with similar infection durations, but contrasted immune dyna-
mics : Sc− = EL6p5 × S2 (DI = 162 days) and Sc+ = EL1s × S3 (DI = 176 days), highlighted on
Figure III.8. Compared to Sc−, Sc+ was associated with a lower ΣPi , similar %(Ai+IFNγ), a
higher %Rc and a lower %Rh.
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Table III.5 Summary of the viral titer and key immune outputs compared with literature
data. Minimal, median, mean and maximal values of : (i) the viral characteristics : infection DI
and detection DD durations, viral peak Vmax and viral peak date Tmax ; (ii) the peak concentrations
of key cytokines : innate antiviral Ai, pro-inflammatory Pi, IL10 and IFNγ ; (iii) the peak values
of the cellular %Rc and the humoral %Rh effectors expressed as percentages of the sum of the
three adaptive effector peaks. The infected macrophages Mi also belong to the key immune outputs
but are not presented here, as the only relevant data found in the literature reported a maximal
Mi number of 15 10
6 cells, representing around 40% of the total macrophage concentration in the
bronchoalveolar lavage fluids [38]. Our results exhibited a maximal Mi percentage ranging between
0.5% and 99%, with a mean value of 42%.
DI DD Vmax Tmax A
peak
i P
peak
i IL
peak
10 IFN
peak
γ %R
peak
c %R
peak
h
min 67 15 103.5 1 5 0.3 0.7 0.03 9 34
median 133 60 107.2 10 176 96 66 4 14 46
mean 151 58 106.9 7 274 165 110 6 18 43
max 244 95 109.3 12 1002 580 580 24 33 50
References from reviews on PRRSv infection [5, 6, 8, 30, 33]
tendency low high high low low(high) high(low)
mean ' 37− 56
range 28− 251 102 − 109 7− 14 0− 103 0− 103 0− 103 0− 103
References from PRRSv experimental infections
[39] > 24 102.5 − 104.5 60 75
[14] > 42 107 1600 40
[31] 0− 2800 0− 1350
[40] 1800 1000
[41] 43 104.5 80− 120
[38, 42] 52 0 ' 139
[43] > 21 103 − 1010 600 450 100
[44] > 14 104.5 − 105.5 0− 328
[45] 52 104 − 106
units DI , DD, Tmax : day Vmax : TCID50/ml A
peak
i , P
peak
i , IL
peak
10 , IFN
peak
γ : pg/ml
112 Impact of exposure on the within-host dynamics
NE [TCID50 ml−1]
D
I
[d
ay
]
50
100
150
200
250
104.3 105.3 106.3 107.3 108.3 109.3
L1 L2 L3 L4 L5 L6
A
NE [TCID50 ml−1]
D
I
[d
ay
]
50
100
150
200
250
10
4
.6
10
7
.3
10
7
.6
10
9
.3
10
9
.6
B
Figure III.7 Infection duration as a linear function of the exposure intensity logarithm
for both designs. A : simple exposure scenarios (design D1) ; B : combined exposure scenarios
(design D2). Simulated infection durations DI are plotted against exposure intensities NE (semi-
log graphs) for each virulence level Svir ∈ {◦S1,4L2,+S3} and for each exposure duration DE
(for each Svir, the higher the DE , the higher the mark). Corresponding linear regression lines are
plotted (for each Svir, the higher the DE , the higher the line).
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Figure III.8 Infection duration as a function of the global immune characteristics for
all scenarios. A : total pro-inflammatory cytokines ΣPi ; B : percentage of antiviral cytokines
among innate antiviral and immuno-regulatory cytokines %(Ai+IFNγ) ; C : percentage of cellular
response among all adaptive effectors %Rc and D : percentage of humoral response among
all adaptive effectors %Rh. Virulence levels are highlighted by colours on the graphs : Svir ∈
{◦S1,4L2,+S3}. Scenarios of particular interest : • corresponds to Sc− = EL6p5 × S2 and +
corresponds to Sc+ = EL1s × S3.
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III.3.1 Exploring the influence of simple exposures
Thanks to a multivariate sensitivity analysis, we quantified the influence of the simple scenario
parameters (design D1) on the viral titer dynamics. We showed that more than 90% of the va-
riability was determined, in descending order, by : the virulence level Svir, the exposure intensity
NE , the interaction between both and the interaction between NE and DE (Figure III.9).
GSI on viral dynamics [%]
Svir : DE
DE
NE : DE
NE : Svir
NE
Svir
0 5 10 15 20 25 30
Figure III.9 Multivariate sensitivity analysis for the viral titer dynamics based on simple
exposure scenarios (design D1). Global sensitivity indices (GSI) of the virulence level Svir,
exposure intensity NE exposure duration DE and their two-way interactions.
To better understand how virulence and exposure influenced the viral titer and the immune
response, we performed sensitivity analyses on each viral and immune characteristic (output).
The viral titer curve is decomposed into several characteristics (e.g. peak) and the immune
characteristics summarise different features of the immune response. Results are presented in
Table III.6 and illustrated in Figure III.10. If an output increases (decreases) with a given
input, we say that this input has a positive (negative) impact on the output.
The exposure intensity NE had a strong and dominant influence (sensitivity indices higher
than 50%) on all the within-host characteristics except the viral peak date Tmax, the infec-
tion duration DI and the percentage of antiviral cytokines %(Ai+IFNγ). In particular, NE
had a positive impact that almost fully explained the variance of the total viral dose ΣV (Fi-
gure III.10A), the total pro-inflammatory cytokines ΣPi (Figure III.10D) and the normalised
number of viral particles neutralised by the humoral response Nneutr/E (Figure III.10K). As
a result, the total viral dose, which is an indicator of the infection severity, increased with the
total pro-inflammatory cytokines whatever the virulence level and the exposure dose. This is
consistent with PRRSv experimental studies which showed that the levels of pro-inflammatory
cytokines were correlated with the severity of pulmonary lesions [39, 46].
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Figure III.10 Impact of scenario parameters on viral and immune characteristics for
simple exposures (design D1). A : total viral dose ; B : infection duration DI ; C : viral
peak Vmax ; D : total pro-inflammatory cytokines ΣPi ; E : percentage of antiviral cytokines
%(Ai+IFNγ) ; F : percentage of cellular effectors %Rc ; G : percentage of humoral effectors %Rh ;
H : normalised number of excreted viral particles Nexcr/E ; I : normalised number of viral particles
having infected macrophages Ninf/E ; J : normalised number of cytolysed infected macrophages
Ncyt/E ; K : normalised number of neutralised viral particles Nneutr/E ; L : normalised number of
phagocyted viral particles Npha/E . All characteristics but the viral peak (all but C) are plotted
against the exposure intensity NE ∈ {L1, L2, L3, L4, L5, L6}, with the virulence level highlighted
in colours : Svir ∈ {◦S1,4S2,+S3} ; replicates (same NE and Svir) and correspond to the
various exposure durations. The viral peak (C) is plotted against the exposure peak Emax, with
the exposure intensity highlighted in colours ; replicates (same NE) correspond to the different
virulence levels and exposure durations. [ – ] = no unit.
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There were few significant interactions (i.e. > 10%). Vmax was influenced by NE ×DE . For
a given NE , the exposure peak Emax was set by DE , so NE × DE corresponds in fact to the
positive impact of Emax (Figure III.10C). Nexcr/E (Figure III.10H), Ninf/E (Figure III.10I)
and Ncyt/E (Figure III.10J) were influenced by NE × Svir. NE had a negative impact on
Nexcr/E and Ninf/E , whereas Svir had a positive impact on these outputs which decreased with
NE . Ncyt/E increased and then decreased as NE increased ; the positive impact of Svir was higher
for intermediate NE values.
Three within-host characteristics were little or not influenced by NE . Tmax was fully deter-
mined by the exposure duration DE , which had a positive impact. It is linked to the contrasted
exposure peak dates between the short (PE = 0.35 and Tmax = 1) and prolonged exposure
(PE = 7 and 9 ≤ Tmax ≤ 12) functions. Tmax was indeed determined by the exposure peak
date (Figure III.11A). DI and %(Ai+IFNγ) were explained by Svir and to a lesser extent by
NE . DI (Figure III.10B) was positively impacted by Svir and NE , whereas %(Ai+IFNγ) (Fi-
gure III.10E) was negatively impacted by Svir and NE . DD is by definition linked to DI , but
Svir had a very low impact on DD (Table III.5). As DD is shorter than DI (Figure III.5), this
suggests that the exposure effect dominates the virulence effect during the first days and weeks.
Without normalisation, the excretion, infection, cytolysis, neutralisation and phagocytosis
increased with NE (results not illustrated). With normalisation, all but the neutralisation ten-
ded to zero for high values of NE , which suggests that these immune mechanisms saturated
for high exposure intensities (Figure III.10H–L). Furthermore, Ncyt/E and Nneutr/E were low,
suggesting that cytolysis and neutralisation had a lower impact on the viral titer reduction than
phagocytosis by macrophages. This is consistent with experimental PRRSv infection results
[7, 8, 12, 14].
III.3.2 Looking at the impact of exposure simplifications
Firstly, we used the results on simple exposure scenarios described above to compare prolonged
and short exposures with the same exposure intensity and the same virulence level. Compared to
the prolonged exposure scenario, the short exposure scenario had (i) a similar infection severity
(marks confounded in Figure III.10A for each exposure intensity NE) ; (ii) a shorter infection
duration, the corresponding coefficient in the linear regression being positive (illustrated in
Figure III.7A) ; and (iii) a higher viral peak and an earlier viral peak date. We deducted (iii)
from the exposure definition and the correlations between the exposure and viral characteristics.
Indeed, compared to prolonged exposures, the short exposures were defined with a lower exposure
peak date (PE = 1 day) and higher exposure peaks (Emax). Moreover, PE and Tmax were
positively correlated, as were Emax and Vmax (Figure III.11).
Secondly, we explored the errors made on the viral characteristics when approximating a
combined exposure scenario by a simple exposure scenario : (a) by neglecting either the short
or the prolonged exposure of the combination ; and (b) by approximating the combined scenario
by a simple scenario with a similar exposure intensity and either a short or the same exposure
duration. Note that the approximation by the simple scenario of the combination with the highest
exposure intensity was both of types (a) and (b) ; it was designated as a type (c) approximation.
We showed previously that the total viral dose (ΣV ) of simple scenarios was fully determined by
the exposure intensity (NE). It was also the case for the combined scenarios (Figure III.12A).
However, the error made when approximating a combined scenario by a simple scenario (∆ΣV )
was not determined by the exposure intensity of the combined scenario (NEs+p , Figure III.12B),
but mainly depended on the exposure combination and on the simple scenario used for the
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Figure III.11 Influence of the exposure peak on the viral peak. A : viral peak date Tmax
plotted against exposure peak date PE ; B : viral peak Vmax plotted against exposure peak
Emax (log-log graph). 8 exposure peak dates were computed (from 1 day to 49 days by 7 days)
for a 50-day exposure duration (p5), an intermediate exposure intensity (L4 = 10
7.3 TCID/ml)
and a reference virulence level (S2). Our results exhibited positive linear correlations (dashed
lines) between the exposure PE and viral Tmax peak dates (R
2 = 0.99), as well as between the
logarithms of the exposure Emax and the viral Vmax peaks (R
2 = 0.98).
approximation (NEs +NEp , Figure III.12C). So, we took the combinations into account in our
exploration. The results are presented in Table III.7.
Good approximations (relative error ∆ < 0.05) of all viral characteristics were only obtained
for the heterogeneous combined exposures (Ei+js+k with i 6= j ; type (c) of the last six columns
in Table III.7), when compared with the simple exposure of the combination that had the
highest exposure intensity (Eis if i = max(i, j) or E
j
k if j = max(i, j) ; rows (c) in Table III.7).
Otherwise, approximations generated notable errors.
The viral characteristics of the homogeneous exposure combinations (Ei+js+k with i = j ; type
(c) of the three first columns in Table III.7) were approximated as follows : (i) the total viral
dose ΣV was similarly underestimated by short and prolonged exposures ; (ii) the infection
duration DI was well estimated by prolonged exposures and sometimes underestimated by short
exposures ; (iii) the viral peak Vmax was well estimated by short exposures and underestimated
by prolonged exposures ; and (iv) the viral peak date Tmax was well estimated by short exposures
and highly overestimated by prolonged exposures.
To conclude, the relative errors were globally lower when the approximation had the highest
exposure intensity of the combination (type (b) in Table III.7). ΣV was similarly approximated
by short (lines Eis or E
j
s in Table III.7) or prolonged (lines Eik or E
j
k in Table III.7) simple
exposures. DI was globally better approximated by short exposures. Vmax and Tmax were globally
better approximated by short exposures. All viral characteristics tended to be underestimated,
except Tmax which tended to be highly overestimated in most cases.
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types (a) and (b) (type (c) approximation) were coded as (b) by •.
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III.4 Discussion
III.4.1 Scope and limits of our approach
We studied the impact of exposure on PRRSv infection and immune dynamics by a modelling
approach. Our results show that the exposure characteristics influence the within-host immune
dynamics. The within-host immune dynamics determines the viral titer, which in turn deter-
mines the infectiousness of the infected pig. The infectiousness contributes to the exposure of
susceptible pigs, together with the pig contact structure, and so the loop is closed. Consequently,
within-host models need to take the exposure into account to represent the immune and viral
dynamics correctly. Between-host models also need to take the exposure of susceptible animals
into account to represent the pathogen transmission, which partly depends on the within-host
dynamics of infected animals [1].
The simplest way to represent the exposure in a model is by way of a positive initial condi-
tion for the pathogen, i.e. a punctual exposure dose. Most studies used this approximation in
experimental infections [4, 17], in within-host models of various viral infections [3], or in immuno-
epidemiological models [1, 47–50]. These theoretical or applied immuno-epidemiological models
aim at modelling the pathogen spread while taking into account the host response to the in-
fection. They mainly pertain to the “nested approach”, in which an immunological model is
linked to an epidemiological model as follows : the epidemiological model includes a time-since-
infection structure for the infected individuals, which corresponds to the time variable of the
immunological model ; moreover, some parameters of the epidemiological model depend on the
within-host variables (e.g. the transmission rate depends on the viral titer). Only few published
immuno-epidemiological models represent the exposure as a time-dependent function related to
the viral titer of infected individuals in contact [51].
We represented the exposure by bell-shaped functions characterised by their duration and
intensity, the latter corresponding to the total viral dose received through exposure. A narrow
bell-shaped function is quite an obvious choice to represent an experimental inoculum. Represen-
ting repeated contacts with infected individuals by such a smooth function is an approximation
that we deemed reasonable, given the high frequency of contacts within a batch. To calibrate
our functions, we used reported experimental inoculation doses for the short exposures [13]. It
was less obvious for the prolonged exposures. Indeed, directly quantifying PRRSv exposure by
contacts in either experimental or natural conditions seems rather difficult. So we assumed that
exposure was related to the infectiousness of the contact animals and hence strongly correla-
ted with their viremia. This assumption was based on experimental protocols which followed
primary infections occurring by contacts with an inoculated animal, conducted for PRRSv [16].
PRRSv strain virulence has an impact on the within-host dynamics. The gradient of virulence
we explored in this study produced realistic results, in the sense that they were consistent with
the variation range observed in the literature (details in the Results section). Strain virulence and
host susceptibility tend to influence the same immune mechanisms (for instance viral excretion),
so our results would still hold for various host susceptibilities : the impact of a more virulent
strain would correspond to the response of a more susceptible pig [19].
We simulated the infection of PRRSv-naive pigs at the post-weaning stage. Infection of post-
weaners was shown to have a strong impact on PRRSv spread at the herd level [6]. However,
if we wanted to take reinfections of older pigs into account, we would need to adapt our model
and represent the memory response, which confers a certain protection against reinfection and
is determined by the activation and orientation of the adaptive response.
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III.4.2 Exposure has an impact on PRRSv spread
Reducing the pig infectiousness should limit PRRSv spread. The infectiousness depends on the
infection duration and severity (linked to the total viral dose). Besides, PRRSv most severe
infections can result in the death of the pig. So the infection duration and severity are two
descriptors of particular interest.
At the within-host scale, our main results involving these descriptors were in agreement with
experimental PRRSv infection results : (i) the level of pro-inflammatory cytokines was positively
correlated with the infection severity [39, 46] ; (ii) short infection durations were associated with
the dominance of the cellular response over the humoral response (for a given strain virulence)
[7, 8, 12, 14] ; (iii) the cytolysis and viral neutralisation exhibited a low influence on the infection
resolution and were inefficient to reduce PRRSv infection severity [7, 8, 12, 14].
Exploring the impact of exposure characteristics on these descriptors, we exhibited more
original results. We found that the infection severity was fully determined by the exposure
intensity. The infection duration increased with the strain virulence and, for a given strain
virulence, it exhibited a positive linear correlation with the logarithm of the exposure intensity
and the exposure duration. Whatever the exposure and strain virulence, the infection duration
decreased while the percentage of antiviral cytokines increased. These results are consistent with
an experimental study on influenza, which found that the exposure dose influenced the infection
dynamics via the antiviral cytokines [4]. Consequently, an estimate of the viral dose received
through exposure should be enough to infer the infection severity. However, to predict the
infection duration, one would also need to know the exposure duration and the strain virulence.
The exposure intensity and duration hence affect the pig infectiousness, which is also modulated
by the strain virulence.
III.4.3 When and how to take PRRSv exposure into account ?
In PRRSv experimental infection of non-isolated pigs, the exposure due to contacts between
inoculated pigs is often considered as negligible. However, there is no study which compares
the within-host dynamics of isolated and non-isolated inoculated pigs. We used our model to
weigh up this hypothesis. For each virulence level and each inoculum dose, we compared a short
exposure scenario, representing the inoculum, with exposure scenarios combining this short
exposure with several prolonged exposures, representing contacts. When the exposure intensity
due to contacts was lower than the inoculum dose, the infection duration and severity were
similar for the short and combined scenarios. When the exposure intensity due to contacts
exceeded the inoculum dose, these viral characteristics became notably higher for the combined
scenarios. Experimental studies showed that the higher the PRRSv strain virulence, the higher
the infectiousness of infected pigs [13, 16]. Moreover, we showed here and in [19] that higher strain
virulences induced longer infections. Therefore, an experimental inoculation of non-isolated pigs
with a highly virulent strain should result in a high exposure by contacts. The within-host
dynamics of pigs inoculated with the same dose of a highly virulent strain, in particular their
estimated infection duration and severity, would then be notably higher for non-isolated pigs
than for isolated pigs.
In modelling approaches and particularly for immuno-epidemiological models, exposure is
a key issue. Most models approximate the exposure by a punctual dose and do not further
investigate its impact. We chose to study the impact of exposure by varying the characteristics
of a given exposure function (a bell-shaped function). We found that the exposure intensity (the
total viral dose received through exposure) and to a lesser extent the exposure duration and
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peak had a strong impact on the within-host dynamics, which could vary according to PRRSv
strain virulence. Fixing the exposure intensity, we looked at the impact of the exposure duration
and peak.
Firstly, from our results on simple exposure scenarios, we deduced that approximating a
prolonged exposure by a short exposure with the same exposure intensity would result in (i) a
good estimation of the infection severity ; (ii) an underestimation of the infection duration ; and
(iii) an overestimation of the viral peak and an underestimation of the viral peak date. Obviously,
when approximating a prolonged exposure by short exposure, the higher the exposure duration of
the prolonged exposure, the worse the errors on the within-host dynamics. As our short exposure
function is a narrow bell-shaped curve, similar errors would be expected when approximating
the exposure by a punctual exposure dose (initial condition).
Secondly, comparing combined exposure scenarios and simple scenarios, we showed that a
short exposure was a better approximation for the viral peak and its date, whereas a prolonged
exposure was a better approximation for the infection duration. The infection severity was
similarly underestimated with both approximations. The approximated exposure duration would
then be chosen according to which viral characteristics we would want to estimate best.
To conclude, a good approximation of the exposure should at least preserve the exposure
intensity, especially to estimate the infection severity. Besides, representing the exposure due
to contacts by a short or even a punctual exposure would tend to underestimate the infec-
tion duration. As the infection severity and duration both contribute to the pig infectiousness,
a prolonged exposure of the adequate intensity would probably be an adequate choice in an
immuno-epidemiological context.
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IV.1 Introduction
Vaccination is the main control strategy used to limit PRRSv infection severity and PRRSv
spread [1]. However, no commercial PRRSv vaccine provides a complete protection against
PRRSv infection. Vaccines only reduce the infection severity and duration and so PRRSv shed-
ding at the between-host scale [1, 2]. Several recent studies reviewed current knowledge and
knowledge gaps that may be relevant for the development of efficient vaccines [1–6]. The main
barriers for the development of efficient vaccines include a partial understanding of the immune
response to PRRSv, the high diversity of PRRSv strains in field conditions and the high variabi-
lity of within-host dynamics depending on PRRSv strain and host susceptibility. Consequently,
the exploration of vaccine efficiency and the identification of conditions needed for vaccines to
have an effect on the immune response are the main challenge for PRRSv control [1, 2, 4, 7].
PRRSv vaccination frequently consists in an inoculation by a more or less modified hypovi-
rulent PRRSv strain to induce an immune response with limited pathogenic effects. During the
induced immune response, the adaptive effectors and antibodies partly differentiate into memory
components (memory T cells and memory B cells). Memory components have a long lifetime
and exhibit no immune functions until they are activated by PRRSv exposure (Section I.1.5).
Depending on the memory component titers induced by vaccination, vaccines exhibit variable
levels of pig protection against PRRSv infection. Consequently, the immune mechanisms pro-
tecting against the viral replication in pigs should be identified and activated by vaccines [6].
Vaccines that can induce strong cross-protective cellular adaptive immunity should have benefits
on the reduction of viraemia and PRRSv-induced clinical signs ; they should also improve the
pig general health condition by reducing secondary complications related to PRRSV-induced
immunodeficiency [2].
The immune response induced by PRRSv infection is only partially effective, although the
mechanisms responsible for this ineffective response are still unknown. Improving the immune
response efficiency remains a challenge [1–6]. Whatever the pathogen, the main immune me-
chanisms promoting pathogen clearance are (i) a cytokine synthesis orientated more towards
antiviral cytokines (including IFNα, TNFα and IFNγ) than immuno-modulatory cytokines (in-
cluding IL10, TGFβ and IL4) ; (ii) a high infected cell destruction by cytotoxic lymphocytes and
natural killers ; and (iii) a high viral neutralisation by antibodies. PRRSv induces an altered
innate response, with (i) a low inflammation, (ii) a cytokine synthesis orientated more towards
immuno-modulatory than antiviral cytokines and (iii) a high target cell permissiveness. This
impaired innate response could play an important role in the poor, delayed and altered adaptive
response and in the prolonged PRRSv infection duration [1–6]. Indeed, the adaptive response
is characterised by an orientation towards the humoral response (so low titers of cytotoxic T
cells and adaptive antiviral cytokines) associated with high syntheses of immuno-modulatory
cytokines but low titers of neutralising antibodies. Given these findings, efficient vaccines would
need to induce (i) a better immediate innate response, (ii) higher levels of antiviral cytokines and
lower levels of immuno-modulatory cytokines and (iii) higher levels of neutralising antibodies
and cytotoxic cells [1–3]. However, experimental studies resulted in controversial conclusions
about the influence of these mechanisms on the infection resolution and protection, which are
described below.
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Antiviral v.s. immuno-modulatory cytokines PRRSv infections by virulent or attenuated strains
showed no correlation between the IL10 levels and the infection duration [1]. The induction
of regulatory T cells (the major TGFβ-producing cells) during the early stages of infection
is considered as one of the mechanisms that establish prolonged infection durations [1, 3].
However, up to now, no correlation between TGFβ and the viremia has been demonstrated
for PRRSv [8]. Reviews suggest that the suppression of IFNγ may have little influence
on the in vivo disease progression [1, 9]. Vaccines promoting the synthesis of antiviral
cytokines or minimising IL10 production were experimented, but their protective effect
was not convincing [1, 2, 7].
Cytotoxic T cells A PRRSv vaccine that induced high cytotoxic T cells protected pigs against vi-
raemia [10]. However, it seems that the cellular response alone cannot curtail the infection.
Long-term persistence of the virus in the host associated with a strong cellular response
were observed [3]. Under field conditions, cytotoxic T cell titers that developed after vac-
cination resulted in a partial protection [11]. Moreover, correlations between the strength
of the cellular response and PRRSv infection duration were highly variable between hosts
and strains [12].
Neutralising antibodies The protection provided by neutralising antibodies is debated [1, 3, 8].
Several papers suggest that clearance of viraemia and high neutralising antibody titers are
not necessarily correlated [10, 13], while others [14, 15] suggest that they are [1, 8]. Some
studies showed that the pig protection against re-infection increased with the neutralising
antibody titer [15]. Most current vaccines result in high levels of neutralising antibodies,
but offer only a partial protection upon challenge [1, 3, 8].
In this context, exploring vaccine efficiency by a within-host model that describes the immune
mechanisms impacted by vaccination should overcome the current field limitations and lead to
new insights.
We developed a lung-based model of PRRSv infection and immune dynamics to PRRSv
in the lung [16] (Appendix A). This lung-based model represents the activation of the adaptive
response and its orientation towards the cellular, humoral and regulatory responses, but does not
detail the adaptive response activation process and the various adaptive components enough to
test vaccine strategies. Published immunological models on other pathogens targeting APC were
not adapted either (Section I.2). Consequently, we extended our lung-based model to represent
PRRSv infection in the main infection sites, i.e. lungs and lymph nodes, by adding (i) the
dendritic cells, which are the main antigen presenting cells, as well as PRRSv secondary target
cells, and (ii) the main components of the three orientations of the adaptive immune response.
The main strengths of this within-host model are the integration of :
• the interactions between PRRSv and its target cells, i.e. macrophages and dendritic cells ;
• the activation of the adaptive response by the dendritic cells ;
• the orientation of the adaptive response towards the cellular, humoral and regulatory
responses, depending on the cytokine environment ;
• key immune functions, including the phagocytosis by macrophages, cytolysis by cytotoxic
lymphocytes and natural killers, viral neutralisation by neutralising antibodies, marking of
viral particles and infected cells by marker antibodies, cytokine syntheses and regulations.
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Our aims are (i) to simulate the immune response induced by current vaccines and the
protection they confer ; (ii) to identify which conditions an efficient vaccine would have to fulfil
to protect the host from PRRSv infection. The within-host model we propose here can address
these issues. However, due to the scarcity and partialness of data, it was not obvious to calibrate
the model, especially the impact of current vaccines. So we conducted a more theoretical study
to illustrate our model potential, aiming at simulating the within-host dynamics of a vaccinated
pig after PRRSv exposure. This study consists of two steps. Firstly, we simulated the immune
dynamics induced by an attenuated live virus vaccine, represented in the model as an infection
by an hypovirulent and non-pathogenic PRRSv strain. We used this simulation to initialise the
immune state of a vaccinated host, in terms of memory B and T cells, as well as antibodies.
Secondly, we exposed the vaccinated host to PRRSv and assessed the vaccine efficiency.
In this chapter, we first describe the mathematical within-host model in some details (Sec-
tion IV.2). Then we calibrate and validate the model (Section IV.3) by (i) defining a refe-
rence scenario and checking its behaviour against the literature and expected dynamic features
(Section IV.3.1) ; and (ii) to explore the model behaviour for various exposure functions (two
durations and three intensities) crossed with three levels of strain virulence (Section IV.3.2).
Finally, we present our vaccination study (Section IV.4) : firstly the vaccination strategy (Sec-
tion IV.4.1) and secondly the results obtained when challenging a vaccinated pig with PRRSv
(Section IV.4.2). We tested two sets of initial conditions corresponding to two activation levels
of the memory response by a given vaccine. We explored the efficiency of these two vaccines
crossed with three virulence levels, two PRRSv exposure durations and three PRRSv exposure
intensities.
IV.2 Model description
The model represents the within-host infection and immune dynamics induced by a primary
PRRSv infection in a PRRSv-naive pig. We assume that the pig is weaned and has no maternal
antibodies, so we can neglect passive immunity. Active immunity induced by vaccination is
introduced later in Section IV.4, so we do not explicitly represent the memory response in this
model.
The model is derived from our lung-based model [16] (Appendix A), which focuses on the
macrophage–virus interactions and highly details the innate immune response and cytokine
regulations. The adaptive immune response is less detailed in the lung-based model, but it
represents the cellular, humoral and regulatory orientations and their main functions. In this
within-host dynamic model, we include the adaptive effectors and detail the intermediate steps
of the adaptive response orientation, their regulations and their immune functions.
We start our model description by an overview of the within-host dynamics (Section IV.2.1)
which is illustrated in Figure IV.1 and synthesised in Table IV.1. Then we detail the model
components. We first present how the cytokine regulations are formalised (Section IV.2.2). Then
we describe the dynamics of the state variables : the antigen presenting cells (Section IV.2.3),
consisting of macrophages (Section IV.2.3.1) and dendritic cells (Section IV.2.3.2) ; the free vi-
ral particles (Section IV.2.4) ; the T cells (Section IV.2.5) ; the cytotoxic cells (Section IV.2.6,
consisting of natural killers (Section IV.2.6.1) and cytotoxic T cells (Section IV.2.6.2) ; the
B lymphocytes (Section IV.2.7.1) and antibodies (Section IV.2.7.2) ; and finally the cytokines
(Section IV.2.8) grouped by function, i.e. pro-inflammatory (Section IV.2.8.1), antiviral (Sec-
tion IV.2.8.2) and immuno-regulatory (Section IV.2.8.3) cytokines.
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IV.2.1 Overview of the within-host dynamics
The model hypotheses are based on current knowledge on the immune response to respiratory
pathogens, reviewed in [17–24], and on PRRSv specificities, reviewed in [1–4, 12, 25, 26]).
The model is characterised by 28 state variables, described in Table IV.1 :
• the free viral particles (V ) ;
• nine effectors of the innate response, composed of three macrophage states (susceptible Ms,
phagocyting Mp and infected Mi ;, three states for conventional dendritic cells (susceptible
Dcs, mature D
c
m and infected D
c
i ) ; two states for plasmocytoid dendritic cells (susceptible
Dps and mature D
p
m) ; and the activated natural killers (NK) ;
• six effectors of the adaptive response, composed of three T cell states (type 1 helper Th1,
type 2 helper Th2 and regulatory Treg T cells) ; the cytotoxic T cells (Tc) ; and two B lym-
phocyte states, producing IgM and IgG antibodies (BMG) and producing IgA antibodies
(BA) ;
• two functional types of antibodies, consisting of neutralising (AN ) and marker (AM ) anti-
bodies ;
• ten cytokines, consisting of the major pro-inflammatory cytokines (Pi : IL1β, IL6, IL8) ; the
antiviral cytokines (%(Ai+IFNγ)), composed of innate (Ai : TNFα, IFNα and adaptive
(IFNγ) cytokines ; the major immuno-regulatory cytokines (IL12, IFNγ , IL10, IL4,TGFβ).
We chose a deterministic continuous time dynamic framework. Our model is hence composed
of a set of 28 ordinary differential equations, which represent the evolution over time of the state
variables. The main processes that drive their evolution over time and that are integrated in the
model are : the macrophage and dendritic cell infection by the virus ; the excretion of free viral
particles by the infected cells ; the phagocytosis of viral particles by the macrophages, resulting
in viral destruction ; the activation of the adaptive response by dendritic cells and macrophages ;
the neutralisation of free viral particles by the neutralising antibodies ; the marking of free viral
particles and infected cells by the marker antibodies ; the destruction of infected cells by the cy-
totoxic lymphocytes and the natural killers ; the recruitment, activation and decay/migration of
the innate effectors ; the activation, proliferation and decay/migration of the adaptive effectors ;
the cytokine syntheses by the effectors and the cytokine decay ; the cytokine regulations. These
mechanisms are illustrated in Figure IV.1 and synthesised in Table IV.1.
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Interactions between PRRSv and APC Adaptive response activation and orientation
Figure IV.1 Simplified scheme of the within-host model focused on the adaptive res-
ponse. The dynamics of the APCs in this model are very similar to those in the lung-based
models (Figure I.1 and I.2).
State variables of the model : free viral particles (V ) ; susceptible APCs (macrophages Ms,
conventional dendritic cells Dcs and plasmacytoid dendritic cells D
p
s) ; activated and non-infected
APCs (phagocyting macrophages Mp, mature conventional dendritic cells D
c
m plasmacytoid den-
dritic cells Dpm) ; infected APCs (macrophages Mi and conventional dendritic cells D
c
i ) ; natural
killers (NK) ; activated helper T-cells (type 1 Th1, type 2 Th2 and regulatory T cells Treg) ; activa-
ted cytotoxic T cells (Tc) ; activated plasmocytes (derivated from the B lymphocytes, either BMG
which synthesise IgM and IgG antibodies or BA which synthesise IgA antibodies) ; antibodies
(neutralising AN or marking AM ) ; and cytokines : pro-inflammatory (IL1β, IL6, IL8), antiviral
(TNFα, IFNα, IFNγ) and the immunoregulatory (pro-Th1 : IL12 and IFNγ , pro-Th2 : IL4 and IL6
and pro-Treg : TGFβ).
Immune interaction represented. Interactions between the APCs and the PRRSv consist of either
the phagocytosis (resulting in the viral destruction and APC activation) or the APC infection
(resulting in the excretion of new viral particles and APC activation) ; the antigen presentation
by Dcm and D
c
i which activate the helper T cells. The subsequent orientation of the adaptive res-
ponse towards the cellular (Th1 which synthesise IL12 and IFNγ) or humoral (Th2 wich synthesise
IL4) or regulatory (Treg which synthesise TGFβ) depends on the immuno-modulatory cytokine
environment. The activation of the cytotoxic lymphocytes and plasmocytes and the antibodiy
synthesis by the last one. The natural killers and the cytotoxic lymphocytes destroy the infected
APCs by cytolysis. The marking antibodies promote the APC phagocytosis while inhibit their
infection and the neutralising antibodies inhibit new interactions between the PRRSv and the
immune cells.
Colour code : virus in green, innate components in red, adaptive components in blue and
components from both innate and adaptive responses in purple.
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IV.2.2 Cytokine regulations
The processes driving the state variable dynamics are regulated by a complex cytokine feedback
system . Some cytokines have opposite effects : for example, the antiviral cytokines up-regulate
the phagocytosis and down-regulate the viral infection, whereas IL10 inhibits the phagocytosis
and promotes the infection. Cytokines regulate the cellular functions through their recognition
by specific receptors, inducing cascaded reactions within the cells. The higher the cytokine
concentration, the stronger the effect. However, there is a limited number of cytokine receptors
on the cell surface, so the effect saturates above a given cytokine concentration.
We formalised the cytokine regulations (up κ+ and down κ−) based on the Michaelis–Menten
function of the cytokine concentration (Ci ) [27–29] as follows :
κ+(Ci) =
vm Ci
km + Ci
, κ−(Ci) =
km
km + Ci
,
where vm denotes the saturation factor and km the half saturation constant.
A cytokine can have three possible effects on a given basic rate (r) :
• activation : r κ+(Ci), the basic rate increases with the cytokine concentration from 0 to
r vm ;
• amplification : r [1+κ+(Ci)], the basic rate increases with the cytokine concentration from
r to r (1 + vm) ;
• inhibition : r κ−(Ci), the basic rate decreases and tends to zero.
Regulations often involve several cytokines (Ci and Cj) which can act
• either independently : κ±(Ci + Cj) ;
• or in synergy :
◦ κ+(Ci Cj) = vm Ci Cjk2m+Ci Cj for an activation or an amplification,
◦ κ−(Ci Cj) = k
2
m
k2m+Ci Cj
for an inhibition.
As very few studies estimate the regulation parameters (k and K) in the literature [29], we
used the same parameter values for all cytokine regulations.
IV.2.3 Antigen presenting cells
PRRSv replicates in antigen presenting cells (APC), mainly in the pulmonary macrophages and
secondarily in the dendritic cells [25]. Both have key immune functions that are hampered by
infection. Macrophages are responsible for the phagocytosis of viral particles, cytokine syntheses
and to a lesser extent, adaptive response activation. Dendritic cells are responsible for cytokine
syntheses, adaptive response activation and to a lesser extent, phagocytosis of viral particles.
The APC activation occurs by the binding of a free viral particle either via toll-like receptors
(TLR), resulting in their simple activation, or via the receptors of the viral infection. More
details are provided in Section I.1.3.
In the lung-based model, the only APC represented are the macrophages. Indeed, dendritic
cells maturate during their migration from the infection site to the lymph nodes, where they
synthesise cytokines. They influence the infection dynamics through the cytokines they synthe-
sise, which are consequently negligible in the lung. Moreover, dendritic cells and macrophages
drive the adaptive response orientation in a similar way. This simplification is appropriate when
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dealing with PRRSv, as the virus also infects dendritic cells. Dendritic cells and macrophages
hence have very similar dynamics and impacts during PRRSv infection [30, 31].
The present within-host model describes the infection and immune dynamics in the lungs
and lymph nodes. So it is more appropriate to explicitly include the dendritic cells. The model
takes into account the main immune functions of each APC : the macrophages are responsible
for phagocytosis, the dendritic cells are responsible for the adaptive response activation and
both synthesise cytokines.
IV.2.3.1 Macrophages
There are three macrophage states in the model : susceptible (Ms), phagocyting (Mp) and
infected (Mi). The model represents the evolution over time of the macrophage concentrations
for these three states.
Recruitment Susceptible macrophages are recruited from the bloodstream (rate RM ). Cyto-
kines IL6 and IL12 co-amplify the macrophage recruitment [32–34] in synergy and IL8 attracts
the macrophages to the infection place [34]. In the absence of virus, the cytokine concentra-
tions are supposed to be negligible and the resulting concentration of susceptible macrophages
is constant : Ms = M
0
s =
RM
µnatM
.
Decay All macrophage states are subject to natural decay and/or migration (rate µnatM ), as well
as apoptosis induced by TNFα (rate µ
ap
M ) [35]. The natural decay rate is considered higher for
infected macrophages than for susceptible and phagocyting macrophages (multiplicative factor
δµ). Moreover, infected macrophages can be destroyed by natural killers (rate µ
inn
M ) and cytotoxic
T cells (rate µadM ). Marker antibodies amplify the cytolysis of infected cells (Section IV.2.7.2).
State changes When susceptible macrophages encounter free viral particles (V ), they can
either phagocyte the virus (rate ηM ) or become infected (rate βM ). We assumed that phagocyting
macrophages revert to the susceptible state after activation loss (rate γM ), whereas infected
macrophages remain infected (i.e. they cannot eliminate the virus). As the phagocytosis of a
viral particle lasts between 1 and 4 hours, we neglected this duration. We also assumed that
macrophages activated by phagocytosis can be infected. However, once infected, macrophages
cannot be infected by other viral particles [36].
Phagocytosis is amplified by the antiviral cytokines (TNFα, IFNα, IFNγ) and inhibited by
the immuno-modulatory cytokines (IL10,TGFβ). Activation loss is amplified by the immuno-
modulatory cytokine. Macrophage infection is amplified by IL10 and inhibited by innate antiviral
cytokines (TNFα, IFNα) and TGFβ. Moreover, marker antibodies amplify the phagocytosis of
free viral particles. We assumed that cytokine regulations and marking act independently.
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Macrophage dynamics It is governed by the recruitment, decay and state changes described
above and results in the following equations.
Susceptible macrophages Ms :
M˙s = +RM [1 + κ
+(IL12 IL6 + IL8)] ←− recruitment
− ηM Ms V κ−(IL10 + TGFβ) [1 + κ+(TNFα + IFNα + IFNγ)]
[
1 + wVA
AM
mVA + V
]
←− activation
+ γM Mp [1 + κ
+(IL10 + TGFβ)] ←− activation loss
− βM Ms V κ−(TNFα + IFNα + TGFβ) [1 + κ+(IL10)] ←− infection
−Ms
(
µnatM + µ
ap
M κ
+(TNFα)
) ←− decay
(IV.1)
Phagocyting (activated) macrophages Mp :
M˙p = + ηM Ms V κ
−(IL10 + TGFβ) [1 + κ+(TNFα + IFNα + IFNγ)]
[
1 + wVA
AM
mVA + V
]
←− activation
− γM Mp [1 + κ+(IL10 + TGFβ)] ←− activation loss
− βM Mp V κ−(TNFα + IFNα + TGFβ) [1 + κ+(IL10)] ←− infection
−Mp
(
µnatM + µ
ap
M κ
+(TNFα)
) ←− decay
(IV.2)
Infected (activated) macrophages Mi :
M˙i = + βM (Mp +Ms) V : κ
−(TNFα + IFNα + TGFβ) [1 + κ+(IL10)] ←− infection
−Mi
(
µnatM δµ + µ
ap
M κ
+(TNFα) + (µ
inn
M NK + µ
ad
M Tc)
[
1 + wMA
AM
mMA +Mi
])
←− decay
(IV.3)
Cytokine syntheses Activated macrophages (either phagocyting or infected) synthesise in-
nate cytokines : pro-inflammatory (Pi : IL1β, IL6, IL8), antiviral (Ai : IFNα,TNFα) and immuno-
regulatory (IL12, IL10,TGFβ) cytokines [17].
IV.2.3.2 Dendritic cells
There are two major sub-types of dendritic cells which are supposed to play a key role in
PRRSv infection : the conventional (Dc) and the plasmocytoid (Dp) dendritic cells [37, 38]. We
represented both in our model.
Conventional dendritic cells The main immune functions of conventional dendritic cells
(Dc) are the antigen presentation to the naive adaptive cells and the synthesis of various cyto-
kines : IL1β, IL6, IL8, IFNα, TNFα, IL12, IFNγ , IL10 and TGFβ.
The immune function modulations induced by PRRSv infection are similar for the macro-
phages and the conventional dendritic cells [3]. The Dc permissiveness to PRRSv is lower than
the macrophage permissiveness [39], but all published studies point out a similar PRRSv repli-
cation rate in Dc and macrophages once infected [30, 39, 40]. Consequently, we modelled the
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Dc dynamics on the macrophage dynamics, with parameters that can differ between the two,
except for PRRSv replication rate (rate e).
The dynamics of conventional dendritic cells is governed by recruitment, decay and state
changes similar to the processes described in Section IV.2.3.1, with maturation replacing pha-
gocytosis. It results in the following equations.
Susceptible conventional dendritic cells Dcs :
D˙cs = +RDc [1 + κ
+(IL12 IL6 + IL8)] ←− recruitment
− ηDc Dcs V κ−(IL10 + TGFβ)] [1 + κ+(TNFα + IFNα + IFNγ)]
[
1 + wVA
AM
mVA + V
]
←− activation
+ γDc D
c
m [1 + κ
+(IL10 + TGFβ)] ←− activation loss
− βDc Dcs V κ−(TNFα + IFNα + TGFβ) [1 + κ+(IL10)] ←− infection
−Dcs
(
µnatDc + µ
ap
Dc κ
+(TNFα)
) ←− decay
(IV.4)
Mature conventional dendritic cells Dcm :
D˙cm = + ηDc D
c
s V κ
−(IL10 + TGFβ)] [1 + κ+(TNFα + IFNα + IFNγ)]
[
1 + wVA
AM
mVA + V
]
←− activation
− γDc Dcm [1 + κ+(IL10 + TGFβ)] ←− activation loss
− βDc Dcm V κ−(TNFα + IFNα + TGFβ) [1 + κ+(IL10)] ←− infection
−Dcm
(
µnatDc + µ
ap
Dc κ
+(TNFα)
) ←− decay
(IV.5)
Infected conventional dendritic cells Dci :
D˙ci = + βDc (D
c
m +D
c
s) V κ
−(TNFα + IFNα + TGFβ) [1 + κ+(IL10)] ←− infection
−Dci
(
µnatDc δµ + µ
ap
Dc κ
+(TNFα) + (µ
inn
Dc NK + µ
ad
Dc Tc)
[
1 + wMA
AM
mMA +D
c
i
])
←− decay
(IV.6)
Plasmocytoide dendritic cells The main immune function of plasmocytoid dendritic cells
(Dp) is the synthesis of innate antiviral cytokines IFNα and TNFα.
Plasmocytoide dendritic cells do not support PRRSv replication [30, 31, 39, 41], so Dp
can either be susceptible (Dps) or mature (D
p
m). The dynamics of plasmocytoid dendritic cells is
governed by recruitment, decay, activation (maturation) and activation loss, that are supposed to
be similar for conventional and plasmocytoid dendritic cells. It results in the following equations.
Susceptible plasmocytoid dendritic cells Dps :
D˙ps = +RDp [1 + κ
+(IL12 IL6 + IL8)] ←− recruitment
− ηDp Dps V κ−(IL10 + TGFβ)] [1 + κ+(TNFα + IFNα + IFNγ)]
[
1 + wVA
AM
mVA + V
]
←− activation
+ γDp D
p
m [1 + κ
+(IL10 + TGFβ)] ←− activation loss
−Dps
(
µnatDp + µ
ap
Dp κ
+(TNFα)
) ←− decay
(IV.7)
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Mature plasmocytoid dendritic cells Dpm :
D˙pm = + ηDp D
p
s V κ
−(IL10 + TGFβ)] [1 + κ+(TNFα + IFNα + IFNγ)]
[
1 + wVA
AM
mVA + V
]
←− activation
− γDp Dpm [1 + κ+(IL10 + TGFβ)] ←− activation loss
−Dpm
(
µnatDp + µ
ap
Dp κ
+(TNFα)
) ←− decay
(IV.8)
IV.2.4 Free viral particles
The virus enters the body through the mucosal surfaces of the respiratory tract. The exposure
function (E(t)) is defined as for the simplified lung-based model (Ë, Section III.2.2) :
E(t) =
NE
ta−1 (DE−t)b−1∫DE
0 t
a−1 (DE−t)b−1 dt
if 0 < t < DE
0 else
with 1 < a < b shape parameters (no unit) for a left-shifted bell-shaped curve,
NE exposure intensity (in TCID50/ml),
DE exposure duration (in days).
When free viral particles (V ) encounter susceptible macrophages or dendritic cells, they can
either be phagocyted (rates η), resulting in viral destruction and cell activation, or they can
infect the macrophages and conventional dendritic cells (rates β), resulting in virus replication
(Sections IV.2.3.1 and IV.2.3.2). Free viral particles are released by infected cells (rate e). The
replication is inhibited by antiviral cytokines. Free viral particles are subject to natural decay and
migration (rate µnatV ). They can also be neutralised by antibodies AN (rate µ
ad
V ). The resulting
dynamics is described in the following equation.
Free viral particles V :
V˙ = + E(t) ←− exposure
− uVM V (ηM (Ms +Mp) + ηDc Dcs + ηDp Dps) κ−(IL10 + TGFβ)
[1 + κ+(TNFα + IFNα + IFNγ)]
[
1 + wVA
AM
mVA + V
]
←− phagocytosis
− uVM V (βM (Mp +Ms) + βDc (Dcm +Dcs))
κ−(TNFα + IFNα + TGFβ) [1 + κ+(IL10)] ←− infection
+ e (Mi +D
c
i ) κ
−(TNFα + IFNα + IFNγ) ←− excretion
− V
(
µnatV + u
V
A µ
ad
V
AN
nVA + V
)
←− decay
(IV.9)
IV.2.5 Helper T cells
Helper T cells orientate the adaptive response towards the cellular, humoral or regulatory res-
ponse. The activation, differentiation and proliferation of helper T cells are described in Sec-
tion I.1.5. Only the broad lines are presented here.
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Naive helper T cells are activated by mature dendritic cells via a major histocompatibility
complex (MHC). As PRRSv replication in dendritic cells down-regulates the expression of MHC
[30, 39, 40], we distinguished the activation rates by Dcm (rate α
m
Th
) and Dci (rate α
i
Th
). We
assumed that the naive helper T cells are not limiting, so we did not represent their dynamics
in the model.
Depending on the cytokine environment, activated helper T cells differentiate into three
effector sub-types :
• type 2 helper T cells (Th2), the default, amplified by IL4 and IL10. We neglected the
amplification by IL10 as it has an indirect influence (see section I.1.5) which is represented
in our model through the regulation of the cytokine synthesis ;
• type 1 helper T cells (Th1) induced by IL12, amplified by IFNγ and inhibited by IL6 ;
• regulatory T cells (Treg) induced by TGFβ and inhibited by IL6.
The proportion piTh of each effector Th is hence defined as follows :
piTh2 =
1 + IL4 + IL6
1 + IL12 + IFNγ + IL4 + IL6 + TGFβ
piTh1 =
IL12 + IFNγ
1 + IL12 + IFNγ + IL4 + IL6 + TGFβ
piTreg =
TGFβ
1 + IL12 + IFNγ + IL4 + IL6 + TGFβ
Then activated helper T cells proliferate and this proliferation is amplified by IL12 and
inhibited by TGFβ. Finally, these cells are subject to natural decay (rate µ
nat
Th
) amplified by
TNFα, which induces their apoptosis. The dynamics of the helper T cells is hence defined by
the following equations.
Type 1 helper T cells Th1 :
˙Th1 = + (α
m
Th
Dcm + α
i
Th
Dci )
IL12 + IFNγ
1 + IL12 + IFNγ + IL4 + IL6 + TGFβ
←− activation
+ pTh Th1 κ
−(TGFβ) [1 + κ+(IL12)] ←− proliferation
− Th1 µnatTh [1 + κ+(TNFα)] ←− decay
(IV.10)
Type 1 helper T cells Th2 :
˙Th2 = + (α
m
Th
Dcm + α
i
Th
Dci )
1 + IL4 + IL6
1 + IL12 + IFNγ + IL4 + IL6 + TGFβ
←− activation
+ pTh Th2 κ
−(TGFβ) [1 + κ+(IL12)] ←− proliferation
− Th2 µnatTh [1 + κ+(TNFα)] ←− decay
(IV.11)
Regulatory T cells Treg :
˙Treg = + (α
m
Th
Dcm + α
i
Th
Dci )
TGFβ
1 + IL12 + IFNγ + IL4 + IL6 + TGFβ
←− activation
+ pTh Treg κ
−(TGFβ) [1 + κ+(IL12)] ←− proliferation
− Treg µnatTh [1 + κ+(TNFα)] ←− decay
(IV.12)
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Th1, associated with the cellular response, synthesise the antiviral cytokine IFNγ and induce
the activation of cytotoxic T cells Tc. Th2, associated with the humoral response, synthesise
IL4 and IL10. Treg, associated with the regulatory response, synthesise two immuno-modulatory
cytokines, IL10 and TGFβ. Moreover, helper T cells induce the synthesis of antibodies by B lym-
phocytes.
IV.2.6 Cytotoxic cells
Cytotoxic cells destroy infected cells by cytolysis. They include natural killers and cytotoxic
T cells.
IV.2.6.1 Natural killers
Natural killers (NK) are effectors of the innate response. Their main immune functions are the
destruction of infected cells and IFNγ synthesis. More details are provided in Section I.1.4.
We represented the dynamics of activated NK (assuming that naive NK are not limiting)
and included the regulations by the most influential cytokines. The recruitment of natural killers
from the bloodstream (rate αN ) requires pro-inflammatory cytokines : IL12 and IL6 co-activate
the recruitment, whereas IL8 acts independently. Natural killers are then activated by IFNγ and
IL12, whereas IL10 inhibits the activation. They are subject to natural death or/and migration
(rate µR). Their equation follows.
Natural killers NK :
N˙K = + αNK κ
−(IL10) κ+(IL12 IL6 + IL8) κ+(IFNγ + IL12) ←− activation
−NK µnatNK ←− decay
(IV.13)
IV.2.6.2 Cytotoxic T cells
Cytotoxic T cells (Tc) are effectors of the adaptive response. They are responsible for the syn-
thesis of two antiviral cytokines IFNγ and TNFα and the destruction of infected cells.
We represented the dynamics of activated Tc (assuming that naive Tc are not limiting). The
activation of cytotoxic T cells is detailed in Section I.1.5. We did not explicitly represent the
licensing step, but the Tc activation (rates αTc) requires activated conventional dendritic cell
(mature Dcm or infected D
c
i ) and Th1. Just as for helper T cells (Section IV.2.5), activation is
followed by proliferation (rate pTc) and natural decay (rate µ
nat
Tc
). The Tc equation follows.
Cytotoxic T cells Tc :
T˙c = + (α
m
Tc D
c
m + α
i
Tc D
c
i ) Th1 ←− activation
+ pTc Tc κ
−(TGFβ) [1 + κ+(IL12)] ←− proliferation
− Tc µnatTc [1 + κ+(TNFα)] ←− decay
(IV.14)
144 Towards an exploration of vaccine efficiency in silico
IV.2.7 B lymphocytes and antibodies
B cells produce antibodies, which characterise the adaptive humoral response.
IV.2.7.1 B cells
We represented the dynamics of activated B cells (assuming that naive B cells are not limiting).
The activation and differentiation are detailed in Section I.1.5. Only the broad lines are presented
here.
To take into account the preliminary steps of naive B-cell activation, we assumed that it
requires Th and free viral particles V (rates αB), with a limiting effect of Th when V saturates :
for high concentrations of V , B-cell activation only depends on Th. Activated B cells become
plasmocytes, which can produce IgM, IgG and IgA antibodies (IgE antibodies are negligible
for PRRSv infection). We assumed that the Th sub-type determines the plasmocyte differen-
tiation. In the presence of free viral particles, the differentiation towards IgM-producing and
IgG-producing plasmocytes (grouped in BMG, as both circulate in blood serum) requires a Th1
or a Th2, whereas the differentiation towards IgA-producing plasmocytes (BA, which are found
in the respiratory tract) requires a Treg. The proliferation (rate pB) is inhibited by TGFβ. B cells
undergo natural decay (rate µnatB ). The equations follow.
IgM- and IgG-producing plasmocytes BMG :
˙BMG = + αB
V
1 + V
(Th1 + Th2) ←− activation
+ pB BMG κ
−(TGFβ) ←− proliferation
−BMG µnatB ←− decay
(IV.15)
IgA-producing plasmocytes BA :
B˙A = + αB
V
1 + V
Treg ←− activation
+ pB BA : κ
−(TGFβ) ←− proliferation
−BA µnatB ←− decay
(IV.16)
IV.2.7.2 Antibodies
IgM, IgG and IgA antibodies can have either a neutralising or a marking function. More details
are provided in Section I.1.5. In the model, we did not represent the dynamics of IgM, IgG and
IgA, but of the two functional groups of antibodies : neutralising (AN ) and marker (AM ) anti-
bodies. Antibodies are produced by plasmocytes (rate ρA). We assumed that a fixed proportion
of antibodies (rN ) act as neutralising antibodies. Note that with this simplifying assumption,
we could consider a single antibody-producing plasmocyte type (B = BMG + BA). Antibodies
undergo natural decay (rate µnatA ). To derive the antibody dynamics, we need to describe the
neutralising and marking functions.
Neutralising antibodies Neutralising antibodies directly block the virus pathogenicity. We
assumed that the neutralisation of free viral particles (V ) by AN is limited by AN when V
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saturate : for high concentrations of V ( nVA), neutralisation only depends on AN . The neu-
tralisation rate is µadV for the virus and u
V
Aµ
ad
V for the antibodies. Parameter u
V
A accounts for
stoechiometry (units of viral particles neutralised by one antibody unit) and units (antibodies
and virus concentrations are measured in different units). The dynamics of AN follows.
Neutralising antibodies AN :
A˙N = + ρA rN (BMG +BA) ←− activation
− µadV
AN V
nVA + V
←− neutralisation
−AN µnatA ←− decay
(IV.17)
Marker antibodies Marker antibodies (AM ) can either mark the virus and facilitate phago-
cytosis, or they can mark infected cells and amplify cytolysis. As for neutralisation, we assumed
that marking by AM of free viral particles (V ), respectively infected cells (Mi and D
c
i ), is limi-
ted by AM when V , respectively infected cells, saturate : for high concentrations of V ( mVA),
respectively infected cells ( mMA ), marking only depends on AM . Parameters wVA , respectively
wMA , account for stoechiometry (units of viral particles, respectively infected cells, marked by
one antibody unit) and units. The dynamics of AM follows.
Marker antibodies AM :
˙AM = + ρA (1− rN ) (BMG +BA) ←− activation
− uVM
AM V
mVA + V
κ−(IL10 + TGFβ) [1 + κ+(TNFα + IFNα + IFNγ)]
(ηM (Ms +Mp) + ηDc D
c
s + ηDp D
p
s) ←− phagocytosis
− AM D
c
i
mMA +D
c
i
(µinnDc NK + µ
ad
Dc Tc)−
AM Mi
mMA +Mi
(µinnM NK + µ
ad
M Tc) ←− cytolysis
−AM µnatA ←− decay
(IV.18)
IV.2.8 Cytokines
Cytokines are small proteins that play a key role in cell-signalling. They are produced by acti-
vated immune cells and affect the behaviour of other cells, sometimes the releasing cell itself.
They act through specific membranous receptors inducing cascaded reactions within the target
cell. They have various functions. In particular, cytokines modulate the balance between the
humoral and cellular responses. Some cytokines enhance or inhibit the action of other cytokines
in complex ways.
In the within-host model, we only integrated the regulations by the ten most influential cyto-
kines. We grouped them into three classes depending on their main function : pro-inflammatory
cytokines (IL1β, IL6, IL8), antiviral cytokines (TNFα, IFNα, IFNγ) and immuno-regulatory
(IFNγ , IL12, IL4, IL10, TGFβ) cytokines. TNFα is generally considered as a pro-inflammatory
cytokine, but we were more interested is its antiviral function.
We assumed that the cytokines are efficient enough to neglect their consumption when they
interact with a cell. So the cytokine dynamics results from their synthesis by immune cells (rates
ρx, where x depends on the cytokine considered) and their natural decay (rate µC)
The main cytokine regulations are summarised in Table IV.2.
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IV.2.8.1 Pro-inflammatory cytokines
Pro-inflammatory cytokines IL1β, IL6 and IL8 amplify the recruitment of innate immune cells
(APC and natural killers). IL6 blocks the differentiation toward the Th1 and Treg. They are
synthesised by the activated APC. The synthesis of IL1β is inhibited by IL10, whereas the
synthesis of IL6 and IL8 is co-activated by IL1β and TNFα.
˙IL1β = +
(
ρMIL1β (Mp +Mi) + ρ
Dc
IL1β
(Dcm +D
c
i )
)
κ−(IL10) ←− synthesis
− IL1β µnatc ←− decay
(IV.19)
˙IL6 = +
(
ρMIL6 (Mp +Mi) + ρ
Dc
IL6 (D
c
m +D
c
i )
)
κ+(IL1β TNFα) ←− synthesis
− IL6 µnatc ←− decay
(IV.20)
˙IL8 = +
(
ρMIL8 (Mp +Mi) + ρ
Dc
IL8 (D
c
m +D
c
i )
)
κ+(IL1β TNFα) ←− synthesis
− IL8 µnatc ←− decay
(IV.21)
IV.2.8.2 Antiviral cytokines
Antiviral cytokines promote the phagocytosis and reduce the infection by inhibiting the permis-
siveness of macrophages and conventional dendritic cells and the viral replication.
Innate antiviral cytokines TNFα also induces the apoptosis of APC and T cells. It is
synthesised by activated APC (Mp,Mi, D
c
m, D
c
i , D
p
m) and cytotoxic T cells (Tc). These syntheses
are inhibited by IL10.
˙TNFα = +
(
ρMTNFα (Mp +Mi) + ρ
Dc
TNFα (D
c
m +D
c
i ) + ρ
Dp
TNFα D
p
m + ρ
Tc
TNFα
Tc
)
κ−(IL10) ←− synthesis
− TNFα µnatc ←− decay
(IV.22)
IFNα is synthesised by infected cells (Mi, D
c
i ) and mature plasmocytoid dendritic cells (D
p
m).
˙IFNα = + ρ
M
IFNα Mi + ρ
Dc
IFNα D
c
i + ρ
Dp
IFNα D
p
m ←− synthesis
− IFNα µnatc ←− decay
(IV.23)
Adaptive antiviral cytokine IFNγ is synthesised by activated conventional dendritic cells
(Dcm, D
c
i ), natural killers (NK), type 1 helper T cells (Th1) and cytotoxic T cells (Tc). These
syntheses are auto-amplified and inhibited by TGFβ and IL10.
˙IFNγ = +
(
ρD
c
IFNγ (D
c
m +D
c
i ) + ρ
NK
IFNγ NK + ρ
Th1
IFNγ
Th1 + ρ
Tc
IFNγ
Tc
)
κ−(TGFβ + IL10) [1 + κ+(IFNγ)] ←− synthesis
− IFNγ µnatc ←− decay
(IV.24)
IFNγ is also an immuno-regulatory cytokine and it orientates the adaptive response towards
the cellular response [22–25, 42, 44, 48].
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IV.2.8.3 Immuno-regulatory cytokines
Immuno-regulatory cytokines have various functions, in particular the regulation of the adaptive
immune response. They also regulate the recruitment of macrophages and natural killers, the
phagocytosis and infection, as well as the cytokine syntheses. They are produced by cells of the
innate and adaptive response.
IL12 co-amplifies the recruitment of innate cells, activates the natural killers, induce the
differentiation of Th towards Th1 and amplify the proliferation of T cells. It is synthesised by
activated macrophages (Mp,Mi) and conventional dendritic cells (D
c
m, D
c
i ), as well as cytotoxic
T cells (Tc). Syntheses by APC are inhibited by IL10, the synthesis by dendritic cell is amplified
by IFNγ .
˙IL12 = +
(
ρMIL12 (Mp +Mi) + ρ
Dc
IL12 (D
c
m +D
c
i ) [1 + κ
+(IFNγ)]
)
κ−(IL10) + ρTcIL12 Tc ←− synthesis
− IL12 µnatc ←− decay
(IV.25)
IL4 amplifies the differentiation of Th towards type 2 helper T cells (Th2) and is synthesised
by Th2.
˙IL4 = + ρ
Th2
IL4
Th2 ←− synthesis
− IL4 µnatc ←− decay
(IV.26)
Immuno-modulatory cytokines IL10 and TGFβ are both immuno-modulatory cytokines.
IL10 inhibits the natural killer activation and the phagocytosis, amplifies the target cell per-
missiveness and inhibits the synthesis of numerous cytokines. IL10 is synthesised by activated
target cells (Mp,Mi, D
c
m, D
c
i ) and regulatory T cells (Treg), both syntheses being amplified by
TGFβ. It is also synthesised by type 2 helper T cells Th2, this synthesis being auto-amplified
and inhibited by TGFβ.
˙IL10 = +
(
ρMIL10 (Mp +Mi) + ρ
Dc
IL10 (D
c
m +D
c
i ) + ρ
Treg
IL10
Treg
)
[1 + κ+(TGFβ)]
+ ρTh2IL10 Th2 κ
−(TGFβ) [1 + κ+(IL10)] ←− synthesis
− IL10 µnatc ←− decay
(IV.27)
TGFβ inhibits the phagocytosis, the target cell permissiveness, the lymphocyte proliferation
as well as the synthesis of IFNγ and IL10 by Th2. It induces the differentiation of Th toward
regulatory T cells (Treg). TGFβ is synthesised by activated conventional dendritic cells and Treg.
˙TGFβ = + ρ
Dc
TGFβ
(Dcm +D
c
i ) + ρ
Treg
TGFβ
Treg ←− synthesis
− TGFβ µnatc ←− decay
(IV.28)
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IV.3 Model validation and numerical exploration
First we calibrated the within-host model and defined a reference scenario. We simulated the
model and checked its within-host dynamics against the literature and our previous studies. We
also checked whether its behaviour was consistent when turning off key immune mechanisms.
Then we explored the model behaviour numerically by simulating various exposure functions
(two durations and three intensities) crossed with three levels of strain virulence. This exploration
is similar to the study conducted in Chapter III, but less thorough. Rather like the on/off study
on key immune mechanisms, it aims at validating the model behaviour.
IV.3.1 Reference scenario
The reference scenario of the within-host model Ì was based on the two previous studies (Sec-
tions II.2.2 and III.2.1), particularly on the simplified lung-based model Ë (Section III.2.1,
Table III.1).
IV.3.1.1 Calibration method
As for the lung-based models, we had to design an ad hoc procedure to estimate the model
parameters (discussed in Section II.2.2). First, we turned off all the mechanisms which are not
represented in Ë. We ran Ì with the reference parameter values of Ë and we checked whether Ì
and Ë simulations were similar. When not, we adjusted the parameter values in order to obtain
the expected dynamics. To do so, we focused on one variable/mechanism at-a-time, by turning
off the others. For instance, focusing on the interactions between the virus and its target cells, we
turned off the dynamics of all other state variables, as well as the cell infection and excretion,
to adjust the parameter that rules target cell activation. This procedure provided a base for
the reference scenario. We also reviewed similar published models to guide the definition of the
parameter values related to the adaptive state variables, such as the synthesis rate of antibodies
or the decay rates of adaptive effectors. Finally, we adjusted the parameter values after having
check that the model parameter values are robust (i.e. reasonable variations of parameter values
still result in realistic model outputs) for the virulence and exposure scenarios we describe in
section IV.3.2.
The model parameters and references are presented in Table IV.3.
IV.3.1.2 Simulations
We simulated the infection of a PRRSv-naive weaned pig, i.e. with no maternal antibodies,
during 300 days. The initial conditions were set as follows :
• Ms(0) = 5 105cells/ml for the susceptible macrophages ,
• Dcs(0) = 5 103cells/ml for the susceptible conventional dendritic cells,
• Dps(0) = 5 102cells/ml for the susceptible plasmocytoid dendritic cells,
All remaining variables were set to zero. The pig was exposed to PRRSv during one day with and
exposure intensity NE = 106.3 TCID50/ml, which corresponds to the reference short exposure of
our previous studies (Sections III.2.2 and II.2.2).
The model was implemented in Scilab 5.3.3 [55].
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IV.3.1.3 Within-host dynamics
We present a synthetic view of the within-host dynamics in Figure IV.2 and all state variables
in Appendix C. To assess the validity of the within-host model Ì, we compare our results with
the literature and with results produced by the lung-based model Ê.
The reference scenario resulted in a realistic behaviour (Section I.1). PRRSv infection lasted
84 days (Figure IV.2A) and was characterised by : more infected APC than activated and
non-infected APC (Figure IV.2B–C) ; lower titres of pro-inflammatory cytokines, antiviral cy-
tokines and IL12 than of immuno-modulatory cytokines (Figure IV.2E–H) ; a cellular response
lower than the humoral and regulatory adaptive responses (Figure IV.2I–K) ; and a low and
delayed titre of neutralising antibodies compared to marker antibodies (Figure IV.2O–P). In-
nate components globally peaked in the first days (red lines in Figure IV.2), whereas adaptive
components globally peaked later (blue lines in Figure IV.2). Infected APC peaks correspond
to 50% of the total APC concentration, compared to the 40% observed by Labarque et al. [56].
Neutralising antibodies peaked 18 weeks post infection, compared to the 10 to 18 weeks reported
in the literature [8, 14, 26]. The cytotoxic T cells Tc peaked during the 4th week post infection,
compared to the 4 to 7 weeks reported in the literature [8, 14, 26]. During the first month post
infection, antibodies mainly consisted of IgM and IgG (more than 50% of BMG plasmocytes
among the total plasmocyte titre up to 50 days post infection). Then they switched to IgA
antibodies (plasmocytes stabilised around 40% of BMG and 60% of BA 100 days post infection).
Labarque et al. [56] reported an IgA peak occurring later than IgG and IgM peaks, after an
experimental infection by PRRSv.
Compared to the reference scenario of the lung-based model Ê (black lines in Figure II.5),
our results (Figure IV.2) exhibit similar tendencies with few quantitative differences :
• a longer infection duration (Ê :72 and Ì : 84 days) ;
• a higher peak of phagocyting macrophages (Ê : 8 103 and Ì : 5 103 cells/ml) and a higher
peak of infected macrophages (Ê : 7 104 and Ì : 1.5 105 cells/ml) ;
• lower peaks of summed pro-inflammatory cytokines IL1β + IL6 + IL8 (Ê : 80 and Ì : 29
pg/ml) and innate antiviral cytokines TNFα + IFNα (Ê : 300 and Ì : 89 pg/ml) ;
• a lower peak of IFNγ (Ê : 6 and Ì : 0.5 pg/ml), a similar peak of IL10 (Ê : 100 and Ì :
165 pg/ml) and a higher peak of TGFβ (Ê : 1 and Ì : 103 pg/ml).
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Figure IV.2 Synthesis of the infection and immune dynamics for the reference scenario
of the within-host model Ì. A viral titer (semi-log graph). Effectors : B infected antigen
presenting cells (Mi+D
c
i ), C phagocyting or mature antigen presenting cells (Mp+D
c
m+D
p
m),
D natural killers (NK in D), I type 1 helper T cells (Th1), J type 2 helper T cells (Th2),
K regulatory T cells (Treg), B cytotoxic lymphocytes (Tc), M plasmocytes producing IgM or
IgG antibodies (BMG) and N plasmocytes producing IgA antibodies (BA). Antibodies : O
neutralising antibodies (AN ) and P marker antibodies (AM ). Cytokines : E pro-inflammatory
cytokines (IL1β + IL6 + IL8), F antiviral cytokines (IFNα + TNFα + IFNγ), G other immuno-
regulatory cytokines promoting the cellular response (IL12) and H immuno-modulatory cytokines
(IL10 + IL4 + TGFβ).
PRRSv in green, innate components in red, adaptive components in blue and both innate and
adaptive components in purple.
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IV.3.1.4 On/off immune mechanisms
To further check if our model simulates a realistic behaviour, we turned off one by one the nine
immune mechanisms which are thought to determine PRRSv infection resolution (Figure IV.3) :
• the synthesis of antiviral cytokines TNFα, IFNα and IFNγ (by setting ρTNFα = ρIFNα =
ρIFNγ = 0 in equations (IV.22,IV.23,IV.24)),
• vs the synthesis of immuno-modulatory cytokines IL10 and TGFβ (by setting ρIL10 =
ρTGFβ = 0 in equations (IV.27,IV.28)),
• the viral replication (by setting e = 0 in equation (IV.9)),
• the target cell infection (by setting β = 0 in equations (IV.1,IV.3,IV.4,IV.6,IV.9)),
• the cytolysis of infected cells by natural killers NK (by setting µinnM = µinnDc = 0 in equa-
tions (IV.3,IV.6)),
• the cytolysis of infected cells by cytotoxic T cells Tc (by setting µadM = µadDc = 0 in equa-
tions (IV.3,IV.6)),
• the target cells apoptosis due to TNFα (by setting µapM = 0, µapDc = µapDp = 0 in equa-
tions (IV.1–IV.8)),
• the phagocytosis by macrophages Mp (by setting ηM = 0 in equations (IV.1,IV.2)),
• the viral neutralisation by antibodies (by setting µadV = 0 in equations (IV.9,IV.17)).
We focused on the resulting viral dynamics and in particular on the infection duration DI ,
presented in Figure IV.3. As expected, (i) the absence of immuno-modulatory cytokines, viral
excretion and target cell infection all resulted in lower infection durations DI than the reference
value DI = 83.5 days ; and (ii) the absence of NK cytolysis, Mp phagocytosis, apoptosis due
to TNFα, Tc cytolysis, antiviral cytokines and viral neutralisation all resulted in higher DI (in
ascending order of DI).
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Figure IV.3 Immune mechanisms efficiency on infection resolution for the reference
scenario. Viral titres over time (semi-log graph) obtained by turning off one by one the nine
immune mechanisms thought to determine PRRSv infection resolution. The nine mechanisms
are colour-coded and listed on the right side of the plot, in ascending order of infection duration
(DI) which is also indicated. The infection duration is defined is defined as the time during which
the viral titre is higher than 10−2 TCID50/ml (note that viral titres are not plotted below this
limit). The infection duration of the reference scenario is marked by the N on the plot.
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Among the nine mechanisms tested, the absence of immuno-modulatory cytokines resulted
in the higher DI reduction and the absence of viral neutralisation or antiviral cytokines resulted
in the higher DI increase. The strong influence of antiviral and immuno-modulatory cytokines
seems consistent with the literature (Section I.1.6).
One other striking result is that the absence of each innate immune mechanism (NK cytolysis,
Mp phagocytosis and apoptosis due to TNFα) induced a clear but feable increase of DI . However,
the literature suggest that these mechanisms should be sufficient to explain prolonged PRRSv
infection durations (Section I.1.6). So we tone down our results, which suggest a low influence of
the innate mechanisms on the infection resolution. Given (i) the high reduction of DI induced
by the absence of viral excretion or target cell infection and (ii) the strong modulation of
the innate mechanisms by the antiviral and immuno-modulatory cytokines, which exhibited a
strong influence on the infection duration and which are also impacted by the strain virulence,
our results seem robust.
Looking at the shape of the viral titre in the absence of viral neutralisation (brown curve in
Figure IV.3), it is interesting to note that only this curve is fairly linear, especially ten days
before the infection resolution. This suggests that the neutralisation reduces tardily the viral
titre. As neutralising antibodies response to PRRSv is weak and delayed (Section I.1.5), this
result is logical.
IV.3.2 Exposure and virulence scenarios
We previously showed that variability in terms of viral exposure (intensity and duration) and
PRRSv strain virulence (and/or pig susceptibility) need to be considered (sections II.4 and III.4)
in order to explore the within-host dynamics after PRRSv infection. So we conducted such a
study on the within-host model. It is similar to the study in Chapter III, but less thorough.
Rather like the on/off study on key immune mechanisms (Section IV.3.1.4), it aims at validating
the model behaviour.
First we define the scenarios and the design of numerical experiments used to explore the
impact of exposure and virulence. Then we present results in terms of viral dynamics and immune
characteristics.
IV.3.2.1 Scenario definition
Exposure We tested three exposure intensities NE ∈ {L1;L3;L5} and two exposure durations
DE : the reference exposure lasting one day (Es exposure) and a prolonged exposure lasting 20
days (Ep2 exposure). Crossing the three exposure intensities with the two exposure durations,
we tested six exposure scenarios.
Virulence levels We tested three virulence levels : Svir ∈ {S1;S2;S3} where S2 is the reference
scenario, S1 a lowly virulent PRRSv strain and S3 a highly virulent strain.
The parameter values of our virulence scenarios are based on the scenarios defined in Sec-
tion III.2.3. Highly virulent strains are assumed to (i) efficiently infect the cells and replicate,
(ii) promote the host capacity to synthesise immuno-modulatory over antiviral cytokines and
(iii) reduce the activation of the adaptive response [1, 4, 47]. We selected the parameters related
to these immune functions as parameters modulated by PRRSv strain virulence :
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• the activation rates of antigen presenting cells η, found in equations (IV.1, IV.2, IV.4, IV.5,
IV.7, IV.8, IV.9) ;
• the infection rates of target cells β, found in equations (IV.1, IV.3, IV.4, IV.6, IV.9) ;
• the viral replication rate e , found in equation (IV.9) ;
• the adaptive effector activation rates by the conventional dendritic cells αTh and αTc , found
in equations (IV.10–IV.12, IV.14) ;
• the synthesis rates of antiviral cytokines by antigen presenting cells (for TNFα : ρMTNFα ,
ρD
c
TNFα
, ρD
p
TNFα
, found in equation (IV.22) ; for IFNα : ρ
M
IFNα
, ρD
c
IFNα
, ρD
p
IFNα
, found in equa-
tion (IV.23) ; and for IFNγ : ρ
Dc
IFNγ
, found in equation (IV.24)) ;
• the synthesis rates of immuno-modulatory cytokines by antigen presenting cells (for IL10 :
ρMIL10 , ρ
Dc
IL10
, found in equation (IV.27) ; and for TGFβ : ρ
Dc
TGFβ
, found in equation (IV.28)).
We varied their reference values from ±35%. The values fro the three virulence levels are presen-
ted in Table IV.4. In the previous study exploring the impact of exposure and strain virulence
(Section III.2.3), we also varied the rates of cytokine syntheses by adaptive effectors. Here, we
assumed that the strain virulence only impacts the immune functions of the antigen presenting
cells.
Table IV.4 Model parameter values for the three virulence levels. The reference value (ref.)
corresponds to Table IV.3, in which the parameters are defined.
Virulence level Svir
Parameters low S1 ref. S2 high S3
activation rates of antigen presenting cells
ηM 1.35 10
−7 10−7 6.5 10−8
ηDc 5.4 10
−5 4 10−5 1.6 10−5
ηDp 1.35 10
−4 10−4 6.5 10−5
infection rates of target cells
βM 5.2 10
−7 8 10−7 1.08 10−6
βDc 1.95 10
−5 3 10−5 4.05 10−5
viral replication rate
e 0.13 0.2 0.27
adaptive effector activation rates
αmTh 1.35 1 0.65
αiTh 1.35 10
−1 10−1 6.5 10−2
αmTc 1.35 10
−2 10−2 6.5 10−3
αiTc 1.35 10
−3 10−3 6.5 10−4
cytokine synthesis rates by antigen presenting cells
ρMTNFα 8.44 10
−3 6.25 10−3 4.06 10−3
ρD
c
TNFα
8.44 10−2 6.25 10−2 4.06 10−2
ρD
p
TNFα
1.35 1 0.65
ρMIFNα 8.44 10
−3 6.25 10−3 4.06 10−3
ρD
c
IFNα
8.44 10−2 6.25 10−2 4.06 10−2
ρD
p
IFNα
1.35 1 0.65
ρD
c
IFNγ
1.35 10−3 10−3 6.5 10−4
ρMIL10 5.2 10
−3 8 10−3 1.8 10−2
ρD
c
IL10
0.26 0.4 0.54
ρD
c
TGFβ
6.5 10−3 10−2 1.35 10−2
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Design of numerical experiments We crossed all virulence and exposure scenarios, resul-
ting in a complete design of numerical experiments with 18 scenarios.
IV.3.2.2 Results and discussion
The viral titre curves over the infection period for the 18 scenarios are presented in Figure IV.4.
We also selected twelve scalar descriptors of the viral and immune dynamics, based on Sec-
tion III.2.4. The results are presented in Figure IV.5. To check the realism of the within-host
dynamics simulated by model Ì, we compared our results with those obtained with the lung-
based model Ë (Section III.3.1). We found very few quantitative data in the literature on the
adaptive component dynamics, so we only discussed the qualitative results.
Within-host characteristics We selected twelve scalar descriptors of the viral and immune
dynamics, based on section III.2.4.
• Infection severity (Section III.2.4) :
◦ infection duration (DI) ;
◦ total viral dose (ΣV ) ;
◦ viral peak Vmax.
The viral peak and infection duration more or less determine the total viral dose and are
hence two components of the infection severity.
• Cytokines :
◦ total pro-inflammatory cytokines (ΣPi , Section III.2.4) ;
◦ total innate antiviral cytokines (ΣAi , defined as ΣPi) ;
◦ percentage of anti-viral cytokines %(Ai+IFNγ) (Section III.2.4).
• Adaptive response orientation :
◦ %Th1, a descriptor of the orientation towards the cellular response, defined as follows :
100
ΣTh1
ΣTh1+ΣTh2+ΣTreg◦ %Th2, a descriptor of the orientation towards the humoral response, defined as follows :
100
ΣTh2
ΣTh1+ΣTh2+ΣTreg
• Immune mechanisms (Section III.2.4) :
◦ the phagocytosis activity, quantified by either Nphag, the total number of viral par-
ticles phagocyted by macrophages, orNpha/E , the normalised number of viral particles
phagocyted by macrophages ;
◦ the cell infection activity, quantified by either Ninf, the total number of viral particles
having infected a target cell, orNinf/E , the normalised number of viral particles having
infected a target cell ;
◦ the viral replication activity, quantified by either Nexcr, the total number of excreted
viral particles by infected cells, or Nexcr/E , the normalised number of viral particles
excreted by infected cells ;
◦ the viral neutralisation activity, quantified by either Nneutr,,the total number of viral
particles neutralised by the antibodies, or Nneutr/E , the normalised number of viral
particles neutralised by the antibodies ;
◦ The cytolysis activity, quantified by either Ncyto, the total number of viral particles
destroyed by the infected cell cytolysis, or Ncyt/E , the normalised number of viral
particles destroyed by the infected cell cytolysis.
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Viral dynamics As expected, the higher the exposure intensity, the exposure duration and
the virulence level, the higher the infection duration (Figure IV.4). As for Ë (Figure III.10A
and B), the total viral dose was fully determined by the exposure intensity (Figure IV.5A) ;
the infection duration was determined first by the virulence level, then by the exposure intensity
and finally by the exposure duration (Figure IV.5B). Scenarios of low virulence S1 resulted
in infection durations between 43 and 99 days ; scenarios of reference virulence S2 in infection
durations between 62 and 114 days ; and scenarios of high virulence S3 in infection durations
between 106 and 157 days (Figure IV.5B). If the variation ranges of the infection durations
were lower than in Section III.3.1, the total viral doses were the same. As the reference scenarios
of both models resulted in slightly different dynamics and the as virulence scenarios were not
exactly the same, these infection duration differences are not surprising.
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Figure IV.4 Viral dynamics among the virulence and exposure scenarios. 18 scenarios were
simulated, crossing 3 exposure intensities NE ∈ {L1;L3;L5} ; 2 exposure durations DE : short
1-day exposure (DEs , solid lines) and prolonged 20-day exposure (DEp2 , dashed lines) ; and 3
virulence levels (Svir) : A low S1, B reference S2 and C high S3.
Immune characteristics Pro-inflammatory cytokines. Our results (Figure IV.5C) exhibited
lower total pro-inflammatory cytokines ΣPi than in Section III.3.1 (Figure III.10D). In both
cases, ΣPi was strongly determined by the exposure intensity NE . Previously, we found that
for a given NE , ΣPi increased with the virulence level (Figure III.10D). In the present case,
ΣPi increased or decreased with the virulence level, depending on the exposure intensity (Fi-
gure IV.5C).
Antiviral cytokines. The total innate antiviral cytokines ΣAi increased with the exposure
intensity and for a given NE , decreased with the increase of the virulence level (Figure IV.5D).
These results are consistent with the way we defined the virulence levels. %(Ai+IFNγ) reached
lower values (between 3 and 29%, Figure IV.5E) than the previous simulations (Section III.3.1,
Figure III.10E) and were differently impacted by the exposure intensity and the virulence
level. Here (vs previously), %(Ai+IFNγ) increased (vs decreased) with NE and for a given NE ,
increased or decreased with Svir (vs decreased). As Svir was defined by varying the cytokine
synthesis rates by the antigen presenting cells (vs by all producing cells), these differences were
expected.
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Adaptive response orientation. The orientation towards the cellular response is characterised
by %Th1 (Figure IV.5F) (vs %Rc in Figure III.10F) and towards the humoral response by
%Th2 (Figure IV.5G) (vs the Rh in Figure III.10G). Whatever the scenario, the %Th1 were
lower than 23%, so the adaptive response was orientated towards the humoral or the regulatory
responses. This is consistent with the previous results. Here, the orientation of the adaptive
response appeared more strongly influenced by the exposure duration and the virulence level
and less strongly by the exposure intensity than previously. There was no clear relation between
the exposure intensity and the adaptive response orientation. For a given exposure intensity,
%Th1 (%Th2) globally increased (decreased) with the increase of the virulence level. This result
contradicts previous results, but could be due to the difference of virulence level definitions.
Immune mechanisms. All normalised immune mechanisms of interest tended to zero for high
exposure intensities, suggesting that they saturated. The immune mechanisms in favour of viral
replication (Nexcr/E in Figure IV.5H vs in Figure III.10H and Ninf/E in Figure IV.5I vs in Fi-
gure III.10I) decreased with the increase of exposure intensity and increased with the virulence
levels. The values reached here were higher than in the previous simulations. The immune mecha-
nisms in favour of viral neutralisation (Ncyt/E in Figure IV.5J vs in Figure III.10J ; Nneutr/E
in Figure IV.5K vs in Figure III.10K and Npha/E in Figure IV.5L vs in Figure III.10L) de-
creased (vs increased or decreased) with the increase of the exposure intensity. Ncyt/E increased
with the virulence level whereas Nneutr/E and Npha/E decreased. The values reached by Ncyt/E
here were higher than in the previous simulations, whereas Nneutr/E and Npha/E were lower.
Synthesis. For a given exposure intensity, infection with a lowly (highly) virulent PRRSv
strain resulted in short (prolonged) infection durations associated with :
• high (low) total levels of innate antiviral cytokines and phagocytosis activity, with low
(high) viral excretion and cell infection ;
• a stronger adaptive response orientation towards the humoral (cellular) compared to the
reference scenario ;
• a low (high) cytolysis activity, but a high (low) viral neutralisation activity.
These results are consistent with the hypotheses published to explain prolonged infection du-
rations (Section I.1.6), suggesting that altering the immune functions of the antigen presenting
cells could hamper the whole immune response.
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Figure IV.5 Within-host characteristics for the virulence and exposure scenarios. 18 sce-
narios were simulated, crossing 3 exposure intensities NE ∈ {L1;L3;L5} ; 2 exposure durations
DE : short 1-day exposure (DEs) and prolonged 20-day exposure (DEp2) ; and 3 virulence levels
(Svir ∈ {•S1,NL2,+S3}.
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IV.4 Within-host dynamics of a vaccinated pig after PRRSv
exposure
To simulate the within-host dynamics of a vaccinated pig after PRRSv exposure, we need to
define the pig the immune state, in terms of memory B and T cells, as well as antibodies.
This information is not readily available, so we had to define a vaccination strategy in silico
(Section IV.4.1). Then we explored the efficiency of two vaccines crossed with three virulence
levels, two PRRSv exposure durations and three PRRSv exposure intensities (Section IV.4.2).
IV.4.1 Vaccination strategy
IV.4.1.1 Immune protection induced by vaccination
If the animal has been exposed to PRRSv previously, by infection or vaccination, the adaptive
response has already been activated and memory components have been induced. It can result
in a (partial) protection even if no detectable antibodies remain. The cells in the expanded clone
are called memory cells [33] and are responsible for the immunological protection conferred by
vaccination. The memory response consists in adaptive effectors (helper T cells, cytotoxic lym-
phocytes and B lymphocytes) and antibodies with prolonged lifetime (several months compared
to a few weeks for the non-memory components) [33]. These memory effectors and antibodies
appear during the adaptive response activation and consist in a given proportion of the activated
adaptive effectors and antibodies. During the primary immune response induced by vaccination
or infection, the memory components have no immune function. However, when the animal is
re-exposed to the pathogen, the memory components quickly undergo a multi-cycle proliferative
expansion and exhibit the same immune functions as the adaptive components from which they
were differentiated. Consequently, the animal with memory components starts with adaptive
components, while they would appear tardily after a primary exposure to the pathogen. This
confers a significant benefit to control the infection.
IV.4.1.2 Current PRRSv vaccines
Vaccination is a strategy currently used to control clinical diseases caused by PRRSv [7]. Many
vaccines have been produced to combat PRRSv [1]. There are at least two types of commercia-
lised PRRSv vaccine : modified-live virus vaccines (or attenuated live virus vaccines) and killed
virus vaccines (or inactivated virus vaccines) [1–3, 7]. In contrast to live vaccines, the inactivated
(or killed) vaccines contain adjuvants [1].
None of the current vaccines is able to prevent respiratory infection, nor pig-to-pig transmis-
sion of the virus [3, 61]. Attenuated live vaccines have been widely used and have shown some
efficacy in reducing disease occurrence and severity, as well as the duration of viraemia and
virus shedding [14, 61]. They induce delayed antibody and cytotoxic lymphocyte responses [7].
Protection provided by attenuated live vaccines is better than by inactivated vaccines [3, 7, 61].
Inactivated vaccines may reduce the levels of viraemia in some pigs, but do not show consistent
benefit against infection [14]. They induce poor cytotoxic lymphocyte response and do not induce
an antibody response [7].
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IV.4.1.3 Vaccination scenarios
In this preliminary exploration of the vaccine efficiency, we focused on the most efficient vaccines :
the attenuated live virus vaccines. PRRSv attenuated live vaccines induce infection of lung and
lymphoid tissues ; the infection durations are similar to infections by virulent viruses and the
vaccinated pigs can transmit the disease to contact pigs ; these vaccines are immunologically
protective, i.e. they eliminate or reduce the infection and disease qualitatively and quantitatively
[1].
In our within-host model, we did not represent the memory component dynamics, but we can
define positive initial conditions for the adaptive components which correspond to the memory
components induced by vaccination. In the literature, there are very few quantitative data
on the adaptive components during PRRSv infection, as well as on the memory component
concentrations induced by vaccination. So we had to find an alternative to inform the vaccinated
pig initial immune state. We used our model to simulate the within-host dynamics induced by
PRRSv vaccination and inform the initial conditions corresponding to a vaccinated pig. To do
so, we had to (i) define the parameter values corresponding to a vaccine scenario ; (ii) determine
how the adaptive components activated by vaccination translate into memory cells. We then
defined the vaccine scenarios and the design of numerical experiments.
Simulation of the within-host dynamics induced by vaccination A vaccination with
an attenuated virus can be assimilated to an infection with a PRRSv strain characterised by a
significant induction of the immune responses (the more the cytotoxic cells and antibodies are
activated, the better the pig protection), but a low severity. Based on this statement, we defined
vaccination as follows :
• a low vaccine exposure intensity : 104.3 TCID/ml ;
• a hypovirulent vaccine strain : the values of the parameters affected by PRRSv strain
virulence (Section IV.3.2) were set to ±50% compared to the reference values (instead of
±35% for the lowly virulent strain S1).
• no viral replication : the replication rate e was set to zero.
We ran the model with these parameter values and we saved the output dynamics. The
within-host dynamics induced by this vaccination exhibited realistic behaviour, illustrated in
Figure IV.6. The infection duration DI was around 40 days ; the neutralising antibodies AN
peaked around 100 days post-vaccination and reached 13 pg/ml ; and the cytotoxic lymphocytes
Tc peaked between the second and the third week post-vaccination and reached 2 10
4 cells/ml.
Definition of the memory response induced by vaccination From the vaccination si-
mulation, we extracted the cumulated concentrations (denoted by Σ) of the adaptive effectors
(Th1, Th2, Treg, Tc, BMG and BA) and antibodies (AN and AM ) activated during the simulation
duration (300 days, denoted by T ) :
IC0M = (ΣTh1 ,ΣTh2 ,ΣTreg ,ΣTc ,ΣBMG ,ΣBA ,ΣAN ,ΣAM )
For instance, the cumulated concentration of Th1 activated ΣTh1 is calculated as follows :
ΣTh1 =
∫ T
t=0
(αmTh D
c
m(t) + α
i
Th
Dci (t))
IL12(t) + IFNγ(t)
1 + IL12(t) + IFNγ(t) + IL4(t) + IL6(t) + TGFβ(t)
dt.
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Figure IV.6 Dynamics of infection, adaptive effectors and antibodies induced by vaccina-
tion from within-host model Ì simulations. A viral titer (semi-log graph, in green). Adaptive
effectors, in blue : B type 1 helper T cells (Th1), C type 2 helper T cells (Th2), D regulatory
T cells (Treg), E cytotoxic lymphocytes (Tc), F plasmocytes producing IgM or IgG antibodies
(BMG) and G plasmocytes producing IgA antibodies (BA). Antibodies, in blue : H neutralising
antibodies (AN ) and I marker antibodies (AM ).
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We obtained the following cumulated values of adaptive effectors and antibodies :
(ΣTh1 , ΣTh2 , ΣTreg , ΣTc , ΣBMG , ΣBA , ΣAN , ΣAM )
IC0M = (7 10
2, 2 103, 2 103, 3 104, 8 106, 5 106, 10, 2 103)
The memory response acquired by the host after vaccination corresponds to a fraction r of
the cumulated values in vector IC0M .
Definition of vaccination strategies We found no relevant data in the literature, so we
tested two values : r1 = 10% and r2 = 40%. We then defined three vaccination strategies
Vs ∈ {No, V1, V2} as follows :
• No corresponds to the reference scenario, without vaccination, defined with zero initial
conditions for the adaptive effectors and antibodies involved in the memory response ;
• V1 is defined by the initial conditions r1 × IC0M ;
• V2 is defined by the initial conditions r2 × IC0M .
Design of numerical experiments We defined a complete design of numerical experiment in
order to explore the within-host dynamics of a vaccinated pig (Vs ∈ {No, V1, V2}) in a variability
context in terms of virulence level (Svir ∈ {S1, S2, S3}), exposure intensity (NE ∈ {L1, L3, L5})
and exposure duration (DE ∈ {DEs , DEp2}), resulting in 54 scenarios.
IV.4.2 Results
We explored the influence of the three vaccine strategies Vs ∈ {No, V1, V2} among the 18 exposure
and virulence scenarios. First, we identified the influence of the vaccine strategies on the viral
dynamics. Then, we explored the immune response associated with the viral dynamics in order
to identify which immune mechanisms were involved in the vaccine strategy efficiency.
IV.4.2.1 Viral dynamics
Viral titer We present the viral titer for the 54 scenarios in Figure IV.7.
Whatever the virulence level and the exposure duration and intensity, the infections were
resolved more rapidly for vaccinated pigs (Figure IV.7, column two and three) than for naive
pigs (Figure IV.7, first column). Moreover, the the V2 vaccine (Figure IV.7, third column)
was more efficient that the V1 vaccine (Figure IV.7, second column). Comparing the viral titre
between the vaccination strategies Vs ∈ {No, V1, V2}, it appears that the vaccination reduced the
viral titre fairly late in the course of infection. Indeed, looking at the shape of the viral dynamics,
we can observe a slope break for vaccinated pigs occurring around 30 days before the infection
resolution without vaccination. Moreover, a fairly linear viral titre was observed in the On/Off
tests above without neutralisation (Figure IV.3). Those two results combined suggest that the
quicker infection resolution induced by vaccination could be due to a higher viral neutralisation
by antibodies.
Viral characteristics We present the viral characteristics (total viral dose ΣV , infection
duration DI and viral peak Vmax) for the 54 scenarios in Figure IV.8.
166 Towards an exploration of vaccine efficiency in silico
0 50 100 150 200
1e
−0
2
1e
+0
0
1e
+0
2
1e
+0
4
1e
+0
6
1e
+0
8
time [day]
Vi
ra
l t
ite
r [T
CI
D 5
0/m
l]
No vaccine x Svir = S1
A
0 50 100 150 200
1e
−0
2
1e
+0
0
1e
+0
2
1e
+0
4
1e
+0
6
1e
+0
8
time [day]
Vi
ra
l t
ite
r [T
CI
D 5
0/m
l]
V1 x Svir = S1
B
0 50 100 150 200
1e
−0
2
1e
+0
0
1e
+0
2
1e
+0
4
1e
+0
6
1e
+0
8
time [day]
Vi
ra
l t
ite
r [T
CI
D 5
0/m
l]
V2 x Svir = S1
C
0 50 100 150 200
1e
−0
2
1e
+0
0
1e
+0
2
1e
+0
4
1e
+0
6
1e
+0
8
time [day]
Vi
ra
l t
ite
r [T
CI
D 5
0/m
l]
No vaccine x Svir = S2
D
0 50 100 150 200
1e
−0
2
1e
+0
0
1e
+0
2
1e
+0
4
1e
+0
6
1e
+0
8
time [day]
Vi
ra
l t
ite
r [T
CI
D 5
0/m
l]
V1 x Svir = S2
E
0 50 100 150 200
1e
−0
2
1e
+0
0
1e
+0
2
1e
+0
4
1e
+0
6
1e
+0
8
time [day]
Vi
ra
l t
ite
r [T
CI
D 5
0/m
l]
V2 x Svir = S2
F
0 50 100 150 200
1e
−0
2
1e
+0
0
1e
+0
2
1e
+0
4
1e
+0
6
1e
+0
8
time [day]
Vi
ra
l t
ite
r [T
CI
D 5
0/m
l]
No vaccine x Svir = S3
G
0 50 100 150 200
1e
−0
2
1e
+0
2
1e
+0
6
time [day]
Vi
ra
l t
ite
r [T
CI
D 5
0/m
l]
V1 x Svir = S3
H
0 50 100 150 200
1e
−0
2
1e
+0
0
1e
+0
2
1e
+0
4
1e
+0
6
1e
+0
8
time [day]
Vi
ra
l t
ite
r [T
CI
D 5
0/m
l]
V2 x Svir = S3
I
Figure IV.7 Viral titre for the virulence, exposure and vaccine scenarios. 54 scenarios were
simulated, crossing 3 exposure intensities NE ∈ {L1;L3;L5} ; 2 exposure durations DE : short
1-day exposure (DEs , solid lines) and prolonged 20-day exposure (DEp2 , dashed lines) ; and 3
virulence levels (Svir) : A low S1, B reference S2 and C high S3 ; 3 virulence levels (§vir) : low S1
(first row), reference S2 (2nd row) and high S3 (3rd row) ; and 3 vaccine scenarios : no vaccine
(1st column), vaccine V1 (2nd column) and vaccine V2 (3rd column).
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Figure IV.8 Viral characteristics for the virulence, exposure and vaccination scenarios.
A–C total viral dose ΣV ; D–F infection duration DI ; G–I viral peak Vmax. 54 scenarios were
simulated, crossing 3 exposure intensities NE ∈ {L1;L3;L5} ; 2 exposure durations DE : short 1-
day exposure (DEs , solid lines) and prolonged 20-day exposure (DEp2 , dashed lines) ; 3 virulence
levels Svir ∈ {•S1,NL2,+S3} ; and 3 vaccine scenarios : no vaccine, vaccine 1 V1 and vaccine 2
V2.
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Whatever the scenario, it appears that vaccination only significantly impacted the infection
duration DI (Figure IV.8D–F) and neither the total viral dose ΣV (Figure IV.8A–C), nor the
viral peak Vmax (G–I).
Without vaccination, the infection lasted on average 96 days (range : 43 to 157 days), 60
days (range : 21 to 105 days) with the V1 vaccine and 49 days (range : 14 to 89 days) with the
V2 vaccine (Figure IV.8D–F). The infection duration was on average 1.7 times lower with the
V1 vaccination strategy and 2.4 times lower with the V2 vaccination strategy compared to the
durations without vaccination. The vaccine efficacy depended on the virulence level and was all
the more efficient for more virulent strains :
• among the low virulence S1 scenarios, the infection duration was 1.5 times lower with V1
and 1.8 times lower with V2, compared with the durations without vaccination ;
• among the reference virulence S2 scenarios, the infection duration was 1.7 times lower with
V1 and 2.3 times lower with V2 compared with the durations without vaccination ;
• among the high virulence S3 scenarios, the infection duration was 2.0 times lower with V1
and 3.0 times lower with V2 compared with the durations without vaccination.
Finally, our results exhibited interactions between (i) the vaccine scenario and the exposure
intensity on the one hand, (ii) the vaccine scenario and the exposure duration on the other hand.
This result can be seen in Figure IV.8D–F : (i) on each frame between colours, neither solid,
nor dashed lines are parallel ; (ii) on each frame between line types, the blue/black/red lines are
not parallel.
IV.4.2.2 Immune response determining the infection resolution
We showed that vaccination only significantly impacts the infection duration. Consequently, we
explored which immune mechanisms are involved in the infection duration regulation among the
mechanisms generally considered as determining for PRRSv resolution.
Innate response Among the innate mechanisms, we focused on the phagocytosis, the infection
and the excretion (Section I.1.4), illustrated in Figure IV.9. The innate immune response
exhibited globally a low influence on the infection duration.
Phagocytosis It is characterised by Nphag and illustrated in Figure IV.9A–C). Without
vaccination, the infection duration was globally positively related to the total number of phago-
cyted viral particles (Figure IV.9A). This suggested that the phagocytosis activity increased
with the infection severity (related to a higher response activation), but is was efficient or at
least sufficient to reduce the infection duration. However, for a given exposure intensity, the
higher the virulence level, the higher the infection duration and the lower the Nphag values. This
suggests that a higher phagocytosis could participate to the reduction of the infection duration.
Vaccination resulted in a reduction of the infection durations whatever the scenario, but the
phagocytosis activity was not notably impacted (Figure IV.9A, B & C). This suggests that the
DI decrease with vaccination is probably not due to a higher phagocytosis activity.
Infection and excretion They are characterised by Ninf and Nexcr, respectively, and
illustrated in Figure IV.9D–F and Figure IV.9G–I), respectively. Without vaccination, the
infection duration was positively related to the total number of viral particles having infect a
cell and to the total number of excreted viral particles (Figure IV.9D & G). The higher the
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exposure intensities and the virulence level, the higher the infection duration, as well as the viral
excretion and cell infection. These results suggest that the cell infection and the viral excretion
strongly determine the infection severity.
Vaccination resulted in a reduction of the infection durations whatever the scenario, but the
cell infection and viral excretion were only reduced for the low exposure intensity. This suggests
that vaccination could result in lower cell infection and viral excretion and hence participate in
the infection duration reduction for low exposures only.
Adaptive response Among the adaptive mechanisms, we focused on the adaptive response
orientation, the infected cell cytolysis and the viral neutralisation (Section I.1.5), illustrated in
Figure IV.10.
Adaptive response orientation The adaptive response orientation towards the cellular
response is characterised by %Th1 (Figure IV.10A–C) and towards the humoral response by
%Th2 (Figure IV.10D–F). Without vaccination, the infection durations globally increased with
the %Th1 (mean=14%) and decreased with %Th2 (mean=29%). This suggests that the reduction
of the infection severity was induced by the orientation of the adaptive response towards the
humoral and not towards the cellular response.
Vaccination resulted in lower infection durations and globally lower %Th1 and %Th2 (and so
higher %Treg) compared infections of non-vaccinated pigs. Indeed, V1 (V2) strategy resulted on
average in 0.48 (0.53) times lower %Th1, in 0.63 (0.91) times lower %Th2, so in 1.3 (1.1) times
higher %Treg. This suggests that stronger orientation towards the regulatory response could
reduce the infection severity.
Regarding the interactions between vaccination and virulence, the highest DI (130 days
on average) resulted from the [No vaccination×S3] scenarios and the smallest DI (46 days on
average) from the [V2 × S1] scenarios. DI in [V2 × S1] scenarios was on average 0.27 times lower
DI than in [No vaccination ×S3] scenarios, associated with on average 0.25 times lower %Th1
(from 19 to 5% on average), on average 0.83 times lower %Th2 (from 25 to 22% on average) and
on average 1.3 times higher %Treg (from 57 to 73% on average).
Regarding the interactions between vaccination and exposure intensity, the highest DI (117
days on average) resulted from [No vaccination ×L5] scenarios and the smallest DI (22 days
on average) from [V2 × L1] scenarios. DI in [V2 × L1] scenarios was on average 0.17 times than
in [No vaccination ×L5] scenarios, associated with on average 0.53 times lower %Th1 (from 17
to 9% on average), on average 1.3 times higher %Th2 (from 27 to 35% on average) and similar
%Treg (56% on average).
Regarding the interactions between vaccination, exposure intensity and virulence, the highest
DI (151 days on average) resulted from [No vaccination ×L5 × S3] scenarios and the smallest
DI (20 days on average) from [V2 × L1 × S1] scenarios. DI in [V2 × L1 × S1] scenarios was on
average 0.13 times lower than in [No vaccination ×L5×S3] scenarios, associated with on average
0.34 times lower %Th1 (from 21 to 7% on average), on average 1.3 times higher %Th2 (from 25
to 32% on average) and on average 1.1 times higher %Treg (from 54 to 61% on average).
These results suggest that the adaptive response orientation could play a significant role in
the infection severity, but a reduction of the infection severity could be associated with various
adaptive response orientations. Consequently, the adaptive response orientation is not sufficient
to conclude on the immune response efficiency regarding the host protection.
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Figure IV.9 Infection duration as a function of the innate immune characteristics
for the virulence, exposure and vaccine scenarios. 54 scenarios were simulated : wi-
thout vaccine (first column), with V1 vaccine (second column) and with V2 vaccine (third co-
lumn). For each vaccine scenario, we represented the exposure intensity NE× virulence level
Svir combinations by : •{L1 × S1};N{1 × S2}; +{L1 × S3}; •{L3 × S1};N{L3 × S2}; +{L3 ×
S3}; •{L5 × S1};N{L5 × S2}; +{L5 × S3}.
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Cytolysis It is characterised by Ncyto and illustrated in Figure IV.10G–I). Without vac-
cination, our results exhibited a positive relation between infection duration and cytolysis (Fi-
gure IV.10G). The higher the exposure intensity or the virulence level, the higher the DI and
Ncyto values. This result suggests that increasing cytolysis activation is not sufficient to reduce
the infection severity.
However, scenarios with vaccination tone down this result. On the one hand, V1 vaccination
for a given exposure intensity resulted in an increase of the cytolysis activity (and a stronger
reduction of DI) among the virulence level (Figure IV.8G–H). On the other hand, V2 vaccina-
tion resulted in increase of the cytolysis activity for the reference and high exposure intensities,
but did not induce stronger DI reductions (Figure IV.8H–I).
Neutralisation It is characterised byNneutr and illustrated in Figure IV.10J–L). Without
vaccination, our results exhibited a low negative relation between infection duration and viral
neutralisation (Figure IV.10J). The higher the virulence level, the lower the neutralisation
activity, but this effect was low. Viral neutralisation was nearly independent from the exposure
intensity, despite marked differences for the associated infection durations. These results suggest
that increasing the neutralisation activity could be efficient but not sufficient to reduce the
infection severity.
The vaccination strategies clearly resulted in an increase of the viral neutralisation, inducing
shorter infection durations (Figure IV.10K–L). Moreover, the differences in terms of neutrali-
sation were more marked for vaccinated than for non-vaccinated pigs. The lower the exposure
intensity, the higher the neutralisation activity ; and the higher the virulence level, the higher
the neutralisation activity. This last point highlights the fact that neutralisation is not sufficient
to explain the infection severity.
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Figure IV.10 Infection duration as a function of the adaptive immune characteristics
for the virulence, exposure and vaccination strategy scenarios. 54 scenarios were simu-
lated : without vaccine (first column), with V1 vaccine (second column) and with V2 vaccine
(third column). For each vaccine scenario, we represented the exposure intensity NE× virulence
level combinations by : •{L1 × S1};N{1 × S2}; +{L1 × S3}; •{L3 × S1};N{L3 × S2}; +{L3 ×
S3}; •{L5 × S1};N{L5 × S2}; +{L5 × S3}.
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IV.5 Discussion
IV.5.1 Modelling approach
We proposed an original integrative model of the within-host dynamics for a virus targeting
antigen presenting cells at the between-cell scale. This model is particularly adapted to simulate
the within-host dynamics of a weaned pig infected by PRRSv, as it represents the immune
mechanisms assumed to determine PRRSv infection resolution and the mechanisms induced
by or regulating these mechanisms. The within-host dynamics is highly variable between hosts
and PRRSv strains and the level of details of our model makes it possible to explore various
strain virulence and host susceptibility levels. As the immune mechanisms determining PRRSv
infection resolution among PRRSv strains and hosts are not fully identified and as we previously
showed that several immune mechanisms can result in similar infection durations (Chapter II
[16]), this point is crucial. Moreover, we considered various exposure intensities and durations, as
we previously showed that exposure impacts the within-host dynamics and interacts in complex
ways with the virulence level (Chapter III).
We addressed the issue of vaccine efficiency on the within-host dynamics. As vaccines involve
the adaptive response, a detailed representation of the adaptive response activation and orien-
tation was required. As the adaptive response is initiated by the innate response and as both
interact in complex ways during the infection duration, we believe that our integrative approach
is particularly adapted. The main challenge for PRRSv vaccination is linked to the high varia-
bility of PRRSv strains. Consequently, taking this variability into account was a prerequisite.
PRRSv being mainly transmitted by contacts, pigs in fields are subject to variable exposures,
depending on their contact structure. As the exposure is rarely considered in within-host ap-
proaches, our exploration could provide new insights. Finally, assessing vaccine efficiency should
be done at both within- and between-host scales. We focused on the within-host scale, but we
considered variability factors from the between-host scale, which is rarely done.
Although our model did not explicitly represent the memory response, we were able to
derive this response from the adaptive response activation. This allowed us to estimate the
initial immune state of a vaccinated pig and hence to compare the within-host dynamics during
PRRSv infection for vaccinated vs naive pigs. The memory response is currently extracted from
the dynamics of the adaptive components, but it would be straightforward to incorporate its
dynamics explicitly. It would require only to duplicate the adaptive components which partially
differentiate into memory components. Furthermore, our adaptive response representation is
well adapted to test heterologous re-infection/vaccination by a PRRSv strain that differs from
the primary infection/vaccination, pending some model extensions. Indeed, the variability in
PRRSv virulence is due to a variability in the viral epitopes and as the adaptive response
is epitope-specific, so simulation of heterologous re-infection and multi-strain infections would
require to duplicate the virus and all immune components, except the cytokines, and to consider
the potential cross-immunisation, i.e. interactions between components specific to one or the
other strain. To our knowledge, no published immunological model proposes such an approach
to re-infection/vaccination. Preliminary results could be obtained by using the model a first
time to simulate the immune response to a given strain and so extract the resulting memory
response ; and then by using the model a second time to simulate a re-infection with a different
strain, after having informed the initial conditions related to the memory response. In some
sense, it is what we did when we simulated PRRSv infection for a vaccinated pig : vaccination
corresponded to a first infection by an hypovirulent strain, as we considered an attenuated live
vaccine, and it was followed by an infection by a more virulent strain.
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IV.5.2 Vaccine efficiency : preliminary results
We used the within-host model (i) to simulate the immune protection induced by vaccination in
terms of memory response activation and (ii) to explore the within-host dynamics of vaccinated
pigs during PRRSv infection, taking into account the variability in strain virulence and exposure.
We discuss below the results of this preliminary exploration in terms of realism and inputs for
further work.
IV.5.2.1 Immune protection induced by vaccination
Vaccination and PRRSv infection were similarly simulated. Indeed, some current vaccines consist
in modified PRRSv strains in order to induce a high and efficient immune response, but with as
low as possible clinical symptoms and infection severity. Consequently, we defined the parameter
values for the vaccination simulation as for a very low virulent strain that is not able to replicate
within the target cells, associated with a low exposure intensity compared to PRRSv inoculation
doses used in experimental infections.
As we proposed here more an illustration of the possible model uses and as there are very
few literature data about the memory response induced by vaccination alone, we believe that
this approach is satisfying. Among current vaccines, we chose to represent a modified-live virus
vaccine rather than a killed virus vaccine, as the former is assumed to be more efficient to protect
from PRRSv infection. Our results exhibited a realistic behaviour, with an infection duration
similar to the durations reported for wild-field strains, as well as a delayed and weak response
of neutralising antibodies and cytotoxic T cells.
IV.5.2.2 Within-host dynamics of vaccinated pigs after PRRSv exposure
We tested two vaccination strategies which differed only in the activation level of the memory
response. Our results exhibited a significant efficiency of both vaccines to reduce the PRRSv
infection duration, but not to reduce the viral peak and the total viral dose. Moreover, we found
that the vaccine impact on the infection and immune dynamics depends on both virulence levels
and exposure. This result underlines the importance of such variability factors when exploring
vaccine efficiency at the within-host scale. We now summarise and discuss the outlines of our
results regarding the current vaccination strategies.
Our vaccine strategies did not improve the innate response Tested vaccination stra-
tegies resulted in quicker infection resolutions, but did not significantly reduce the total viral
dose and the viral peak. This suggests that these vaccination strategies improve the adaptive
response but not the innate response. Indeed, tested vaccination strategies did not significantly
promote an efficient innate immune response. The phagocytosis activity was similar with and
without vaccination. The APC infection and viral excretion activities were reduced only for low
exposure intensities. As these activities are modulated by antiviral and immuno-modulatory
cytokines, a vaccine capable of promoting the synthesis of antiviral cytokines and/or inhibiting
the synthesis of immuno-modulatory cytokines would be more efficient.
Previous reports demonstrated various negative effects of PRRSv on innate immune func-
tions, including direct cytolysis, suppression of phagocytosis and antigen presentation activities
and alteration of the cytokine patterns [3, 26, 31]. For example, down-regulation of IFNα is a
crucial step in PRRSv pathogenesis [3], as IFNα significantly inhibits PRRSv replication and
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is important for the induction of adaptive IFNγ-producing cells. Conversely, the up-regulation
of IL10 explains several immunological phenomena observed in PRRSv infection [2]. Vaccine
that can minimise IL10 production or enhance IL10 blockade and/or promote the synthesis of
antiviral cytokines following PRRSv exposure should be explored [2, 7].
Recent interest in improving the immune response to PRRSv vaccines lies in the better use
of vaccine adjuvants [7]. Several kinds of vaccine adjuvants have been studied for their ability to
potentiate the immune response to PRRSv vaccines, reviewed in Charerntantanakul [7]. Adju-
vants include cytokines, chemical reagents and bacterial products. Some of them possess innate
immune stimulatory properties,i.e. APC activation and pro-inflammatory cytokine production.
To date, commercial PRRSv modified live and killed vaccines have tried these adjuvants. Only
some of them, however, enhanced the adaptive immune response or increased the vaccine efficacy
[7]. Vaccines promoting the synthesis of IFNα due to the addition of adjuvants were tested but
the results were not concluding [7]. At present, there is no information whether conventional
PRRSv vaccines can inhibit IL10 production in vaccinated pigs after PRRSv exposure. Current
modified live vaccines can either enhance or suppress IL10 production, depending on the chal-
lenge viral strains [2]. Future studies are, therefore, required to seek new vaccine adjuvants that
can potentiate immunogenicity and protective efficiency of PRRSv vaccines [7]. Complementing
experimental approaches, our model can be used to address this issue.
Most current vaccines are developed to improve the adaptive response, in particular the
neutralising antibody and cytotoxic T cell responses [1–3, 7]. However, several studies support
the assumption that PRRSv-induced inefficient adaptive response is at least partly determined
by the weak and altered innate response [1]. Moreover, there is increasing evidence that the innate
response to PRRSv is epitope-dependent and could hence be improved by vaccination. PRRSv
nucleocapsid protein (N) could be involved in the up-regulation of IL10 synthesis [3, 51, 62] and
nsp1 and nsp2 in the down-regulation of IFNα and TNFα syntheses [8, 62]. Although PRRSv
nucleocapsid protein can significantly induce IL10, it should be noted that previous works on
vaccine using nucleocapsid protein or gene alone were discouraging [2]. The nsp2 protein is the
most variable part of the virus. So a modified live vaccine developed from a low virulent strain
(and so resulting in a lower alteration of the innate cytokine synthesis) should induce a more
efficient innate response. Further experimental studies on the link between the viral epitope and
the innate response to PRRSv are required and would guide the development of more efficient
vaccines.
Vaccine efficiency and regulatory response Whatever the virulence and exposure scena-
rios, infection of vaccinated pigs resulted in lower infection durations and globally lower percen-
tages of Th1 and Th2 (and so higher percentages of Treg) compared to the infection of naive pigs.
This suggests that a stronger orientation towards the regulatory response could help the infec-
tion resolution. This preliminary result should be confirmed by experimental data. We illustrate
the kind of interpretations we can make from a such exploration of the vaccine efficiency and
the resulting tracks to guide the development of more efficient vaccines.
The regulatory response during PRRSv infection has been poorly explored [1, 2]. It is conside-
red that enhanced Treg activities can exacerbate negative immuno-modulatory effects in PRRSv
re-exposure [2]. However, it would be interesting to follow Treg in pigs vaccinated with conventio-
nal modified live vaccines (MLV), as they may significantly interfere with the vaccine efficiency,
in particular with the activation of PRRSv-specific memory populations [2]. It is well-known
that the expression of TGFβ may either favour or hinder the onset of an efficient host immune
regulatory response and that a late regulatory response would be responsible for limiting the
inflammation and hence protecting the host against severe PRRSv infection (Section I.1.5.1).
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We showed that the higher the memory response activation by vaccination, the higher the vac-
cine efficiency (V2 vs V1 strategies). This suggests that a higher adaptive response activation
by vaccination or during a primary infection induces a higher host protection from re-infection.
Consequently, an efficient vaccine should induce a strong adaptive immune response but a mode-
rate inflammatory response (as it is responsible for pulmonary damages). Moreover, we showed
that the vaccine efficiency did not exhibit a linear relation with the induced memory response
level. So efficient vaccines would have to balance the adaptive response activation (and so the
protection level) and the inflammatory response activation (and so the infection severity). This
should be improve by adding adjuvant or develop a vaccine which also induce a significant
regulatory response.
Moreover, TGFβ, mainly synthesised by the Treg, is known to induce IgA antibodies, which
express significant neutralising functions in the mucosal surfaces. One of the hypotheses to
explain prolonged PRRSv infection is the weak and delayed activation of neutralising antibodies.
Moreover, PRRSv infection may persist for long periods with low replication rates in the infection
sites, including the lungs. Consequently, the regulatory response could significantly help the
PRRSv infection resolution in the lung mucosal surfaces.
Vaccine efficiency in relation to strain virulence and exposure intensity The vac-
cination strategies we tested exhibited a variable efficiency, depending on the strain virulence
and the exposure scenarios, and resulted in variable adaptive immune responses. Vaccination
strategies were more efficient for highly virulent strains. Highly virulent strains in field generally
result in high exposure due to contacts. Considering scenarios of high exposure intensity and vi-
rulence level [L5×S3], compared to a naive pig response, vaccination induced (i) lower %Th1 and
either higher %Treg (V2 strategy) or higher %Th2 (V1 strategy) ; (ii) a higher cytolysis activity ;
and (iii) a higher viral neutralisation activity. Considering scenarios of low exposure intensity
and virulence level [L1 × S1], compared to a naive pig response, vaccination induced (i) lower
%Th1 and %Th2 and higher of %Treg ; (ii) a similar cytolysis activity ; and (iii) a higher viral
neutralisation activity. Considering all these results together, it seems that a vaccine inducing
only higher neutralising antibody titres would be less efficient than a vaccine inducing both
higher neutralising antibody and cytotoxic lymphocyte titres. This result is consistent with the
dominant assumption to explain prolonged PRRSv infections (Section I.1.5.1).
We defined our vaccine as a modified live attenuated virus with a very low virulence. Conse-
quently, the infection of a vaccinated pig by highly virulent PRRSv strain (S3 scenario) could
correspond to a challeng with a different PRRSv strain from the one used for vaccination (hete-
rologous challenge). Diaz et al. [10] showed that protection against the development of viraemia
was significantly better in pigs with higher levels of cytotoxic T cells subjected to an heterologous
challenge, compared to pigs with lower levels of cytotoxic T cells challenged with a PRRSv strain
similar to the one used for vaccination. Our results are consistent with these findings, although
they must be interpreted cautiously, as our model does only allow to explore an heterologous
re-infection with a full cross-protection. Exploring the within-host dynamics following heterolo-
gous challenges taking into account cross-protection levels in field condition would require model
adaptations such as those presented in Section IV.5.1.
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Vaccination is the main control strategy used to limit PRRSv infection severity and PRRSv
spread [1]. However, PRRSv commercial vaccines do not provide a complete protection against
PRRSv infection, but only allow to reduce the infection severity and duration and so PRRSv
shedding at the between-host scale [1, 2]. The major reason for vaccines lacking efficiency is that
the mechanisms determining PRRSv infection duration are still poorly understood and exhibit
a strong variability among PRRSv strains and hosts [1, 3–6]. In this context, we addressed three
issues in this thesis :
• First, considering an isolated pig, we explored the immune mechanisms which determine
PRRSv infection resolution for various pig susceptibility and strain virulence levels (Chap-
ter II).
• Then, we added a variability factor from the between-host scale considering that pigs in
herds can be subject to various exposures (Chapter III).
• Finally, we proposed a preliminary exploration of the efficiency of current commercial
vaccines on the within-host dynamics, taking into account the variability in both strain
virulence and exposure (Chapter IV).
This work provides new insights to better understand and control PRRSv infection. We
showed that apparent inconsistencies among experimental studies and assumptions proposed to
explain PRRSv prolonged infection can be explained by the influence of PRRSv strain virulence
and host susceptibility on the within-host dynamics. Moreover, the exposure intensity and du-
ration also impact the within-host dynamics and their influences were variable depending on the
strain virulence. Consequently, variability in exposure and strain virulence/host susceptibility
should not be neglected. Finally, we showed that an immunological model could be helpful to
(i) test the efficiency of current vaccines and (ii) identify the needed conditions in term of im-
mune mechanisms induced by a vaccination to reach a given level of protection against PRRSv
infection.
We first synthesise here the main results of our within-host approach and their insights and
limits regarding the major issues of PRRSv infection control. We then discuss the prospects
offered by (i) a model extension for multi-strain system regarding the exploration of vaccine
efficiency at the within-host scale and (ii) coupling both within- and between-host dynamics
regarding the exploration of PRRSv spread and vaccine efficiency at the herd level.
1 Insights from the within-host approach to better understand
and control PRRSv infection
We first considered a PRRSv infection of an isolated pig i.e. in controlled experimental condi-
tions. However, as PRRSv is mainly transmitted by contacts, a pig in the field is subject to
variable exposures. The impact of variable exposures on the within-host dynamics has not yet
been explored for PRRSv infection. We so explored this issue. These allowed us to determine
which immune mechanisms are involved in PRRSv resolution and which variability factors im-
pact the within-host dynamics. Then we were able to propose a modelling framework to explore
the efficiency of current commercial PRRSv vaccines. Finally, we presented the major common
limit of our modelling approaches, the model calibration and hence validation and we present
the custom-made experimental infection which has been implemented to unravel this limit.
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1.1 Which immune mechanisms determine PRRSv infection resolution ?
Reviews suggest that the concepts proposed to explain prolonged PRRSv infection have not
yet been experimentally proved ; in particular, the roles of the cytokines and the orientation
of the adaptive response need to be more clearly elucidated [1–3, 7]. We addressed this issue
considering infection of either isolated pigs or in field conditions and taking into account at least
the variability in PRRSv strain virulence.
1.1.1 Regarding isolated pigs
We used our lung-based model to explore the influence strain virulence and host susceptibility,
which are linked to : (i) the virus capacity to infect the cell and replicate, (ii) the host capacity
to synthesise antiviral vs immuno-modulatory cytokines in response to PRRSv infection, and
(iii) the activation and orientation of the adaptive response towards the cellular, humoral or
regulatory. Recent studies hypothesise that these variations are due to cascaded reactions ini-
tiated by the macrophage–virus interactions [3, 4, 8, 9]. Both macrophage permissiveness and
viral replication impact the cytokine synthesis, which in turn regulates them. Discriminating
their respective influences of macrophage permissiveness and cytokine synthesis is very difficult
experimentally. Published experimental studies on PRRSv infection (reviewed in [1–5, 10–13])
are highly heterogeneous and differ on : (i) the monitoring duration, (ii) the measured immune
components, (iii) the viral strain, (iv) the pig genotype. Our integrative model allowed go beyond
the experimental limitations.
We obtained contrasted dynamics in terms of immune response and infection duration among
virulence and susceptibility scenarios, suggesting hypotheses to explain the apparent contra-
dictions between published results. We observed that high levels of antiviral cytokines and a
dominant cellular response were associated with either short, the usual assumption, or long in-
fection durations, depending on the immune mechanisms involved (cytokine synthesis capacities
or macrophage permissiveness). Indeed, high antiviral (immuno-modulatory) cytokine synthesis
rates, corresponding to a low (high) virulence or susceptibility level, resulted in short (prolon-
ged) infection durations associated with high (low) levels of antiviral cytokines and a dominant
cellular (humoral and regulatory) response. Conversely, low (high) macrophage permissiveness,
corresponding to a low (high) virulence or susceptibility level, resulted in short (prolonged)
infection durations associated with low (high) levels of antiviral cytokines and a dominant hu-
moral (cellular) response. We showed that to identify and understand the immune mechanisms
responsible for the infection duration, at least (i) the levels of innate antiviral cytokines, (ii) the
level of IL10 (a good indicator of the infected macrophage level) and (iii) the relative levels of
IL10 and IFNγ (a good indicator of adaptive response orientation) need to be monitored. These
results provide new insights to better construe the experimental results variability. Moreover,
they suggest that there is not efficient mechanisms to resolve PRRSv infection whatever the
virulence and the susceptibility but rather few mechanisms which are not exclusive and can be
involved in various proportions depending on the strains and the hosts. Whatever the strain
virulence and host susceptibility, the infection duration was linked to some immune variables :
(a) the level of pro-inflammatory cytokines was a good indicator of the infection severity ; and
(b) a dominant regulatory response was associated with a prolonged infection.
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1.1.2 Regarding infection in field
PRRSv is mainly transmitted by close contacts with an infected pig [13]. Some epidemiological
studies pointed out that the spread of PRRSv depends on the pig contact network, the pig infec-
tiousness and the pig susceptibility [14, 15]. The infectiousness and susceptibility are influenced
by several factors, which probably interact in a complex way [16] : the PRRSv strain virulence
[1–3, 17], the pig genetic resistance to PRRSv infection [1, 4, 18], as well as the exposure in-
tensities and inoculation routes [19–21]. Experimental studies found that (i) the infectiousness
is a log-normal-like function of the time post-infection [19] and that (ii) PRRSv infection pro-
bability is a logistic function of the initial inoculum dose [20]. Studies on other viruses showed
that the initial inoculum dose determines the within-host immune dynamics and course of infec-
tion [22, 23]. However, no such studies were conducted for PRRSv, neither experimentally, nor
through a modelling approach. We used our model to explore the exposure impact on PRRSv
within-host dynamics, representing the exposure variability in terms of intensity, duration and
peak.
At the within-host scale, our main results were in agreement with results obtained for isola-
ted pigs and experimental PRRSv infection results : (i) the level of pro-inflammatory cytokines
was positively correlated with the infection severity [24–26] ; (ii) short infection durations were
associated with the dominance of the cellular response over the humoral response (for a given
strain virulence) [1–4, 26] ; (iii) the cytolysis and viral neutralisation exhibited a low influence on
the infection resolution and were inefficient to reduce PRRSv infection severity [1–4]. Exploring
the impact of exposure characteristics on these descriptors, we exhibited more original results.
We found that the infection severity was fully determined by the exposure intensity. The infec-
tion duration increased with the strain virulence and, for a given strain virulence, it exhibited
a positive linear correlation with the logarithm of the exposure intensity and the exposure du-
ration. Whatever the exposure and strain virulence, the infection duration decreased while the
percentage of antiviral cytokines increased. These results are consistent with an experimental
study on influenza, which found that the exposure dose influenced the infection dynamics via the
antiviral cytokines [23]. Consequently, an estimate of the viral dose received through exposure
should be enough to infer the infection severity. However, to predict the infection duration, one
would also need to know the exposure duration and the strain virulence. The exposure intensity
and duration hence affect the pig infectiousness, which is also modulated by the strain virulence.
Given these findings, the PRRSv exposure and the pig susceptibility/strain virulence should
not be neglected for exploring either the within or between-host dynamics induced by PRRSv
infection.
1.1.3 Synthesis
We showed that depending on the strain virulence/pig susceptibility and the PRRSv exposure,
various immune mechanisms are involved in PRRSv infection resolution. Both innate and adap-
tive mechanisms, involving cytokines regulations, exhibited a strong influence on the within-host
dynamics, which is consistent with the assumptions reported in the literature [1, 3–6]. Conse-
quently, the whole immune response and the variability factors from the between-host dynamics
(strain virulence, pig susceptibility, viral exposure) have to be considered to understand which
immune mechanisms are responsible for PRRSv infection resolution. Given the complexity of the
immune response and the high variability between host and strains, our modelling approaches
provided a powerful framework.
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1.2 Efficiency of the current commercial PRRSv vaccines
Having identified the mechanisms determining for the PRRSv within-host dynamics, we were
interested in the exploration of the efficiency of current vaccines. Our aims were (i) to simulate
the immune response induced by current vaccines and the protection they confer ; (ii) to identify
which conditions an efficient vaccine would have to fulfil to protect the host from PRRSv infec-
tion. However, due to the scarcity and partiality of data, it was difficult to calibrate the model,
especially the impact of current vaccines. So, we conducted a more theoretical study aiming
at simulating the within-host dynamics of a vaccinated pig after PRRSv exposure. This study
consisted of two steps. Firstly, we simulated the immune dynamics induced by an attenuated live
virus vaccine, represented in the model as an infection by an hypo-virulent and non-pathogenic
PRRSv strain. We used this simulation to initialise the immune state of a vaccinated host, in
terms of memory B and T cells, as well as antibodies. Secondly, we exposed the vaccinated host
to PRRSv and assessed the vaccine efficiency.
We showed that our model is well adapted to (i) estimate the memory response induced by
a vaccine and (ii) explore the within-host dynamics after an homologous challenge of vaccinated
pigs. The infection resolution of vaccinated pigs did not involve the innate response, but offered
a partial protection involving the neutralisation activity by antibodies and/or the infected cell
cytolysis by cytotoxic T cells. The protection level varied depending on the PRRSv exposure,
the strain virulence and the activation level of the memory response by the vaccine. Our results
were consistent with the tendencies reported in experimental studies. We discuss our results to
provide a better understanding of the vaccine efficiency variability and to guide the development
of more efficient vaccines. Although realistic, this exploration remains a theoretical study. A finer
and more applied exploration would require experimental data.
1.3 Common limits of our modelling approaches : model calibration and va-
lidation
Whatever our issues, the model calibration and hence validation is the major weak point. In-
deed, published PRRSv experimental infection data exhibit a strong heterogeneity (in term of
monitoring durations, measured immune components, viral strain and pig genotype). Moreover,
among the variables included in our model, only a few were monitored in each experimental
study and there were few measures over time. Consequently, based on these data, classical para-
meter estimation methods were not suitable to calibrate our model and we had to design an ad
hoc procedure. We so defined a reference scenario as robust as possible, checking that the model
results were consistent with the available experimental data and that varying the parameter
values around the reference values still resulted in realistic dynamics. For each applied issue, we
discussed the validation limits of our approaches and we pointed out that experimental studies
would be needed to validate our results and conclusions.
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1.3.1 Experimental infection
To address this issue, we designed an experimental infection study in collaboration with the
Anses Laboratory in Ploufragan (France), as part of the ANR project MIHMES 1. This experi-
mentation, completed in summer 2014, resulted in successful infections and globally successful
laboratory analysis. The main strengths of this experimentation regarding the published experi-
mental PRRSv infections are (i) the infection by either low or high virulent two PRRSv strains in
same experimental conditions, (ii) the monitoring of both innate and adaptive immune compo-
nents, including more components of interest than most of the published experimental data and
(ii) the monitoring duration which was higher than the infection duration for most monitored
pigs. The experimentation is succinctly described below.
Outlines of the experimental protocol Eighteen 5-weeks old SPF piglets free from PRRSv
and without maternal immunity derived from the Anses SPF herd were used. They were housed
in air-filtered level-3 bio-security facilities in three isolated batches consisting in either eight
pigs inoculated by the European Lena PRRSv strain (a high virulent strain belonging to the
sub-genotype 3) or five pigs inoculated by the European Finistere PRRSv strain (a moderate
virulent strain belonging to the sub-genotype 1) or five pigs kept as negative controls. Eight
pigs instead of five were used for the batch infected by the Lena strain as this PRRSv strain
induces a high mortality rate. Indeed, three pigs over eight died before the end of the experiment.
Besides clinical signs, the protocol consisted in monitoring the viral titer and the concentration
of immune components of interest (including both innate and adaptive components and the
major cytokines) in both the broncho-alveolar lavage (BAL) fluids and the blood from 3 to 43
days after PRRSv infection. At the end of the experiment, pigs were euthanised and the immune
components of interest were measured in the lymph nodes. The immune components of interest
and the sample frequency were selected according the model needs (partly regarding the lacks
in published experimental data), the results from the lung-based model exploration and the
experimental constraints.
Monitored components Among the immune effectors, we monitored (i) the total concen-
tration of monocytes, macrophages and activated lymphocytes and (ii) the concentration of
T lymphocytes, including cytotoxic T cells and natural killers, B cells and phagocyting cells
(in BAL only). Among the cytokines, we monitored the innate antiviral IFNα and TNFα,
the pro-inflammatory IL8 cytokine and the immuno-regulatory IL12, IFNγ (only in BAL as
it was undetectable in the blood) and TGFβ. Finally, we also monitored the antibody titres as
sample/positive (S/P) ratio.
The viral titer was monitored by PCR, the immune cells were monitored by flow cytometry
and cytokines and antibodies were monitored by ELISA assays.
Samples As the dynamics in the first days evolve rapidly, we collected four samples within
the first week, two samples within the second week and one sample by week for the four last
weeks. The viral titer was monitored for each of these samples but all the immune components
were not as some of them are known to appear tardily. For instance, we started to monitor the
natural killers and the cytotoxic T cells from 15 days post infection.
1MIHMES : Multi-scale modelling, from animal Intra-Host to Metapopulation, of mechanisms of pathogen
spread to Evaluate control Strategies, see http://www6.inra.fr/mihmes
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1.3.2 Future work
We will use these experimental data to calibrate our models, in particular, the within-host model.
This will allow us to validate (or redefine the reference scenario) and to check up our preliminary
results from the efficiency exploration of current commercial PRRSv vaccines, presented in
chapter IV. This work will be valuated by a publication.
2 Towards a multi-strain approach to guide the development of
more efficient vaccines
Our within-host model is adapted to simulate an infection of either a naive pig to a given
PRRSv strain or an infection of a vaccinated pig (or a re-infection) for homologous challenges
or heterologous challenges assuming a full cross-protection. However, several PRRSv strains can
coexist in the same area and in the same time in field conditions and it is well known that the
cross-protection involved during heterologous either re-infection or infection after vaccination is
only partial [1–3, 27]. Developing vaccine that can provide a broad cross-protection protection
against circulating PRRSv strains has become a major challenge for current vaccine development
[7].
Considering the protection level induced by a given vaccine against an heterologous challen-
ged, we identified two issues :
• First, the memory response is epitope specific, so a vaccine protecting against various
PRRSv strains has to be multi-epitopes (which can be common) among the epitope range
of PRRSv strains in order to the memory cells induced by the a such vaccine recognise
the various PRRSv strains. This issue, recently discussed be Hu and Zhang [7], require a
better characterisation of the antigenic regions of the PRRSv strains in order to identify
and use the appropriate combinations of regions for efficient multi-epitope vaccines, named
universal vaccines.
• Then, assuming an universal vaccine, the induced memory response should be efficient
whatever the PRRSv strain. Indeed, the various PRRSv strains induced various immune
responses (titer and relative levels of antibodies, cytotoxic T cells, adaptive response orien-
tation, . . .) depending on the viral epitopes and which exhibit various efficiency in PRRSv
infection resolution and protection. Consequently, the efficiency of the immune response
induced by such vaccines should be explored, and a modelling approach would provide a
powerful tool to reach this issue.
We here present these two issues where experimental and modelling approaches provide com-
plementary insights to guide the development of more efficient vaccines.
2.1 Experimental approach to guide the development of PRRSv universal
vaccines
Due to the antigenic heterogeneity of the PRRS virus, current commercial PRRSV vaccines
(killed-virus and modified-live vaccines) are of unsatisfactory efficacy, especially against hetero-
logous infection [7]. Continuous efforts have been devoted to develop better PRRSv vaccines.
Experimental PRRSv vaccines, including live attenuated vaccines, recombinant vectors expres-
sing PRRSv viral proteins, DNA vaccines and plant-made subunit vaccines, have been developed.
However, the genetic and antigenic heterogeneity of the virus limits the value of almost all of
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the PRRSv vaccines tested. Developing a universal vaccine that can provide broad protection
against circulating PRRSv strains has become a major challenge for current vaccine development
[7]. For PRRSv infection, protection is conferred by the humoral immune response, represented
by neutralising antibodies and by the cellular immune response, represented by the cytotoxic
T cells. Thus, an effective universal PRRSv vaccine must invoke a strong response against diverse
field strains from both T cells and B cells [7].
The first strategy would be to develop multi-strain vaccines consisting of antigenically distinct
strains, as in the case for poliovirus vaccines [7]. Up to now, results from experimental multi-
strains PRRSv vaccines did not exhibit a higher efficiency than single-strain vaccines [7, 28].
The second strategy would be the development of conserved-region vaccines [7]. Its purpose is to
incorporate into vaccines B cell and T cell epitopes from the most conserved regions of the virus.
They would thus have high probability of interacting with the circulating viruses. Therefore
identifying conserved regions of the viral proteome is the starting point for this strategy. The
third strategy would be the development of poly-epitope vaccines [7]. It is based on the fact that,
despite PRRSv great genetic and antigenic variability, a cross-protection does exist involving a
strong T cell and B cell responses, even between genetically distant type 1 and type 2 strains.
However, the limited knowledge on T cell and B cell epitopes among the PRRSv strains is still
a barrier for the design of a poly-epitope vaccine [7].
2.2 Modelling approach to guide the development of more efficient vaccines
For PRRSv, numerous experimental studies showed that various PRRSv strains (and so various
PRRSv vaccines) induced various immune response and resulted in various memory responses
and so various protection levels with only partial cross-protections [1–3, 27] against heterologous
challenge. Consequently, in addition to the variable level of cross-protection linked to the variable
level of viral epitope recognition, there is also a variable level of cross-protection due to the
variability of the immune response induced by the various PRRSv strains, which is also epitope
dependent. On the one hand, the immune system is designed to rapidly recall pre-existing cross-
reactive immune responses from memory immunity and any such responses should therefore
provide an advantage over a re-infection comparatively to a primary infection of a naive host.
On the other hand, recalled responses may also result in a less efficient immune response over an
heterologous re-infection than that seen in na¨ıve individuals. In particular for PRRSv infection,
as various PRRSv strains induce variable immune responses, a recalled response from a primary
exposure by a given PRRSv strain should be less efficient over an heterologous re-infection
than from a primary exposure by the re-challenged PRRSv strain. Consequently, the immune
mechanisms protecting against PRRSv infection depending on the PRRSv strains and whatever
the PRRSv strain (if they are) should be identified [1, 3].
We showed in this thesis that the apparent inconsistencies between experimental data in term
of which immune mechanisms are determining for the PRRSv infection resolution should be ex-
plained by considering the immune mechanism variability involved depending on the PRRSv
strain (see Chapter II). However, this approach is insufficient to conclude on the immune me-
chanisms protecting against PRRSv infection depending on the PRRSv strains and whatever the
PRRSv strain. Our preliminary exploration of the current vaccine efficiency (see Chapter IV)
exhibited that an hypo-virulent PRRSv strain vaccine induce a memory response which would be
more protective against a hyper-virulent PRRSv strain than against an hypo-virulent PRRSv
strain. This result supports the assumption that the cross-protection level induced by a vac-
cine dose not only depend on the memory component ability to recognise the PRRSv epitopes,
but also on the induced immune response, which is epitop dependent. However, we assumed
a full cross-protection, which is not realistic. Consequently, a finer exploration would require
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a straightforward model adaptation to consider the partial cross-protection, i.e. a multi-strain
within-host model, introduced in the Section IV.5.1. The memory response dynamics has first
to be incorporated explicitly. It would require only to duplicate the adaptive components which
partially differentiate into memory components. Then, model adaptation for heterologous re-
infection and multi-strain infections would require to duplicate (for two strains) the virus and
all immune components, except the cytokines, and to consider the potential cross-immunisation,
i.e. interactions between components specific to one or the other strain.
It has been previously pointed out that a careful consideration of the within-host dynamics
in such context of re-infection by either homologous or heterologous challenge would help to
develop more informative models of pathogen spread at the herd level [29]. Multi-strain within-
host models are classically used in immuno-epidemiological models [30–34] and in particular
to explore the host-pathogen co-evolution, whereas we found only one published multi-strain
immunological model [35]. Such models have to consider how the various immune mechanisms
of the both innate and adaptive immune responses interact to resolve the pathogen infection
at the within host level [29]. Our within-host model provides then an interesting framework to
reach this issue whatever the pathogen. Finally, multi-strain within-host model will provide new
insights for the pathogen spread at the within-host scale and for linking within to between-host
dynamics in immuno-epidemiological models [29].
3 Towards an immuno-epidemiological approach
The within-host dynamics is impacted by several factors which can vary at the between-host
scale and can exhibit a temporal dynamics, such as the host susceptibility, the pathogen strain
virulence and the pathogen exposure. The within-host dynamics determines in turn the suscep-
tibility of the pig (and in particular its protection level) and its infectiousness, which are specific
to the pathogen strains. The between-host dynamics of a pathogen transmitted by contacts is
determined by the contact structure, the host susceptibility and the host infectiousness of in-
dividuals in contacts. Consequently, the within and between-host pathogen spread interact in
a temporal dynamics way and are linked by the health status of hosts and by the pathogen
exposure (from between-host towards within-host dynamics) and the host infectiousness (from
the within-host towards the between-host dynamics). In a context of temporal and between-host
variability of the within-host dynamics to a pathogen (as for the PRRSv), neglecting either the
within-host dynamics at the between-host scale or the between-host dynamics at the within-
host scale would be too strong simplifications. As a result, understand, predict and control the
spread of such pathogens at the herd level each requires the consideration of the within-host
dynamics and its interactions with the between-host dynamics, named immuno-epidemiological
approaches.
For PRRSv control, immuno-epidemiological framework would be particularly adapted as :
• the immune dynamics to PRRSv is highly variable depending on the host, the PRRSv
strain and the PRRSv exposure. The within-host dynamics variability results in a varia-
bility of health status and so in the probability of an infectious pig to infect another pig
and of a pig either naive or (partially) protected to be infected ;
• the major PRRSv control measure is the vaccination, which directly involves the within-
host dynamics and provides variable protection level depending on the host health status,
its interactions with the other pigs and PRRSv strain challenged. None of the current
commercial vaccines provides a full protection, exhibits a variable efficiency depending on
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the PRRSv strain against an homologous challenge and only a partial (and more often a
poor) cross-protection against heterologous challenge ;
• several PRRSv strains coexist in the same area and in the same time in field conditions,
so the efficiency of a vaccination strategy at either the within-host or herd level should be
considered regarding the dynamical interactions between the two scales.
In this thesis, we showed that understand, predict and control the within-host dynamics to
PRRSv infection requires an integrative view of the immune response (including the innate
and adaptive dynamics and their interactions involving cytokine regulations). Consequently, our
within-host model provides a powerful framework in the prospect of an immuno-epidemiological
approach. After an introduction presenting the immuno-epidemiological approaches, we discuss
the insights and limits of our within-host approach regarding an immuno-epidemiological ap-
proach prospect in term of linking both scale through (i) the exposure/infectiousness and (ii)
the health status of hosts. Finally, we discuss the insights of using an immuno-epidemiological
model to explore the efficiency of current PRRSv vaccines and to guide the development of more
efficient vaccines.
3.1 Introduction to immuno-epidemiological models
Immunological and epidemiological models has historically been considered as separate disci-
plines. Most immunological models are self-contained and do not incorporate links to the epi-
demiology of the disease. In particular, these type of models ignore the amount of pathogen
transmitted (i.e. the infectiousness) and the status of the immune system at infection (i.e. the
protection and/or susceptibility levels).
Epidemiological models take into account the heterogeneity of within-host dynamics by des-
cribing the population through discrete classes depending of the health status of individuals,
mainly susceptible, infected and non-infectious (latent), infected and infectious and recovered-
immune status. Hosts can be refined by introducing subcategories of infected hosts. Standard
epidemiological models assume that each host is infected with the same amount of pathogen
and exhibits the same time course of infection. Some epidemiological models (i) include time-
since-infection structure to account for variable infectiousness during infection and so implicitly
account for the pathogen load of the individuals and/or (ii) are structured by time-since-recovery
and so implicitly account for the temporal loss of protection recovery. Yet, most epidemiological
models do not take into account the pathogen load of infected individuals and the detailed im-
mune status during infection. However, some infections are characterised by a strong variability
in the immune dynamics between-host, which can result in a strong variability in the infec-
tiousness of the infected hosts and the protection level of the susceptible hosts. In these cases,
classical epidemiological approaches are insufficient, in particular to explore the vaccine strategy
efficiency at the herd level or to guide the development of more efficient vaccine strategies.
Given this context, immuno-epidemiological models, bridging the gap between immunology
and epidemiology combining within and between-host approaches, provides new perspectives [32,
36]. They examine how the within-host dynamics differences among hosts affect the between-host
dynamics to produce the epidemiological dynamics observed in heterogeneous host populations
[36]. Immuno-epidemiological approaches have first been developed for macroparasitic (helminth)
infections and malaria [36]. It is a field of increasing interest and numerous models applied to
various diseases, such as Influenza [32, 37–40] or HIV [32–34], has been developed and consider
assumptions about acquired immunity to study spread of infection [41–44] or host-pathogen co-
evolution [45–47]. One type of immuno-epidemiological models is the nested approach, developed
in Gilchrist and Sasaki [45], which provides a simple framework for linking immunological and
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epidemiological models. The nested modelling approach embeds a mechanistic ODE model of
host-pathogen disease dynamics into a time-since-infection epidemiological model of infection
by linking epidemiological parameters such as transmission rate or duration of infectiousness
[45, 46, 48]. The two models are linked by two mechanisms.
1. Through a structural variable. The epidemic model is structured through time-since-
infection, used as an independent variable in the immunological model only for the infected
individual class of the epidemiological model.
2. Through parameters. Parameters of the epidemiological model are expressed as functions of
the dependent variables of the immunological model. For instance, the transmission rate
is proportional to the pathogen titer within the host and the disease-induced virulence
depends on both the infection and immune dynamics within the host.
For diseases with recovery, the main disadvantage of this nested approach is that the host immune
status upon recovery is not retained, i.e. each new infection has to start with the same immune
status. Ideally, for diseases that allow repeated infections and/or exhibiting variable levels of
protection depending on the time-since-infection, the hosts and the the pathogen strain (such
as for PRRSv infections), we would like to retain the immune status, so that upon re-infection
the immune system can mount a more efficient response and clear the pathogen faster. For these
issues, stochastic discrete-time Agent Based Models (ABM) would be more adapted as proposed
by Lukens et al. [37], Steinmeyer et al. [44]. In ABM, individuals are represented as autonomous
agents whose within-host dynamics and in particular infectious status is followed in time. The
infection propagates in the population according to disease transmission and duration rules,
where between-host variability is represented in the form of statistical distributions.
Whatever the pathogen, a major challenge for the area is how to choose an appropriate
abstraction : for a given system, how should we move from the full immune dynamics at the
individual host level to reasonable assumptions that can be incorporated into population models
[29]. In other word, which is the ideal detail level of the within-host model and which are links
between the within-host and the between-host models that may be implemented. We discuss
this issues in the two following sections regarding the PRRSv infections : why and how to link
(i) the exposure and the infectiousness and (ii) the within-host dynamics and the health status
at the herd level.
3.2 From the viral exposure to the pig infectiousness
At the between-host scale, the infection spread, the infectiousness of infected individuals (i.e.
the amount of pathogen transmitted) and the host contact structure determine the exposure of
susceptible individuals, which can trigger new infections. At the within-host scale, the exposure,
the individual susceptibility and the pathogen virulence drive the immune dynamics, which
dictates the infection duration and severity, as well as the infectiousness of infected individuals.
Exposure hence links the between-host to the within-host dynamics, whereas infectiousness
links the within-host to the between-host dynamics. Steinmeyer et al. [44], which proposed
theoretical immuno-epidemiological approaches, showed that between-host models need to take
the exposure of susceptible animals into account to represent the pathogen transmission, which
partly depends on the within-host dynamics of infected animals. Studies on other viruses than
PRRSv showed that the initial inoculum dose determines the within-host immune dynamics and
course of infection [22, 23]. On PRRSv, experimental studies found that (i) the infectiousness is
a function of the time post-infection [19] and that (ii) PRRSv infection probability is a logistic
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function of the initial inoculum dose [20]. However, the impact of exposure on the within-host
dynamics, which is regarded as a key issue [22, 23, 44], has not been explored for PRRSv
infection.
We showed that the PRRSv exposure has an influence on the viral titer (see chapter III) so on
the infectiousness of an infected pig and consequently on the PRRSv spread at the herd level. We
found that the exposure intensity (the total viral dose received through exposure) and to a lesser
extent the exposure duration and peak had a strong impact on the within-host dynamics, which
could vary according to PRRSv strain virulence. The simplest way to represent the exposure
in a model is by way of a positive initial condition for the pathogen, i.e. either a punctual
exposure dose due to a punctual contact or the total viral dose received through exposure. Most
studies used this approximation in experimental infections [20, 23], in within-host models of
various viral infections [22], or in immuno-epidemiological models [30, 44, 46, 48, 49]. Only few
published immuno-epidemiological models represent the exposure as a time-dependent function
related to the viral titer of infected individuals in contact [41]. In order to identify the best way to
represent the PRRSv exposure in models, we looked at the impact of the exposure duration and
peak for a given exposure intensity. We showed that a good approximation of the exposure should
at least preserve the exposure intensity, especially to estimate the infection severity. Besides,
representing the exposure due to contacts by a short or even a punctual exposure would tend
to underestimate the infection duration. As the infection severity and duration both contribute
to the pig infectiousness, a prolonged exposure of the adequate intensity would probably be an
adequate choice in an immuno-epidemiological context.
3.3 From the immune dynamics to the health status
The health status of individuals determines their probability to be infected by or to infect other
individuals. During infection, the temporal variability of health status is generally represented in
epidemiological models by discrete classes depending of the health status of individuals. However,
for pathogen infection exhibiting a high variability of the within-host dynamics between hosts,
the classical representation of health status in epidemiological models is too simple and would
result is wrong estimations of the pathogen spread at the population level. Then, immuno-
epidemiological models are powerful to unravel this limit. The health status of individuals are
directly determined by their within-host dynamics and their probability to infect (or/and be
infected by) another individual could be defined as a continuous function of their within-host
pathogen titer (or/and their immune response). In the previous subsection, we discussed the
link between infectiousness of an infected individual and exposure of a susceptible individual,
which involves the pathogen titer of the infected individuals in contact. Here, we discuss the link
between the host susceptibility level during the infection time and the health status at the herd
level. Susceptibility of host depends on its own characteristics (such as its age, genotype, . . .)
and its infectious past. Considering a naive host (i.e. it has never encountered the pathogen),
a successful infection results in the activation of the immune response and the establishment
of a memory response which is specific to the pathogen. Then, if this immunised host is re-
exposed to the same pathogen after the infection resolution, the immune system is designed
to rapidly recall the memory response, which provides either an advantage over a re-infection
comparatively to a primary infection of a naive host or in a less efficient immune over an
heterologous re-infection than that seen in naive individuals. Considering the memory response
is consequently necessary when the hosts which can be challenged several times (depending on
the pathogen and/or the time-duration of interest). Moreover, the protection level (and so the
host susceptibility) conferred by the memory response exhibits a temporal variability, which can
be variable between host. Finally, for some diseases, several pathogen strains can circulate in
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the same area and in the same time, and as the memory response is specific to the pathogen
strain, the protection level resulting from an exposure to a given strain would vary depending
on re-challenged pathogen strain. This last point is related to the cross-protection, determined
by the host, the pathogen strain and the infectious past of the host. In turn, the duration of
infectiousness is affected by the protection level of the host and this will consequently impact
the pathogen spread at the herd level. Consequently, a careful consideration of the within-host
dynamics in such context of re-infection by either homologous or heterologous challenge would
help us to develop more informative models of pathogen spread at the herd level [29].
For PRRSv, numerous experimental studies showed that various PRRSv strains induced
various immune response and so variable infection severity and duration resulting in variable
infectiousness [17, 19] and resulted in variable memory responses and so variable protection levels
with only partial cross-protections [1–3, 27]. As a result, an immuno-epidemiological model
is required to simulate the PRRSv spread at the herd level linking the within-host immune
dynamics and the health status of hosts and considering the variable protection levels depending
on hosts, PRRSv strains and infectious past of host. This implies to follow the dynamics of each
host of the herd during the time window of interest thanks an ABM immuno-epidemiological
model. Moreover, as several PRRSv strains can co-exist in the same area and in the same time,
the immuno-epidemiological model should consider a multi-strain system.
Concerning the within-host scale, our within-host model extended to a multi-strain system
would be particularly adapted for PRRSv disease, as presented in the subsection 2.2. Indeed,
PRRSv exhibits (i) numerous evasion strategies to the immune system altering both innate and
adaptive components ; (ii) a high variability in evasion strategies (and consequently of in immune
dynamics during infection) between-hosts and strains and (iii) a co-existence of several strains
in the same area and in the same time. Consequently, simulating the within-host dynamics to
such pathogens requires an integrative view of the immune response specific to a given strain
including the innate and adaptive components dynamics and their interactions, as proposed in
our within-host model.
To make tractable population models of multiple strains, modellers typically make relatively
simple assumptions about the nature of partial cross-immunity [29]. For example, a partially
immune host can be treated as having a lower probability of becoming infected (reduced sus-
ceptibility) and/or a lower probability of transmitting the infection to others (reduced trans-
missibility). Among the published immuno-epidemiological models, none represented explicitly
the link between the multi-strain immune dynamics and the health status of host in the herd
including the cross-protection. However, each proposed an interesting framework and combi-
ning the various approaches would result in a more adapted immuno-epidemiological model.
Luo et al. [50] defined a nested two-strain immuno-epidemiological model where all hosts are
naive at the beginning of the simulations, hosts can be re-infected with the same strain and
each infection increases the immune status of the host. Such framework could be extended to
also consider the cross-protection. Similarly, Lythgoe et al. [34] proposed a nested multi-strain
immuno-epidemiological model where the host infectiousness depends on the strain and the
host, but the host protection dynamics is not considered and the within and between-host dy-
namics are linked only through the infectiousness. Lukens et al. [37] defined a mono-strain ABM
immuno-epidemiological model where immune characteristics are extracted from the within-host
dynamics and used as parameters of the epidemiological model to generate population response
variability. This framework is particularly adapted to our heterogeneity level, but should be
extended to a multi-strain system.
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3.4 Vaccination strategies at the herd level
Vaccination is implemented at the within-host scale, but the vaccination strategy is designed at
the herd level. Consequently, exploring the vaccination strategy efficiency at the herd level is
required. Whatever the pathogen, this issue has been addressed as a key challenge for disease
control by Metcalf et al. [51], which pointed out challenges in modelling vaccine preventable
diseases at both within and between-host scales in a recent review. One of them is to develop
models that can address the vaccine efficiency issue at the within-host scale [51]. Briefly, the
success of vaccines at an individual level is determined by the induced immune dynamics and
the resulting memory response. Vaccine efficiency can exhibit a temporal variability and can
vary depending on host, pathogen strain and infectious past of host. Carefully calibrated immu-
nological models will ultimately touch on a large number of critical immune and vaccine-related
questions such as what are the immunodynamics responsible for protecting against infection,
against disease, and against onward transmission [51]. We addressed the vaccination issue at the
within-host scale in subsection 2.2. Then, in a such context of variability, exploring the vaccina-
tion strategy efficiency at the herd level would required immuno-epidemiological approach [51].
However, linking within-host immune processes with population effects such as herd immunity
remains an open and important question [51].
The major PRRSv control measure is the vaccination, but none of the current commercial
vaccines provides a full protection and the development of more efficient vaccines, in particular
to provide a better cross-protection, is still a major challenge for PRRSv control. Given the high
variability in vaccine efficiency at the within-host scale depending on the PRRSv strain against
an homologous challenge and the only partial (and more often a poor) cross-protection against
heterologous challenge, an immuno-epidemiological approach would be particularly helpful for
PRRSv infection. We showed that a fine exploration of the vaccine efficiency at the within-host
scale required a multi-strain within-host model (see subsection 2.2) and immuno-epidemiological
approach applied to PRRSv required an ABM multi-strain immuno-epidemiological model (see
subsection 3.3). So such immuno-epidemiological model would be adapted to explore the vaccine
strategy efficiency at the herd level.
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4 Synthesis
In this thesis, we presented integrative within-host modelling approaches applied to PRRSv
infections. This work provides new insights in the understanding of the immune response to
PRRSv depending on the host susceptibility, PRRSv strain virulence and PRRSv exposure. We
also introduce a framework to explore the efficiency of current PRRSv vaccines at the within-host
scale and to guide the development of more efficient vaccines. Our within-host modelling fra-
mework is particularly adapted to PRRSv infection, its main strengths regarding the published
immunological models are : (i) an explicit and detailed representation of both major innate and
adaptive immune mechanisms, (ii) an integrative view of the within-host dynamics representing
the interactions between the innate and adaptive responses at the between-cell scale and (iii)
the integration of the complex regulation by the major pro-inflammatory, antiviral and immuno-
modulatory cytokines. Beyond the application to PRRSv, our model could easily be adapted
to other respiratory pathogens and so provide a within-host framework for a various patho-
gens. The major limit of our modelling approach is the model calibration and hence validation,
which would required experimental data. To reach this issue, we implemented a custom-made
experimental infection. Finally, we conducted this work regarding the prospect of better control
PRRSv spread at the herd level using immuno-epidemiological approaches. In particular, our
work provides new insights on the within-host dynamics depending on factors which can vary
at the herd level (PRRSv strain virulence, host susceptibility and PRRSv exposure) which were
looked at independently and simultaneously. As a result, we showed that :
• our within-host model has the required level of detail in terms of immune mechanisms to
be embedded in an PRRSv epidemiological model ;
• a straightforward model extension to multi-strain system would result in a well adapted
within-host model for an immuno-epidemiological approach ;
• the within and between-host dynamics to PRRSv should be linked through both the ex-
posure/infectiousness and the immune dynamics/health status.
Looking at the efficiency of vaccination, which is the major control measure to control PRRSv
spread at the herd level, our extended model would allow a fine exploration at the within-host
scale and provides an interesting framework for the exploration at the herd level thanks an
immuno-epidemiological approach.
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lung-based model of Chapter II
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A.1 Complete model description
This model describes the infection and immune dynamics induced by a pathogen targeting
pulmonary macrophages in the lung. It focuses on the macrophage–virus interactions and highly
details the innate immune response and cytokine regulations. The adaptive immune response
is less detailed but includes the cellular, humoral and regulatory orientations and their main
functions.
The model is characterised by 18 state variables : the free viral particles ; five effectors of the
innate response, consisting of four macrophage states (susceptible, phagocyting, infected and
latent, infected and excreting the virus) and the natural killers ; three effectors of the adaptive
response, representing the cellular, humoral and regulatory responses ; nine cytokines composed
of the major pro-inflammatory (IL1β, IL6, IL8), the innate antiviral (TNFα, IFNα) and the
immuno-regulatory (IFNγ , IL12, IL10, TGFβ) cytokines.
We chose a deterministic continuous-time dynamic framework. Our model is hence a set of
18 ordinary differential equations, which represent the evolution over time of the state variables.
The main processes that drive their evolution over time and that are integrated in the model
are : the phagocytosis of the viral particles by the macrophages ; the macrophage infection by
the virus ; the excretion of free viral particles by the infected macrophages ; the recruitment and
decay/migration of the macrophages ; the activation and decay/migration of the other effectors ;
the cytokine productions by the immune cells and their decay ; the cytokine regulations.
The functional diagram of the system appears in Figure 1 (main text). Figure 2 (main
text) gives a schematic representation of the model (without regulations). Parameter descriptions
and values are synthesised in Table 1 (main text). The cytokine regulations and syntheses
represented in our model as well as the related literature references are summarised in Table S1
and Table S2 respectively.
We first present how the cytokine regulations are formalised in the model and then describe
the dynamics of the various state variables : macrophages, free viral particles, natural killers,
effectors of the adaptive response and cytokines.
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A.1.1 Cytokine regulations
Cytokines regulate the cellular functions through their recognition by specific receptors, inducing
cascaded reactions within the cells. The higher the cytokine concentration, the stronger the effect.
However,
there is a limited number of cytokine receptors on the cell surface, so the effect saturates
above a given cytokine concentration. We formalised the cytokine effects by a Michaelis–Menten
function (κ) of the cytokine concentration (Ci) as follows :
κ(Ci) =
K Ci
Ci + k
,
where K represents the saturation factor and k the half-saturation cytokine concentration [1–3].
Considering a flow (R), which can either be an inflow (e.g. recruitment) or an outflow (e.g.
decay), a cytokine can have three possible effects listed below.
• Activation : R κ(Ci). The flow is only possible in the presence of the cytokine and it
increases with the cytokine concentration.
• Amplification : R [1 + κ(Ci)]. The flow increases with the cytokine concentration.
• Inhibition : R/[1 + κ(Ci)]. The flow decreases with the cytokine concentration.
Regulations often involve several cytokines (Ci and Cj), which can act
• either independently :
◦ co-activation : R [κ(Ci) + κ(Cj)],
◦ co-amplification : R [1 + κ(Ci)] [1 + κ(Cj)],
◦ co-inhibition : R/([1 + κ(Ci)] [1 + κ(Cj)]) ;
• or in synergy :
◦ co-activation : R κ(Ci, Cj) = R κ(Ci) κ(Cj),
◦ co-amplification : R [1 + κ(Ci, Cj)] = R [1 + κ(Ci) κ(Cj)],
◦ co-inhibition :R/[1 + κ(Ci, Cj)] = R/[1 + κ(Ci) κ(Cj)].
As very few studies estimate the regulation parameters (k and K) in the literature [3], we
used the same parameter values for all cytokine regulations.
A.1.2 Macrophage dynamics
Macrophages phagocyte and destroy the virus, but they are also target cells for the virus.
Activated macrophages (either phagocyting or infected) present the viral antigen and acti-
vate the adaptive response. The macrophage activation also induces the synthesis of innate
cytokines : pro-inflammatory (IL1β, IL6, IL8), antiviral (IFNα,TNFα) and immuno-regulatory
(IL12, IL10,TGFβ) cytokines [4].
States In the model, macrophages can either be susceptible (Ms), phagocyting (Mp), or infec-
ted ; in this latter case, they are either latent (Ml) or excreting the virus (Me). We represented
the evolution over time of the macrophage concentrations for these four states.
Decay All macrophage states are submitted to natural death or/and migration (rate µnatM ), as
well as apoptosis induced by TNFα (rate µ
ap
M ) [5]. The natural death rate is considered higher for
infected macrophages than for susceptible and phagocyting macrophages (multiplicative factor
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δµ). Moreover, infected macrophages can be destroyed by natural killers (rate µ
inn
M ) and cells
from the cellular response (rate µadM ).
Recruitment Susceptible macrophages are recruited from the bloodstream (rate Am). Cyto-
kines IL6 and IL12 co-amplify the macrophage recruitment [6–8] in synergy and IL8 attracts the
macrophages in the infection place [8]. In the absence of virus, the cytokine concentrations are
supposed to be negligible and the resulting concentration of susceptible macrophages in the lung
is constant : Ms = M
0
s =
Am
µnatM
.
Phagocytosis and infection When susceptible macrophages encounter free viral particles
(V ), they can either phagocyte the virus (rate η) or become infected (rate β). We assume
that phagocyting macrophages revert to the susceptible state after viral destruction (rate γ),
whereas infected macrophages remain infected (i.e. they cannot eliminate the virus). We also
assume that the infected and phagocyting states are exclusive and that once phagocyting or
infected, macrophages cannot phagocyte or be infected by other viral particles [9].
The phagocytosis is amplified by the antiviral cytokines (IFNα,TNFα, IFNγ) and inhibited
by the immuno-modulatory cytokines (IL10,TGFβ) – . The phagocytosis ending is amplified by
the antiviral cytokines and inhibited by IL10. The macrophage infection is amplified by IL10 and
inhibited by innate antiviral cytokines (IFNα,TNFα) and TGFβ.
Viral excretion Infected macrophages are first latent (mean duration 1/λ) before they start
excreting. The transition between the latent and excreting states (rate λ) is inhibited by the
antiviral cytokines. Excretion is supposed to be transitory and excreting macrophages may revert
to the latent state in the presence of antiviral cytokines.
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M˙s = Am [1 + κ(IL12, IL6)] [1 + κ(IL8)] ←− recruitment
− η Ms V [1 + κ(TNFα)] [1 + κ(IFNα)] [1 + κ(IFNγ)]
[1 + κ(IL10)] [1 + κ(TGFβ)]
←− phagocytosis
+ γ Mp
[1 + κ(TNFα)] [1 + κ(IFNα)] [1 + κ(IFNγ)]
1 + κ(IL10)
←− phagocytosis ending
− β Ms V 1 + κ(IL10)
[1 + κ(TNFα)] [1 + κ(IFNα)] [1 + κ(TGFβ)]
←− infection
−Ms (µnatM + µinfM TNFα) ←− decay
M˙p = η Ms V
[1 + κ(TNFα)] [1 + κ(IFNα)] [1 + κ(IFNγ)]
[1 + κ(IL10)] [1 + κ(TGFβ)]
←− phagocytosis
− γ Mp [1 + κ(TNFα)] [1 + κ(IFNα)] [1 + κ(IFNγ)]
1 + κ(IL10)
←− phagocytosis ending
−Mp (µnatM + µapM TNFα) ←− decay
M˙l = β Ms V
1 + κ(IL10)
[1 + κ(TNFα)] [1 + κ(IFNα)] [1 + κ(TGFβ)]
←− infection
− λ Ml 1
[1 + κ(TNFα)] [1 + κ(IFNγ)] [1 + κ(IFNα)]
←− excretion
+ ν Me [κ(TNFα) + κ(IFNγ) + κ(IFNα)] ←− excretion ending
−Ml (µnatM δµ + µapM TNFα + µinnM NK + µadM Rc) ←− decay
M˙e = λ Ml
1
[1 + κ(TNFα)] [1 + κ(IFNγ)] [1 + κ(IFNα)]
←− excretion
− ν Me [κ(TNFα) + κ(IFNγ) + κ(IFNα)] ←− excretion ending
−Me (µnatM δµ + µapM TNFα + µinnM NK + µadM Rc) ←− decay
A.1.3 Viral dynamics
The virus enters the body through the mucosal surfaces of the respiratory tract and replicates
in the pulmonary macrophages.
We represented the evolution over time of the free viral particles (V ). When they encounter
susceptible macrophages (Ms), they can either be phagocyted by the macrophages (rate η),
resulting in viral destruction, or they can infect the macrophages (rate β), resulting in virus
replication. Free viral particles are released in the lung by excreting macrophages (rate e). They
can be neutralised by antibodies represented by the humoral response Rh (rate µ
ad
V ). They are
also submitted to natural death and migration outside the lung (rate µnatV ).
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V˙ = e Me ←− replication
− η Ms V [1 + κ(TNFα)] [1 + κ(IFNα)] [1 + κ(IFNγ)]
[1 + κ(IL10)] [1 + κ(TGFβ)]
←− phagocytosis
− β Ms V 1 + κ(IL10)
[1 + κ(TNFα)] [1 + κ(IFNα)] [1 + κ(TGFβ)]
←− infection
− V (µnatV + µadV Rh) ←− decay
A.1.4 Natural killer dynamics
Natural killers are effectors of the innate response. Their main immune functions are the des-
truction of infected cells and IFNγ synthesis [4, 8, 10, 11]. These cytotoxic cells are recruited on
the infection by pro-inflammatory cytokines. Their proliferation and immune functions are acti-
vated by several cytokines (IFNγ , IL12, IL15, IL18, IL21, IFNαβ), whereas IL10 inhibits the natural
killer differentiation and their immune functions [10].
We represented the dynamics of activated natural killers (NK) and only included the regula-
tions by the most influential cytokines. The recruitment of natural killers from the bloodstream
(rate αN ) requires pro-inflammatory cytokines : IL12 and IL6 co-activate the recruitment, whe-
reas IL8 acts independently. Natural killers are then activated by IFNγ and IL12, whereas IL10
inhibits the activation. They are submitted to natural death or/and migration (rate µR).
N˙K = αN
[κ(IL12, IL6) + κ(IL8)] [κ(IFNγ) + κ(IL12)]
[1 + κ(IL10)]
←− recruitment & activation
− µR NK ←− decay
A.1.5 Adaptive effector dynamics
The adaptive response activation begins with the naive CD+4 T cell differentiation by antigen
presenting cells (dendritic cells or macrophages) within the lymphoid tissues. Depending on the
cytokine profiles in the lymph nodes, CD+4 T cells differentiate in one of three main CD
+
4 effector
types, which each have specific immune functions : type 1 T helpers (Th1, belonging to the
cellular response), type 2 T helpers (Th2, belonging to the humoral response) and regulatory T
lymphocytes (Treg, belonging to the regulatory response) [4, 12–19]. The differentiation towards
Th1 is induced by IL12 and amplified by IFNγ . The differentiation towards Th2 is induced by IL6
and amplified by IL4. The differentiation towards Treg is induced by TGFβ and amplified by IL10.
The cytokines responsible for the differentiation towards a CD+4 effector type simultaneously
inhibit the differentiation towards the two other types. After the differentiation step, the CD+4
effectors express their specific immune functions and proliferate. Th1 synthesise the IL2 and IFNγ
cytokines. In addition, they are responsible for the differentiation of the CD+8 T cells in cytotoxic
lymphocytes (CTL). CTL synthesise IFNγ and TNFα and destroy the infected macrophages.
Th2 synthesise IL4 and IL10. In addition, they are the main activator of the B lymphocytes
(through IL4 and IL10), which produce the neutralising antibodies. Treg synthesise the TGFβ
and IL10 immuno-modulatory cytokines. In summary :
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• The cellular response : (i) includes the Th1 and CTL ; (ii) is activated by IL12 and IFNγ
and inhibited by IL6, IL10 and TGFβ ; and (iii) is responsible for the synthesis of IL2, IFNγ
and TNFα.
• The humoral response : (i) includes the Th2, B lymphocytes and antibodies ; (ii) is activated
by IL6, IL4 and IL10 and inhibited by IL12, IFNγ and TGFβ ; and (iii) is responsible for
the synthesis of IL4 and IL10 and for the viral particle neutralisation.
• The regulatory response : (i) only includes the Treg ; (ii) is activated by TGFβ and IL10
and inhibited by IL6, IL12 and IFNγ ; and (iii) is responsible for the immune response
inhibition through its synthesis of the TGFβ and IL10 immuno-modulatory cytokines.
In our model, we represented the adaptive response by three effectors corresponding to the
three main orientations : cellular (Rc), humoral (Rh) and regulatory (Rr) responses. As for the
NK cells, we only represented the dynamics of the activated effectors.
Based on the model proposed by Yates et al. for the regulation of T helper cell populations
[19], we synthesised the dynamics of each adaptive effector by three steps : activation by activated
macrophages (rate αR), proliferation (rate pR) and decay. We represented the regulations of the
activation and proliferation steps by the most influential cytokines : IFNγ , IL12, IL10 and TGFβ.
The decay includes the natural decay (rate µR) and the Activation Induced Cell Death
(AICD) induced by the interaction with a Th1 from the Rc compartment (rate δRc) [19].
Cellular response [16–18, 20–23] Rc represents the type 1 T helper cells and the cytotoxic
lymphocytes. Activation is amplified by IFNγ and IL12 and inhibited by IL10. Proliferation
is activated by IFNγ and IL12 and inhibited by IL10 and TGFβ. Rc synthesises IFNγ and is
responsible for the destruction of infected cells.
R˙c = αR (Mp +Ml +Me)
[1 + κ(IFNγ)] [1 + κ(IL12)]
1 + κ(IL10)
←− activation
+ pR Rc
[κ(IFNγ) + κ(IL12)]
[1 + κ(IL10)] [1 + κ(TGFβ)]
←− proliferation
− µR Rc − δRc Rc2 ←− decay
Humoral response [16–18, 24] Rh represents the type 2 T helper cells, the B lymphocytes
and the antibodies. Activation is amplified by IL10 and inhibited by IFNγ and IL12. Proliferation
is activated by IL10 and inhibited by IFNγ , IL12 and TGFβ. Rh synthesises IL10 and is responsible
for the neutralisation of free viral particles through antibodies.
R˙h = αR (Mp +Ml +Me)
[1 + κ(IL10)]
[1 + κ(IFNγ)] [1 + κ(IL12)]
←− activation
+ pR Rh
κ(IL10)
[1 + κ(IFNγ)] [1 + κ(IL12)] [1 + κ(TGFβ)]
←− proliferation
− µR Rh − δRc Rc Rh ←− decay
Regulatory response [16–18, 25] Rr represents the represents the regulatory T cells. Acti-
vation is amplified by IL10 and TGFβ and inhibited by IFNγ and IL12. Proliferation is activated
by TGFβ and inhibited by IL10, IFNγ and IL12. Rr synthesises IL10 and TGFβ.
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R˙r = αR (Mp +Ml +Me)
[1 + κ(IL10)] [1 + κ(TGFβ)]
[1 + κ(IFNγ)] [1 + κ(IL12)]
←− activation
+ pR Rr
κ(TGFβ)
[1 + κ(IL10)] [1 + κ(IFNγ)] [1 + κ(IL12)]
←− proliferation
− µR Rr − δRc Rc Rr ←− decay
A.1.6 Cytokine dynamics
Cytokines are small proteins that play a key role in cell-signalling. They are produced by acti-
vated immune cells and affect the behaviour of other cells, sometimes the releasing cell itself.
They act through specific membranous receptors inducing cascaded reactions within the target
cell. They have various functions. In particular, cytokines modulate the balance between the
humoral and cellular responses. Some cytokines enhance or inhibit the action of other cytokines
in complex ways.
In the model, we only integrated the regulations by the nine most influential cytokines. We
grouped them into three classes depending on their main function : pro-inflammatory (IL1β,
IL6, IL8), antiviral (TNFα, IFNα, IFNγ) and immuno-regulatory (IL12, IL10, TGFβ) cytokines.
TNFα is generally considered as a pro-inflammatory cytokine, but we were here more interested
is its antiviral function.
We assumed that the cytokines are efficient enough in order to neglect their consumption
when they interact with a cell. So the cytokine dynamics results from their synthesis by immune
cells (rates ρx, where x depends on the cytokine considered) and their natural death (rate µC)
The main cytokine regulations are summarised in Table A.1 and the cytokine syntheses in
Table A.2.
Pro-inflammatory cytokines [4, 6–8, 31, 35] Pro-inflammatory cytokines IL1β, IL6 and
IL8 amplify the recruitment of macrophages and activated natural killers. They are synthesised
by the activated macrophages. As we had no information on their respective production rate,
we used the same synthesis rate (ρPi) for the three cytokines. The synthesis of IL1β is inhibited
by IL10, whereas the synthesis of IL6 and IL8 is co-activated by IL1β and TNFα.
˙IL1β = ρPi (Mp +Ml +Me)
1
1 + κ(IL10)
←− synthesis
− µC IL1β ←− decay
˙IL6 = ρPi (Mp +Ml +Me) κ(IL1β,TNFα) ←− synthesis
− µC IL6 ←− decay
˙IL8 = ρPi (Mp +Ml +Me) κ(IL1β,TNFα) ←− synthesis
− µC IL8 ←− decay
Antiviral cytokines Antiviral cytokines promote the phagocytosis and reduce the infection
by inhibiting the macrophage permissiveness and/or the viral replication.
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Table A.2 Cytokine syntheses. Production of cytokines included (X) in the model by innate or
adaptive immune cells.
* Pro-inflammatory cytokines Pi = IL1β, IL6, IL8
† Global references : [4, 12–15, 17, 36, 39, 40]
Cytokines
pro-inf. innate antiviral immuno-regulatory
Pi* TNFα IFNα IFNγ IL12 IL10 TGFβ References
Innate cells
Activated macrophages X X X X X [8, 41]†
Activated natural killers X [8, 11]†
Adaptive cells
Cellular effectors X †
Humoral effectors X †
Regulatory effectors X X †
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The innate antiviral cytokines TNFα and IFNα are synthesised by activated macrophages
[5, 6, 20, 21, 26–29, 31]. IL10 inhibits the synthesis of TNFα.
˙TNFα = ρTNFα (Mp +Ml +Me)
1
1 + κ(IL10)
←− synthesis
− µC TNFα ←− decay
˙IFNα = ρIFNα (Ml +Me) ←− synthesis
− µC IFNα ←− decay
The adaptive antiviral cytokine IFNγ is synthesised by cells of the cellular response (Rc) and
natural killers (NK). This synthesis is auto-amplified. It is also amplified by IFNα and TNFα, in
synergy with IL12, and inhibited by IL10 and TGFβ. IFNγ is also an immuno-regulatory cytokine
and it orients the adaptive response towards the cellular response [16–18, 20–23].
˙IFNγ = ρIFNγ (Rc + NK)
[1 + κ(IFNγ)] [1 + κ(IL12,TNFα)] [1 + κ(IL12, IFNα)]
[1 + κ(IL10)] [1 + κ(TGFβ)]
←− synthesis
− µC IFNγ ←− decay
Immuno-regulatory cytokines [12–18] The immuno-regulatory cytokines IL12, IFNγ (see
above), IL10 and TGFβ have various functions, in particular the regulation of the adaptive
immune response. They also regulate the recruitment of macrophages and natural killers, the
phagocytosis and infection, as well as the cytokine syntheses. They are produced by cells of the
innate and adaptive response.
IL12 co-amplifies the recruitment of macrophages, activates the natural killers and orients
the adaptive response towards the cellular response. It is synthesised by activated macrophages.
Its synthesis is inhibited by IL10.
˙IL12 = ρIL12 (Mp +Ml +Me)
1
1 + κ(IL10)
←− synthesis
− µC IL12 ←− decay
IL10 and TGFβ are both immuno-modulatory cytokines. IL10 inhibits the natural killer
activation and the phagocytosis, it amplifies the macrophage permissiveness and it orients the
adaptive response towards the humoral and regulatory responses. IL10 is synthesised by activated
macrophages and cells of the regulatory (Rr) and humoral (Rh) responses. Its synthesis by
macrophages and Rr is amplified by TGFβ, whereas its synthesis by Rh is auto-amplified and
inhibited by TGFβ.
˙IL10 = ρIL10
(
(Mp +Ml +Me +Rr) [1 + κ(TGFβ)] +Rh
1 + κ(IL10)
1 + κ(TGFβ)
)
←− synthesis
− µC IL10 ←− decay
TGFβ inhibits the phagocytosis and macrophage permissiveness and orients the adaptive
response towards the regulatory response. In the model, we neglected the synthesis of TGFβ by
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activated macrophages, so it is only synthesised by cells of the regulatory response.
˙TGFβ = ρTGFβ Rr ←− synthesis
− µC TGFβ ←− decay
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A.2 Supplementary figures
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Figure A.1 Preliminary sensitivity analysis : comparison of the phagocytosis and
infection activities. This figure results from the 243 simulations performed for the preliminary
sensitivity analysis. A : Percentage of phagocyting macrophages among all macrophages over
time (maximum 14%). B : Percentage of infected macrophages over time (maximum 100%).
C : Phagocytosis activity as a percentage of the phagocytosis and infection flows, i.e. the ratio
between the concentration of susceptible macrophages becoming phagocyting macrophages per
unit of time and the concentration of susceptible macrophages becoming phagocyting or latent
infected macrophages per unit of time × 100. At a given time, if a simulation is above the 50%
red line, its phagocytosis flow is higher than its infection flow. These figures show that, even if
there are few phagocyting macrophages at all times, the phagocytosis activity can be dominant
over the infection activity at given times for susceptible macrophages.
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Figure A.2 Parameter space exploration : viral titer. This figure results from the 6561
simulations performed for the sensitivity analysis. A : Viral titer over time (red curve : refe-
rence scenario S0). B : Distribution of the viral titer at day 200. Some simulations resulted in
infection persistence, others in infection resolution occurring at various dates. The viral titer
at day 200 was heterogeneously distributed : 56% of the simulations had a viral titer lower
than 2 log10(TCID50/ml), which is usually considered as the infection resolution ; the remai-
ning simulations had viral titers ranging between 2 and 8.96 log10(TCID50/ml). More precisely :
(i) 3.7% of the simulations had a viral titer higher than the maximal initial inoculation titer
(7 log10(TCID50/ml)) and (ii) 90% of the simulations had a viral titer lower than its correspon-
ding inoculation titer (4, 5 or 7 log10(TCID50/ml)). In the lung, PRRSv infection lasts 56 days
on average [21] and can be longer than 200 days [42, 43].
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Figure A.3 Parameter space exploration : cumulative number of phagocyting ma-
crophages. This figure results from the 6561 simulations performed for the sensitivity analysis.
A : Cumulative number of phagocyting macrophages (cMP ) over time (red curve : reference
scenario S0). B : Distribution of cMP at day 1. C : Distribution of cMP at day 200. cMP was
highly variable between simulations : between 0.5 and 106.7 macrophages/ml on the first day, and
between 1.4 and 108.4 macrophages/ml at day 200. Most simulations rapidly increased during the
first days and then tended to a threshold. This means that the phagocytosis activity was maximal
at the beginning of the infection, which is consistent with the literature. Simulations that did
not saturate corresponded to persistent infection. To our knowledge, there are no experimental
studies that measure the concentration of phagocyting macrophages during a PRRSv infection.
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Figure A.4 Parameter space exploration : percentage of infected macrophages. This
figure results from the 6561 simulations performed for the sensitivity analysis. A : Percentage of
infected macrophages among all macrophages (%Mi) over time (red curve : reference scenario
S0). B : Distribution of the %Mi peak value. C : Distribution of the %Mi peak date. The
peak is defined as the maximum value of %Mi over the course of infection. The %Mi dynamics
was highly variable among simulations but tended to decrease after the first weeks of infection.
At day 200, %Mi was higher than 60% for only 4% of the simulations and lower than 1% for
84% of the simulations. 55% of the simulations peaked during the first week. For 80% of the
simulations, the %Mi peak was lower than 20%. Some experimental studies showed a peak of
infected macrophages of around 40% during the first week of a PRRSv infection [44]. During
the first week, only 5% of the simulations had %Mi peaking between 20 and 60%, which is
consistent with the experimental results.
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The model presented here is a simplified version of a model that we published previously [1].
Changes are highlighted in italics in the following description, which includes all equations and
details our modelling assumptions. We checked that both models produced similar simulations
for the reference scenario (not illustrated).
B.1 Model presentation
The model aims at simulating the infection and immune dynamics induced by PRRSv in the lung.
We chose a deterministic continuous-time dynamic framework. Our model is hence a set of 14
ordinary differential equations, which represent the evolution over time of the state variables : the
free viral particles (V ) ; the susceptible (Ms), phagocyting (Mp) and infected (Mi) macrophages ;
the natural killers (NK) ; the cellular (Rc), humoral (Rh) and regulatory (Rr) adaptive effectors ;
the pro-inflammatory (Pi, grouping IL1β, IL6 and IL8), innate antiviral (Ai, grouping IFNα and
TNFα) and immuno-regulatory cytokines (IL12, adaptive anti-viral : IFNγ , immuno-modulatory :
IL10 & TGFβ). The main processes that drive their evolution over time and that are integrated
in the model are : the phagocytosis of the viral particles by the macrophages ; the macrophage
infection by the virus ; the excretion of free viral particles by the infected macrophages ; the
recruitment and decay/migration of the macrophages ; the activation and decay/migration of
the other effectors ; the cytokine productions by the immune cells and their decay ; the cytokine
regulations.
The functional diagram of the system appears in Chapter III, Figure III.1. Figure B.1 gives
a schematic representation of the model (without regulations). Parameter descriptions and values
are synthesised in Table 1 (main text). The cytokine regulations and syntheses represented
in our model, as well as the related literature references are summarised in Table B.1 and
Table B.2 respectively.
We first present how the cytokine regulations are formalised in the model and then describe
the dynamics of the various state variables : macrophages, free viral particles, natural killers,
effectors of the adaptive response and cytokines.
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Figure B.1 Scheme of the model : state variables and flows (without regulations). The
state variables consist of : the free viral particles (V ) ; the susceptible (Ms), phagocyting (Mp)
and infected (Mi) macrophages ; the natural killers (NK) ; the cellular (Rc), humoral (Rh) and
regulatory (Rr) adaptive effectors ; the pro-inflammatory cytokines (Pi), the innate antiviral
cytokines (Ai) and the immuno-regulatory cytokines (IL12, IFNγ , IL10 & TGFβ). The flows
represented are : the viral exposure E(t) ; the recruitment of susceptible macrophages (Am) ; the
activation of natural killers (αR) and cells of the adaptive response (αR) ; the decay of the free
viral particles (µV ), the macrophages (µM*), the natural killers (µN ), the adaptive cells (µR) and
the cytokines (µC) ; the macrophage state changes, i.e. phagocytosis (η and γ) and the infection
(β) ; the excretion of free viral particles by infected macrophages (e) and the cytokine syntheses
by activated immune cells (ρ*). For the sake of readability, the cytokine and cell regulations and
not drawn and some parameter notations (marked with ∗) are simplified.
B.2 Cytokine regulations
The processes driving the state variable dynamics are regulated by a complex cytokine feed-
back system (presented in Figure III.1). Some cytokines have opposite effects : for example,
the antiviral cytokines up-regulate the phagocytosis and down-regulate the viral infection, whe-
reas IL10 inhibits the phagocytosis and promotes the infection. Cytokines regulate the cellular
functions through their recognition by specific receptors, inducing cascaded reactions within the
cells. The higher the cytokine concentration, the stronger the effect. However, there is a limited
number of cytokine receptors on the cell surface, so the effect saturates above a given cytokine
concentration.
We formalised the cytokine regulations (up κ+ and down κ−) based on the Michaelis–Menten
function of the cytokine concentration (Ci ) [2–4] as follows :
κ+(Ci) =
vm Ci
km + Ci
, κ−(Ci) =
km
km + Ci
,
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where vm denotes the saturation factor and km the half saturation constant.
Compared to [1], the down-regulation function κ− is simplified.
A cytokine can have three possible effects on a given basic rate (r) :
• activation : r κ+(Ci), the basic rate increases with the cytokine concentration from 0 to
r vm ;
• amplification : r [1+κ+(Ci)], the basic rate increases with the cytokine concentration from
r to r (1 + vm) ;
• inhibition : r κ−(Ci), the basic rate decreases and tends to zero.
Regulations often involve several cytokines (Ci and Cj) which can act
• either independently : κ±(Ci + Cj) ;
• or in synergy :
◦ κ+(Ci Cj) = vm Ci Cjk2m+Ci Cj for an activation or an amplification,
◦ κ−(Ci Cj) = k
2
m
k2m+Ci Cj
for an inhibition.
Compared to [1], effects involving multiple cytokines are simplified.
As very few studies estimate the regulation parameters (km and vm) in the literature [4], we
used the same parameter values for all cytokine regulations.
B.3 Macrophage dynamics
Macrophages phagocyte and destroy the virus, but they are also target cells for the virus.
Activated macrophages (either phagocyting or infected) present the viral antigen and activate
the adaptive response. The macrophage activation also induces the synthesis of innate cytokines :
pro-inflammatory (IL1β, IL6, IL8), antiviral (IFNα,TNFα) and immuno-regulatory (IL12, IL10)
cytokines [5].
In the model, macrophages can be susceptible Ms, phagocyting Mp, or infected and excreting
the virus Mi. We represented the evolution over time of the macrophage concentrations for these
three states.
Compared to [1], we grouped the latent and excreting macrophage states into a single infected
state.
Decay All macrophage states are submitted to natural death or/and migration (rate µnatM ), as
well as apoptosis induced by TNFα (rate µ
ap
M ) [6]. The natural death rate is considered higher for
infected macrophages than for susceptible and phagocyting macrophages (multiplicative factor
δµ). Moreover, infected macrophages can be destroyed by natural killers (rate µ
inn
M ) and cells
from the cellular response (rate µadM ).
Recruitment Susceptible macrophages are recruited from the bloodstream (rate Am). Cy-
tokines IL6 and IL12 co-amplify the macrophage recruitment in synergy [7–9]. IL8 attracts the
macrophages to the infection place [9].
Compared to [1], we grouped the pro-inflammatory cytokines IL1β, IL6 and IL8 and hence sim-
plified their action on the macrophage recruitment.
In the absence of virus, the cytokine concentrations are supposed to be negligible and the
resulting concentration of susceptible macrophages in the lung is constant : Ms = M
0
s =
Am
µnatM
.
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Phagocytosis and infection When susceptible macrophages encounter free viral particles
(V ), they can either phagocyte the virus (rate η) or become infected (rate β). We assume
that phagocyting macrophages revert to the susceptible state after viral destruction (rate γ),
whereas infected macrophages remain infected (i.e. they cannot eliminate the virus). We also
assume that the infected and phagocyting states are exclusive and that once phagocyting or
infected, macrophages cannot phagocyte or be infected by other viral particles [10].
The phagocytosis is amplified by the antiviral cytokines (Ai and IFNγ) and inhibited by
the immuno-modulatory cytokines (IL10,TGFβ). The phagocytosis ending is amplified by the
antiviral cytokines and inhibited by IL10. The macrophage infection is amplified by IL10 and
inhibited by innate antiviral cytokines (Ai) and TGFβ.
Susceptible macrophages :
M˙s = Am [1 + κ
+(Pi IL12)] ←− recruitment
− η Ms V κ−(IL10 + TGFβ) [1 + κ+(Ai + IFNγ)] ←− phagocytosis
+ γ Mp κ
−(IL10) [1 + κ+(Ai + IFNγ)] ←− phagocytosis ending
− β Ms V κ−(Ai + TGFβ) [1 + κ+(IL10)] ←− infection
−Ms
(
µnatM + µ
inf
M κ
+(Ai)
)
←− decay
Phagocyting macrophages :
M˙p = η Ms V κ
−(IL10 + TGFβ) [1 + κ+(Ai + IFNγ)] ←− phagocytosis
− γ Mp κ−(IL10) [1 + κ+(Ai + IFNγ)] ←− phagocytosis ending
−Mp
(
µnatM + µ
inf
M κ
+(Ai)
)
←− decay
Infected macrophages :
M˙i = β Ms V κ
−(Ai + TGFβ) [1 + κ+(IL10)] ←− infection
−Mi
(
µnatM δµ + µ
inf
M κ
+(Ai) + µ
inn
M NK + µ
adap
M Rc
)
←− decay
B.4 Viral dynamics
The virus enters the body through the mucosal surfaces of the respiratory tract and replicates
in the pulmonary macrophages.
We represented the evolution over time of the free viral particles (V ). The inflow of these free
viral particles is given by the time-dependent exposure function (E(t)). When they encounter
susceptible macrophages (Ms), they can either be phagocyted by the macrophages (rate u η),
resulting in viral destruction, or they can infect the macrophages (rate u β), resulting in virus
replication. Free viral particles are released in the lung by excreting macrophages (rate e). The
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viral replication is inhibited by antiviral cytokines. Free viral particles can be neutralised by
antibodies represented by the humoral response Rh (rate µ
ad
V ). They are also submitted to
natural death and migration outside the lung (rate µnatV ). .
Compared to [1], we considered that the phagocytosis or macrophage infection consume uTCID50
virus per macrophage. As we set u = 1[TCID50/cell], this modification finally induced no change.
Moreover, the cytokine regulations that applied to the macrophage change of state between the
infected latent and excreting states in [1], apply to the viral excretion in this model.
V˙ = E(t) ←−exposure
− u η Ms V κ−(IL10 + TGFβ) [1 + κ+(Ai + IFNγ)] ←− phagocytosis
− u β Ms V κ−(Ai + TGFβ) [1 + κ+(IL10)] ←− infection
+ e Mi κ
−(Ai + IFNγ) ←−excretion
− V
(
µnatV + µ
adap
V Rh
)
←−decay / migration
B.5 Natural killer dynamics
Natural killers are effectors of the innate response. Their main immune functions are the des-
truction of infected cells and IFNγ synthesis [5, 9, 11, 12]. These cytotoxic cells are recruited
on the infection site by pro-inflammatory cytokines. Their proliferation and immune functions
are activated by several cytokines (IFNγ , IL12, IL15, IL18, IL21, IFNαβ), whereas IL10 inhibits the
natural killer differentiation and their immune functions [11].
We represented the dynamics of activated natural killers (NK) and only included the re-
gulations by the most influential cytokines. Their recruitment from the bloodstream (rate αN )
requires pro-inflammatory cytokines Pi and IL12. Natural killers are then activated by IFNγ and
IL12, whereas IL10 inhibits the activation. They are submitted to natural death or/and migra-
tion (rate µR).
Compared to [1], the effects of the pro-inflammatory cytokines on the macrophage recruitment
are simplified, as for the susceptible macrophages.
˙NK = αN κ
−(IL10) κ+(IL12 Pi) κ+(IL12 + IFNγ) ←− recruitment & activation
− µR NK ←− decay
B.6 Adaptive effector dynamics
The adaptive response activation begins with the naive CD+4 T cell differentiation by antigen
presenting cells (dendritic cells or macrophages) within the lymphoid tissues. Depending on the
cytokine profiles in the lymph nodes, CD+4 T cells differentiate into one of three main CD
+
4
effector types, which have specific immune functions : type 1 T helpers (Th1, belonging to the
cellular response), type 2 T helpers (Th2, belonging to the humoral response) and regulatory T
lymphocytes (Treg, belonging to the regulatory response) [5, 13–20]. The differentiation towards
Th1 is induced by IL12 and amplified by IFNγ . The differentiation towards Th2 is induced by IL6
and amplified by IL4. The differentiation towards Treg is induced by TGFβ and amplified by IL10.
The cytokines responsible for the differentiation towards a CD+4 effector type simultaneously
inhibit the differentiation towards the two other types. After the differentiation step, the CD+4
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effectors express their specific immune functions and proliferate. Th1 synthesise the IL2 and IFNγ
cytokines. In addition, they are responsible for the differentiation of the CD+8 T cells in cytotoxic
lymphocytes (CTL). CTL synthesise IFNγ and TNFα and destroy the infected macrophages.
Th2 synthesise IL4 and IL10. In addition, they are the main activator of the B lymphocytes
(through IL4 and IL10), which produce the neutralising antibodies. Treg synthesise the TGFβ
and IL10 immuno-modulatory cytokines. In summary :
• The cellular response : (i) includes Th1 and CTL ; (ii) is activated by IL12 and IFNγ ,
inhibited by IL6, IL10 and TGFβ ; and (iii) is responsible for the synthesis of IL2, IFNγ
and TNFα.
• The humoral response : (i) includes Th2, B lymphocytes and antibodies ; (ii) is activated
by IL6, IL4 and IL10, inhibited by IL12, IFNγ and TGFβ ; and (iii) is responsible for the
synthesis of IL4 and IL10 and for the viral particle neutralisation.
• The regulatory response : (i) only includes Treg ; (ii) is activated by TGFβ and IL10,
inhibited by IL6, IL12 and IFNγ ; and (iii) is responsible for the immune response inhibition
through its synthesis of the TGFβ and IL10 immuno-modulatory cytokines.
In our model, we represented the adaptive response by three effectors corresponding to the
three main orientations : cellular (Rc), humoral (Rh) and regulatory (Rr) responses. As for
the NK cells, we only represented the dynamics of the activated effectors. Based on the model
proposed by Yates et al. for the regulation of T helper cell populations [20], we synthesised the
dynamics of each adaptive effector by three steps : activation by activated macrophages (rate
αR), proliferation (rate pR) and decay. We represented the regulations of the activation and
proliferation steps by the most influential cytokines : IFNγ , IL12, IL10 and TGFβ. The decay
includes the natural decay (rate µR) and the Activation Induced Cell Death (AICD) induced by
the interaction with a Th1 from the Rc compartment (rate δRc) [20].
Cellular response [17–19, 21–24] Rc represents the type 1 T helper cells and the cytotoxic
lymphocytes. Activation is amplified by IFNγ and IL12 and inhibited by IL10. Proliferation
is activated by IFNγ and IL12 and inhibited by IL10 and TGFβ. Rc synthesises IFNγ and is
responsible for the destruction of infected cells.
R˙c = αR (Mp+Mi) [1 + κ
+(IFNγ + IL12)] κ
−(IL10) ←− activation
+ pR Rc κ
+(IFNγ + IL12) κ
−(IL10 + TGFβ) ←− proliferation
− µR Rc − δRc Rc2 ←− decay
Humoral response [17–19, 25] Rh represents the type 2 T helper cells, the B lymphocytes and
the antibodies. Activation is amplified by IL10 and inhibited by IFNγ and IL12. Proliferation is
activated by IL10 and inhibited by IFNγ , IL12 and TGFβ. Rh synthesises IL10 and is responsible
for the neutralisation of free viral particles through antibodies.
R˙h = αR (Mp +Mi) [1 + κ
+(IL10)] κ
−(IFNγ + IL12) ←− activation
+ pR Rh κ
+(IL10) κ
−(IFNγ + IL12 + TGFβ) ←− proliferation
− µR Rh − δRc Rc Rh ←− decay
Regulatory response [17–19, 26] Rr represents the represents the regulatory T cells. Acti-
vation is amplified by IL10 and TGFβ and inhibited by IFNγ and IL12. Proliferation is activated
by TGFβ and inhibited by IL10, IFNγ and IL12. Rr synthesises IL10 and TGFβ.
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R˙r = αR (Mp +Mi) [1 + κ
+(IL10 + TGFβ)] κ
−(IFNγ + IL12) ←− activation
+ pR Rr κ
+(TGFβ) κ
−(IFNγ + IL12 + IL10) ←− proliferation
− µR Rr − δRc Rc Rr ←− decay
B.7 Cytokine dynamics
Cytokines are small proteins that play a key role in cell-signalling. They are produced by acti-
vated immune cells and affect the behaviour of other cells, sometimes the releasing cell itself.
They act through specific membranous receptors inducing cascaded reactions within the target
cell. They have various functions. In particular, cytokines modulate the balance between the hu-
moral, cellular and regulatory responses. Some cytokines enhance or inhibit the action of other
cytokines in complex ways.
In the model, we only integrated the regulations by the most influential cytokines. We
grouped them into three classes depending on their main function : pro-inflammatory (Pi =
IL1β + IL6 + IL8), antiviral (innate Ai = TNFα + IFNα and adaptive IFNγ) and immuno-
regulatory (IL12, IFNγ , IL10 and TGFβ) cytokines. TNFα is generally considered as a pro-
inflammatory cytokine, but we were here more interested is its antiviral function. IFNγ is an
antiviral and immuno-regulatory cytokine.
Compared to [1], we represented (i) the pro-inflammatory cytokines IL1β, IL6 and IL8 by a single
variable Pi ; (ii) the innate antiviral cytokines TNFα and IFNα by a single variable Ai.
We assumed that the cytokines are efficient enough in order to neglect their consumption
when they interact with a cell. So the cytokine dynamics results from their synthesis by immune
cells (rates ρyx, where x depends on the cytokine considered and
y depends on the producing
cells) and their natural death (rate µC).
The main cytokine regulations are summarised in Table B.1 and the cytokine syntheses in
Table B.2.
Pro-inflammatory cytokines [5, 7–9, 32, 36] Pi = IL1β+IL6+IL8 amplify the recruitment of
macrophages and natural killers. They are synthesised by activated macrophages. The synthesis
of IL1β is inhibited by IL10, whereas the synthesis of IL6 and IL8 is co-activated by IL1β and
TNFα.
P˙i = ρPi (Mp +Mi) [κ
−(IL10) + 2 κ+(Pi Ai)] ←− synthesis
− µC Pi ←− decay
Antiviral cytokines Antiviral cytokines promote the phagocytosis and reduce the infection
by inhibiting the macrophage permissiveness and/or the viral replication.
Innate antiviral cytokines are represented by Ai = TNFα + IFNα. TNFα is synthesised by
activated macrophages, IFNα by infected macrophages [6, 7, 21, 22, 27–30, 32]. IL10 inhibits the
synthesis of TNFα.
A˙i = ρAi (Mp +Mi) κ
−(IL10) + ρAiMi ←− synthesis
− µC Ai ←− decay
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Table B.2 Cytokine syntheses. Production of cytokines included (
√
) in the model by innate or
adaptive immune cells.
∗ Pro-inflammatory cytokines Pi = IL1β + IL6 + IL8.
∗∗ Innate antiviral cytokines Ai = TNFα + IFNα.
† Global references : [5, 13–16, 18, 37, 40, 41]
Cytokines
pro-inf. innate antiviral immuno-regulatory
P ∗i A
∗∗
i IFNγ IL12 IL10 TGFβ References
Innate cells
Activated macrophages
√ √ √ √
[9, 42]†
Activated natural killers
√
[9, 12]†
Adaptive cells
Cellular effectors
√ †
Humoral effectors
√ †
Regulatory effectors
√ √ †
The adaptive antiviral cytokine IFNγ is synthesised by cells of the cellular response (Rc)
and natural killers (NK). This synthesis is auto-amplified. It is also amplified by Ai, in synergy
with IL12, and inhibited by IL10 and TGFβ. IFNγ is also an immuno-regulatory cytokine and it
orientates the adaptive response towards the cellular response [17–19, 21–24].
˙IFNγ = (ρ
inn
IFNγ NK + ρ
ad
IFNγ Rc) [1 + κ
+(IL12 Ai) + κ
+(IFNγ)] κ
−(IL10 + TGFβ) ←− synthesis
− µC IFNγ ←− decay
Immuno-regulatory cytokines [13–19] IL12, IFNγ (see above), IL10 and TGFβ have various
functions, in particular the regulation of the adaptive immune response. They also regulate the
recruitment of macrophages and natural killers, the phagocytosis and infection, as well as the
cytokine syntheses. They are produced by cells of the innate and adaptive response.
IL12 co-amplifies the recruitment of macrophages, activates the natural killers and orientates
the adaptive response towards the cellular response. It is synthesised by activated macrophages.
Its synthesis is inhibited by IL10.
˙IL12 = ρIL12 (Mp +Mi) κ
−(IL10) ←− synthesis
− µC IL12 ←− decay
IL10 and TGFβ are both immuno-modulatory cytokines. IL10 inhibits the activation of na-
tural killers and the phagocytosis, it amplifies the macrophage permissiveness and it orientates
the adaptive response towards the humoral and regulatory responses. IL10 is synthesised by ac-
tivated macrophages and cells of the regulatory (Rr) and humoral (Rh) responses. Its synthesis
by macrophages and Rr is amplified by TGFβ, whereas its synthesis by Rh is auto-amplified
and inhibited by TGFβ.
˙IL10 =
(
ρinnIL10 (Mp +Mi) + ρ
ad
IL10 Rr
)
[1 + κ+(TGFβ)]
+ ρadIL10 Rh [1 + κ
+(IL10)] κ
−(TGFβ) ←− synthesis
− µC IL10 ←− decay
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TGFβ inhibits the phagocytosis and macrophage permissiveness and orientates the adaptive
response towards the regulatory response. In the model, we neglected the synthesis of TGFβ by
activated macrophages, so it is only synthesised by cells of the regulatory response.
˙TGFβ = ρTGFβ Rr ←− synthesis
− µC TGFβ ←− decay
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C.1 Outputs of the reference scenario
C.1.1 PRRSv and antigen presenting cells
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Figure C.1 PRRSv and antigen presenting cell dynamics for the reference scena-
rio. C Viral titer (V , semi-log graph). Antigen presenting cells : A infected macrophages
(Mi), D phagocyting macrophages (Mp) and G susceptible macrophages (Ms) ; B in-
fected conventional dendritic cells (Dci ), E mature conventional dendritic cells (D
c
m)
and H susceptible conventional dendritic cells (Dcs) ; F mature plasmocytoid dendritic
cells (Dpm) and I susceptible plasmocytoid dendritic cells (D
p
s).
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Figure C.2 Dynamics of adaptive effectors, natural killers and antibodies for the
reference scenario. Cellular effectors : A type 1 helper T cells (Th1) ; D cytotoxic T cells
(Tc) ; G natural killers (NK). Humoral effectors : B type 2 helper T cell(Th2) ; E plasmocytes
synthesising IgM or IgG antibodies (BMG) ; F plasmocytes synthesising IgA antibodies (BA).
Regulatory effectors : C regulatory T cells (Treg). Antibodies : H neutralising antibodies
(AN ) ; I marker antibodies (AM ).
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Figure C.4 PRRSv and antigen presenting cells dynamics for the 54 scenarios tes-
ted. C Viral titer (V , semi-log graph). Antigen presenting cells : A infected macrophages
(Mi), D phagocyting macrophages (Mp) and G susceptible macrophages (Ms) ; B infected
conventional dendritic cells (Dci ), E mature conventional dendritic cells (D
c
m) and H susceptible
conventional dendritic cells (Dcs) ; F mature plasmocytoid dendritic cells (D
p
m) and I susceptible
plasmocytoid dendritic cells (Dps . The 54 scenarios correspond to the 3 vaccination strategies
(Vs ∈ {No, V1, V2}), crossed with 3 virulence levels (Svir ∈ {S1, S2, S3}), 2 exposure durations
(DE ∈ {DEs = 1 day, DEp2 = 20 day}), and 3 exposure intensities (NE) highlighted in colours :
L1= 10
4.3 TCID50/ml, L3= 10
6.3 TCID50/ml, L5= 10
8.3 TCID50/ml.
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Figure C.5 Dynamics of adaptive effectors, natural killers and antibodies for the 54
scenarios tested. Cellular effectors : A type 1 helper T cells (Th1) ; D cytotoxic T cells
(Tc) ; G natural killers (NK). Humoral effectors : B type 2 helper T cell(Th2) ; E plasmo-
cytes synthesising IgM or IgG antibodies (BMG) ; F plasmocytes synthesising IgA antibodies
(BA). Regulatory effectors : C regulatory T cells (Treg). Antibodies : H neutralising antibodies
(AN ) ; I marker antibodies (AM ). The 54 scenarios correspond to the 3 vaccination strategies
(Vs ∈ {No, V1, V2}), crossed with 3 virulence levels (Svir ∈ {S1, S2, S3}), 2 exposure durations
(DE ∈ {DEs = 1 day, DEp2 = 20 day}), and 3 exposure intensities (NE) highlighted in colours :
L1= 10
4.3 TCID50/ml, L3= 10
6.3 TCID50/ml, L5= 10
8.3 TCID50/ml.
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1 Journal publications
1. Go N., Belloc C., Bidot C., Touzeau S., 2014. Why, when and how should exposure be
considered at the within-host scale ? A modelling contribution to PRRSv infection. Submitted
to Epidemics, December 2014.
Abstract – Understanding the impact of exposure on the within-host dynamics
and its outcome in terms of infectiousness is a key issue to better understand
and control the infection spread. It has not been fully explored yet, neither in ex-
perimental infections, nor in modelling studies, which mostly represent exposure
by a punctual dose. We tackled this issue by a modelling approach focused on
the Porcine Reproductive and Respiratory Syndrome virus (PRRSv), a major
concern for the swine industry. PRRSv immune response is partially understood
and highly variable depending on viral strains and host susceptibilities.
We used a mathematical model representing PRRSv immune and infection dy-
namics in the lung ; we built designs of numerical experiments to explore the
impact of exposure intensity, duration and peak, as well as strain virulence,
on characteristics of the viral and immune dynamics ; we then quantified their
impact by sensitivity analyses and descriptive statistics.
We found that the infection severity was fully determined by the exposure in-
tensity. The infection duration increased with the strain virulence and, for a
given strain, exhibited a positive linear correlation with the exposure intensity
logarithm and the exposure duration.
Exposure simplifications should hence at least preserve the exposure intensity.
Besides, representing the exposure due to contacts by short or even punctual
exposures would tend to underestimate the infection duration. As the infec-
tion severity and duration both contribute to the pig infectiousness, a prolon-
ged exposure of the adequate intensity would be recommended in an immuno-
epidemiological context.
2. Go N., Bidot C., Belloc C., Touzeau S., 2014. Integrative model of the immune
response to a pulmonary macrophage infection : what determines the infection duration ?
PLoS ONE 9(9) :e107818. doi : 10.1371/journal.pone.0107818.
Abstract – The immune mechanisms which determine the infection duration
induced by pathogens targeting pulmonary macrophages are poorly known. To
explore the impact of such pathogens, it is indispensable to integrate the various
immune mechanisms and to take into account the variability in pathogen viru-
lence and host susceptibility. In this context, mathematical models complement
experimentation and are powerful tools to represent and explore the complex
mechanisms involved in the infection and immune dynamics. We developed an
263
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original mathematical model in which we detailed the interactions between the
macrophages and the pathogen, the orientation of the adaptive response and
the cytokine regulations. We applied our model to the Porcine Reproductive
and Respiratory Syndrome virus (PRRSv), a major concern for the swine in-
dustry. We extracted value ranges for the model parameters from modelling and
experimental studies on respiratory pathogens. We identified the most influen-
tial parameters through a sensitivity analysis. We defined a parameter set, the
reference scenario, resulting in a realistic and representative immune response to
PRRSv infection. We then defined scenarios corresponding to graduated levels of
strain virulence and host susceptibility around the reference scenario. We obser-
ved that high levels of antiviral cytokines and a dominant cellular response were
associated with either short, the usual assumption, or long infection durations.
We showed that, to identify and understand the immune mechanisms respon-
sible for the infection duration, we need at least (i) the levels of innate antiviral
cytokines, (ii) the level of IL10 (a good indicator of the infected macrophage le-
vel), and (iii) the relative level of IL10 and IFNγ (good indicators of the adaptive
response orientation). Available PRRSv vaccines lack efficiency. By integrating
the main interactions between the complex immune mechanisms, this modelling
framework could be used to help designing more efficient vaccination strategies.
2 Oral presentations in conferences
1. Go N., Belloc C., Bidot C., Touzeau S., 2014. Modelling the infection and immune
dynamics induced by a pathogen targeting pulmonary macrophages : influence of strain vi-
rulence and host exposure. In 9th European Conference on Mathematical and Theoretical
Biology (ECMTB 2014) , Go¨teborg (Sweden), June 2014. http://ecmtb2014.org/
Abstract – The immune mechanisms which determine the infection severity
and duration induced by pathogens targeting pulmonary macrophages are poorly
known. To explore the impact of such pathogens, it is indispensable to integrate
the various immune mechanisms and to take into account the variability in
pathogen virulence, host susceptibility, and host exposure to the pathogen. In
this context, we developed an original ODE model representing the infection and
immune dynamics induced by a pathogen targeting pulmonary macrophages in
the lung. Compared to previous modelling studies, we detailed the macrophage-
pathogen interactions, the innate immune response, and the cytokine regulations.
The adaptive immune response included the cellular, humoral, and regulatory
orientations, and their main functions.
The model obtained has 14 state variables : the free viral particles ; four effec-
tors of the innate response, consisting of three macrophage states (susceptible,
phagocyting, and infected) and the natural killers ; three effectors of the adap-
tive response, representing the cellular, humoral and regulatory responses ; seven
cytokine groups consisting of the major pro-inflammatory, the innate antiviral
and the immuno-regulatory (IFNγ , IL12, IL10, TGFβ) cytokines. The main pro-
cesses integrated in the model are : the phagocytosis of the viral particles by the
macrophages ; the macrophage infection by the virus ; the excretion of free vi-
ral particles by the infected macrophages ; the recruitment and decay/migration
of the macrophages ; the activation and decay/migration of the other effectors ;
the cytokine productions by the immune cells and their decay ; the cytokine
regulations.
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We calibrated our model for the Porcine Reproductive and Respiratory Syn-
drome virus (PRRSv), a major concern for the swine industry. We extracted
value ranges for the model parameters from modelling and experimental studies
on respiratory pathogens. We identified the most influential parameters through
a sensitivity analysis.
We first used our model to explore the influence of strain virulence and host
susceptibility on the infection duration and immune dynamics. We obtained
contrasted dynamics, suggesting hypotheses to explain the apparent contradic-
tions between published results : high levels of antiviral cytokines and a dominant
cellular response were associated with either short, the usual assumption, or long
infection durations. In addition, we extracted some synthetic and original ele-
ments from our work to characterise immune mechanisms and their impact on
the infection duration.
We then used our model to explore the impact of host exposure on the infection
duration and severity for various levels of strain virulence. We tested several func-
tions to account for experimental inoculations or natural infections (by contact).
We performed multivariate sensitivity analysis to identify the influences of strain
virulence, dose and duration exposure on the viral and immune dynamics. We
found that the maximal inoculation dose, the exposure duration and the viru-
lence levels highly influenced the viral and immune dynamics. In particular, (i)
short and high exposures induced high viral peaks associated with a cellular and
antiviral responses and (ii) high virulence, high or/and prolonged exposure in-
duced prolonged infection associated with a strong immune response activation
and a dominante humoral response.
2. Go N., Bidot C., Belloc C., Touzeau S., 2013. Modelling of immune response to a
respiratory virus targeting pulmonary macrophages : exploration of the host susceptibility and
viral virulence. In Systems Biology Approach to Infectious Processes (SBIP 2013), Lyon
(France), May 2013. http://sbip2013.sciencesconf.org/
Abstract – Respiratory viruses are responsible for tissue damages and local
inflammation. The best strategy to control their severity is to limit the infection
while maintaining an efficient immune response. Given this context, the case
when the macrophage is the target cell of infection is of interest. Indeed, pulmo-
nary macrophages (i) are responsible for inflammation and viral destruction by
phagocytosis and (ii) participate in the induction and orientation of the adaptive
immune response. Consequently, macrophage infection hampers the whole im-
mune response. The interaction between macrophages and virus during the first
steps of infection has not been throughly investigated in experimentale studies
and is not detailed in models of immune response. Consequently, the influence of
macrophage–virus interactions on the infection resolution is unknown. Here, we
propose an original model of the immune response centred on the macrophage
– virus interactions. We represent all macrophage infectious statuses, their im-
mune functions, and the interactions between innate and adaptive responses
taking into account the cytokines regulations. We use the model to study the
relative influence of macrophage – virus interactions on the infection resolution
by a multivatiate sensitivity analysis. Then, we explore the influence of macro-
phage immune functions by considering two levels of host susceptibility and viral
virulence. We conclude that both repilication rate of the virus and host capacity
to synthetize anti-viral cytokines are key for infection resolution.
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3. Go N., Bidot C., Belloc C., Touzeau S., 2013. Modelling the interactions between
the PRRSv and its target cells : conditions for virus clearance. In 9e`me colloque du re´seau
franc¸ais d’Immunologie des Animaux Domestiques (IAD), Paris (France), January 2013.
https://colloque6.inra.fr/iad/Programme
Abstract – Efficient vaccines are lacking for the control of Porcine Reproduc-
tive and Respiratory Syndrome Virus (PRRSV) infection, a major concern for
swine industry. The interactions between the virus and the immune system are
only partially understood. The first steps of the innate immune response seem
crucial for the infection outcome. The PRRS virus replicates mainly in the pul-
monary macrophages which play a key role in the innate immunity mechanisms.
They are responsible for inflammation and viral destruction by phagocytosis
and they participate in the induction and orientation of the adaptive immune
response. During a PRRS infection, macrophages also act as target cells for the
virus, which can hamper the immune response. To explore these complex mecha-
nisms and test biological hypothesis, we propose an original model centred on
macrophage - virus interactions in the lung. Comparatively to previous modelling
studies we highly detail the temporal dynamics of the innate immune response
to better understand the influences of the macrophage-virus interactions on the
viral clearance. We use a system of eighteen state variables : the viral particles,
the four macrophage states (healthy, phagocyting, infected non excreting and
infected excreting), the nine major cytokines involved in the macrophage dy-
namics (IL1β, IL6, IL8, IL10, IL12, TNFα, IFNα, IFNγ , TGFβ) and four other
immune cells (natural killers, cells involved in the humoral and cellular adaptive
immune responses and regulatory cells). Cytokine productions by the immune
cells are represented. The macrophages interactions with the viral particles are
regulated by the cytokines. Activation/inhibition effects of the cytokines are in-
cluded. These numerous interactions result in a complex non-linear model. To
calibrate our model, we combined data from experimental and modelling stu-
dies on the PRRS virus and similar pathogens. To explore the relative influence
of the immune mechanisms on the virus clearance we conducted a multivariate
sensitivity analysis using the R package multisensi. We showed that the first
steps of macrophage-virus interactions are crucial for the outcome of the PRRS
virus infection. As expected, the promoting of the cellular response favoured the
viral clearance. In further studies we will use the model in order to test control
measures to resolve the infection. Moreover, our model can be easily adapted
and applied to other pathogens infecting macrophages.
4. Go N., Bidot C., Belloc C., Touzeau S., 2012. Modelling the interactions between
virus and pulmonary macrophages as target cells in a respiratory infection : conditions for
virus clearance. In 11th International Conference on Artificial Immune System (ICARIS),
Taormina (Italy), August 2012. http://www.artificial-immune-systems.org/icaris/
2012/
Abstract – Respiratory infections are a major issue for both human and animal
health. To control their severity, the best strategy is to limit the inflammation
while maintaining an efficient immune response. Macrophages play a key role
in the innate immunity mechanisms. They are responsible for inflammation and
viral destruction by phagocytosis and they participate in the induction and orien-
tation of the adaptive immune response. However, when macrophages also act
as target cells for the infection, the immune response is hampered. Some recent
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studies suggest that the innate immune mechanisms could play a key role in the
virus clearance. Our goal is to further explore the influence of these mechanisms.
We chose a modelling approach to combine data from several studies in order to
represent the immune response dynamics. We have developed an original model
centred on macrophage - virus interactions in the lung. We use a system of eigh-
teen state variables : the viral particles, the four macrophage states (healthy,
phagocyting, infected non excreting and infected excreting), the nine major cy-
tokines involved in the macrophage dynamics (IL1β, IL6, IL8, IL10, IL12, TNFα,
IFNα, IFNγ , TGFβ) and the main other immune cells (natural killers, cells in-
volved in the humoral and cellular adaptive immune response and regulatory
cells). The temporal dynamics of the innate immune response is highly detailed
compared to previous modelling studies. Cytokine productions by macrophages
and other immune cells are represented. The macrophages interactions with the
viral particles are regulated by the cytokines. Activation/inhibition effects of
the cytokines are included. These numerous interactions result in a complex
non-linear model. The model was calibrated for the porcine reproductive and
respiratory syndrome virus, a major respiratory pathogen in swine production.
We used the model to explore the influence of the innate immune mechanisms
on the virus clearance. Our results could suggest new orientations in vaccine
development. Moreover, our model can easily be adapted and applied to other
pathogens infecting pulmonary macrophages.
3 Posters in conferences
1. Go N., Bidot C., Belloc C., Touzeau S., 2013. Identification of key immune mecha-
nisms for Porcine Reproductive and Respiratory Syndrome Virus resolution of infection by a
modelling approach. In 4th International Conference on Infectious Disease Dynamics (EPI-
DEMICS 4), Amsterdam (The Netherlands), November 2013. http://www.epidemics.
elsevier.com/previous-conferences.html
Abstract – The Porcine Reproductive and Respiratory Syndrome (PRRS) is a
major concern for the swine industry. The host response presents a high temporal
and between-host variability in particular the host infectiousness. Therefore, to
predict and control the infection spread, one first needs to better understand
the within-host dynamics. However, the immune mechanisms are still poorly
understood. To explore their impact on the infection resolution, we chose a
modelling approach.
We first developed an original model of the infection and immune dynamics in
the lung. We represented the interactions between target cells (macrophages)
and viral particles (phagocytosis and infection), the innate immune response,
the adaptive response orientation (regulatory, humoral and cellular responses)
and the cytokine regulations. We calibrated the model to literature data. We per-
formed a multivariate sensitivity analysis to identify the model key parameters
for the infection resolution. We then explored the influence of host susceptibility
and viral virulence.
Our first results show that the parameters involved in the macrophage-virus in-
teractions have a strong impact on the viral titer. Compared to a reference scena-
rio with intermediate conditions of virulence and susceptibility (black plain line),
conditions in favour of infection (red dashed line) highly increased the infection
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duration, while lower conditions (blue dotted line). Moreover, the infection se-
verity is positively correlated to the proportion of infected macrophages, the
concentration of immuno-modulatory cytokines and the orientation towards the
regulatory adaptive response.
We are currently integrating a better representation of the immune dynamics
outside the lung and a more detailed adaptive response. Our results suggest that
the macrophage-virus interactions can determine the infection outcome, while
they have been neglected in previous studies. As a consequence strategies pro-
moting innate immunity, such as selection of less susceptible pigs, could improve
the control of PRRS if associated with vaccines.
2. Go N., Bidot C., Belloc C., Touzeau S., 2013. Exploration of the macrophage – virus
interactions during a Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infection
by a modelling approach. In 64th Annual Meeting of the European federation of animal
science (EAAP 2013) , Nantes (France), August 2013. http://www.eaap2013.org/
Abstract – Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)
infection is a major concern for swine industry. Our partial understanding of
the interactions between the virus and the immune system is the major reason
for the lack of efficient control measures. The PRRS virus replicates mainly in
the pulmonary macrophages which (i) are responsible for inflammation and viral
destruction by phagocytosis and (ii) participate in the induction and orientation
of the adaptive immune response. Consequently, macrophage infection hampers
the whole immune response. The interactions between macrophages and virus
during the first steps of infection have not been thoroughly investigated and
their influence on the infection resolution is unknown. Here, we propose an ori-
ginal model simulating immune and infection dynamics to explore these complex
mechanisms and test biological hypotheses. We highly detail the immune func-
tions and infectious statuses of macrophages and take into account interactions
between innate and adaptive responses and cytokines regulations. We use the
model to study the relative influence of macrophage–virus interactions on the
infection resolution comparatively to adaptive mechanisms .
3. Go N., Bidot C., Belloc C., Touzeau S., 2013. Exploration of the immune response
to the PRRSv by a modelling approach. In 5th European Symposium of Porcine Health
Management (ESPHM 2013), Edinburgh (UK), May 2013. http://www.esphm2013.org/
Abstract – PRRSV replicates mainly in the pulmonary macrophages which
(i) are responsible for inflammation and viral destruction by phagocytosis and
(ii) participate in the induction and orientation of the adaptive immune res-
ponse. Experimental studies have shown that PRRSV is able to inhibit innate
immunity, to reduce the gamma interferon synthesis and to limit the efficiency
of neutralizing antibodies. Moreover the virulence and the resulting interaction
with the host immune system are variable between viral strains. Our limited
understanding of the interaction between the virus and the immune system is
the main obstacle in the evaluation of control measures and the development of
more efficient vaccines. To explore these complex mechanisms and test biologi-
cal hypotheses, we propose an original model of the immune response centred
on macrophage - virus interactions in the lung. Comparatively to previous mo-
delling studies we highly detailed the temporal dynamics of the innate immune
response to better understand the effect of the macrophage-virus interactions on
the viral clearance. To explore the relative influence of the immune mechanisms
3 Posters in conferences 269
on the infection outcome we conducted a multivariate sensitivity analysis using
the R package multisensi. We showed that the first steps of macrophage-virus
interactions are crucial. We used the model to explore the immune response to
strains of variable virulence and to determine the required conditions for viral
clearance.
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What is PRRS?
Arterivirus, small enveloped
RNA (nucleocapsid core)
A major concern for the swine industry:
– Present in most pig-producing areas throughout the world
– Responsible for significant production losses
– Numerous commercial vaccines, but
• not efficient enough to eradicate the infection
• confering only a partial protection
→ allow to reduce the disease spread and the symptom severity
Need to improve the vaccine efficiency at the host level!
2
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PRRSv spread
– Transmission: direct contacts
– Spread [Nodeljik et al., 2003]:
• contact structure
• prevalence
• susceptibility: genotype (breed...), age & infectious past [Lunney et al., 2010]
• infectiousness: viral titer (immune dynamics) [Charpin et al., 2012]
– Protection (∼ immune status): memory response
Susceptible Infected Immune
Infection or
Vaccination
Exposure
PR
R
S
v
Immunity loss
Infectiousness
3
272
INTRODUCTION MODEL RESOLUTION VACCINATION CONCLUSION
PRRSv within-host dynamics
PRRSv targets antigen presenting cells→ infection & immune response
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→ Prolonged and severe infection; weak memory response
[Zimmerman et al., 2006; Mateu & Diaz, 2008; Darwich et al., 2010; Murtaugh & Genzow, 2011;
Gomez-Laguna et al., 2013; Buttler, 2014] 4
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PRRSv specificities
PRRSv hampers the whole immune response
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→ Prolonged and severe infection; weak memory response
[Zimmerman et al., 2006; Mateu & Diaz, 2008; Darwich et al., 2010; Murtaugh & Genzow, 2011;
Gomez-Laguna et al., 2013; Buttler, 2014] 5
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PRRSv experimental data
Suceptible Infected Immune
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[Labarque et al. 2000; Labarque et al. 2003; Molina et al. 2008; Gomez-Laguna et al. 2010]
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PRRSv variability
• Host susceptibility: pig genotype (breed...)
• PRRSv virulence: PRRSv strain
type 1 = European genotype < type 2 = American genotype
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[Diaz et al. 2012; Weesendrop et al. 2013]
PRRSv strains co-exist in the field
→ Vaccination challenge:
– Specificity to a strain
– Cross-protection ∼ PRRSv strains
Virulence→ innate mechanisms
→ Immune & infection dynamics?
7
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PRRSv variability
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Link: viral dynamics↔ innate & adaptive mechanisms?
Variable adaptive response→ variable protection levels
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Thesis issues
1. Which immune mechanisms determine the infection resolution?
A- Naive & isolated pig: [Go et al., 2014]
depending on virulence
B- Naive pig in the field: [Go et al., 2014 (submitted)]
depending on virulence & exposure (infectiousness of contact pigs)
2. Which immune mechanisms determine the protection?
Vaccinated pig in the field:
depending on virulence, exposure & memory response
→ Modelling approach:
• linking immune mechanisms & viral titer
→ difficult with experimental approaches (scale, technical constraints)
• strain virulence & host susceptibility variability
→ costly with experimentation
9
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Outline
1. Introduction
2. Modelling approach
• Model scheme
• Model equations
• Model overview
• Calibration
3. Which immune mechanisms determine the infection resolution?
4. Exploration of vaccine efficiency
5. General conclusion
10
INTRODUCTION MODEL RESOLUTION VACCINATION CONCLUSION
Modelling approach
Scale: integrative view at the between-cell scale
– PRRSv infection hampers and is regulated by the innate & adaptive
immune mechanisms
– PRRSv variability affects immune mechanisms
Formalism: deterministic dynamic system (ODE)
evolution over time of PRRSv and immune component concentrations
Literature review:
– immune mechanisms involved during PRRSv infection
– published models (applied to PRRSv or other pathogens targeting APC)
Either [detailed but partial ] or [global but with few explicit mechanisms]
→ ORIGINAL MODEL of PRRSv within-host dynamics
11
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Model scheme – Within-host dynamics
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Model equations (1/2)
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Model equations (2/2)
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Model overview
State variables [28]
– PRRSv [1]
– Innate response: APC [8], NK [1]
– Adaptive response: Cellular [2], Humoral [5], Regulatory [1]
– Cytokines [10]: Pro-inf [3], Antiviral [4], Immuno-mod [3]
Parameters:
MECHANISMS: PARAMETERS [76]
- APC-virus interactions [9]
- Adaptive response activation [2]
- Adaptive response orientation [8]
- Cytotoxic cell functions [4]
- Antibody functions [6]
- Cytokine synthesis [27]
- Cytokine functions [2]
- Other (recruitment, decay, . . . ) [19]
→ Next step: model calibration
15
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Calibration
Few experimental data, high variability and uncertainty→ ad hoc method
1. Exploration
(a) Data collection from models on similar pathogens
(b) Definition of large parameter ranges→ exploration
Parameter set 1
Parameter set 2
.
.
.
Parameter set n
Model
Viral titer
16
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Calibration
Few experimental data, high variability and uncertainty→ ad hoc method
1. Exploration
(a) Data collection from models on similar pathogens
(b) Definition of large parameter ranges→ exploration
2. Selection
(a) Definition of quantitative criteria for realistic dynamics (viral titer mainly)
(b) Identification of realistic parameter sets→ reference scenario
Exploration Realistic dynamics
Reference
scenario
16
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Calibration
Few experimental data, high variability and uncertainty→ ad hoc method
1. Exploration
(a) Data collection from models on similar pathogens
(b) Definition of large parameter ranges→ exploration
2. Selection
(a) Definition of quantitative criteria for realistic dynamics (viral titer mainly)
(b) Identification of realistic parameter sets→ reference scenario
3. Sensitivity analysis
(a) Robustness: varying the parameter values→ realistic dynamics
(b) Identification of most influential parameters
16
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Outline
1. Introduction
2. Modelling approach
3. Which immune mechanisms determine the infection resolution?
Suceptible InfectedInfection
Viral titer
Immune dynamics
Strain virulence; Exposure
?
• Method
• Main results
4. Exploration of vaccine efficiency
5. General conclusion
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Method
ModelScenarios:
- Virulence
- Exposure
Characteristics:
- Viral 
- Immune
Analyses:
- Statistics 
- Sensitivity
Descriptive
statistics
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Method – Virulence scenarios
ModelScenarios:
- Virulence:
aa
   Cytokine synthesis: Im vs Av
aa   
   APC permissiveness & viral replication
- Exposure
Characteristics
18
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Method – Exposure scenarios
ModelScenarios:
- Virulence
- Exposure:
Characteristics
DE
0 10 20 30 40 50
10
−2
1
10
2
10
4
10
6
10
8
DE
NE
0 10 20 30 40 501
e−
02
1e
+0
4
1e
+1
0
Ex
po
su
re
 (t
)
time [days]
Ex
po
su
re
 (t
)
time [days]
intensity
duration
18
INTRODUCTION MODEL RESOLUTION VACCINATION CONCLUSION
Method – Viral characteristics
ModelScenarios Characteristics:
- Viral:
- Immune
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Method – Immune characteristics
ModelScenarios Characteristics:
- Viral
- Immune:
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Which mechanisms determine the resolution?
Virulence:
low Av & high Im → high humoral
high permissiveness → high cellular → prolonged duration
→ could explain apparent inconsistencies between experimental results
Exposure:
infection duration = virulence + exposure intensity + exposure duration
→ Insights for modelling:
• Explicit mechanisms of virulence & host susceptibility
• Exposure intensity + duration
• Key parameters linked to APC-PRRSv interactions
→ Insights for experimentations:
• Measurable indicators:
• Pro-inflammatory cytokines→ infection severity
• IL10 (immuno-modulatory cytokine)→ infected APC
• Relative titers of Av & Im cytokines→ adaptive response orientation
19
283
INTRODUCTION MODEL RESOLUTION VACCINATION CONCLUSION
Outline
1. Introduction
2. Modelling approach
3. Which immune mechanisms determine the infection resolution?
4. Exploration of vaccine efficiency
Suceptible Infected Immune InfectedInfection
Viral titer
Immune dynamics
Strain virulence; Exposure; Memory response 
Vaccination
?
• Vaccination implementation
• Results
• Conclusion
5. General conclusion
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Vaccination implementation
Modified-live PRRSv vaccine
1st step: Vaccination?
∼ Infection by an hypo-virulent PRRSv strain
→ Simulation with adapted parameters (naive pig & hypo-virulent strain)
2nd step: Memory response?
∼ % of adaptive effectors with prolonged lifetime
→ Cumulated number of activated cells (Th, Tc , B) & antibodies from 1st step
→ Two memory activation levels: V1 ≡ 10% & V2 ≡ 40%
3rd step: Vaccinated pig?
∼With memory response
→ Initial conditions for the adaptive response: V1 or V2
Numerical design ∼ 54 scenarios:
3 vaccination strategies (No, V1,V2)
x 3 virulence levels
x 3 exposure intensities x 2 exposure durations
21
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Results – Viral titer
– No impact on the total viral dose & viral peak,
– Clear impact on the infection duration
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– The higher the memory activation, the higher the vaccine efficiency
– The higher the virulence, the higher the vaccine efficiency
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Results – Viral titer
– No impact on the total viral dose & viral peak,
– Clear impact on the infection duration
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Results – Infection duration & immune response
Innate mechanisms (phagocytosis, infection, excretion): ∅
Adaptive response orientation: no clear pattern, globally towards regulatory
Adaptive mechanisms: ↗ [neutralisation, cytolysis]→ infection duration↘
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Conclusion
Results→ towards more efficient vaccines
Assumptions:
– Live-modified vaccine (hypo-virulent strain)
– Full cross-protection
– No adjuvant
Prospects:
– Role of the regulatory response?
– Vaccines with adjuvant to improve the innate response?
– Multiple strains→ cross-protection?
24
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Outline
1. Introduction
2. Modelling approach
3. Which immune mechanisms determine the infection resolution?
4. Exploration of vaccine efficiency
5. General conclusion
• Thesis insights
• Main limits
• Towards an immuno-epidemiological approach
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Thesis insights
A powerful tool...
– Original within-host between-cell dynamic model
(innate response, adaptive response orientation, cytokine regulations)
– Ad hoc calibration method
(parameter space exploration & constraints on observed outputs)
... to:
– Better understand the interactions between immune mechanisms
– Guide further experiments
– Test & help the design of more efficient control strategies at the host
level
26
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Main limits
Model calibration & validation
→ Implementation of an experimental infection:
2 PRRSv strains, monitoring key immune components
Full cross-protection
→ Towards a multi-strain model with explicit memory dynamics
27
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Towards an immuno-epidemiological approach
Susceptible Infected Immune
Infection or
Vaccination
Exposure
PR
R
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v
Immunity loss
Infectiousness
+ Between-host variability (variable susceptibility parameters)
+ Multiple strains (model with cross-protection)
+ Model reduction→ at least:
[APC, functional cytokines, cellular effectors, neutralising antibodies]
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Towards an immuno-epidemiological approach
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Towards an immuno-epidemiological approach
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Thank you!
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Re´sume´
Mode´lisation de la re´ponse immunitaire au virus du Syndrome Dysge´ne´sique
et Respiratoire Porcin (SDRPv)
Le SDRPv est responsable de pertes e´conomiques mondiales et son controˆle est un enjeu majeur pour
la production porcine. La vaccination, principale mesure de controˆle, ne permet pas d’e´radiquer l’infection
et confe`re seulement une protection partielle de l’hoˆte. Ce manque d’efficacite´ est principalement due a`
grande variabilite´ de virulence des souches du SDRPv, induisant des dynamiques intra-hoˆte tre`s variables.
L’objectif de cette the`se est de mieux comprendre les interactions entre le virus et la re´ponse immunitaire,
dans l’optique d’ame´liorer le controˆle de cette maladie. Pour cela, une approche de mode´lisation dyna-
mique et de´terministe a e´te´ choisie. Nous avons de´veloppe´ un mode`le immunitaire original qui consiste
en une repre´sentation inte´grative de la dynamique intra-hoˆte. Il de´crit les me´canismes immunitaires a`
l’e´chelle inter-cellulaire, incluant la re´ponse inne´e, l’activation et l’orientation de la re´ponse adaptative,
ainsi que leurs re´gulations complexes par les principales cytokines. Nos premiers re´sultats montrent que
des dure´es d’infection similaires mais associe´es a` des dynamiques immunitaires contraste´es s’expliquent
par la prise en compte des me´canismes immunitaires impacte´s par la virulence. Cela apporte de nouvelles
pistes pour expliquer les incohe´rences apparentes entre re´sultats expe´rimentaux. Nous avons ensuite
montre´ que l’exposition, dont l’effet est souvent ne´glige´, a un impact sur la dynamique intra-hoˆte qui
varie en fonction de la virulence. Finalement, nous avons explore´ la dynamique intra-hoˆte induite par
l’infection d’animaux vaccine´s, ouvrant des pistes pour ame´liorer l’efficacite´ des vaccins. Cette the`se ap-
porte e´galement de nouvelles pistes pour guider les approches futures, aussi bien expe´rimentales que par
mode´lisation, ainsi que des perspectives prometteuses pour le controˆle du SDRPv a` l’e´chelle du troupeau.
Mots-cle´s : SDRPv, pathoge`ne respiratoire, mode`le mathe´matique, dynamique intra-hoˆte, e´chelle inter-
cellulaire, re´ponse immunitaire (inne´e et adaptative), virulence de la souche, exposition, vac-
cination
Abstract
Modelling the immune response to the Porcine Reproductive and Respiratory
Syndrome virus (PRRSv)
PRRSv is responsible for significant worldwide production losses and its control is a major challenge
for the swine industry. Vaccination, the main control measure, does not allow to eradicate the infection
and only confers a partial protection to the host. This lack of efficiency is mainly due to the strong
variability in PRRSv strain virulence, which induces highly variable within-host dynamics. This thesis
aims at better understanding the interactions between the virus and the immune response in order to
improve PRRSv control. To tackle this issue, a dynamic and deterministic modelling approach was
chosen. We developed an original immunological model consisting in an integrative representation of
the within-host dynamics. It describes the immune mechanisms at the between-cell scale, including the
innate response, the activation and orientation of the adaptive response and their complex regulations by
the major cytokines. Our first results show that similar infection durations associated with contrasted
immune dynamics are explained by the consideration of the immune mechanisms affected by the strain
virulence. They provide new insights to explain apparent inconsistencies between experimental data.
We then showed that the exposure, whose effect is often neglected, has an impact on the within-host
dynamics, which varies depending on the virulence level. Finally, the within-host dynamics induced by
the infection of a vaccinated pig was explored, providing new insights to improve vaccine efficiency. This
thesis also provides new insights to guide further experimental and modelling approaches and promising
prospects for PRRSv control at the herd level.
Keywords: PRRSv, respiratory pathogen, mathematical model, within-host dynamics, between-cell scale,
immune response (innate and adaptive), strain virulence, exposure, vaccination
